<SEC-DOCUMENT>0001628280-20-016121.txt : 20201109
<SEC-HEADER>0001628280-20-016121.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109171324
ACCESSION NUMBER:		0001628280-20-016121
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		201298715

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rmti-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f,d:f43c117d09de4ff289c1029a77c923e4--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:rmti="http://rockwellmed.com/20200930" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmti-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl80LTEtMS0xLTA_4f08180e-301e-4347-9193-6614b26b5018">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl83LTEtMS0xLTA_9fb2a8ea-dd6a-4198-b354-71d169b2e05f">false</ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl84LTEtMS0xLTA_05a12cc7-017e-4687-ac81-49a30b7845ec">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl8xNi0xLTEtMS0w_369ea955-1ed6-4e74-a109-2a1b78e98001">2020</ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl8xNy0xLTEtMS0w_38c8bf57-ba04-41f6-8fa0-40ffa2e93f91">Q3</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4edbeec154354697ac72b6c4e6eeaac5_I20201106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iad39fc18340148d88260925cf2c71125_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b30bbe1b55344bba8275550c225febe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86da6c4fcadb41b5ba4b5da76c54ba82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd1887cf65f41b2b3d36bbd39db4838_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i770863e42a2a48b4a60892bc1e12c8e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5894f7b1235408b9757424526f72c51_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70104b9963d5482b955d81352e01cba0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edaf9e76a1545639356ff49ed8463fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97de709080c4090915c065a4968de18_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6c114819494195977381d6b0db0dea_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75307b6d43bf458db7da774b1cf7e073_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613f46abca3040f28bb46ad26bea4e91_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb4d607639d417e882b6b1325d73420_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice592ffedeac499c8ffccc365e8a2547_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fd4f38167e440080bf667eae2b6adc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i668ce7c09fd243489fd8aa0744ebe327_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73fc87614fb147bcab7ea2ebc4329b29_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c0d288358b418e8a8e6005137b98d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc60d8ab5c84122b3c9526037d9fbbf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7aeab489a5041d3971baf867a877f96_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb47d4544bfe478d982c81e288fe8773_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2321752f47434c87f33cf993521b05_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158adda0535d4568a317d0212af41201_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d75f31ec2c24f38ae359072561380f1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6868d13e9543fb9846f82e219eb2d8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1c76ded1ff4405a15cfd8dec9de35e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie513e505eaa642a0ba67d4d26a26bc6f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7c8b7f5c8a4cd9a5e31c6ce7907dc2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8e35d265294eb3abef852d48f6016b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8327e54a894540d387fb1c21d05a7962_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90da80b5c0294f05980472837370ff77_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f5bee8a4224cc9bb993e924ffa5275_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1b70d7f95f940b99b2e2d713e8c2e9c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a91033410234d9b93822df743ab2cd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffceb5a770d1470989b074fcb3ce1c72_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id350ff27398e46e386d5e77a30fd2dcd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf404915f16f48298abfdbae0b2660b1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9d133aad0c4316be6655984efa94c8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf8c061dd424cdabc54af0c6e572255_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e28682b96b4df0b51ff9264ab162b4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6687bd6e9d42cf8aa0d9cbc3831aa7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb0f9c17c8145e8885d3c5be256df8f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a806c9950844789a211562273ac4bd5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669cbdb570ec462e90fee94d26485af7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870c6dec364a4c55b84f57f46e3d3d59_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c5a6d1ecfac490aa90fc495766c743e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa01447503b345c3a703ee4cff530762_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55eb32ecc0864f59969698ad4c39091f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ed909e37eb4f2d80b62754e1ac5a7d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d3225f700f14b8eaa7dae5e7b000ccd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad981cf655894d8b8f4cb43bc0028978_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1303e4f07304f0ea1c7de0894409f16_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3554a067052149da9e0237073b75129d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785da024692147b885c403a33b86064c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f6b8ee17a940baa698ca9d3509e8c2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86aa439c9264e91b122ec5e8b121f23_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i584df65c9c7541bfbca2050c1a065f5e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b182882e4024d7293ceaabba4bd8ccb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2261e4d5acc643928364085bf274f5eb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2275794073f343e286251f69c0725483_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1587de2669b493e879da7e102635c4b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec8a2522d62421e89cd4c2750585635_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988157eb43c948b0b48c71a792211e1c_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-23</xbrli:startDate><xbrli:endDate>2020-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8980a286d764741a6a0535b98f103cb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib149f28b57b5455b83b33022698763a7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3001b9e27cde4f58a61cf8c157040421_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea41dcc63ed476d8dbece309c6ad63e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ec1516b6ae4e118fa7217f2aa0bd68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc89f567f4234735a146c9ace53adbb1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5349e0526343b290ff0221f6aed37a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c484a5d97547fb92216812c28b5a52_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>rmti:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ia771c78851094cf0b22dcaa46810686b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5917e109c9e540b5b6b275de9b444283_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb07690b76f1481ebb6c2909fa5e7323_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4464409c4ae443058ce462975a7634db_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ff30259c1441b2a0a4f0b559884a2f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e0725267804eca91f6f04b1aba0ed8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062b8ca84b4145329ac1a0509078f58f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39fc677e9a549b382f949b298ba067b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8fb70070b246648e8f8997628ff47a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1095befdd04d445e80654a04a53cabdb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad9123b89e14db8adc3fd5832999d21_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief873247bf6b42c0ab6113a99352b4a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697255d93ed5459aac6fe8eef560cb51_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bba929d51d492abd362e87e6ba9825_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a16aafd4b73410cb11d551d736d5525_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663f506330f048d4a93e2d6cc47aa6d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754bf852083a492293cd350270a1a844_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6675c9f60fba4ff7b0a180e9cf9b6f2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285b58ffd3fc4e8b92453fe7ecc0598e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf229f34c7b64e8bb5ea23ba69e5fd1f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96af2b1201d74f70a53001fcf34f9ffc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e93fcfaef8544759969602319623bfd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2130d942bd5e454aac8d0d51dac98817_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeaeac98cba349d5b79b6b44e11381b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id737660a634e4a9c9bdbe80a2a316639_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccc5ba795194400bf9c6a11150113a9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee231374be0442fb8029ebfdc1a3e6c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b06e779ddd644c9a0b0ff6c7875bd45_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d53e2964d824b1d90da68f8b963d64d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc0c1d935564e1a813e0e93ec99c70a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8795859a4344592a375c53c2fe649cf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c9575f496b407abf0680d511ae8619_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia261e596f7ae4be4a6bfacfd41985358_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117b1cfaa32c4e209267190df3a1d335_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6d5deee8c245e59ff7998cea9f8e8c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc5f4e7510d42e78b5fcd4d6ca0877d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f0fc5632f44fa892279e11d3f5f64a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67baf02b08254808bd4df548744d90af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6af98eb7bd4e238f6b0b2894b4556f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a805e442db408f92e45e37dfa077e0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d19f7511cb04600801f9d98fef26b60_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482a8f6c3a59419eb4648b61db88d5db_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15fbd0feab424ce1bcc0b1fb2ec36625_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4437cf163a249a1b01639218fdce4af_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida40c86298494cfd939804f4adf6c2c7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7b126708c34e6d8b8b6e745bac3bdb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a80d3ff4034599a93526645efcf37d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ade2e7c43f8418e9e161bca2328cc73_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a93ba8c220648ca851f5aecd304d30c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b41310bebe843d3905f65a72974bd97_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c343d1a1ad409c88aaec6888f258d7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaeb1dae1cf94b168309faa699ac9f94_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50342dbb79e5499b9df2cb4e61d5be82_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37b023ab7a5491390c1523729301141_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1e2dfcd2804d95882c57e1cd29577d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f56a098641f4adabdbc54bd9bf3cebd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36cb5fa1a574affb0e19d405b184779_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a4ecd57bc74263aa9d096516b7427a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a70e4d101944330a1355aa4af4afef6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1db5ea92241540b2a00b5cc4513365e7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95bbeb2e83814978a01e4b5de1f38535_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c1e6721d294667908c33dbde50345a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444bb9b794c448cfbeb71eeb7d6b7942_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a21751e445646ee893fa1935f34c449_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68dd4e2cc7543f086a97c70aee4f3fd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2ce83af8934687a4f96e799ec9b7dd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bbacc3c3f74215a538c3cb78cdda7d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id68098fe4a9b439eaacc7f7d0c5bcbdd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e195e8a16b54620a94c67cd6bc415f3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98cefbf199d9465dae391afe67bf6d55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3adad74f372a48a99515a279dafd740f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fbfc3f90f54f06aa5a33e2c9b0418c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7264bcffa714400896107154c6920431_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e656f96253442ab7ee60c4d60cfdfc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieede3c5dcc3a49f1b95a145c32e7e7bd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1439b9bc31504073b9a6b6f1af0e5f94_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521d8220c1444234b7c2ff570a6a0903_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47777114a06c45f2824489ae3e94ab1a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e371b1d2074f71ae9ec6f96bf78fc3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5eda16ab0e411eb51123b3346dcd32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75c9d8788794de588ddd02a124be433_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib11597e3775d4b5f9e6494de29d10293_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericDialysateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd74d8095764a1eb76ef37b3b5b33ae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericAPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59f19af41fc488a9449247c776c5edd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490ec924f1484c5ab8de1f20a08eac2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ea955020dc4aeda5d463477492921f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724d030ef47645d9b041ce7ef4a3f9fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e7800000fe40fdb031acb81db02074_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdae022f9c94d2cacaaf617ee81281b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf6b93155d0417884bb4a768fae1f99_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied2d61a12cde4716914c1b6f8b1a5984_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9ae312db51145cc9a83894a56a1cbb5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id517adcb738e4b869a1855cf0dc6e89c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd0e24d44954042a9d519b591fd1314_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52774d95e2b2417085a873bc7c2ef34f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib51e33cf4bfd4008b1b122e6683c1a98_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0427b48c8964f40b6989681e03bf46d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259025889eae4268ae9b6e57e34ee6d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9668e4db871491a984f75bb8da0189f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51b254d9485419498fa51735863171b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89138f962f14daa953625c2f528ae33_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bdc1b8fe88f47298e47838b329a17c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8d7d55df774d63a47aea6d31334501_D20200114-20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-14</xbrli:startDate><xbrli:endDate>2020-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if753017f31704051a4c4bf411897fbe2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ae4f19c274445bb160007dae42042b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4718c450d0ef47158d07ef1e72752de0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91abe0affe46442896b337be936db0c0_D20200907-20200907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-07</xbrli:startDate><xbrli:endDate>2020-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ccd6e7c5ec24a5893a434fbdcebfbb4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eeaf45b733e4e779dfcac83f1129f11_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0831beb2ab467c80a2cd6478135fd1_D20190322-20190322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-22</xbrli:startDate><xbrli:endDate>2019-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if133411b23494ef4a52b411a10736bc0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2b087a0e4f4228929a2c5ee622983c_I20200204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c8a3f51c2d4520bd74c294ecf97017_I20200204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041fa2ada3f74f73bd7d90fb6dfb76f2_D20200206-20200206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-06</xbrli:startDate><xbrli:endDate>2020-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if132963a047b41d2a24b8a07ea731b8b_I20200206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5508c49bd924868bbf229130f33ee19_I20200219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab29bf3438904c79b711f873e3ceeb8c_I20200219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia502bbba04754e9aba66622648340936_I20200923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486841c65b234f6cbf7712dbae65542d_I20200923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rmti:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782ec4f251e84caf91c4d307a48529b0_I20200923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rmti:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-23</xbrli:startDate><xbrli:endDate>2020-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fae665e3ecf4ecaa260ed16b9864327_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9942ba6c87d84e62962ab243afb9c8b2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1198ab5b58240dbb1f5bfeca60211a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fd1a1eeb924cc5b1b07ab373a25223_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if383605b1d784fb1a8ff6c886fb8e59d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7e169bbaa94542ac7a76cb79b52918_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1daf26803ee746bc8aea3bb5e7e6adef_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id854eccd72ff423c94105e0747d833e3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62e59b988f854af6a2f19b812a92527f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4dad30bf674f2b81a41e72d5349c55_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ac32bf162f4c268157cf1641fa843a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6646233751964c4fb0aa59ba0eda8b5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f27d81d3cfe41f691685d6efd73d522_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaba2c2351e144d5bcab77648873bd5f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6551685fb24049b682909f7a5086db3f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10f9f4004419417e9412857f5acd3c8b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4a248d9fbf4a9dbd4e6806f7db82dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5579dd55e4b6461ba7c91e665d52fee3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a801e210d094fa18659b7a2f0a4f400_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb8a240bd284c4e9463f5dd7b8a6c70_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efe4199c6e74202909ae855d11ce621_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909683c4233b4a22804c27ebf1e6c92b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515e2b0a4fef415196a45d1b5751f530_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564592058228420b94ffbc322e7090c4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6606daf6bf13495a89c4cb1a8572fecf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9890f223334395a55787fcbfde8291_D20200417-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0fd29e788d64550b340302d86755201_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51825a238efa425a9b7252dd4452dcdd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfccd25c8636494a85d9d1d3f1d09ba3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b5bdfb4ab9b4caa9c0806d213fcfb9a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2d2e0642bf45b09fe5f2a6bfa06696_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d733cb7a0441e9ae832f027f97a0a6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f601d2948df4553b7179e093cc01b77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1282277c8624ede8e591db387da49dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1fe840a7dd542c2836bd0373f092156_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744dc4048e2e4f8794db00508bd3d7b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b33a9d825ac4f1abca98c67b705a726_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc0b7d956b44d84a62ad0c4ec9b6942_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:CertainEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed2b90c22864608b60a3b3225ad1530_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb2ee2e447941fdb9ab2c2d6386827c_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d39c6c2580451195d91bed252a4a52_D20200417-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885bcca89a364caf8262446d9b98366c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f1121abfa849c8b1387a55992b3591_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9db72d78c14bd0bafdf4d133155def_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-07</xbrli:startDate><xbrli:endDate>2018-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2db876957c441ca0969f774801ddfa_I20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>rmti:installment</xbrli:measure></xbrli:unit><xbrli:context id="i2362cb7d4e704216966ce8696c3475f7_D20181007-20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-07</xbrli:startDate><xbrli:endDate>2018-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759a54d69ef1425aa8087f8817c5243c_I20181015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc86daf3763428e93f171eb558edf4a_I20190115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5fafdd17b044d38ca4687c5c170b5b_I20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a755fb188b4af39fd3307f039573d2_I20190415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79757255bddd4b608922f96cd3af93ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79863bdc8a984b328ab874faf1c4b1cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7cf56169344015943de2cc62f7eab3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:MasterServicesAndIpAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2985ad7b6c3459abea9cf473c3ffba0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:MasterServicesAndIpAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd4514ac70647b48f7ba3276ef1d345_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i3145caf8d4884ddf8790d54cebdc6132_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffda10ef89254fc8b784470695ac1a39_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a68746f2fdd4216add87ba69b052f3f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4ac606416e4e319806c6b97ba5e4a9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68138705a9e4ae8b0ad29ba0248671c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656a4eb3707c4c909af7978cd89b8b65_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bf20809ab9443ebd612edde24ebe08_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d16d753feea42379fc36a6fc4802303_D20200801-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43d3fec43e04417ac3e08e63a74b5a6_D20190807-20190807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">rmti:SettlementAgreementWithAllPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-07</xbrli:startDate><xbrli:endDate>2019-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36da30ff01749b28487000f6715ba77_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d9fbef3e73446cbd0ee3d7923afae2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">rmti:SettlementAgreementWithAllPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918e1ec310cd4501850ee5a1d190849e_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74badfe283474cd495162707af80f4c0_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550d13f16af14526aa4aba8c018e3653_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3bca046ce7d4f19a430c177d2515e64_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6c0e6eb376449797262cd45e197f26_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2795cf61054796b20b23bef364d55e_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad74bef55824ee587591169cd823d18_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21bb6146027445a9e33a3043534e284_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>rmti:day</xbrli:measure></xbrli:unit><xbrli:context id="ic5bb31ec7a444c18904dfe090598b734_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99be750d121e4bba9049423b4facb83d_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if43c117d09de4ff289c1029a77c923e4_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEy_e07b7f43-62c9-45ca-9b45-75fc1edb41d1">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6NzJkYjlmMzk4MjFjNDdiOGExMmZmYzU1ZjcxZGVlZDEvdGFibGVyYW5nZTo3MmRiOWYzOTgyMWM0N2I4YTEyZmZjNTVmNzFkZWVkMV8wLTAtMS0xLTA_78bc75c9-fe51-4000-9b8b-99df3d5636ff">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8xODY_b10146fa-8703-425a-a4d6-5d6feeea859e">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6OTlmNzVlMzZhMzk2NDM4YTg5NTdjMDU5MGY1MWNhMzIvdGFibGVyYW5nZTo5OWY3NWUzNmEzOTY0MzhhODk1N2MwNTkwZjUxY2EzMl8wLTAtMS0xLTA_e87a356b-7cca-41bb-b650-3e6df795e135">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEz_ec1f85b8-8ccd-420e-907d-000804d2728f">000-23661</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA2_deb64334-533a-43cd-a323-8f5e4c5565ca">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.886%"><tr><td style="width:1.0%"></td><td style="width:36.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8wLTAtMS0xLTA_78153657-8149-4e30-b940-f8c98d3addd3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8wLTMtMS0xLTA_a82a4fee-9ac7-4570-8347-229361471a1b">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer <br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NDkz_ed193788-3f29-4fd0-94d0-a693429184d7">30142 S. Wixom Road</ix:nonNumeric>, <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NTE4_4f11f56a-7835-4507-a61e-8e9d33e200cd">Wixom</ix:nonNumeric>, <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NTI5_faf2815e-e7bf-47b6-a12a-905a0e93c449">Michigan</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTMtMS0xLTA_d0265eeb-a1ad-49b9-9644-a0b849020e9e">48393</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA3_0007e7b7-936a-4df5-81cd-404d53c8206f">248</ix:nonNumeric>) <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA4_4f8b495c-908d-4ec1-8881-e871a9d566ac">960-9009</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcx_60bcefa7-2e1e-4bb0-b1f8-6a106bfe222b">411 Hackensack Avenue, Suite 501</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcy_ab5c2e1b-b28f-4b1e-a747-d58786f5f3db">Hackensack</ix:nonNumeric>, <ix:nonNumeric contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcz_9caa5c9e-a969-40f8-af8d-865c9ff8f2e9">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjc1_9e4bd5dc-9dfd-4b2b-96a9-2dbca62a094a">07601</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if changed since last report)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA5_1db1bb6f-5061-43fd-8673-3c8b8e5174c2">Yes</ix:nonNumeric> &#160; &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEw_f7f02d6a-e73d-4a6e-89e3-e3951c2175bb">Yes</ix:nonNumeric> &#160; &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.625%"><tr><td style="width:1.0%"></td><td style="width:20.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8wLTItMS0xLTA_35d3518e-1afa-40ce-9633-01a38ee0e4ca">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8xLTMtMS0xLTA_e130e5ab-fc56-4425-b5fe-6a7b4ea89969">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8yLTMtMS0xLTA_97385001-a01d-4d56-85ca-82a73d31da5f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEx_423edbeb-0629-4301-82b0-2184e441ac2b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:30.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTAtMS0xLTA_7a2891c8-b2a3-49df-9c86-fbf0ab808b68">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTItMS0xLTA_7958c794-3437-452b-8d38-ae836e2e17a6">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTQtMS0xLTA_df3ae346-81cc-4b4e-8f6f-0399869037e4">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding&#160;as of November&#160;6, 2020 was <ix:nonFraction unitRef="shares" contextRef="i4edbeec154354697ac72b6c4e6eeaac5_I20201106" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTAx_91d02ae9-f98e-48e5-8c74-3b6721e27e24">93,573,165</ix:nonFraction>.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rockwell Medical,&#160;Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Form&#160;10-Q</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_10">Part&#160;I &#8212; Financial Information (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_13">Item 1 - Financial Statements </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_16">Condensed Consolidated Balance Sheets as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_16"> September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_16"> 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_22">Condensed Consolidated Statements of Operations for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_22">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_22"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25">Condensed Consolidated Statements of Comprehensive Loss for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25">N</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25">ine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_28">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_28"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_31">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_31">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_31"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_106">Item 2 - Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_124">Item 3 - Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_127">Item 4 - Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_130">Part&#160;II &#8212; Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_133">Item 1 -&#160;&#160;&#160;&#160;Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_136">Item 1A - Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_151">Item 6 -&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if43c117d09de4ff289c1029a77c923e4_154">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="if43c117d09de4ff289c1029a77c923e4_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div id="if43c117d09de4ff289c1029a77c923e4_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-bottom:5pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMy0xLTEtMS0w_7ff17067-ea1f-4c72-96c4-97ffcb215340">56,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMy0zLTEtMS0w_d2491536-01ca-44de-b6cf-c047c768c54d">11,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNC0xLTEtMS0w_87f9f49d-2bb1-47e6-9c36-6cbb0b229cad">10,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNC0zLTEtMS0w_e28a4ba7-2299-4550-aeb7-8c2d4bc0b514">14,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNS0xLTEtMS0w_0292a2d4-ea71-43e8-9ae6-04d185f45a6f">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNS0zLTEtMS0w_dcb21e67-e60b-48a7-951e-6b0aa3af8020">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNy0xLTEtMS0w_e6a531d5-5c9e-4afa-b65c-31c98aa011e1">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNy0zLTEtMS0w_e23875a4-f434-4059-a8af-6af8a8e0d257">3,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and Other Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOC0xLTEtMS0w_d8ed525b-7c76-4b46-a591-3aef8b34ae03">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOC0zLTEtMS0w_efc5d897-8185-44af-8e8f-3bf8f45af281">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOS0xLTEtMS0w_0bea495a-32ee-4796-875a-0368f3861739">77,943</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOS0zLTEtMS0w_9f084993-ddef-45dd-85b8-f1f535b39c30">36,874</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and Equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTAtMS0xLTEtMA_afb240ca-3912-4135-a83f-9c7652c1cd79">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTAtMy0xLTEtMA_ad9d57c0-5003-477e-b03c-9a4e4115eb64">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, Non-Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTEtMS0xLTEtMA_a7b48273-05c1-44de-8b16-db3c718adddb">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTEtMy0xLTEtMA_08e1c409-c36f-444e-94d4-9cd31c3f11fd">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of Use Assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTItMS0xLTEtMA_62cb2eb3-3c04-43fc-8abe-bc10ebe01f48">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTItMy0xLTEtMA_4ffcaae0-e227-4804-a972-802917223856">3,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTMtMS0xLTEtMA_3378a75f-63b0-4634-8ab6-b3d46669b9cc">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTMtMy0xLTEtMA_1904ac1b-610e-4d05-aa34-c7f77fa39ad0">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Non-Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTQtMS0xLTEtMA_93c009a3-4199-4209-92f5-15e725096259">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTQtMy0xLTEtMA_6b0091ad-2617-4f4c-a58a-15f27528cae4">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTUtMS0xLTEtMA_3f288a42-dc45-4b34-b683-405088916195">85,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTUtMy0xLTEtMA_a3f10b2d-82d5-4237-bfc1-d684870f8dc5">44,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTctMS0xLTEtMA_da346131-5f65-43af-8efb-c9f952452f13">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTctMy0xLTEtMA_9da97838-c0ad-44f8-99f2-2c32e6f0cb69">3,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTgtMS0xLTEtMA_6adbc6b8-df04-4158-ba25-78ea5545b38d">4,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTgtMy0xLTEtMA_88f12186-9401-44b0-aa17-3365e567a4fa">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LitigationReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTktMS0xLTEtMA_ef266eaf-a3be-4886-a963-df80020d3cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:LitigationReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTktMy0xLTEtMA_4fb35f1e-a856-4cf4-90fb-502e4da4a6b6">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability - Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjAtMS0xLTEtMA_0cc19fe2-d84a-45c3-8813-c9b281c1316b">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjAtMy0xLTEtMA_1fd00f77-5ae5-4e5b-a694-174ef6eece6c">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred License Revenue - Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjEtMS0xLTEtMA_db898287-02eb-4bda-b67b-6525ed33799d">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjEtMy0xLTEtMA_4b3ce81a-e634-4ef5-be6a-13b8b85d5b0e">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance Financing Note Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjItMS0xLTEtMA_477fda52-2785-4ce7-b123-ffb0559215c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:NotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjItMy0xLTEtMA_25654c3a-2c4b-4658-ada1-963da96ea5fa">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjMtMS0xLTEtMA_38fe4e7e-dba1-4877-9cca-23386a6eba9d">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjMtMy0xLTEtMA_236ffb08-e911-4ee5-a9ea-b69dbdb4166b">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liability - Related Party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjQtMS0xLTEtMA_ac8837f0-4324-4e78-ab38-1218ee8dcb9b">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjQtMy0xLTEtMA_be3249f3-ea83-45db-9710-7e4c900543d7">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjUtMS0xLTEtMA_266a4d00-6027-4c16-b7b2-c2837cfed183">12,708</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjUtMy0xLTEtMA_d01e2f79-1de1-4f47-9cbf-4bf427c754f9">12,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability - Long-Term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjctMS0xLTEtMA_40c26c91-38f8-4fc2-a334-a5ac3c671c39">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjctMy0xLTEtMA_68ab30cf-9f7b-4523-9f95-97fa40b0be3d">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, Net of Issuance Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjgtMS0xLTEtMA_60aac1e2-10ff-4139-a370-45a604d4f5be">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjgtMy0xLTEtMA_a619a4a6-897c-4db4-af45-527430c8d6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred License Revenue - Long-Term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjktMS0xLTEtMA_d8295abd-f5a2-4ebe-ad3a-5f19ab287719">8,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjktMy0xLTEtMA_bdb6cd76-8d1b-4a3e-ba0e-1272f3a8af13">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzAtMS0xLTEtMA_8b7a3f0b-f984-4b22-a5fd-1fb32ff902c1">43,161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzAtMy0xLTEtMA_9af9e765-413b-4916-9b83-f52ec1cdf501">23,997</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzItMS0xLTEtMA_76469328-4ae3-4324-988c-9820d3ae4d16"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzItMy0xLTEtMA_1ce9e05c-afce-48d6-a2a3-94c99df9121b"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1ODc_c2c0db0f-ef53-4bbe-9fd4-d5acaae71654"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1ODc_d3307e1a-ff4b-48be-a7ac-3362f7190703">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1OTk_62a9eacf-117b-475e-80f9-ecdae81e5d62"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1OTk_ffeb870e-028d-41be-925f-32386c8bfcee">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_208eb3a3-03f7-4d65-b03e-2c79a978f159"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_33a0d1b1-9336-436b-903e-e6d1c9b19373"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_46c05ecf-13d2-4813-9ae2-00a945ed75c0"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_4b6e24b5-31eb-41cc-b660-06ab820d9676">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMS0xLTEtMA_d09e6b90-ba0a-44af-acb7-0afa4c8a3471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMy0xLTEtMA_1e79c432-84ec-4af0-8809-6ac5caf65625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2MjM_242c1fc6-efaf-4583-98c4-074eacbbe5b7"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2MjM_54a09952-506e-4fb1-a1cb-bd7386543eba">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2Mzc_79b1ecc8-3782-4cff-81b2-e419b7485f75"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2Mzc_96074e2c-07d0-4993-b908-5f5874d42511">170,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NTI_08086c21-0419-46f3-8abd-7c758c5f9f33"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NTI_8834268b-a848-459a-a555-26bffc9244d6">93,573,165</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NjU_83fff684-49bd-4205-ab79-d2e74c156e72"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NjU_b142312f-668b-4209-8b5f-6fef734aebca">65,378,890</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMS0xLTEtMA_80c19a09-fc98-4bea-8643-1f52b8b0e33e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMy0xLTEtMA_4b601ded-362b-4532-8039-6df5588fd388">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid-in Capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzctMS0xLTEtMA_7866b1e9-6bd6-4898-bbbc-9913d579d5c2">370,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzctMy0xLTEtMA_c3f1c9dc-d264-4081-9bab-255560edc562">326,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzgtMS0xLTEtMA_32f0f087-85e7-477c-b72d-fdb370334d39">328,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzgtMy0xLTEtMA_b95ab015-c489-4283-a2d0-30d073663170">306,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzktMS0xLTEtMA_9a7eae2b-2295-47d4-b9d9-f896bd286568">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzktMy0xLTEtMA_1a8651f8-4b5a-44ec-9558-9d017a54c7d8">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDAtMS0xLTEtMA_54f5e6dd-2e28-4c64-a9b9-b8429be22ba5">42,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDAtMy0xLTEtMA_024598f7-dc01-4afa-9474-7bbb9e5b4ac2">20,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDEtMS0xLTEtMA_0f586496-a43b-4961-a014-b461796b70a6">85,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDEtMy0xLTEtMA_ab14574a-1447-47d6-8fd1-abad69566914">44,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands, Except Per Share Amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi0xLTEtMS0w_f3ec7c29-ab80-45a0-97b8-5f9fd4789e27">15,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi0zLTEtMS0w_1f9d633a-e235-4a61-b498-d407a407bb17">15,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi01LTEtMS0w_f716290f-e01a-48ab-90d8-f7df76bd4dc8">47,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi03LTEtMS0w_ac559955-7e91-4847-8e2c-898ffeaf2046">45,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy0xLTEtMS0w_5e69e40f-c23c-42e3-94a9-19f6f0b5169e">14,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy0zLTEtMS0w_12ef22bf-ba52-47af-a45c-eb6d284918e3">15,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy01LTEtMS0w_5fc50af0-db01-4a9f-a750-cf3b265b30ba">44,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy03LTEtMS0w_31023278-0c4f-4113-96c9-31447aac70a6">44,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC0xLTEtMS0w_290ca396-6f81-4228-a44b-43324890d71b">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC0zLTEtMS0w_7f536514-13b2-483a-a09e-9c74267d5b12">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC01LTEtMS0w_05af3146-9456-4bf5-8cd6-886704462d01">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC03LTEtMS0w_09dc8b84-e995-4c54-979f-f978de4dc52a">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS0xLTEtMS0w_8217ba02-889d-4554-a7e3-4279a3dba91d">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS0zLTEtMS0w_a2586a45-fe75-4430-a0ce-eb2fc0c73a25">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS01LTEtMS0w_61b739ef-3d1d-4e11-ac42-fc53de56d237">5,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS03LTEtMS0w_0c933087-be97-499a-99bc-bc0ad7f885e8">7,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi0xLTEtMS0w_c518a801-f1e3-4973-89b4-317a0900e3b7">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi0zLTEtMS0w_cfe3bb05-c2cb-4a8b-a9a0-6eb3ccb91bd6">4,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi01LTEtMS0w_347a40e8-07f5-43e3-9334-e633c373bdaf">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi03LTEtMS0w_90a73ae8-c984-41ac-a0d5-17ef00ac1fcb">16,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy0xLTEtMS0w_74c20570-5202-43df-9ab4-89aa49d365d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy0zLTEtMS0w_5e925ad8-eb79-4047-b823-cfe75ff827bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy01LTEtMS0w_c0309a93-4cc1-44c7-883c-91194fc89aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy03LTEtMS0w_2957a03d-ffd3-4d09-8616-36faa68bf91a">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC0xLTEtMS0w_1ce80426-bd30-4235-bbba-2f8499b02b7d">1,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC0zLTEtMS0w_71a5f5b8-3295-41cd-9196-eeae08dfc092">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC01LTEtMS0w_656c48d9-3e58-409e-8aef-66d99542cfaf">5,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC03LTEtMS0w_ff2705d8-c893-4fce-82e1-6e5080b64123">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS0xLTEtMS0w_93b1e5fa-ef85-4656-b211-d4cefa429a92">6,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS0zLTEtMS0w_00f858c3-21b9-4fb2-b3c4-aa93b0a9c9bc">7,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS01LTEtMS0w_a608dfe8-574c-48df-98b0-328bdbb0a040">20,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS03LTEtMS0w_a2083582-e7de-422d-9b3d-0c54b8ee24eb">27,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized Gain on Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItMS0xLTEtMA_f0613f47-5dad-44ee-9580-0d0dd2f66f47">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItMy0xLTEtMA_8c3af980-2f18-4d76-864d-892872a692b1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItNS0xLTEtMA_45148139-2c1b-468d-bf6f-ce1a2c8b36f3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItNy0xLTEtMA_3d443216-553a-4676-9a57-1334d8856aba">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtMS0xLTEtMA_89232b44-cddf-45e9-b864-844927afa1f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtMy0xLTEtMA_3d4d4cfa-131d-49c3-9d9e-814811c0e4f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtNS0xLTEtMA_d435a884-1f08-4d94-b2b9-5bcfdfe93b60">837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtNy0xLTEtMA_85afd1e9-97c8-4bd9-85fc-51f314900d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtMS0xLTEtMA_993b3653-f5e3-444a-bcc7-3d67781d57a8">666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtMy0xLTEtMA_fb4ef9c7-1fbd-4da0-ba03-aeec24614250">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtNS0xLTEtMA_37aaa3a6-dd8c-4e38-9392-df4381cc6131">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtNy0xLTEtMA_3cafc109-d922-4a12-8ec1-e6a0ec73d0f1">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtMS0xLTEtMA_3496005c-1d2e-43a2-b61e-d893f092e016">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtMy0xLTEtMA_cce5988f-7a34-42e1-a05c-da800b42c621">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtNS0xLTEtMA_004bf35f-eea7-4d2a-a61f-3a04ba2c7f8b">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtNy0xLTEtMA_eed45fbc-1b5a-4fa3-8579-cbb15d99fde9">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Other Income (Expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtMS0xLTEtMA_7a320300-5e03-4cb9-9b18-41fbbd393c0b">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtMy0xLTEtMA_3bc526bc-854a-4c35-90f7-de07d0083bc2">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtNS0xLTEtMA_3a835a0b-91a0-4a99-a770-6643188ddcc4">1,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtNy0xLTEtMA_36da26a7-1755-43da-a9c8-376988335578">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtMS0xLTEtMA_5bfdf19e-02ca-4ec6-855a-fce7c3d13ff6">7,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtMy0xLTEtMA_98dcd546-3110-4165-9187-ddc7a29682e7">7,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtNS0xLTEtMA_10a7fa07-6488-4844-b594-f01b4d6d9c06">22,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtNy0xLTEtMA_be4e9cc5-5464-4556-82d0-e3ac1c289ee6">26,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Net Loss per Share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtMS0xLTEtMA_13bde4a6-c57d-4aa0-9a2f-f2bc866ce5bc">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtMy0xLTEtMA_583554ce-db9a-4632-982f-2be993428e32">0.12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtNS0xLTEtMA_b64eea50-92fb-44ed-9e4b-119cd3878bf3">0.32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtNy0xLTEtMA_6a76e8b9-398f-4850-a0de-356c882fee22">0.45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Weighted Average Shares Outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtMS0xLTEtMA_a09987c6-5e0d-4b36-876b-d586329b541d">71,811,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtMy0xLTEtMA_a1efaf54-c924-4f79-9a4b-b9dfd039ecce">63,796,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtNS0xLTEtMA_b1569074-05a3-44e4-9584-a088a72c2272">69,594,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtNy0xLTEtMA_368daf0d-1e06-499c-b52b-4f7f9833e70d">59,728,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi0xLTEtMS0w_6d1c78bc-846b-447e-8367-e3bfe7e010c7">7,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi0zLTEtMS0w_c23ced00-a846-42dc-8895-0f4398010172">7,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi01LTEtMS0w_58fb9a71-adf7-4e9b-84f7-3027cd8800d1">22,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi03LTEtMS0w_c71eeb7b-ef2f-4fac-aec9-a42d4f8c56ff">26,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy0xLTEtMS0w_ddd3093e-1b8b-4f2a-bd02-dc43cdcf3048">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy0zLTEtMS0w_421de530-31ff-4a0b-947d-7aee8a730e8a">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy01LTEtMS0w_7cda7a81-4391-4c4e-bcee-55fe345d9a2d">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy03LTEtMS0w_8d1f3de0-4dce-4c8d-b6e5-b498fb9a0f4f">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC0xLTEtMS0w_cc9eb18c-6508-41a5-8b7b-41f34e70d261">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC0zLTEtMS0w_2752600c-33f9-40cd-be9a-5ae3e9d55b2d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC01LTEtMS0w_df7a324e-aef1-49ff-b085-841eb7a763a1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC03LTEtMS0w_82c1df07-fbb9-4d41-8b6b-e21e6ded5d79">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive Loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS0xLTEtMS0w_87843695-1b06-4475-8ca6-e45792aef8ad">7,347</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS0zLTEtMS0w_623f4dba-1d61-44a8-939c-3859393c4833">7,850</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS01LTEtMS0w_13ae6864-b632-4472-8391-d20eaf05c61b">22,230</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS03LTEtMS0w_d121b007-e7e6-403a-bec2-606c67288309">26,817</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMON STOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>OTHER<br/>COMPREHENSIVE<br/>INCOME</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL<br/>STOCKHOLDERS'<br/>EQUITY</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January&#160;1,&#160;2020</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b30bbe1b55344bba8275550c225febe_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0xLTEtMS0w_7bc7089c-dc6e-4a37-a874-d4e3fab4db60">65,378,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b30bbe1b55344bba8275550c225febe_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0zLTEtMS0w_394b45d6-6938-4d02-925f-8a79ada6074f">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86da6c4fcadb41b5ba4b5da76c54ba82_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi01LTEtMS0w_495c2d24-5714-41ab-a305-bd4427e124ff">326,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbd1887cf65f41b2b3d36bbd39db4838_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi03LTEtMS0w_df0211c7-b666-425b-99c0-dcc7e2e1ee86">306,516</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770863e42a2a48b4a60892bc1e12c8e9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi05LTEtMS0w_129275ca-f5e8-4940-8734-dd7f7d8053b0">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0xMS0xLTEtMA_5654f23c-6e1a-496d-a020-501e9e6c94f4">20,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5894f7b1235408b9757424526f72c51_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMy03LTEtMS0w_7e905127-560f-4557-8afb-b39d869b756e">7,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMy0xMS0xLTEtMA_fea0e366-8036-4e79-bdc7-38fdce6460ec">7,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70104b9963d5482b955d81352e01cba0_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNC05LTEtMS0w_1c5dd92e-6e0c-49d8-9dab-aa425c416aee">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNC0xMS0xLTEtMA_b615ca12-a3da-4464-b351-95ec40717837">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70104b9963d5482b955d81352e01cba0_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNS05LTEtMS0w_ea8f9e4a-7a03-4e5f-b67d-ea8fd74290b2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNS0xMS0xLTEtMA_ee91490a-ab3d-488f-80d7-750058449fd8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Public Offering</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0xLTEtMS0w_f829dee6-24a9-4c1b-aa34-a1d2153c631a">3,670,212</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0zLTEtMS0w_c79103c1-30a3-48dd-baf7-76dd6a656a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edaf9e76a1545639356ff49ed8463fe_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi01LTEtMS0w_67054cfd-78f5-4525-befe-2115aa310036">8,003</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97de709080c4090915c065a4968de18_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0xMS0xLTEtMA_a4dd1f46-eea3-40c0-a26d-cf520d8655e4">8,003</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Warrants related to Debt Financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNy01LTEtMS0w_a04ff76c-b97e-46b9-8263-37f3f34f8426">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNy0xMS0xLTEtMA_b40ea7bd-8c78-484d-b1c8-dc5e96a6029a">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOC01LTEtMS0w_b1a7b84a-c0e7-4e08-b1c1-27e8743106b7">935</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOC0xMS0xLTEtMA_f4e40a85-9dce-427c-8a38-ee64363ad454">935</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc6c114819494195977381d6b0db0dea_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0xLTEtMS0w_3e6849f2-06da-4b42-9d60-755c7cbea592">69,049,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6c114819494195977381d6b0db0dea_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0zLTEtMS0w_542ce200-038f-42db-ae24-7ef442c78843">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75307b6d43bf458db7da774b1cf7e073_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS01LTEtMS0w_97e30b6f-3117-4367-966f-4df9cc3fd635">336,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i613f46abca3040f28bb46ad26bea4e91_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS03LTEtMS0w_e559bc5a-ef4c-40db-bbf3-187c6c385fcf">314,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb4d607639d417e882b6b1325d73420_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS05LTEtMS0w_a081ba08-7125-4ea3-87ab-4a95d86fc73f">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice592ffedeac499c8ffccc365e8a2547_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0xMS0xLTEtMA_24d75056-c6c2-4463-a112-40357018e7e6">21,774</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94fd4f38167e440080bf667eae2b6adc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTAtNy0xLTEtMA_0b8e681f-5b30-432e-9568-7efbfae97c63">6,893</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTAtMTEtMS0xLTA_3130b617-ac51-41ed-a945-a2f530f07b39">6,893</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTEtOS0xLTEtMA_e5ea5fad-fe80-4185-ae79-8c48e30e47db">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTEtMTEtMS0xLTA_c2d923c9-ca86-442b-9e34-cc0893d106b3">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTItOS0xLTEtMA_bc1ddbb9-9326-4e38-873c-fb7247c944e0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTItMTEtMS0xLTA_39d750dd-1a2f-4ce8-a353-024a2e87aad9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/At-the-Market Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMS0xLTEtMA_b62237d2-0188-437e-8e14-91c72eebd055">987,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMy0xLTEtMA_55973cfe-ceb4-453c-87c1-221fd8edd068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668ce7c09fd243489fd8aa0744ebe327_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtNS0xLTEtMA_79bfc99e-f1a7-438f-a994-b2a79a00c70a">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73fc87614fb147bcab7ea2ebc4329b29_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMTEtMS0xLTA_57267280-9438-4351-92bd-d66280c9ae4a">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of Restricted Stock Units Issued, net of taxes withheld</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMS0xLTEtMA_bcf8cbe8-7323-4fde-8d52-1cc0923af549">120,104</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMy0xLTEtMA_d407b707-08f6-4373-ac0b-9bb8a7aa7afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtNS0xLTEtMA_45e11bc6-74d9-4026-a7a9-087bb23252c7">19</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMTEtMS0xLTA_db01795c-5f70-4698-a280-9d1c5e2fd8a5">19</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630" decimals="-3" name="rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTUtNS0xLTEtMA_3772a580-a10a-4633-a33d-288fba7be39f">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" name="rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTUtMTEtMS0xLTA_e87a0628-09d2-4622-8eac-7abd13e014fb">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation expense</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTYtNS0xLTEtMA_9bdd366d-eefc-4cd6-a1eb-f0f98eb8be04">1,461</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTYtMTEtMS0xLTA_bebae314-f429-44d1-95e1-3c8961b53d11">1,461</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2c0d288358b418e8a8e6005137b98d5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMS0xLTEtMA_0c057ec3-2a52-4db5-b679-f71ef3f0807b">70,156,922</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c0d288358b418e8a8e6005137b98d5_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMy0xLTEtMA_fd1c1243-ffdf-4c77-8e6d-1701ca1924a3">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc60d8ab5c84122b3c9526037d9fbbf_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctNS0xLTEtMA_5d18c0a3-d26e-4d06-a3cf-173698e5e0f0">337,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7aeab489a5041d3971baf867a877f96_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctNy0xLTEtMA_bfea0e51-f2cc-406c-a453-0ae0c9bd0e3c">321,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb47d4544bfe478d982c81e288fe8773_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctOS0xLTEtMA_d573e027-8d2a-4bc3-96ea-4d2acfa7fa35">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2321752f47434c87f33cf993521b05_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMTEtMS0xLTA_65f8cd4f-3f5e-4452-b95b-f7932a9f4c85">16,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158adda0535d4568a317d0212af41201_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTgtNy0xLTEtMzI1_42f3914f-97e4-47b5-b9d7-c0bc55d09927">7,350</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTgtMTEtMS0xLTMyNQ_4b7e334c-6bf0-4858-b7ca-f1c66c519998">7,350</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTktOS0xLTEtMzI1_7124270a-50ce-47db-b369-5c51d478f242">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTktMTEtMS0xLTMyNQ_fb7ebfa9-41d1-4455-9c58-74264c831cf1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjAtOS0xLTEtMzI1_92cedce7-32c2-49ea-b42b-fc79d0f2f6bc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjAtMTEtMS0xLTMyNQ_2ef4e357-d164-4495-99a4-cfe706bcfe6f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMS0xLTEtMzMy_5a534353-4a9d-4679-b6c7-7de9ad53c590">23,178,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMy0xLTEtMzM3_febc4ae5-976f-4e6e-a9b1-5c11ee596773">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d75f31ec2c24f38ae359072561380f1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtNS0xLTEtMzQy_5d1feb95-e24e-41a0-b774-17035e4a6305">32,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6868d13e9543fb9846f82e219eb2d8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMTEtMS0xLTM1Nw_07557b71-50d9-4c0f-98f7-e420be36eb1c">32,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/At-the-Market Offering</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMS0xLTEtMzI3_c6dcdb76-ec2f-4302-ba88-e389d3283b01">140,892</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMy0xLTEtMzI3_180bdcb0-3cba-4a0c-980a-5a0fb38cdabf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1c76ded1ff4405a15cfd8dec9de35e_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItNS0xLTEtMzI3_05caabd6-4593-4efc-afb4-0a87889933aa">284</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie513e505eaa642a0ba67d4d26a26bc6f_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMTEtMS0xLTM1Nw_29f4e4fe-9a20-47ff-8c91-2eae0c9134d1">284</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of Restricted Stock Units Issued, net of taxes withheld</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMS0xLTEtMzMy_0a8712f5-66f5-4dad-840e-02dd03105479">96,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMy0xLTEtMzM3_e17dbe49-97dc-449b-a216-01d64c22082a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMTEtMS0xLTM1Nw_0271e878-f805-4c73-b2de-bff89a5c4409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation expense</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7c8b7f5c8a4cd9a5e31c6ce7907dc2_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjQtNS0xLTEtMzQy_82e4404e-c872-49bf-b7bf-fcade0b626af">250</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjQtMTEtMS0xLTM1Nw_2c7bf9d4-7fd1-40f9-b671-98a956f25caf">250</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMS0xLTEtMzI3_e1064730-3357-43f2-b8e4-ad20edaa0b87">93,573,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMy0xLTEtMzI3_4ad53af1-7139-4908-8d14-ba66adbaecc9">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8e35d265294eb3abef852d48f6016b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtNS0xLTEtMzI3_a0adb378-b8f7-42a2-8c9a-64b9eaf3e076">370,760</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8327e54a894540d387fb1c21d05a7962_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtNy0xLTEtMzI3_bbbd6a60-5f52-4774-a037-26a7e6f80686">328,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90da80b5c0294f05980472837370ff77_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtOS0xLTEtMzI3_7115074b-b463-4755-ae5a-0e58c52e4440">49</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMTEtMS0xLTMyNw_9b180337-5b90-40cc-905c-da6c151328fb">42,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.358%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMON STOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>OTHER<br/>COMPREHENSIVE<br/>INCOME</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL<br/>STOCKHOLDERS'<br/>EQUITY</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January&#160;1,&#160;2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32f5bee8a4224cc9bb993e924ffa5275_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0xLTEtMS0w_4d487fde-bf02-4d75-ac34-d1217fbe72e1">57,034,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f5bee8a4224cc9bb993e924ffa5275_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0zLTEtMS0w_7412770a-38dd-4084-9073-beec706bc4d5">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b70d7f95f940b99b2e2d713e8c2e9c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi01LTEtMS0w_b849e31a-9677-4f21-a2e5-b7c9109840f3">299,596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a91033410234d9b93822df743ab2cd9_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi03LTEtMS0w_b9a5790d-bbfa-4e99-ad45-022e36155338">272,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffceb5a770d1470989b074fcb3ce1c72_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi05LTEtMS0w_e4c2e6a0-7945-4451-9fae-825fd523fdc0">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id350ff27398e46e386d5e77a30fd2dcd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0xMS0xLTEtMA_7e6e647f-2ca5-47c9-ba04-a3112792aef2">27,277</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMy03LTEtMS0w_35d55239-dfe2-44f0-99ca-332a6f2227eb">8,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMy0xMS0xLTEtMA_44a37f58-5aa0-4b05-8e21-2cd66f4d3dd0">8,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNC05LTEtMS0w_11a5bf1b-5df3-42d5-acfa-741095c44cc2">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNC0xMS0xLTEtMA_31fc4df3-9871-41e0-9ec6-d6134dec3392">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNS05LTEtMS0w_5da49076-37dc-4ece-98df-0680f298770f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNS0xMS0xLTEtMA_d3191f35-8125-4725-9d62-7a156e967777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of Employee Stock Options, Net of Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0xLTEtMS0w_93ac05de-dd3c-46cf-a2c2-46832cb2a8d2">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0zLTEtMS0w_a716f623-2611-4202-8ada-5cb3cea2dc14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi01LTEtMS0w_71c39c66-c1f9-40ae-b165-f5e5b2202157">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0xMS0xLTEtMA_ee54c8e2-a758-4a80-a961-ad783efed4ef">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delivery of common stock underlying restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0xLTEtMS0w_87f82780-f7cb-489d-8ee5-b7990e9c5230">64,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0zLTEtMS0w_206e13e6-0c3e-4c38-b5d7-9fa59757aae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy01LTEtMS0w_78fa009e-b35d-4dd0-a794-abb630127490">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0xMS0xLTEtMA_0104dc50-1f30-4c0b-888c-8d1a230b2035">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOC01LTEtMS0w_2af259dd-d2f9-4164-81ca-9702aa786004">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOC0xMS0xLTEtMA_2fe723dd-776d-43bb-a8aa-bb8395cd6992">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0xLTEtMS0w_f321e6fb-df9b-4761-bd97-bce7bb563971">57,128,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0zLTEtMS0w_bdf31753-ad4f-4445-bdb2-ee63e52f3e5d">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf404915f16f48298abfdbae0b2660b1_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS01LTEtMS0w_d4008e4d-5df3-480b-9b4d-179994099b29">301,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf9d133aad0c4316be6655984efa94c8_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS03LTEtMS0w_90eab165-ac52-4934-8142-3957c2617036">281,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf8c061dd424cdabc54af0c6e572255_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS05LTEtMS0w_ffd30dcf-da17-450b-8112-3dccac6d96c4">56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e28682b96b4df0b51ff9264ab162b4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0xMS0xLTEtMA_db9abb1b-2e30-4fa9-aa93-fa7503b2ae66">20,161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba6687bd6e9d42cf8aa0d9cbc3831aa7_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTAtNy0xLTEtMA_b3737ff1-5d4f-4885-83a3-d782f78159a9">10,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTAtMTEtMS0xLTA_a667882d-59df-4ef7-91fd-80586ee7c8f3">10,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTEtOS0xLTEtMA_cd962b5e-65d1-457f-b941-b5968b9b58dd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTEtMTEtMS0xLTA_82efd651-effc-4431-a386-53313cf2d07d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTItOS0xLTEtMA_a511ecfe-4b88-40a8-a27d-9c88d92004b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTItMTEtMS0xLTA_0da0a461-015a-468d-bbed-06548491147a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMS0xLTEtMA_a2b99c0f-d425-450e-bda3-4a184f3afe10">5,833,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMy0xLTEtMA_e00359d9-7a6f-494e-a952-6ed64d4cd030">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb0f9c17c8145e8885d3c5be256df8f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtNS0xLTEtMA_71ca4253-f2d3-4199-b817-91be456f7684">16,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a806c9950844789a211562273ac4bd5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMTEtMS0xLTA_a765c8d2-2173-4d13-abe6-06ef21a11a44">16,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/At-the-Market Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMS0xLTEtMA_c5ef1239-99dc-4e8a-8400-b771648f2775">437,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMy0xLTEtMA_dee620dd-f4b0-4c2b-89f2-019357ec7415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669cbdb570ec462e90fee94d26485af7_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtNS0xLTEtMA_aaa43f35-287f-46c7-a183-35a54134c41d">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870c6dec364a4c55b84f57f46e3d3d59_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMTEtMS0xLTA_323b0ab8-5077-4a5d-a2c3-d08c42b1d5a5">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5a6d1ecfac490aa90fc495766c743e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTUtNS0xLTEtMA_48ac7176-65fd-4a08-b35b-dc83d51d8b23">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTUtMTEtMS0xLTA_04e0f4c2-5a99-47a0-8483-befd12648a76">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa01447503b345c3a703ee4cff530762_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMS0xLTEtMA_0a2a15b9-3eb1-419e-8ac2-fa735a5b6075">63,398,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa01447503b345c3a703ee4cff530762_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMy0xLTEtMA_f73447cb-3402-40c2-9bad-8e0310a5218f">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55eb32ecc0864f59969698ad4c39091f_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtNS0xLTEtMA_c8410d62-4e9c-4463-8ed6-38d5d350b506">320,877</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75ed909e37eb4f2d80b62754e1ac5a7d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtNy0xLTEtMA_0b00baa0-239e-4b1c-b928-86a4e88aa7c3">291,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3225f700f14b8eaa7dae5e7b000ccd_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtOS0xLTEtMA_460baabb-c7ef-480e-91b9-01a67a79f644">68</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad981cf655894d8b8f4cb43bc0028978_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMTEtMS0xLTA_a4e70a30-468c-4c7a-8ceb-d2729a72d2ab">29,592</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1303e4f07304f0ea1c7de0894409f16_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTctNy0xLTEtMzIx_f76d0b15-6960-48ae-a8a4-42519016dcf0">7,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTctMTEtMS0xLTMyMQ_1ffe6d0c-057c-4093-a617-0f0e5f07af17">7,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTgtOS0xLTEtMzIx_68516f03-23a7-438b-9d7b-bb12baeaa64c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTgtMTEtMS0xLTMyMQ_84bedcfc-432e-44c2-826b-ff4d3368f94f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTktOS0xLTEtMzIz_70c6930d-b12d-4034-a692-91ecb208e2f9">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTktMTEtMS0xLTMyMw_928fbfb1-44b8-4a27-a6f0-2e203bce3d6a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delivery of common stock underlying restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMS0xLTEtMzIz_f1430ec0-1a14-4e53-931e-de33c54db16e">62,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMy0xLTEtMzIz_8f0264e7-4cc8-4c0d-b8c0-1368afcf9dbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3554a067052149da9e0237073b75129d_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtNS0xLTEtMzIz_3a073a88-8100-4716-b94e-ac1e93167be2">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMTEtMS0xLTMyMw_ec854161-e465-4cfc-b3ff-66a42861f2b1">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i785da024692147b885c403a33b86064c_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMS0xLTEtMzIz_a4a78ea5-8cfc-4a42-af76-dddc9684a45a">425,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785da024692147b885c403a33b86064c_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMy0xLTEtMzIz_6a4ba0e5-0a82-4a42-bff9-017985a42616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f6b8ee17a940baa698ca9d3509e8c2_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtNS0xLTEtMzIz_c414b9cf-afae-4179-97bb-9432a8fec50c">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86aa439c9264e91b122ec5e8b121f23_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMTEtMS0xLTMyMw_ac19e8fa-3c92-492b-8fc3-43f437dec1f6">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3554a067052149da9e0237073b75129d_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjItNS0xLTEtMzIz_0d1ba29e-64ff-4ed9-b912-3010fea0e1b8">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjItMTEtMS0xLTMyMw_2a6dc790-9cd3-4611-9da7-866641b2e30f">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i584df65c9c7541bfbca2050c1a065f5e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMS0xLTEtMzIz_8dfe58fd-c68e-454f-847b-1aef7c56788f">63,887,384</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i584df65c9c7541bfbca2050c1a065f5e_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMy0xLTEtMzIz_468e633a-f439-4d50-8ec3-1aa653347499">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b182882e4024d7293ceaabba4bd8ccb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtNS0xLTEtMzIz_e37f2eb6-358c-42d2-90ff-06bab9d9612d">322,837</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2261e4d5acc643928364085bf274f5eb_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtNy0xLTEtMzIz_733a444b-8a68-4d00-acfd-cddb0af8c989">299,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2275794073f343e286251f69c0725483_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtOS0xLTEtMzIz_6306327f-b934-46d8-82ff-59ec3370d233">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMTEtMS0xLTMyMw_6938141b-8e5d-4430-bf78-01993249646e">23,702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-right:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the nine months ended September&#160;30, 2020 and 2019 </span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMy0xLTEtMS0w_217ff6f0-4b22-4542-883c-d25870047f48">22,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMy0zLTEtMS0w_7abf426a-2f48-42c0-ab13-02da63af571b">26,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNS0xLTEtMS0w_16719d27-f249-417c-be9f-490a39fd2924">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNS0zLTEtMS0w_97165700-da1e-4c0c-addf-ac9aa3e3ead7">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNi0xLTEtMS0w_84a712b4-5b7c-4d66-aaa4-f81185b0422c">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNi0zLTEtMS0w_0d2c8773-4cc9-4896-b0f1-de294851f01a">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNy0xLTEtMS0w_d2b31c92-25ab-4165-a4b3-8c53cd594c61">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNy0zLTEtMS0w_515e3bcc-c68b-4e3b-9819-bec28fa34478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in Inventory Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOC0xLTEtMS0w_7c89f2a6-7049-4b8c-b4f3-a77524bc6d10">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOC0zLTEtMS0w_68ba6a11-8c53-4da9-ba98-89780fbeae91">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of Right of Use Asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOS0xLTEtMS0w_6f42f6d3-55a5-4172-9177-cb6a868e613a">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOS0zLTEtMS0w_7fcd0a4b-b1b9-4d0d-b892-e66e81e95e71">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of Debt Financing Costs and Accretion of Debt Discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTAtMS0xLTEtMA_fbc57e5b-1be3-49e1-b9a0-3c22861e85a8">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTAtMy0xLTEtMA_db560217-38a2-4d00-bf1d-8697997ca178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss (Gain) on Disposal of Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTEtMS0xLTEtMA_574bb06d-f8f9-488a-9f66-10923a66a991">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTEtMy0xLTEtMA_c952c57a-2f55-4b8b-add7-1055c0fdb89c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized (Gain) on Sale of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTItMS0xLTEtMA_ef313abb-d94e-40f4-88c3-9a5fe8167d0d">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTItMy0xLTEtMA_8f084526-8f9f-43bd-8b98-a80faa70b483">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTMtMS0xLTEtMA_1efc23fd-db46-4afe-8284-ddbc83256202">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTMtMy0xLTEtMA_8b691736-0726-4ddb-814d-08d01245c89e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Assets and Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Accounts Receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTUtMS0xLTEtMA_bc4052c1-8012-4015-9ae6-79499bd86a24">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTUtMy0xLTEtMA_bf4d422b-d9d2-4cee-9619-ac654730e4bf">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Insurance Receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTYtMS0xLTEtMA_7da24aa9-4f65-448c-be5c-dbcb5a1d6aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTYtMy0xLTEtMA_1d74e76c-d97b-4477-b832-b18dc8aafcc2">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Increase) Decrease in Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTctMS0xLTEtMA_84b6209a-8bf6-459b-a37e-d4f8b1dab624">953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTctMy0xLTEtMA_c78c9186-5f30-4085-a00f-cb8607553127">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Prepaid and Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTgtMS0xLTEtMA_20b9b243-420d-45d2-bd0d-0f5085391bbd">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTgtMy0xLTEtMA_bc2782c0-fffc-4e59-aba5-812766c298a2">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase (Decrease) in Accounts Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTktMS0xLTEtMA_522be999-a977-4e57-9901-ea4facd3c83c">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTktMy0xLTEtMA_c893041c-0aff-426c-9c81-84beecb498bd">1,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Settlement Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjAtMS0xLTEtMA_d9899276-bfb0-4f73-9518-3fa8949754da">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjAtMy0xLTEtMA_d8531b31-bb28-4988-bbbe-c8c6dc29debc">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Lease Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="rmti:IncreaseDecreaseInOperatingLeaseLiabilites" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjEtMS0xLTEtMA_5c69676c-727d-458e-a7cc-4d9d976d5d99">1,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="rmti:IncreaseDecreaseInOperatingLeaseLiabilites" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjEtMy0xLTEtMA_003416ac-0dfe-4d15-80ab-fc06551c0017">1,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase (Decrease) in Other Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjItMS0xLTEtMA_2fad458d-a16e-429c-add4-7d3bad3fc940">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjItMy0xLTEtMA_c5921c8c-e952-4671-9fb6-b10c87387e0e">1,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Deferred License Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjMtMS0xLTEtMA_109c50b5-9e0c-477a-9cee-c521990f0deb">1,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjMtMy0xLTEtMA_55116eb1-5d20-42f1-9b9c-e2cd13570a10">1,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 42.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Assets and Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjQtMS0xLTEtMA_48b18595-17ba-4799-8a0a-93532be7f25e">1,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjQtMy0xLTEtMA_8e9da7ca-7416-4842-835a-7640f632b0b7">2,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 42.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Used In Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjUtMS0xLTEtMA_adf9458f-6646-42e6-8ab1-3e0b20678e0a">21,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjUtMy0xLTEtMA_59372a96-7d4d-40c6-ad16-3f8f2471cf93">21,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjctMS0xLTEtMA_922abe59-b599-443d-b50e-8fb9a3386939">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjctMy0xLTEtMA_9769364f-ab80-4f91-8f12-935d920fb7ff">34,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sale of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjgtMS0xLTEtMA_9a91e8a4-53bc-47d4-b218-5b9747b94381">27,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjgtMy0xLTEtMA_d28f5519-7e43-47d0-8d62-5d8a90f626ec">30,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjktMS0xLTEtMA_52a94caa-d96c-4807-b52c-387130bd8f09">970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjktMy0xLTEtMA_524821fa-e4e8-4efd-b763-132fd80d8a76">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of Research and Development Licenses (Related Party)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzAtMS0xLTEtMA_2619029b-0513-4462-8ccc-477426c27459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzAtMy0xLTEtMA_744036d5-ca3a-4075-b9c3-63fc7f0ff120">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 42.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided By (Used In) Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzEtMS0xLTEtMA_142e1dc1-beeb-404f-9fbd-385ebe9d1557">2,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzEtMy0xLTEtMA_77da4753-01b8-4403-bea5-7b6e32ed2c3f">4,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzMtMS0xLTEtMA_885b7622-c7d0-4403-872a-5f12486d8f48">22,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzMtMy0xLTEtMA_a69da893-5a43-4922-b4f5-7ece7e867333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt Issuance Costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzQtMS0xLTEtMA_24f0d18b-d967-4b59-b5ac-757bd97fce37">1,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzQtMy0xLTEtMA_d29982e7-a205-4134-83f7-4bfba1f2f463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on Short Term Note Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzUtMS0xLTEtMA_c954db60-b965-4c1c-9aaa-51a2b6fed5bf">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzUtMy0xLTEtMA_1fd38609-41eb-448d-9582-a64d92cb38d9">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Issuance of Common Stock / Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzYtMS0xLTEtMA_43e86993-3e1c-4537-864f-3b6194aa7f5a">43,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia1587de2669b493e879da7e102635c4b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzYtMy0xLTEtMA_aa6ca036-aec2-48e0-9d8d-9470f7c2877e">18,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering Costs from the Issuance of Common Stock / Public Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzctMS0xLTEtMA_0a647ea5-35da-443b-8524-069db610711e">2,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia1587de2669b493e879da7e102635c4b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzctMy0xLTEtMA_28aba756-f939-40a1-b016-12d76c53c5f7">1,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Issuance of Common Stock / At-the-Market Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzgtMS0xLTEtMA_019ff18e-f2e2-4c45-8c33-6e56fb2fe79e">2,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idec8a2522d62421e89cd4c2750585635_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzgtMy0xLTEtMA_d1e26b0f-2924-4e37-a54e-8cedef43daaf">2,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering Costs from the Issuance of Common Stock / At-the-Market Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzktMS0xLTEtMA_c085f22b-2800-4e11-b42c-d9bbf3e320df">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idec8a2522d62421e89cd4c2750585635_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzktMy0xLTEtMA_b11505bd-ab91-484b-a96c-f99640617be7">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Exercise of Employee Stock Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDAtMS0xLTEtMA_c47ec6b5-a262-419e-8ad7-65f09fad1a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDAtMy0xLTEtMA_7c5b7a54-167a-4d1b-9bc9-8f39833284fe">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase of Common Stock to Pay Employee Withholding Taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDEtMS0xLTEtMA_7fbad686-4fac-4d54-851a-dd8595b9a8ee">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDEtMy0xLTEtMA_d94cbd6d-8c0c-446a-a72e-3cee4357b9bc">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 42.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided By Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDItMS0xLTEtMA_9dd518be-8916-4ef2-85ea-4e60539566c1">63,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDItMy0xLTEtMA_7ab34b84-d679-4ac7-b3b1-f32ff9ab6780">18,583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase (Decrease) in Cash and Cash Equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDQtMS0xLTEtMA_f085c756-ed51-4b3a-a30d-a25301571530">44,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDQtMy0xLTEtMA_6895e4aa-2577-4d5a-be21-85f4ff026415">8,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents at Beginning of Period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDUtMS0xLTEtMA_81ffb11c-9a90-452b-aadc-08f0949de4d2">11,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id350ff27398e46e386d5e77a30fd2dcd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDUtMy0xLTEtMA_39879fcb-b1b3-46c0-8708-28880fa9c807">22,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents at End of Period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDYtMS0xLTEtMA_508d531d-2619-4dd6-8c2d-df6334e2befd">56,614</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDYtMy0xLTEtMA_cea43af6-228a-4c8b-b5a3-8e1a19532d14">14,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Disclosure of Cash Flow Information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Paid for Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDktMS0xLTEtMA_2dc00775-ef2f-41c3-b31f-7327a944b9b2">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDktMy0xLTEtMA_ac6c8907-0e92-4dab-a76b-9fc08c02b605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Disclosure of Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Unrealized Loss on Marketable Securities Available-for-Sale</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTEtMS0xLTEtMA_8d08faaf-49a4-4768-91d2-7b46ea0307b9">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTEtMy0xLTEtMA_b08b3c28-5626-4a15-a60d-cdced841323b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance Financing Note Payable</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTMtMS0xLTEtMA_3376d4c9-f759-4e7d-a33c-5b203d45f5ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTMtMy0xLTEtMA_6b7cae94-ac3f-4ec8-b0d7-d80d1d72e03e">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value of Warrants issued related to Debt Financing</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTUtMS0xLTEtMA_7687e808-98e3-40ee-bc8b-1e1e0bca8a79">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTUtMy0xLTEtMA_827ad139-1905-4663-95fb-131e0a533f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="if43c117d09de4ff289c1029a77c923e4_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zNy9mcmFnOmVmOTAxNDhkMDUzNzQzODM4NTRiYmQ2ZTNjYmY0OTg3L3RleHRyZWdpb246ZWY5MDE0OGQwNTM3NDM4Mzg1NGJiZDZlM2NiZjQ5ODdfMTY4Mw_11a0581f-1e0c-4de2-a6b5-219a01d50187" continuedAt="ica090679d6e040ec8070b6790ad74d5a" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="ica090679d6e040ec8070b6790ad74d5a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. and subsidiaries (collectively, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, or the &#8220;Company&#8221;), is a biopharmaceutical company dedicated to improving outcomes for patients with iron deficiency and iron-deficiency anemia,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate citrate (&#8220;FPC&#8221;) therapeutic platform. The first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients.&#160;We initiated commercial sales of Triferic Dialysate during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. Our lead indication is developing FPC for the treatment of iron deficiency anemia in patients undergoing home infusion therapy. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients&#8217; lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triferic&#174;&#160;is a registered trademark of Rockwell Medical, Inc.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="rmti:LiquidityAndFinancialConditionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMzQ1NQ_befb70e1-e0d6-4976-8075-524095515b4c" continuedAt="ifb07bca0cf3b48358b57122a1bb7ff63" escape="true">Liquidity and Capital Resources</ix:nonNumeric></span></div><ix:continuation id="ifb07bca0cf3b48358b57122a1bb7ff63" continuedAt="ib5bda06e0c1d4ea784f6c257ff2ab58d"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfODE_015b53d1-727e-4a47-8f82-2fcc98ae0bce">56.6</ix:nonFraction> million of cash and cash equivalents, $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTE0_0123e024-279e-4c98-ad7c-4e405b467a43">10.7</ix:nonFraction> million of investments available-for-sale, working capital of $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:WorkingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTcx_deca2a15-1e64-4b5a-a1ff-bd5104be1039">65.2</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMjA0_7c6ad8bb-cf75-4063-aebc-e89a04292679">328.7</ix:nonFraction> million. Net cash used in operating activities for the nine months ended September&#160;30, 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMjkx_a7c7f092-372e-4591-bd2a-ee3f58a0a0cf">21.1</ix:nonFraction> million. Management evaluated the Company&#8217;s ability to continue as going concern for at least the next 12 months from the filing of this report. Based on the currently available working capital, capital raise and debt financing described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzQ1_aec888e9-0702-4b2f-9a51-44d8a886a4d4">3,670,212</ix:nonFraction> shares of its common stock for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzkx_c2257c58-5b5b-4866-ab3d-5e44d39129da">8.0</ix:nonFraction> million, net of issuance costs. On March 16, 2020, the Company closed a debt financing transaction with net proceeds at closing of approximately $<ix:nonFraction unitRef="usd" contextRef="i988157eb43c948b0b48c71a792211e1c_D20200316-20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfOTMx_33584fca-9b6a-47c4-b355-f900412cbc17">21.2</ix:nonFraction> million, net of fees and expenses (See Note 15 for further detail). On September 23, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzE0NjgyNTU4NDIwOA_7a7090ba-075d-405b-ad99-0fcf135e0f8d">23,178,809</ix:nonFraction> shares of its common stock for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzE0NjgyNTU4NDIyMA_15d18d5f-0d49-4bc1-bcc9-e2973c8f15ce">32.7</ix:nonFraction>&#160;million, net of issuance costs (see Note 10 for further detail).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTA1NQ_ea8669df-1830-4420-8703-b35a875e947e">1,128,608</ix:nonFraction> shares of its common stock as part of its sales agreement with Cantor Fitzgerald &amp; Co. for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTE2MQ_31ebf2f7-238d-42cd-a94d-3dd6d60aadfd">2.3</ix:nonFraction> million, net of issuance costs. Approximately $<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:SaleofStockRemainingSalesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTIwMg_cd355f18-e2e0-4cab-9e23-383dbb6ed7c1">32.3</ix:nonFraction> million remains available for sale under this facility. See Note 10 for further detail.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the commercialization of Triferic Dialysate and Triferic AVNU,  executing upon our plans for enhancing Triferic's medical capabilities, generating additional data for Triferic and developing Triferic for new therapeutic indications. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing.&#160;If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company is subject to certain covenants and cure provisions under our Loan Agreement with Innovatus.  As of the date of this report, the Company believes that it will either be able to satisfy such covenants or, in the event of  a breached covenant, exercise cure provisions to avoid an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity (See Note 15 for further detail).</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib5bda06e0c1d4ea784f6c257ff2ab58d"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Our international business development activities may also be negatively impacted by COVID-19, especially with the recent surge in infections and resulting quarantines or shelter-in-place orders. Depending on the severity of the impact on our sales and marketing efforts, the timing of our commercial launch of Triferic AVNU could be delayed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, the recent domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4Nw_81be22bd-b259-4504-bdd6-4b9b5359c286" continuedAt="i0ed3c9bb8178455cb931935c6f90b6eb" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0ed3c9bb8178455cb931935c6f90b6eb" continuedAt="i8e7852ed71854124a6dce37a6e3eb6e4"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (&#8220;U.S.&#8221;) of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (&#8220;SEC&#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at September&#160;30, 2020, condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and condensed consolidated statement of changes in shareholder&#8217;s equity for the three and nine months ended September&#160;30, 2020 and 2019 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020 or for any future interim period. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2019 and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 as filed with the SEC on Form 10-K on March 17, 2020. The Company&#8217;s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4OA_f2638519-38e4-47bd-b114-18dc7c9e3d68" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4OQ_a8fe242e-026e-4598-9e24-ee329e6562c0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5MA_f34c1108-3a3a-4459-852b-5dc458259195" continuedAt="i2d2bf08b3939474680edd242dcb0aa3c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8e7852ed71854124a6dce37a6e3eb6e4"><ix:continuation id="i2d2bf08b3939474680edd242dcb0aa3c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div></ix:continuation><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5Mg_8c729a7b-85ce-4a3e-9324-fe912daf13f0" continuedAt="ifea8d5d2c6104bac974296be12383003" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (&#8220;EPS&#8221;), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifea8d5d2c6104bac974296be12383003">Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.</ix:continuation> <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5Mw_f8a6410b-064d-4350-8987-06b771e9ac46" continuedAt="i0800b75b1f3141779cabb48ced738f55" escape="true">Securities that could potentially dilute net income&#160;per share in the future that were not included in the computation of diluted loss per share were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i0800b75b1f3141779cabb48ced738f55"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib8980a286d764741a6a0535b98f103cb_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMi0xLTEtMS0w_9c4810c1-378a-4f1c-bef1-c095ad822374">6,682,192</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib149f28b57b5455b83b33022698763a7_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMi0zLTEtMS0w_a82c16ae-bca2-445c-a1d0-ad1e148145b6">8,170,382</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3001b9e27cde4f58a61cf8c157040421_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMy0xLTEtMS0w_c9c8753b-bb38-412b-88dd-86aa95e83de0">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0ea41dcc63ed476d8dbece309c6ad63e_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMy0zLTEtMS0w_792b2350-5b02-4bcc-8ad5-c996e762e467">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i73ec1516b6ae4e118fa7217f2aa0bd68_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNC0xLTEtMS0w_36328ce6-6e98-46e7-8337-b479632b98f6">245,405</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idc89f567f4234735a146c9ace53adbb1_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNC0zLTEtMS0w_dcfd644e-f58d-443e-af3f-e116b40da14f">1,324,172</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae5349e0526343b290ff0221f6aed37a_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNS0xLTEtMS0w_cad2985d-468e-4b6b-a0fb-c84556fde95f">26,426,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic3c484a5d97547fb92216812c28b5a52_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNS0zLTEtMS0w_3c9150dd-1504-484b-b354-0119ff3ab29e">2,770,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNi0xLTEtMS0w_530808dd-c105-4349-a506-97bde9e26a07">33,501,260</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNi0zLTEtMS0w_51983327-be52-4311-99a1-6557ac6cbaec">12,412,135</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4Ng_2ca9a456-29e7-4460-a892-195ba38b906a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company&#8217;s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company&#8217;s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company as adopted on January 1, 2020, and did not have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxMw_a4b92eee-76fe-4892-830f-8ee170a0db90" continuedAt="ic9749d8c6e9c4a91b44b0a598a77d591" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic9749d8c6e9c4a91b44b0a598a77d591" continuedAt="i46ddf07bb3804ef2b29be430d25b0cb5"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.&#160;&#160;For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.&#160;&#160;In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under <ix:nonFraction unitRef="agreement" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="rmti:NumberOfDistributionAndLicenseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfMjk1NQ_b16c07a4-d292-4984-8ac0-ff214027aee8">four</ix:nonFraction> distribution and license agreements that have been deferred as a contract liability.&#160;&#160;The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (&#8220;Wanbang&#8221;) and Sun Pharmaceutical Industries Ltd. ("Sun Pharma") and amounts to be received Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.&#160;&#160;The amounts received from Baxter Healthcare Corporation (&#8220;Baxter&#8221;), are recognized as revenue at the point in time that the estimated product sales under the agreement occur.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company&#8217;s distribution agreement with Baxter (the &#8220;Baxter Agreement&#8221;), and for the majority of the Company&#8217;s international customers, the Company recognizes revenue at the shipping point, which is generally the Company&#8217;s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:durday" name="rmti:AveragePaymentTermOfCustomers" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDQxMg_0cd6a551-1d8a-4aa3-8cca-7f4306920da6">30</ix:nonNumeric> days, while distributor payment terms average <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" format="ixt-sec:durday" name="rmti:AveragePaymentTermOfDistributors" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDQ1Ng_c1604845-79fc-464b-9046-a2210db26aa9">45</ix:nonNumeric> days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxNA_9a4219d0-b9c2-48f5-bd07-fdd4ca4d266e" continuedAt="ifd23e7b6bc694c59a447d9666b475b44" escape="true">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i46ddf07bb3804ef2b29be430d25b0cb5" continuedAt="ia51ed646f3ec40869f2074ff69558d5d"><ix:continuation id="ifd23e7b6bc694c59a447d9666b475b44"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:29.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia771c78851094cf0b22dcaa46810686b_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0xLTEtMS0w_7bd61b34-e7e9-4a72-a741-a91e044738b9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5917e109c9e540b5b6b275de9b444283_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0zLTEtMS0w_81add3e4-2488-4088-8aa0-f99151d5d9b1">228</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibb07690b76f1481ebb6c2909fa5e7323_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy01LTEtMS0w_41d33c57-8cd6-42a5-a250-ec9a488d3b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4464409c4ae443058ce462975a7634db_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy03LTEtMS0w_b8be65a3-698f-490d-880c-d86404529b11">609</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3ff30259c1441b2a0a4f0b559884a2f_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy05LTEtMS0w_3a88aaeb-0b56-4526-90dc-6eec4253522e">609</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i05e0725267804eca91f6f04b1aba0ed8_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0xMS0xLTEtMA_bcd2ea57-2d31-47da-aaac-3853802ee26b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i062b8ca84b4145329ac1a0509078f58f_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0xLTEtMS0w_9fad2641-410a-4706-abe6-391fe9525072">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic39fc677e9a549b382f949b298ba067b_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0zLTEtMS0w_ed1be790-1b79-4949-836f-df7ed031931b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6d8fb70070b246648e8f8997628ff47a_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC01LTEtMS0w_5dce488e-7a4a-4a5a-814d-00d52ded30d5">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1095befdd04d445e80654a04a53cabdb_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC03LTEtMS0w_f05a68c8-0d53-4939-885e-ea490ac94527">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icad9123b89e14db8adc3fd5832999d21_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC05LTEtMS0w_a0857a6a-2b9c-413f-acc8-685a122024ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ief873247bf6b42c0ab6113a99352b4a7_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0xMS0xLTEtMA_ff3ba592-78ae-406c-a2b8-963698b5f569">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0xLTEtMS0w_22d826b7-5b25-4a0a-b63c-af2830cca80a">284</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i697255d93ed5459aac6fe8eef560cb51_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0zLTEtMS0w_82421fea-e519-455a-ab25-74303a94e3a9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i74bba929d51d492abd362e87e6ba9825_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS01LTEtMS0w_f6d6b384-c9ff-4025-871c-92739602f281">56</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a16aafd4b73410cb11d551d736d5525_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS03LTEtMS0w_8c58034b-a92f-46c0-b544-79e60355316f">776</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i663f506330f048d4a93e2d6cc47aa6d9_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS05LTEtMS0w_471b165a-f1ee-439e-a890-1c0e64d39396">609</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i754bf852083a492293cd350270a1a844_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0xMS0xLTEtMA_98662ead-02d4-45ab-94ca-b7a5fcbe0e9b">167</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6675c9f60fba4ff7b0a180e9cf9b6f2b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0xLTEtMS0w_840d92cd-fb68-45f3-bcdb-30b5ddbc7b11">14,506</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i285b58ffd3fc4e8b92453fe7ecc0598e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0zLTEtMS0w_dae40942-873f-4ac5-9367-7fe001b7edf8">13,470</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf229f34c7b64e8bb5ea23ba69e5fd1f_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy01LTEtMS0w_8a6da72b-498a-4ec0-9776-0ea1ff378987">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96af2b1201d74f70a53001fcf34f9ffc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy03LTEtMS0w_ccd23600-77c9-44e3-af90-0c50700d998a">44,786</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e93fcfaef8544759969602319623bfd_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy05LTEtMS0w_b1d2ffd2-f84b-4551-a110-848958999b3a">40,295</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2130d942bd5e454aac8d0d51dac98817_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0xMS0xLTEtMA_4e340139-1496-4879-905d-36423a1a1d16">4,491</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieeaeac98cba349d5b79b6b44e11381b8_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0xLTEtMS0w_b968a3b4-f49c-4e7b-afea-d8dbd969a583">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id737660a634e4a9c9bdbe80a2a316639_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0zLTEtMS0w_0702d56e-d13f-4889-9172-a2011ac3d902">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icccc5ba795194400bf9c6a11150113a9_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC01LTEtMS0w_289b510c-993d-45a3-ae4a-83ad38a0c8f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee231374be0442fb8029ebfdc1a3e6c8_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC03LTEtMS0w_52580b5a-a315-4cae-9653-f704ecc9c5d7">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b06e779ddd644c9a0b0ff6c7875bd45_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC05LTEtMS0w_e4141752-78f5-4b4f-986b-1c28a629c77d">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d53e2964d824b1d90da68f8b963d64d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0xMS0xLTEtMA_72c98bb7-63c3-4d36-beb1-e3411f36015f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8cc0c1d935564e1a813e0e93ec99c70a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0xLTEtMS0w_a072ca68-f8d6-4d69-9435-279fb6361869">14,996</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8795859a4344592a375c53c2fe649cf_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0zLTEtMS0w_27e05bca-e5eb-4a0c-b038-65fd7727112d">13,960</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0c9575f496b407abf0680d511ae8619_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS01LTEtMS0w_98743b17-7b89-4dd5-8068-9044bbb80b98">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia261e596f7ae4be4a6bfacfd41985358_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS03LTEtMS0w_60ebd675-c0e0-4f1e-8159-9a282f991aa6">46,257</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i117b1cfaa32c4e209267190df3a1d335_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS05LTEtMS0w_1e3a6d5d-ef9a-42e6-aade-3fe93ff8b64c">41,766</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d6d5deee8c245e59ff7998cea9f8e8c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0xMS0xLTEtMA_79154cef-585a-44ac-ada5-8c2d97cdd963">4,491</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMS0xLTEtMA_d9a421a8-374b-424a-89e7-815152dcfcc6">15,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iadc5f4e7510d42e78b5fcd4d6ca0877d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMy0xLTEtMA_dd4258df-aebf-44b1-b11a-30b3aed06159">14,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id7f0fc5632f44fa892279e11d3f5f64a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtNS0xLTEtMA_6ef89fed-c56e-425e-92db-a2c0b15a1b8b">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtNy0xLTEtMA_6510ad84-bb34-4fb0-b67f-4f9fbaef64f7">47,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i67baf02b08254808bd4df548744d90af_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtOS0xLTEtMA_be4258f9-6cba-4176-83d9-631ead9435b7">42,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ief6af98eb7bd4e238f6b0b2894b4556f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMTEtMS0xLTA_5befdfba-cea9-4e2c-8437-964be1a556db">4,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:29.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if3a805e442db408f92e45e37dfa077e0_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0xLTEtMS0w_1d3e74d6-6ee7-440c-90e9-012051a28fb6">98</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d19f7511cb04600801f9d98fef26b60_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0zLTEtMS0w_29582686-da45-4539-a2f0-9569ba0d100c">98</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i482a8f6c3a59419eb4648b61db88d5db_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy01LTEtMS0w_0d52cbe1-3c70-4696-bc2b-905b251ebb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15fbd0feab424ce1bcc0b1fb2ec36625_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy03LTEtMS0w_d7ba55dd-69f0-4702-8722-e888aae4ac6c">112</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic4437cf163a249a1b01639218fdce4af_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy05LTEtMS0w_216d2e07-b211-44d6-b2da-be1c70a963a5">112</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ida40c86298494cfd939804f4adf6c2c7_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0xMS0xLTEtMA_331ab385-fc7e-4fad-bc35-be18c5ceb1b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab7b126708c34e6d8b8b6e745bac3bdb_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0xLTEtMS0w_1522fd58-5d5a-4a93-b712-e52e5d3247ba">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22a80d3ff4034599a93526645efcf37d_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0zLTEtMS0w_1ef10cf1-012f-45bc-b98c-49c78b35f5a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1ade2e7c43f8418e9e161bca2328cc73_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC01LTEtMS0w_ad7e7a24-03b9-476f-aaf8-704fa2fd6dae">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6a93ba8c220648ca851f5aecd304d30c_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC03LTEtMS0w_574e1c1b-ddcf-4569-9fc3-e8e705d0bed0">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b41310bebe843d3905f65a72974bd97_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC05LTEtMS0w_0c181407-6bda-4a9c-9d70-f41bb72d8a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i45c343d1a1ad409c88aaec6888f258d7_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0xMS0xLTEtMA_863f122c-b06d-4219-9390-6880d2c1b80d">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaeb1dae1cf94b168309faa699ac9f94_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0xLTEtMS0w_9ad62537-5010-4f2e-bb19-3c92e5be4616">166</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50342dbb79e5499b9df2cb4e61d5be82_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0zLTEtMS0w_82ffb55d-85e3-41c8-a8a1-ea3aaf05cab6">98</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37b023ab7a5491390c1523729301141_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS01LTEtMS0w_d0262fe3-23b8-468e-8b42-493038b39c75">68</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf1e2dfcd2804d95882c57e1cd29577d_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS03LTEtMS0w_76f69084-a092-4fc9-85cf-9c8bafdbe1a5">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f56a098641f4adabdbc54bd9bf3cebd_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS05LTEtMS0w_da8e2032-e65f-4246-8289-0b8b5bb3ef53">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib36cb5fa1a574affb0e19d405b184779_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0xMS0xLTEtMA_1cebb83c-14b3-4bfe-a7a4-6206f9f1b78c">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i85a4ecd57bc74263aa9d096516b7427a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0xLTEtMS0w_aaa1449d-3c2f-40bb-9067-61e9535f4e4b">14,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6a70e4d101944330a1355aa4af4afef6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0zLTEtMS0w_5c270d39-0061-4d6a-bb87-239a0d3016ed">13,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1db5ea92241540b2a00b5cc4513365e7_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy01LTEtMS0w_e5de495f-a97d-49f1-92fa-14976d162ce1">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95bbeb2e83814978a01e4b5de1f38535_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy03LTEtMS0w_7b2833b6-4a2d-4a55-b602-92e7500f48ed">44,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if1c1e6721d294667908c33dbde50345a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy05LTEtMS0w_a3f86771-287b-457d-9109-81ab08cb5328">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i444bb9b794c448cfbeb71eeb7d6b7942_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0xMS0xLTEtMA_1dd3a04e-2bb8-4816-84eb-cb6500c39bb2">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a21751e445646ee893fa1935f34c449_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0xLTEtMS0w_6ff23acc-7a0b-4444-806c-4678f0a50da4">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic68dd4e2cc7543f086a97c70aee4f3fd_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0zLTEtMS0w_508adcb6-7f78-4a01-bb05-a61420f41e48">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d2ce83af8934687a4f96e799ec9b7dd_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC01LTEtMS0w_b23c1b9c-6121-4f0b-9839-c7ef4e657591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32bbacc3c3f74215a538c3cb78cdda7d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC03LTEtMS0w_5db85de2-0ee0-48f4-aa0d-f6453359c91e">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id68098fe4a9b439eaacc7f7d0c5bcbdd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC05LTEtMS0w_166c8424-406e-48c0-bf6e-f067e13ac098">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e195e8a16b54620a94c67cd6bc415f3_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0xMS0xLTEtMA_9c9f84d6-e19c-438b-aa76-ec8a2015f5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98cefbf199d9465dae391afe67bf6d55_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0xLTEtMS0w_1887b6de-1077-4307-ba89-d6145613dd27">15,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3adad74f372a48a99515a279dafd740f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0zLTEtMS0w_cefdcc88-8b02-4345-b3df-6cd6f670df63">13,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia9fbfc3f90f54f06aa5a33e2c9b0418c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS01LTEtMS0w_59b58669-f72f-4f50-845a-67becec64a49">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7264bcffa714400896107154c6920431_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS03LTEtMS0w_1b70f53b-ba34-41f8-8516-e56bfc4f0f8e">45,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7e656f96253442ab7ee60c4d60cfdfc_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS05LTEtMS0w_661d1cd1-9f21-46cf-b015-c22fc4a31ab2">40,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieede3c5dcc3a49f1b95a145c32e7e7bd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0xMS0xLTEtMA_3361e824-27a1-40cd-ad27-fb1100d1a669">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMS0xLTEtMA_85c0c746-c40a-4672-890a-454f08cf05b7">15,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1439b9bc31504073b9a6b6f1af0e5f94_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMy0xLTEtMA_73b02a0b-a51c-4e4c-b0c4-db7eabb4cfc8">13,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i521d8220c1444234b7c2ff570a6a0903_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtNS0xLTEtMA_cffd39cb-f106-476d-baab-fbce90d7734f">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtNy0xLTEtMA_903efcb7-e42f-405c-89ba-3340ace7154f">45,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47777114a06c45f2824489ae3e94ab1a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtOS0xLTEtMA_b01cecef-47d2-409b-b15e-ef48db7900ad">40,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i16e371b1d2074f71ae9ec6f96bf78fc3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMTEtMS0xLTA_69feb644-535f-4321-bd8a-334368622700">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxNQ_463d9ead-cab3-41a4-a4f8-ebd72c195874" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMS0xLTEtMS0w_e7afb665-0deb-489d-93af-f34575e7753f">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMS0zLTEtMS0w_85c6a9d7-7e0f-4cdb-9908-986433ae81c3">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMi0xLTEtMS0w_cc295dbe-bad8-4d9f-81b0-0fe69e8fe7b7">10,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMi0zLTEtMS0w_7430e92d-1094-4f57-b61c-a9d2503c003e">12,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_13abc0fb-9b9e-4224-8118-20bc69bade33"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_57a7cb29-fc14-44c6-b819-f167fdb81e43"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_a5ab62eb-68b0-45c3-b550-c7bd216d969e"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_d3eed59f-014d-4534-87cc-09c7e775510a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material losses recognized related to any receivables arising from the Company&#8217;s contracts with customers for the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and September&#160;30, 2019, the Company did not recognize any material bad-debt expense. There were <ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTAxOQ_08b54ac0-aa11-4b63-acd2-18719af0e419"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTAxOQ_3036d832-740d-4566-aee8-240da6ae5a4c">no</ix:nonFraction></ix:nonFraction> material contract assets recorded on the condensed consolidated balance sheet as of September&#160;30, 2020 and December&#160;31, 2019.&#160;&#160;The Company does not generally accept returns of its concentrate products and <ix:nonFraction unitRef="usd" contextRef="i8e5eda16ab0e411eb51123b3346dcd32_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTE5Ng_80fe13f6-edf2-47ce-8fba-7ec94eeb63ae"><ix:nonFraction unitRef="usd" contextRef="if75c9d8788794de588ddd02a124be433_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTE5Ng_d7cc7c92-7759-408a-a66f-cdd1242460d8">no</ix:nonFraction></ix:nonFraction> material reserve for returns of concentrate products was established as of September&#160;30, 2020 or December&#160;31, 2019.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020, revenue recognized from performance obligations related to prior periods was not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia51ed646f3ec40869f2074ff69558d5d">Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjAwOQ_30865db1-d36e-4433-9258-dd7869bf0756">10.7</ix:nonFraction> million as of September&#160;30, 2020. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $<ix:nonFraction unitRef="usd" contextRef="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjU5NQ_54373609-8e0d-4380-a1ab-d26e09106b6d">7.7</ix:nonFraction> million as of September 30, 2020, which is being amortized ratably through expiration of the Baxter Agreement on October 2, 2024.</ix:continuation></span></div><div id="if43c117d09de4ff289c1029a77c923e4_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RleHRyZWdpb246YTZkYTcyMmI0NDBlNDAzZDg1ZTk2MTcyZmVhZGM2MWNfNTA5_3ac4ef6e-76a2-4b26-ae53-e1481357321b" continuedAt="ib144d94476de46cca215e5ffb911c0c2" escape="true">Investments - Available-for-Sale</ix:nonNumeric></span></div><ix:continuation id="ib144d94476de46cca215e5ffb911c0c2"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RleHRyZWdpb246YTZkYTcyMmI0NDBlNDAzZDg1ZTk2MTcyZmVhZGM2MWNfNTEw_89b4f93e-abcd-4e65-9e62-1f5e41b3f781" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019 (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy0xLTEtMS0w_adf8722e-81bc-4bc4-bb1a-c43f714a0c34">10,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy0zLTEtMS0w_f7c89f12-b763-4d2d-b2f3-2ff8466a50ca">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy01LTEtMS0w_73bb0ae6-0445-4e43-be33-a69b643fe503">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy03LTEtMS0w_90e6839d-26f8-4bcc-85ec-283df6008870">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy05LTEtMS0w_0580e5c4-4a73-4838-8ddc-c5cb317b2294">10,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy0xLTEtMS0w_d6f27e5f-adf9-41ad-a950-21c9a6f7dd6e">14,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy0zLTEtMS0w_80970e3e-6e0e-42ce-bb3a-b26f6522b47b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy01LTEtMS0w_589659dd-f52d-4fc4-be12-b6c17f5017c7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:zerodash" name="rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy03LTEtMS0w_6beb2854-f977-4492-878f-cee983454f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy05LTEtMS0w_ed8ee8c1-f63e-4989-a47e-d9de1c8ef5af">14,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNjc5_b32d8533-202b-4c1a-9b21-480190928ae5" continuedAt="ie7076365c00049e8a21a7e902365781c" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ie7076365c00049e8a21a7e902365781c"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNjgw_8244bc4c-ae20-4404-ac29-57804b346a32" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of September&#160;30, 2020 and December&#160;31, 2019 are as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:74.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMS0xLTEtMS0w_1b7c2d8b-fa37-45d7-aa54-1371b8e0b8bc">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMS0zLTEtMS0w_c8891c37-3807-452a-9aaa-684df4767880">2,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMi0xLTEtMS0w_4e2e221c-3f9c-4989-895b-9042d93ff83d">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMi0zLTEtMS0w_4ed24cdd-9673-490c-8c3f-994ff6c96399">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMy0xLTEtMS0w_254d5f88-ec06-4328-a1eb-3becd67cc3a4">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMy0zLTEtMS0w_98ced0ba-71e4-4d09-8c74-b3ae9d13751f">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="rmti:CurrentAndNonCurrentInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfNC0xLTEtMS0w_e56c6151-5214-45c8-ad8c-9d22d8105850">4,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="rmti:CurrentAndNonCurrentInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfNC0zLTEtMS0w_aaf570ca-bc72-4b0f-8658-181182a1f27c">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we classified $<ix:nonFraction unitRef="usd" contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMTE5_354a7f61-fcba-40fc-bb34-62bede8da8b2">0.9</ix:nonFraction> million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of September&#160;30, 2020, the total Triferic inventory was $<ix:nonFraction unitRef="usd" contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzE0_d2a64fe3-4e7a-489c-b3b7-df3e266a6470">3.8</ix:nonFraction> million, against which we had reserved $<ix:nonFraction unitRef="usd" contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzQ4_cd994f70-9ea4-42fb-bfdc-8c3a849b3e1e">2.7</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzU2_24c13d9d-4388-4597-9fa0-265039dfe81e">1.1</ix:nonFraction> million net value of Triferic inventory consisted of $<ix:nonFraction unitRef="usd" contextRef="ib11597e3775d4b5f9e6494de29d10293_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNDA0_0c48d718-73e5-4722-a100-e8ac6b9c7112">0.1</ix:nonFraction> million of Triferic Dialysate finished goods with expiration dates ranging from December 2020 to May 2021, $<ix:nonFraction unitRef="usd" contextRef="i5bd74d8095764a1eb76ef37b3b5b33ae_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNTA2_f5d37b68-6319-4078-a7f5-064f4eb22ae3">0.3</ix:nonFraction> million of Triferic API with estimated remaining shelf life extending through 2021, and $<ix:nonFraction unitRef="usd" contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNTg5_9332c4f9-e41f-4aa3-b945-1ccfe18805b3">0.7</ix:nonFraction> million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjUx_036e8cf3-0ead-440e-be70-b75e891b51a9" continuedAt="i47cc9f0fa96e49e3b6a00a5a56a77182" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i47cc9f0fa96e49e3b6a00a5a56a77182"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjUy_cbf84d31-5456-4f0b-af41-d4d0ce827469" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia59f19af41fc488a9449247c776c5edd_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMS0xLTEtMS0w_403c63b8-559e-45a3-afbb-bc22599ff023">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i490ec924f1484c5ab8de1f20a08eac2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMS0zLTEtMS0w_0bcc1484-332b-46eb-9fc1-5e5921f0de65">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i09ea955020dc4aeda5d463477492921f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMi0xLTEtMS0w_6e3dd796-c7c5-4999-b5b3-42702cb5aea4">5,454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i724d030ef47645d9b041ce7ef4a3f9fa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMi0zLTEtMS0w_f8c4c0d8-128c-441e-9770-a596cb7f8940">4,673</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology&#160;&amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7e7800000fe40fdb031acb81db02074_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMy0xLTEtMS0w_157d63b7-a356-4833-836e-cb4f55f364b4">1,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idcdae022f9c94d2cacaaf617ee81281b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMy0zLTEtMS0w_7adb3069-5a23-4cc5-b577-b02a17bf6df3">1,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icaf6b93155d0417884bb4a768fae1f99_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNC0xLTEtMS0w_57533263-9a87-49d6-a906-7bbc20342231">653</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied2d61a12cde4716914c1b6f8b1a5984_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNC0zLTEtMS0w_9df952d9-b504-41d1-ba9a-b89c1e840829">653</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNS0xLTEtMS0w_ed165561-2a93-45f3-a3a7-f06d7d4190d7">9,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNS0zLTEtMS0w_1903a94b-5fac-4abb-978f-a7c2991f4728">8,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNi0xLTEtMS0w_83f3c575-e9a3-471f-a1a5-05c2cc003c64">6,320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNi0zLTEtMS0w_24deb101-2e61-41e9-a3a1-ee42cca8dd30">5,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNy0xLTEtMS0w_a64358e4-2f55-4565-9d5b-ad4d2d5b46dc">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNy0zLTEtMS0w_58bc32d4-8121-4e6b-a608-f8d94a36241f">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended September&#160;30, 2020 and 2019 totaled $<ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMTgy_1ddac299-e225-43e3-8d88-c46ce3a7a91d"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMTgy_1fe52702-0bbe-465a-8bd9-5d3250bb3b41">0.2</ix:nonFraction></ix:nonFraction> million. Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 totaled $<ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjQ5_3e8ff51b-8afd-4143-bb89-26cc172a1202"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjQ5_cdc782a3-0c8e-4691-9f8f-23d4b8127475">0.6</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RleHRyZWdpb246YTkwOWFkMzQyOGU2NDAwNDllZjA3MGM4MmU2YmY5MzFfOTQ_d8ef7abc-be5d-41e0-90fd-1843d9fbae92" continuedAt="iff20606ceb024bfca5aa5e18372e5353" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="iff20606ceb024bfca5aa5e18372e5353"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RleHRyZWdpb246YTkwOWFkMzQyOGU2NDAwNDllZjA3MGM4MmU2YmY5MzFfOTU_0b40db73-3579-4355-8594-6a94b54fbc05" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research&#160;&amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMS0xLTEtMS0w_c9d3a0db-9e95-4988-93f7-60d9c353942e">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMS0zLTEtMS0w_3065c2af-6723-45a8-b281-58897c94b4bc">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMi0xLTEtMS0w_91769ab8-3d10-4a70-b34a-56b339151a8d">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMi0zLTEtMS0w_fa23d65a-4e90-4dd6-80e3-fa1ea01eeb74">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Legal Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMy0xLTEtMS0w_9bdffb1a-cc6a-473c-b212-802a1cd1a08b">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMy0zLTEtMS0w_4c61b517-9332-412a-8bd5-eb50e23b0c39">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Marketing Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNC0xLTEtMS0w_e048b6c9-3bf9-40fc-9ff8-4f7f09ad4739">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNC0zLTEtMS0w_b9bae5b6-c01b-4df6-bac9-db4b90b154d7">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNS0xLTEtMS0w_fce66b5c-7f55-4ca4-9927-28e16b94ea4b">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNS0zLTEtMS0w_a00d5e74-3440-4db5-912c-09619e3f5906">2,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNi0xLTEtMS0w_48e63a62-06b4-49b9-934f-d946a4eb4c6b">4,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNi0zLTEtMS0w_6d327680-efca-482e-8471-f3e091a81471">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="rmti:ContractWithCustomerDeferredRevenueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjg3Ng_0eeae032-42eb-46d1-86be-72811d3da635" continuedAt="ib26d485c122d4422ad3971bc9822996e" escape="true">Deferred Revenue</ix:nonNumeric></span></div><ix:continuation id="ib26d485c122d4422ad3971bc9822996e" continuedAt="i080b5622a80748dba1b6f0c6af669ee8"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031" decimals="-6" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTMy_1df9de6c-4c42-4674-8ee1-83a3e687856b">20</ix:nonFraction> million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="ic9ae312db51145cc9a83894a56a1cbb5_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQw_4a828cf0-c37d-4b5a-93e4-a0cf58e959e1"><ix:nonFraction unitRef="usd" contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQw_92f9ee07-6b23-4ab8-8204-43000c7a129d">0.5</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id517adcb738e4b869a1855cf0dc6e89c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQ3_bf9414b4-e389-42dc-a22d-185b03859e5f"><ix:nonFraction unitRef="usd" contextRef="ifbd0e24d44954042a9d519b591fd1314_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQ3_d0534de2-b164-43eb-a759-c8e908da72e4">1.5</ix:nonFraction></ix:nonFraction> million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Baxter Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTU2_08939702-caf2-4497-88bc-4f7b7171b1b1">7.7</ix:nonFraction> million as of September&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i52774d95e2b2417085a873bc7c2ef34f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTcy_3c6e66ca-56cd-4b23-952a-71bbdb0d2076">9.1</ix:nonFraction> million as of December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a &#8220;Refund Trigger Event&#8221; occurs under the Baxter Agreement, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from October 1, 2020 to December 31, 2021, Baxter would be eligible for a <ix:nonFraction unitRef="number" contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930" decimals="INF" name="rmti:DeferredRevenueBenefitPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfODcx_373e847f-507d-4f76-a2c3-b136a3ed1931">25</ix:nonFraction>% refund of the Baxter Agreement&#8217;s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020, Baxter would be eligible for a partial refund of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:PartialRefund" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTMxMw_ac5af178-c7b4-4434-b0b1-aeea965252f7">5.0</ix:nonFraction> million. In no event does the Baxter Agreement require more than one refund be paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ib51e33cf4bfd4008b1b122e6683c1a98_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTUzMg_2472c328-b8f6-48d3-a6f8-3c2cb00e8aa7">4.0</ix:nonFraction> million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="ie0427b48c8964f40b6989681e03bf46d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTY5Nw_7bbee17e-1cfa-4610-9dac-2ff04c202568"><ix:nonFraction unitRef="usd" contextRef="i259025889eae4268ae9b6e57e34ee6d7_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTY5Nw_c0174cc4-83db-47d8-afdf-9a8beeddef50">53,000</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if9668e4db871491a984f75bb8da0189f_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTcwNA_0bc09c94-8425-47aa-bfc6-357493599675"><ix:nonFraction unitRef="usd" contextRef="ic51b254d9485419498fa51735863171b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTcwNA_f5c9af91-2617-4cd3-b95d-ff0ea2eb3ca8">0.2</ix:nonFraction></ix:nonFraction> million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Wanbang Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="ie89138f962f14daa953625c2f528ae33_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTgxNA_0759f4c9-9aa6-43cc-b10f-43818e45d686">2.8</ix:nonFraction> million as of September&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i4bdc1b8fe88f47298e47838b329a17c5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTgzMA_a3d105c1-9a28-41a6-986b-c8c941377217">3.0</ix:nonFraction> million as of December&#160;31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i080b5622a80748dba1b6f0c6af669ee8"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma  Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i8f8d7d55df774d63a47aea6d31334501_D20200114-20200114" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjMxNg_cdbeb386-7c65-49c6-a530-b978e7551929">0.1</ix:nonFraction> million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate in India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="if753017f31704051a4c4bf411897fbe2_D20200701-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjgyMw_49e62233-1689-48a6-8f39-e4bda57f682e">2,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i49ae4f19c274445bb160007dae42042b_D20200101-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjgzMA_b65e1b71-32e9-4dff-831c-4910e70313f5">7,500</ix:nonFraction> during the three and nine months ended September&#160;30, 2020, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="i4718c450d0ef47158d07ef1e72752de0_I20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjc0ODc3OTA3NTA4MQ_b9e756ba-b0ee-4465-9e05-5bf4d117bda6">92,500</ix:nonFraction> as of September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i91abe0affe46442896b337be936db0c0_D20200907-20200907" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNjA0NzMxMzk1NzI0NQ_a1aaf8c5-e6ec-471e-8ad3-c7754627b49b">0.2</ix:nonFraction> million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and  Jeil Pharma, will guide the development and execution for Triferic Dialysate in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of <ix:nonFraction unitRef="usd" contextRef="i8ccd6e7c5ec24a5893a434fbdcebfbb4_D20200701-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTQ5NzU1ODE0NDcwNg_59aa8589-1997-4118-97a1-7eb83a3e16f5"><ix:nonFraction unitRef="usd" contextRef="i0eeaf45b733e4e779dfcac83f1129f11_D20200101-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTQ5NzU1ODE0NDcwNg_d9cc3d1f-91d6-497a-a632-7e0dccad424b">nil</ix:nonFraction></ix:nonFraction> during the three and nine months ended September&#160;30, 2020.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzg4Ng_027a497f-8d3d-48e6-afa9-f5ae1fdb7daf" continuedAt="ie1724a5e39284bc08cd7cb33ee2e805e" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="ie1724a5e39284bc08cd7cb33ee2e805e" continuedAt="ifa18decc4ebb406dabd3156372fa500d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDI2_97364b1f-6ab2-4c97-8fb6-b5077ba4be4c"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDI2_b445d91d-7341-4834-933e-3b6054e2cdb0">2,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDU2_38cd7456-0bb7-4349-bda7-2f361ddc392c"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDU2_e51701fa-99f3-43a1-aa4f-513f9a424603">0.0001</ix:nonFraction></ix:nonFraction> par value per share, authorized and <ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_162fb920-6c6a-4f90-b70b-6aee23e4af13"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_9470b901-1815-456e-96e0-5d61617f2350"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_94ba16c9-c285-405a-a852-4408e5e11cee"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_b2c6e3f7-9311-4c03-a846-f33a942b5505">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNTg4_c6a05288-a945-4a51-81b7-41da49dbe67c"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNTg4_d372388e-48c0-4a1b-b03b-730ffc457112">170,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjE1_4be43020-a2f3-47cd-bfdc-bc3d54bab6e4"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjE1_b75bc55f-bdbc-433a-aa0d-898cb40e7e00">0.0001</ix:nonFraction></ix:nonFraction> par value per share, authorized and <ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjU0_38bf8eef-abae-41ad-a71e-6fa44996423e"><ix:nonFraction unitRef="shares" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjU0_f66d9837-8c79-4924-aa69-9660057aef81">93,573,165</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjYx_c29c2ed6-efdd-4c47-8fde-ede1e43a1cfd"><ix:nonFraction unitRef="shares" contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjYx_deb51d24-786f-4167-9421-53535917babb">65,378,890</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering (or "At the Market" Offering)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell from time to time shares of the Company&#8217;s common stock through the Agent. The offering and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ice0831beb2ab467c80a2cd6478135fd1_D20190322-20190322" decimals="INF" format="ixt:numdotdecimal" name="rmti:SalesAgreementThresholdSaleOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMTA1MA_0bd73887-684e-4f48-bd54-3ac3777ecd91">40.0</ix:nonFraction> million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018,&#160;the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#8217;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes.&#160;The Company may suspend or terminate the Sales Agreement at any time.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjA0OQ_86011ddc-de88-4cbf-977e-f7020f0c0cbb">1,840,443</ix:nonFraction> of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjEzNg_a2ee3f58-4144-4907-98e8-7ec03c9fc18f">5,383,079</ix:nonFraction>, at a weighted average selling price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjE5Mw_acede774-94b7-428c-8d4a-fa470eb139cc">2.92</ix:nonFraction>. The Company paid $<ix:nonFraction unitRef="usd" contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjIxNA_4f3e0b3c-809b-439a-adb2-cc541ef4bf2b">309,479</ix:nonFraction> in commissions and offering fees related to the sale of the common stock. For the nine months ended September&#160;30, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjMzNw_a1a3a1ba-1ff6-41d6-94fc-a0e2f5e4ba0b">1,128,608</ix:nonFraction> of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjQyNA_b420fc08-c7de-4e11-ab33-8e1ed9d9378d">2,325,478</ix:nonFraction>, at a weighted average selling price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjQ4MQ_8089fe60-eea9-42cd-b68c-67b59fc67f8b">2.06</ix:nonFraction>. The Company paid $<ix:nonFraction unitRef="usd" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="rmti:PaymentsOfStockIssuanceCostsAndCommissionsFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjUwMg_d0877772-d512-418f-b116-355c19c7895a">63,000</ix:nonFraction> in commissions and offering fees related to the sale of common stock. Approximately $<ix:nonFraction unitRef="usd" contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:SaleofStockRemainingSalesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjU4OQ_89509765-8e22-4515-bb68-c1388a32978f">32.3</ix:nonFraction> million remains available for sale under this facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="ifa18decc4ebb406dabd3156372fa500d"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not required to sell any shares at any time during the term of the facility.  Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering of Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to <ix:nonFraction unitRef="shares" contextRef="i7f2b087a0e4f4228929a2c5ee622983c_I20200204" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzE4NQ_d2ae286d-efba-4129-a9ab-33e16b59b94f">3,670,212</ix:nonFraction> shares of its common stock, which included <ix:nonFraction unitRef="shares" contextRef="i05c8a3f51c2d4520bd74c294ecf97017_I20200204" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzIzMQ_4eb8ec26-d384-4dbb-a05f-70f8abe923de">478,723</ix:nonFraction> optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February&#160;6, 2020, the Company closed the sale of <ix:nonFraction unitRef="shares" contextRef="i041fa2ada3f74f73bd7d90fb6dfb76f2_D20200206-20200206" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzM3MQ_d2892353-8690-414e-91ae-c4d054794b5e">3,191,489</ix:nonFraction> shares of its common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if132963a047b41d2a24b8a07ea731b8b_I20200206" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzQzMw_b0430e48-5552-4a5a-a860-d88e9822aaf4">2.22</ix:nonFraction> per share (the "Offering"). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;19, 2020, the underwriter exercised its over-allotment option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ib5508c49bd924868bbf229130f33ee19_I20200219" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzU1Mg_7b3c98c0-98b4-4add-8db1-e8bf06a3eb73">478,723</ix:nonFraction> shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iab29bf3438904c79b711f873e3ceeb8c_I20200219" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzU3Ng_6c5d542d-7825-4869-9953-895ce580918e">2.22</ix:nonFraction> per share, which closed on February&#160;21, 2020. The Company raised a total of $<ix:nonFraction unitRef="usd" contextRef="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzY0MA_c43123dc-e165-4e7a-b76e-3506382c5837">8.0</ix:nonFraction> million, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzY2OQ_99b347f1-113d-48db-a539-eba73eae17cc">0.1</ix:nonFraction> million, relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;2020 Purchase Agreement&#8221;) with certain purchasers named therein, pursuant to which the Company agreed to issue and sell to several institutional and accredited investors in a registered direct offering, <ix:nonFraction unitRef="shares" contextRef="ia502bbba04754e9aba66622648340936_I20200923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTA5NQ_9596074a-099c-48f1-a068-27f8e8d04e47">21,818,544</ix:nonFraction> shares of common stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE0Mw_5dfe2f27-f458-4240-95e3-d66b2527754e">23,178,509</ix:nonFraction> shares of common stock (the &#8220;Warrants&#8221;) at a combined purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE1MQ_628151e3-808c-4356-862a-f12b6d88c9c2">1.51</ix:nonFraction> per share. Each Warrant is exercisable for <ix:nonFraction unitRef="shares" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUyOA_0a45764a-adef-4692-9877-d4debd595d93">one</ix:nonFraction> share of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjMyMg_908679d5-f87e-4284-a25f-0ae02a11a079">1.80</ix:nonFraction> per share. The Warrants are immediately exercisable and will expire on September 25, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offered to certain purchasers pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTEzMA_fec2abe9-3099-4df3-ac50-86aef5c28e50">1,360,265</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of common stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is sold to the public in the offering, minus $<ix:nonFraction unitRef="usdPerShare" contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE2MA_1cadddfc-ced4-4e5b-a83e-602cf151378d">0.001</ix:nonFraction>, and the exercise price of each Pre-Funded Warrant is $<ix:nonFraction unitRef="usdPerShare" contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE2OQ_1cadddfc-ced4-4e5b-a83e-602cf151378d">0.001</ix:nonFraction> per share. The Pre-Funded Warrants were exercised in conjunction with the issuance of common stock under the Securities Purchase Agreement. The Company received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjM3NA_fa3249d6-2cdd-4ffd-bc38-9b4189078441">35.0</ix:nonFraction>&#160;million in connection with the offering, before deducting placement agent fees and related offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjM4OQ_6d4fac02-8f2d-42af-950b-ac0e74e4197d">2.3</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder (together with its affiliates) may not exercise any portion of the Warrant to the extent that the holder would own more than <ix:nonFraction unitRef="number" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="4" name="rmti:ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQwMw_7127eb0c-8cd3-46ac-bd9d-8413c9e36a91">9.99</ix:nonFraction>% (or, at the holder&#8217;s option upon issuance, <ix:nonFraction unitRef="number" contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923" decimals="4" name="rmti:ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQxMA_25500372-e04c-4d3f-b9a6-4e7650bc534b">4.99</ix:nonFraction>%) of the Company&#8217;s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay H.C. Wainwright &amp; Co., LLC (the "Placement Agent") a cash fee of <ix:nonFraction unitRef="number" contextRef="ia502bbba04754e9aba66622648340936_I20200923" decimals="INF" name="rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQxNw_eec594a0-8483-49ef-820b-ba14ad4ec1e3">6.0</ix:nonFraction>% of the aggregate gross proceeds raised in the offering, minus $<ix:nonFraction unitRef="usd" contextRef="ia502bbba04754e9aba66622648340936_I20200923" decimals="-3" format="ixt:numdotdecimal" name="rmti:SaleOfEquityAmountPayableForServicesRelatedToOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQyMw_5b28d031-d8b1-4048-81f7-82fb74cefd14">420,000</ix:nonFraction> payable by the Company to a financial advisory firm for services related to the offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company agreed to pay the Placement Agent (i) <ix:nonFraction unitRef="number" contextRef="ia502bbba04754e9aba66622648340936_I20200923" decimals="INF" name="rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQzMw_7064d758-4c50-449b-a502-638a6f3e9d1c">6.0</ix:nonFraction>% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants through December 25, 2021 and (ii) <ix:nonFraction unitRef="number" contextRef="ia502bbba04754e9aba66622648340936_I20200923" decimals="INF" name="rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQzOQ_50a9ccbe-0f58-4ac2-a623-48ccb81f756d">4.0</ix:nonFraction>% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants subsequent to December 25, 2021. The Company also agreed to pay the Placement Agent non-accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-3" format="ixt:numdotdecimal" name="rmti:SaleOfEquityPlacementAgentFeeNonAccountableExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ0NQ_5d55137d-47e8-481d-b790-4ce8eeda6162">50,000</ix:nonFraction> as well as $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-2" format="ixt:numdotdecimal" name="rmti:SaleOfEquityPlacementAgentFeeClearingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ1NA_a7ea0d05-2a8f-4c13-a88a-98110bf83fd4">12,900</ix:nonFraction> for the clearing fees of the Placement Agent in connection with the offering.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the common stock for the 2020 Purchase Agreement as equity on the accompanying consolidated balance sheets as of September 30, 2020. The amount allocated to common stock was $<ix:nonFraction unitRef="usd" contextRef="i1fae665e3ecf4ecaa260ed16b9864327_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ3MQ_ad219307-0168-47b2-8f45-204f38a3ed04">26.1</ix:nonFraction>&#160;million. This allocation is equal to the total proceeds of $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ4Ng_e9a803b6-e2d0-4241-8614-bdf890ccee72">35.0</ix:nonFraction>&#160;million less the amount allocated to Warrants of $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUwMQ_fb469cee-6520-4f36-a858-f1fe9c79295e">8.9</ix:nonFraction>&#160;million and is also net of the direct and incremental costs associated with the 2020 Purchase Agreement of $<ix:nonFraction unitRef="usd" contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUxNQ_3e6c8ea4-b25d-46b2-87fb-8aa8227162d5">2.3</ix:nonFraction>&#160;million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the 2020 Purchase Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMg_5547e631-8270-449b-ae66-6ede540dee4d" continuedAt="i3ec41a452fad477a9c9cff6cecab57c4" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i3ec41a452fad477a9c9cff6cecab57c4" continuedAt="ia0f2ffb2bad84013be0473c3156a142f"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMw_8381af8b-ef60-4a71-bb6b-da552a5a5481" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and nine months ended September&#160;30, 2020 and 2019 as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC0xLTEtMS0w_22c142c6-63dc-4d43-be4c-94f733742abd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC0zLTEtMS0w_64005e50-a56b-4be1-b913-70546e439224">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC01LTEtMS0w_559b2ad0-c8ea-48cc-8772-9e38227d0c8a">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC03LTEtMS0w_edd2015c-7f3e-40b0-852a-1b558788a606">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS0xLTEtMS0w_6453742f-7e64-47f6-bd8b-a33acae5bda5">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS0zLTEtMS0w_2dde4109-4c88-4a3e-9feb-89213b8586a2">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS01LTEtMS0w_59046b5c-43ca-49b2-9890-e7afddd545f6">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS03LTEtMS0w_f4be3bd6-ff7d-4628-bf68-ca7fba847c98">1,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi0xLTEtMS0w_6e3e9018-b4db-4b33-93fc-cb02dfc7e03a">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9942ba6c87d84e62962ab243afb9c8b2_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi0zLTEtMS0w_d24c0e63-39eb-41f2-9c24-141849d7d2c6">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia1198ab5b58240dbb1f5bfeca60211a5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi01LTEtMS0w_773e13a6-21da-446c-b440-42644454c402">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7fd1a1eeb924cc5b1b07ab373a25223_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi03LTEtMS0w_f9ef313d-e3ff-4cde-81fd-52f83ec08c82">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC0xLTEtMS0w_026e0d46-a8dd-44dd-8f3e-b2ac12e458f6">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC0zLTEtMS0w_0c7f5ccc-1e58-4586-830d-6ef2c0276963">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC01LTEtMS0w_8b986f0b-d15f-4f5d-a9a4-314363c5832c">1,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC03LTEtMS0w_8c1e819b-c9aa-40c4-83ee-e1fb70cd7497">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS0xLTEtMS0w_64bc6ced-01a5-43c7-8d12-42d55b73dfff">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS0zLTEtMS0w_91ed52b9-1a13-4112-b5cb-9595b6b22088">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS01LTEtMS0w_70e59f06-bc3b-4845-85ff-a18dc1f7e6e2">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS03LTEtMS0w_e6ba897d-123b-4750-b699-d0b1fd11e244">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if383605b1d784fb1a8ff6c886fb8e59d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtMS0xLTEtMA_828bd7b5-db10-45b5-9c4f-66809f761996">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1c7e169bbaa94542ac7a76cb79b52918_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtMy0xLTEtMA_e2879e4b-f7bb-443f-96a3-15f3ac75aab1">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1daf26803ee746bc8aea3bb5e7e6adef_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtNS0xLTEtMA_1fa61485-07bc-40d5-98da-2e21bff8b71d">1,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id854eccd72ff423c94105e0747d833e3_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtNy0xLTEtMA_b6449643-cf80-4852-8aef-f9c6c1803e2b">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtMS0xLTEtMA_efd86b4b-0a65-4336-8cd7-85ed07648f3a">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtMy0xLTEtMA_b5fad535-deea-474d-b0de-a99fe4747685">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtNS0xLTEtMA_176ce488-3229-4509-9483-6ceab39b393c">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtNy0xLTEtMA_3d91e32a-6084-4caa-98f7-a2cfb615370d">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNg_9afad217-da41-4fd6-a09a-69b477cc54e7" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i62e59b988f854af6a2f19b812a92527f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMS0xLTEtMS0w_aec8d3d7-4a32-4017-b416-9a52eaf24bd4">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62e59b988f854af6a2f19b812a92527f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMS0zLTEtMS0w_1f83efc5-7a34-4494-b3bf-8747b709cbe2">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieb4dad30bf674f2b81a41e72d5349c55_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMi0xLTEtMS0w_6a1eda65-5895-48c4-ac41-56ff942c4a76">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb4dad30bf674f2b81a41e72d5349c55_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMi0zLTEtMS0w_176bf418-557a-4b6e-8cc4-fe96b3040196">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87ac32bf162f4c268157cf1641fa843a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMS0xLTEtMS0w_3acabd80-8da7-4eaf-b214-5ed7bd816c61">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87ac32bf162f4c268157cf1641fa843a_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMS0zLTEtMS0w_c5b6f091-49de-402a-9efa-9f82e7407261">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMi0xLTEtMS0w_c0eac8b5-e439-4b23-a121-2418d9dbcd70">146,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMi0zLTEtMS0w_9a094b87-fbf4-49a5-b361-6a83c010e53c">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of <ix:nonNumeric contextRef="i6646233751964c4fb0aa59ba0eda8b5e_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTA1_956e0242-b8b6-47bf-ad45-4161cd64fcbe">20</ix:nonNumeric> months. As of September&#160;30, 2020, unvested restricted stock awards of <ix:nonFraction unitRef="shares" contextRef="i8f27d81d3cfe41f691685d6efd73d522_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTU1_1d02e149-f9c2-49f8-b609-b1aa668542b0">146,800</ix:nonFraction> were related to performance-based awards.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia0f2ffb2bad84013be0473c3156a142f" continuedAt="i314342cf231441a9a60cfdac965d1920"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><ix:nonNumeric contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNw_c100cd3c-99d7-41a7-973f-09a932decf9b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMS0xLTEtMS0w_d2232ad6-d08c-4c58-a15c-cc69598e84fd">463,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMS0zLTEtMS0w_967f224b-ad43-429b-8093-15c123444cbf">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMi0xLTEtMS0w_0e6455d8-118e-45b0-aea7-9b6fe7da9e8b">188,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMi0zLTEtMS0w_a582ff66-133a-4db0-acb8-c9542d0ddd36">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMy0xLTEtMS0w_fdcf4c2f-cb77-4eec-9b56-8f05b2aeb133">247,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMy0zLTEtMS0w_34735c33-b1f5-4315-81fe-e8fd8a71cd80">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNC0xLTEtMS0w_f5000ab7-46ac-47eb-aca4-22e71253a4cb">159,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNC0zLTEtMS0w_c87b765c-924b-4011-a493-35e82b2b0529">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNS0xLTEtMS0w_d12ecadb-d448-4dca-b125-b27c8084cab9">245,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNS0zLTEtMS0w_75029e95-ca61-4336-a3ab-770cbf27408e">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6551685fb24049b682909f7a5086db3f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMS0xLTEtMS0w_1f9b22e4-82f3-44fd-9ff3-01111c63f4ed">472,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6551685fb24049b682909f7a5086db3f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMS0zLTEtMS0w_a38bcebf-9d6e-426e-a6ef-acd5b5f0a411">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMi0xLTEtMS0w_a00bb50a-cdf6-4e01-9b7a-6ba786ea9b93">222,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMi0zLTEtMS0w_06c86115-1caa-409c-8987-28ba4c7faf3f">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMy0xLTEtMS0w_d7fb8a7d-a222-425b-b529-651b89d19b6d">4,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMy0zLTEtMS0w_39471782-4a67-4213-8d44-9901df4358f6">4.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0xLTEtMS00MDQ_40d2ccc0-ecf2-4881-84c3-c5503b384f80">96,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0zLTEtMS00MDg_2f6f812e-b631-461a-9560-af52afb36da4">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i10f9f4004419417e9412857f5acd3c8b_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0xLTEtMS0w_12fbdc2e-24f1-4782-ae18-25a5696e422b">593,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10f9f4004419417e9412857f5acd3c8b_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0zLTEtMS0w_586445cf-80fa-4429-bfc9-e92ec0fb98f1">4.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service&#160;based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from <ix:nonNumeric contextRef="icf4a248d9fbf4a9dbd4e6806f7db82dc_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA0Ng_29147244-ad1f-4755-af61-ebd2465e0e38">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i5579dd55e4b6461ba7c91e665d52fee3_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA1Mg_7441dac4-4da5-4071-b42e-543c11cdb322">3</ix:nonNumeric> years. Stock-based compensation expense of <ix:nonFraction unitRef="usd" contextRef="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA5Mg_f5508d19-b839-47e7-aff6-ac4e82fec0dc">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA5OQ_acd5ab75-f03a-4a16-9ae3-f518f2726bdc">0.2</ix:nonFraction> million was recognized during the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTE5OA_66286be8-2a19-4e40-b2b7-614292e2b8dd">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTIwNQ_9cf26cdd-8018-40d7-b6bb-f7f8da26f0b5">1.3</ix:nonFraction> million was recognized during the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, the unrecognized stock-based compensation expense was $<ix:nonFraction unitRef="usd" contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTMzMg_bf90550e-53ca-4c4d-b1f0-23a68a503aea">0.3</ix:nonFraction> million, which is expected to be recognized over an estimated weighted average remaining term of less than <ix:nonNumeric contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTQyNA_25dfa33c-0f1a-4998-aa1c-20f900ab9494">1</ix:nonNumeric> year. Included in the forfeited service-based restricted stock units are <ix:nonFraction unitRef="shares" contextRef="i8a801e210d094fa18659b7a2f0a4f400_D20200417-20200417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTQ5NQ_eda83b6b-c6db-416c-8fdf-8d27aecce13f">96,541</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idcb8a240bd284c4e9463f5dd7b8a6c70_D20200703-20200703" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NjEzMQ_fb8bce1a-9d5e-42ab-b287-f38adc6cd003">55,556</ix:nonFraction> units related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the former Chief Financial Officer on July 3, 2020, respectively. These forfeited awards reduced stock-based compensation expense by $<ix:nonFraction unitRef="usd" contextRef="i6efe4199c6e74202909ae855d11ce621_D20200417-20200417" decimals="-5" format="ixt:numdotdecimal" name="rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTY3OQ_75159b14-7903-4fe2-9a38-c114b3f3a7ab">0.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><ix:nonNumeric contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxOA_6b4ab492-d4d0-493d-924a-24d86bc3bd24" continuedAt="i20010e02b32a402a97216d1f7f4fc271" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i909683c4233b4a22804c27ebf1e6c92b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMS0xLTEtMS0w_98bed087-c2d1-421e-9994-c27e59404b26">988,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i909683c4233b4a22804c27ebf1e6c92b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMS0zLTEtMS0w_ff280253-58f7-4839-8f67-cec86fabee1e">4.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMi0xLTEtMS0w_c606bfa4-1d67-4656-bcae-3c5f025e63ce">988,958</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMi0zLTEtMS0w_4445a93a-20b1-45ac-9788-60dcf69eb563">4.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMy0xLTEtMS0w_6efa3812-14cf-4357-98ff-cbe2d537afa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMy0zLTEtMS0w_25b22fe1-0521-41db-8ed2-15666ae6174c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i314342cf231441a9a60cfdac965d1920" continuedAt="i151737a798bd433a8025b2cc702b6ca9"><ix:continuation id="i20010e02b32a402a97216d1f7f4fc271"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i564592058228420b94ffbc322e7090c4_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMS0xLTEtMS0w_a571d75e-3b66-4fc4-a0c0-23d5f43ad966">988,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i564592058228420b94ffbc322e7090c4_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMS0zLTEtMS0w_86df8a00-ee5a-42fe-ae76-9d2379b1f722">4.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6606daf6bf13495a89c4cb1a8572fecf_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMi0xLTEtMS0w_5695007f-a014-4ae1-9e56-dff7a93acdfb">988,958</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6606daf6bf13495a89c4cb1a8572fecf_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMi0zLTEtMS0w_338da928-92f0-4639-955a-ae957d9f8591">4.48</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based restricted stock units was ($<ix:nonFraction unitRef="usd" contextRef="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA1MQ_de04c420-30ce-4dd1-9672-63bb51d9326f">0.1</ix:nonFraction>) million and ($<ix:nonFraction unitRef="usd" contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA1OA_7548598a-62d7-40ed-9e69-d4e209946fff">1.1</ix:nonFraction>) million during the three and nine months ended September&#160;30, 2020 and ($<ix:nonFraction unitRef="usd" contextRef="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA5NQ_84e6e78f-c298-438d-9ffe-842878845838">0.3</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjEwMg_9bcfddee-cfa9-42a7-92b0-0a479edf63ed">0.5</ix:nonFraction> million for the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTQ3OQ_fecfc325-0abb-45b8-985c-f2b06cbc340d">no</ix:nonFraction> unrecognized stock-based compensation expense related to performance-based restricted stock units. The forfeited performance-based restricted stock awards of <ix:nonFraction unitRef="shares" contextRef="i0c9890f223334395a55787fcbfde8291_D20200417-20200703" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjQxOA_fac51f0b-6d39-4f46-96b8-0ab7a8096740">988,958</ix:nonFraction> is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense for the three and nine months ended September&#160;30, 2020 by $<ix:nonFraction unitRef="usd" contextRef="ie0fd29e788d64550b340302d86755201_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjU5NQ_83f318ec-5795-4b87-bbcc-13fa9e434be9">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51825a238efa425a9b7252dd4452dcdd_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTQ4OA_a6fb42ba-cc59-428f-ac47-b20439aa3d55">1.4</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxOQ_279d8914-015c-456d-9ea1-ac7ebca6fdb6" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the nine months ended September&#160;30, 2020 were based on the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibfccd25c8636494a85d9d1d3f1d09ba3_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMS0xLTEtMS0wL3RleHRyZWdpb246MWVjYWM4OTFkNmRhNDM1Yzg5MWUxMTU0NjA3M2Q5NjFfMzg0ODI5MDY5NzIzOA_fd10dfd3-a995-4f7d-b11d-c2f1ce16efe5">1.17</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i2b5bdfb4ab9b4caa9c0806d213fcfb9a_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMS0xLTEtMS0wL3RleHRyZWdpb246MWVjYWM4OTFkNmRhNDM1Yzg5MWUxMTU0NjA3M2Q5NjFfMzg0ODI5MDY5NzI0Ng_bb5b436d-556e-4450-9ef3-51fed073e45a">2.90</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMi0xLTEtMS0wL3RleHRyZWdpb246NWQyZDFjNmVjNDg4NGRjZjljOWExN2I3OWI3ZjY3ZDZfMzg0ODI5MDY5NzIzOA_33bce73d-6477-4403-a96d-caed6eda62be">68.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMi0xLTEtMS0wL3RleHRyZWdpb246NWQyZDFjNmVjNDg4NGRjZjljOWExN2I3OWI3ZjY3ZDZfMzg0ODI5MDY5NzI0Ng_2c161600-8b62-4142-9cbd-3b1ff8f9554f">75.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMy0xLTEtMS0wL3RleHRyZWdpb246YTVmNDkxZmFlMjU2NGE1ODliYTZkMWVhZDY5NTgzM2NfMzg0ODI5MDY5NzIzOA_d83c2121-a073-4159-8f11-66c157743ba2">0.31</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMy0xLTEtMS0wL3RleHRyZWdpb246YTVmNDkxZmFlMjU2NGE1ODliYTZkMWVhZDY5NTgzM2NfMzg0ODI5MDY5NzI0Ng_e6483552-0cbb-4c0e-8400-8da0932ce7c7">1.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e2d2e0642bf45b09fe5f2a6bfa06696_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1Zjc4ZjkyMTY4NDlhOWJkZGZhMzcwMGRlYTNhNTJfMzg0ODI5MDY5NzIzMQ_d18003ee-ea03-4ab3-bf7e-0da692c062b0">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="i07d733cb7a0441e9ae832f027f97a0a6_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1Zjc4ZjkyMTY4NDlhOWJkZGZhMzcwMGRlYTNhNTJfMzg0ODI5MDY5NzIzOA_35431f5a-91e9-4286-80dc-9259d87bf710">6.0</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMA_937103b4-43b5-43bf-8dd4-c1cc9475b3f6" continuedAt="i1341cf08fa4b428ab18b8931374ef506" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS0xLTEtMS0w_ff2e4092-0639-4efa-a160-2d619200055e">8,210,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS0zLTEtMS0w_28dabc7f-98fb-490e-8c85-223a6bf1fe40">7.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1282277c8624ede8e591db387da49dd_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS01LTEtMS0w_11db5ebd-2360-4fc9-83bc-f83001b816e2">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS03LTEtMS0w_2853ce24-4845-4f90-8e35-edeb90f24296">107,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi0xLTEtMS0w_d07a2589-f33e-4b53-a8e9-a77b0437d5a5">2,252,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi0zLTEtMS0w_470c1b4d-5e27-4eb8-b088-f27ab8ea9bf2">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" format="ixt-sec:duryear" name="rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi01LTEtMS0w_366e9af5-b3f5-4fb4-a8ac-794f0b583f91">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNC0xLTEtMS0w_0df79c49-b15d-415a-9d5b-4574def2f679">440,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNC0zLTEtMS0w_ce1a9afa-bf79-4fad-afac-b5254775c578">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNS0xLTEtMS0w_0dbba6bf-f705-49b8-a0de-bbbb6e0a9cf8">4,090,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNS0zLTEtMS0w_059ed9c7-5675-4397-84f7-d0734cd219e2">8.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi0xLTEtMS0w_f3b08667-1c6c-4660-b970-7115305f0318">5,932,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi0zLTEtMS0w_364cc3b2-9e4c-4339-9b17-e9f385cba294">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi01LTEtMS0w_fb5c8108-6d3b-4100-9a52-90652ae121c1">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi03LTEtMS0w_03d05237-bd5e-4a7f-a1e7-992a73733e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC0xLTEtMS0w_ababc750-5923-40fc-a4ef-2ae4e2759181">2,889,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC0zLTEtMS0w_a017e088-1ab9-4f3e-a16e-95a6970ccc90">6.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC01LTEtMS0w_3d7bc692-c303-449c-8b4d-10a8a7070938">3.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC03LTEtMS0w_5f480627-303a-4131-b06c-16a5b977df62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i151737a798bd433a8025b2cc702b6ca9" continuedAt="i392802ae60a84ed6a69f80d2751cf6c8"><ix:continuation id="i1341cf08fa4b428ab18b8931374ef506"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS0xLTEtMS0w_6e0beb0b-0dfe-4581-85a9-2a0d75e45348">7,856,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS0zLTEtMS0w_5dac6ee1-438b-41f4-9b18-ab6bc79df4ff">7.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i744dc4048e2e4f8794db00508bd3d7b5_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS01LTEtMS0w_029b06d3-85e1-46fb-a5d7-fac955ef0c12">5.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS03LTEtMS0w_7e29256d-6d31-49d2-8683-625f4970cb3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi0xLTEtMS0w_9efef392-3015-4f62-a408-607e92ccfa0c">576,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi0zLTEtMS0w_3864bec3-ceda-46ab-81bf-6bf6e99388d1">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" format="ixt-sec:duryear" name="rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi01LTEtMS0w_28ac9a87-beaa-4657-80d8-0ea0d8428287">9.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi03LTEtMS0w_ff88d8ae-3842-409c-8809-90ecda2a0637">12,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMy0xLTEtMS0w_bbb7cd79-bae7-44d1-8b83-718dc1ebd1f9">30,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMy0zLTEtMS0w_bb229b84-46e4-4958-aa95-1711fafdc074">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNC0xLTEtMS0w_bb1dd0ed-6e3c-4afa-9275-99b9865ff156">620,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNC0zLTEtMS0w_022ce076-77ee-4c4b-8cb4-2e532c980582">6.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS0xLTEtMS0w_a6ba9e59-6631-4d0a-8faa-b8a930d37813">7,782,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS0zLTEtMS0w_ed11ea6b-de10-484a-9910-03361689949d">7.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS01LTEtMS0w_7a3abbe1-46a5-4604-a262-e335301864c9">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS03LTEtMS0w_9a4b04e6-04b7-44e5-9df6-d501780e7ab0">12,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy0xLTEtMS0w_e828aaf6-6284-440e-9763-94b2054c5f32">6,340,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy0zLTEtMS0w_640203e0-34a7-4b03-9863-fe941c3bfa6e">8.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy01LTEtMS0w_751fd433-244c-42fc-8808-b847ffdefeef">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy03LTEtMS0w_ace568a3-6457-4749-b5f4-6a3fab779eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="i6cc0b7d956b44d84a62ad0c4ec9b6942_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTQ5NzU1ODE0NDc0OQ_d71081b6-b911-4e88-833c-56b0a8fd6a3e">2,252,344</ix:nonFraction> shares of common stock to certain employees. &#160;During the nine months ended September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTQ5NzU1ODE0NDc1OA_f6f79efb-ae06-4d0f-9a85-b299e924d2a0">440,026</ix:nonFraction> shares were forfeited. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $<ix:nonFraction unitRef="usd" contextRef="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzU1Nw_11397310-db49-4a17-b69f-e7501521de7a">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzU2NA_ef744c44-92a6-430a-a46a-83f1f082ec00">1.0</ix:nonFraction> million for the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense recognized for service-based stock options was $<ix:nonFraction unitRef="usd" contextRef="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzY4OQ_9ed9ca9a-f981-49ff-b55f-6d0fac155734">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzY5Ng_d52953f8-761d-40e4-b021-1391e3e4da42">1.8</ix:nonFraction> million for the three and nine months ended September&#160;30, 2019, respectively.&#160;As of September&#160;30, 2020, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzg1OQ_105b91c2-fa9b-4207-853f-1a3738dc22eb">2.8</ix:nonFraction> million, which is expected to be recognized over an estimated weighted average remaining term of <ix:nonNumeric contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzI5ODUzNDg4ODc0OA_2b8a5683-ef09-4487-a69d-832285f24ad9">2.4</ix:nonNumeric> years.&#160;Included in the forfeited service-based stock options are <ix:nonFraction unitRef="shares" contextRef="iaed2b90c22864608b60a3b3225ad1530_D20200417-20200417" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDAxMw_f899a692-c439-4b41-9c08-b2afa6c238ac">129,375</ix:nonFraction> unvested options related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and <ix:nonFraction unitRef="shares" contextRef="i6bb2ee2e447941fdb9ab2c2d6386827c_D20200703-20200703" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTUwMg_842ce612-b858-4aab-a406-c5438be9607e">222,222</ix:nonFraction> unvested options related to the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense by $<ix:nonFraction unitRef="usd" contextRef="i40d39c6c2580451195d91bed252a4a52_D20200417-20200703" decimals="-5" format="ixt:numdotdecimal" name="rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDIwOA_654f2d0d-38a5-4d17-909a-ea97915e45e2">0.5</ix:nonFraction> million. Included in the expired  service-based stock options are <ix:nonFraction unitRef="shares" contextRef="i885bcca89a364caf8262446d9b98366c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDI2OQ_b1ccd4a3-6cfd-4b9d-8cde-f1a8ce776eb7">3,783,335</ix:nonFraction> options related to the settlement with the former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. See Note 14 for further details.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Stock Options</span></div><ix:nonNumeric contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMQ_010e1f07-0f9d-4fe2-a19e-af321812ef2c" continuedAt="idd3df12332c345c8802a75154903a7ac" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i72f1121abfa849c8b1387a55992b3591_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMS0xLTEtMS0w_3c3e8eb2-c69d-4284-8261-b349d5c63c9a">388,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72f1121abfa849c8b1387a55992b3591_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMS0zLTEtMS0w_7ac6d377-0141-402a-ac9d-5d392ae717e6">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMi0xLTEtMS0w_e40d5da4-2d8c-45d9-88f7-5c7560d654cb">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMi0zLTEtMS0w_59d03fbc-9777-4977-b4d8-8fb5e0e0a826">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMy0xLTEtMS0w_aee061fb-f9c0-4429-a5b8-43d2d92c897a">388,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMy0zLTEtMS0w_e985067d-a597-4aab-ab9e-0011fe09a1e2">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNC0xLTEtMS0w_e42e8a59-56aa-4c04-b9c4-966574e988a8">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNC0zLTEtMS0w_b6fc9cb0-3945-44ef-8529-5a159f7454d8">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNi0xLTEtMS0w_5730d421-edde-43d5-b615-cf6235d75140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNi0zLTEtMS0w_120bc48a-61dc-4708-9d0e-6c8534e92a88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i392802ae60a84ed6a69f80d2751cf6c8"><ix:continuation id="idd3df12332c345c8802a75154903a7ac"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMS0xLTEtMS0w_e6b03449-a525-432b-a4a7-35ef392593cc">388,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMS0zLTEtMS0w_afdf57fe-169e-4488-8952-983b6369653b">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMi0xLTEtMS0w_a24198e6-b671-4e32-a8c7-77d07f9972a0">388,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMi0zLTEtMS0w_7026dd80-5a85-41aa-81de-b534af24b6c8">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfNC0xLTEtMS0w_0a7e1d90-00e8-4fed-a5fe-f7d5c5cdf470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfNC0zLTEtMS0w_ecc8465a-2757-4ccf-b27d-0e1b516fcdca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based stock options was $<ix:nonFraction unitRef="usd" contextRef="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDc4NA_0f0cae9e-1a56-44d5-ae62-9439123c3f9d">0.1</ix:nonFraction> million and ($<ix:nonFraction unitRef="usd" contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDc5MQ_fcc8cdde-5de3-4fad-906a-2867a7d5acce">0.4</ix:nonFraction>) million for the three and nine months ended September&#160;30, 2020. Stock-based compensation expense recognized for performance-based stock options was $<ix:nonFraction unitRef="usd" contextRef="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDkwNg_5fe76d11-f978-4df9-8ffe-1a8c49148a97">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDkxMw_cd6d24c1-2d1b-4ce3-9d86-bfcf8fcca078">0.4</ix:nonFraction> million during the three and nine months ended September&#160;30, 2019. As of September&#160;30, 2020, the unrecognized stock-based compensation expense related to unvested performance-based stock options was $<ix:nonFraction unitRef="usd" contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTA3NA_abb53d11-940e-4648-9d20-561a7a5bedd3">0.4</ix:nonFraction> million. The forfeited unvested performance-based stock options of <ix:nonFraction unitRef="shares" contextRef="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTEzNg_b1195cd6-ca56-4b2f-bcf6-feae2be293ad">388,125</ix:nonFraction> is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited options reduced stock-based compensation expense by $<ix:nonFraction unitRef="usd" contextRef="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417" decimals="-5" format="ixt:numdotdecimal" name="rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNA_4e44bbbc-d47c-476b-afd9-bc9b1939d36f">0.7</ix:nonFraction> million.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjMxMA_e4c5b834-c324-424d-9d7d-246358d16754" continuedAt="ic2e7ce48543646c7aede0eccb53130d5" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ic2e7ce48543646c7aede0eccb53130d5" continuedAt="ifeb86380f084481e866a104fb5e87462"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic&#174; product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the &#8220;Charak MSA&#8221;) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into <ix:nonFraction unitRef="agreement" contextRef="i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007" decimals="INF" format="ixt-sec:numwordsen" name="rmti:NumberOfAdditionalAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNTY2_47a1f954-b59a-4c28-a472-ee388bbad32b">three</ix:nonFraction> additional agreements described below related to the license of certain soluble ferric pyrophosphate (&#8220;SFP&#8221;) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provided for a payment of $<ix:nonFraction unitRef="usd" contextRef="i8b2db876957c441ca0969f774801ddfa_I20181007" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODEx_72d4d4f5-5121-4e83-9065-75b6afafc799">1.0</ix:nonFraction> million to Dr. Gupta, payable in <ix:nonFraction unitRef="installment" contextRef="i2362cb7d4e704216966ce8696c3475f7_D20181007-20181007" decimals="INF" format="ixt-sec:numwordsen" name="rmti:RelatedPartyNumberOfInstallmentPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODM5_0000b8f7-fb79-4bcc-bbf8-9a074b38ff32">four</ix:nonFraction> quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="i759a54d69ef1425aa8087f8817c5243c_I20181015" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_5a0a84a5-2a68-4686-8c34-505af79cca4b"><ix:nonFraction unitRef="usd" contextRef="i2cc86daf3763428e93f171eb558edf4a_I20190115" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_7a73458c-626d-4e94-a4ac-ca7b5ad7c760"><ix:nonFraction unitRef="usd" contextRef="i9b5fafdd17b044d38ca4687c5c170b5b_I20190715" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_c7928de6-39bf-4306-b350-395753265c8c"><ix:nonFraction unitRef="usd" contextRef="id6a755fb188b4af39fd3307f039573d2_I20190415" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_d25232a2-4675-42f3-b427-d84055d92eaf">250,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i79757255bddd4b608922f96cd3af93ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="rmti:InstallmentPaymentToRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTIyNg_ce96be25-2cb5-436f-8c35-d82a155bf926">1.0</ix:nonFraction> million and accrued $<ix:nonFraction unitRef="usd" contextRef="i79863bdc8a984b328ab874faf1c4b1cf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="rmti:RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTI0MQ_603cdcd2-8a26-4e99-aa5f-a545c1204885">0.1</ix:nonFraction> million for the reimbursement of certain legal expenses during the year ended December&#160;31, 2019. As of September&#160;30, 2020, the Company has fulfilled its reimbursement obligation of certain legal expenses and accrued $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTQ4Ng_3629f0e0-57b7-440d-bfc7-e8fcd5bdbad6">0.1</ix:nonFraction> million relating to certain IP reimbursement expenses and certain sublicense royalty fees as a related party payable on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the &#8220;Charak Amendment&#8221;), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company&#8217;s Triferic&#174; product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic&#174; (now Triferic AVNU), dated as of October 7, 2018 (the &#8220;IV Agreement&#8221;), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ifeb86380f084481e866a104fb5e87462"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic&#174;, dated as of October 7, 2018 (the &#8220;TPN Agreement&#8221;), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN&#8221;) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 805)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Clarifying the Definition of a Business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $<ix:nonFraction unitRef="usd" contextRef="i5b7cf56169344015943de2cc62f7eab3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="rmti:PaymentsToAcquireAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjA0NA_5fe92358-e13e-43ac-82a5-e5ebf723d3ce">1.1</ix:nonFraction> million purchase price paid and accrued for these assets has been expensed in the Company&#8217;s statement of operations for the year ended December&#160;31, 2018. In addition, because the potential milestone payments are not yet considered probable, <ix:nonFraction unitRef="usd" contextRef="ic2985ad7b6c3459abea9cf473c3ffba0_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="rmti:AssetAcquisitionMilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjI2NQ_ca7baad7-7649-4dfe-826c-fee39cb5a675">no</ix:nonFraction> milestone payments have been accrued at September&#160;30, 2020.</span></div></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160; <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwNg_086cfe09-cf80-4748-87f2-1a76cf7ddf4f" continuedAt="ic07ae3c8654348c0a9e7d7658cd54e26" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ic07ae3c8654348c0a9e7d7658cd54e26" continuedAt="i6cdd7c60aa2a4c9e8b8fddbe62aa3ccf"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to <ix:nonNumeric contextRef="idfd4514ac70647b48f7ba3276ef1d345_I20200930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjUy_426c0274-915a-49be-9228-bce9a9007330">five years</ix:nonNumeric>. We occupy a <ix:nonFraction unitRef="sqft" contextRef="i3145caf8d4884ddf8790d54cebdc6132_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjY4_751161ca-8295-436b-9934-bfd05b6d920b">51,000</ix:nonFraction> square foot facility and a <ix:nonFraction unitRef="sqft" contextRef="iffda10ef89254fc8b784470695ac1a39_I20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjk4_f9d81c50-0beb-43e5-a04c-39ae74d5209c">17,500</ix:nonFraction> square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a <ix:nonFraction unitRef="sqft" contextRef="i1a68746f2fdd4216add87ba69b052f3f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNDMz_4af7097d-6590-44c5-b3d8-c2bd1c6ece38">51,000</ix:nonFraction> square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a <ix:nonFraction unitRef="sqft" contextRef="idc4ac606416e4e319806c6b97ba5e4a9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNTI0_65826efa-a38f-4f2b-a801-3e276aa12ea1">57,000</ix:nonFraction> square foot facility in Greer, South Carolina&#160;under a lease expiring February 2023. In addition, we occupy a <ix:nonFraction unitRef="sqft" contextRef="if68138705a9e4ae8b0ad29ba0248671c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNjM2_2d8b69ab-1b78-4da6-9996-cde6d619bc82">1,408</ix:nonFraction> square foot office space in Greer, South Carolina under a lease expiring April 2021. Finally, we executed a lease for <ix:nonFraction unitRef="sqft" contextRef="i656a4eb3707c4c909af7978cd89b8b65_I20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNzYx_e77e2545-6b20-45ca-afdf-de36a8d135ea">4,100</ix:nonFraction> square feet of office space in Hackensack, New Jersey with a lease term beginning on April 1, 2019 and expiring on July 1, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company had operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfOTQ3_4dc00ebf-dfee-459a-8d7d-f1c60f468747">2.2</ix:nonFraction> million and right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfOTc3_27bdb151-9b39-4127-91f9-b354f6e8a6b4">2.1</ix:nonFraction> million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwNw_f1e769bf-a3c0-4bf2-99d6-bc370738cf24" continuedAt="iefba079c0bab436eb03b0c4ca7576145" escape="true">The following summarizes quantitative information about the Company&#8217;s operating leases (table in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6cdd7c60aa2a4c9e8b8fddbe62aa3ccf"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="iefba079c0bab436eb03b0c4ca7576145"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:44.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi0xLTEtMS0w_d3f971c2-dc2a-49af-b6cd-36abdd664522">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi0zLTEtMS0w_09c64a32-90b4-4cc0-8634-0d5bd9d30526">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi01LTEtMS0w_12f4f8ab-2484-4513-bbc5-89c0a8ae8214">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi03LTEtMS0w_27411385-e248-4257-8eab-8d8b9673d73e">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy0xLTEtMS0w_00dfb168-2a53-42e8-abe5-597fad0baa9d">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy0zLTEtMS0w_921fe085-e380-4469-97fc-9aea2b68b1cf">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy01LTEtMS0w_b158b5a5-5d16-40a3-bdad-ec2709e475ee">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy03LTEtMS0w_4eff18d4-eafc-4ad4-83aa-910ed0be653c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC0xLTEtMS0w_6b521346-055b-4c5d-bffb-421fda3499e0">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC0zLTEtMS0w_36faafbe-e60c-4a31-b41f-814f990e6762">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC01LTEtMS0w_541072ad-4edf-47e8-9c03-bf2d5ed13b3f">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC03LTEtMS0w_98b824ba-e24d-4a80-a099-6e027482830a">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS0xLTEtMS0w_d8f80754-13de-4040-a250-150bf69dc58b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS0zLTEtMS0w_430b86c6-435f-4fb1-a93c-b34fd982bdb2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS01LTEtMS0w_2db5ed2d-e0ca-4dc9-8f49-e571f250cf67">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS03LTEtMS0w_b82c6aef-f9d3-4898-999c-e1bf4dc6b755">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi0xLTEtMS0w_2b8d546f-7c8e-4cc4-aaee-031e245336b9">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi0zLTEtMS0w_c8c977c0-19f9-43af-b81d-f478be6df67f">626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi01LTEtMS0w_f652673e-a003-43c0-aa08-7b78cd843266">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi03LTEtMS0w_240997dc-e2c7-4f62-abe1-913550af995b">1,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS0xLTEtMS0w_deb64223-f1c2-4884-a8aa-fd2a5ff8534a">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS0zLTEtMS0w_ca9452ad-4290-4dda-a024-cbb1f203d4e7">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS01LTEtMS0w_ff03bf99-9881-4d7e-b209-f7fbdcf035cd">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS03LTEtMS0w_227ab767-68a9-44b8-8e3f-f68788ea52e1">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtMS0xLTEtMA_33096f18-53d4-4920-931b-bd22cb514d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtMy0xLTEtMA_51a094ac-3060-4151-99db-fa1d160f75fa">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtNS0xLTEtMA_97f9e0fb-394c-4e8a-bcde-cb73fd661698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtNy0xLTEtMA_de8f8823-2d3f-4dc0-86c2-37d6e53a4179">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term &#8211; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtMS0xLTEtMA_758556e1-c65b-4ff2-96e4-258561df0727">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtMy0xLTEtMA_27e375ab-90b2-469a-bf58-8553003df2f1">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtNS0xLTEtMA_44a24fba-d12d-4724-bb80-b599fa1d2f04">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtNy0xLTEtMA_14762af6-2b92-4679-9e84-ebc58d30b53f">1.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate &#8211; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItMS0xLTEtMA_f9231bd7-82d5-4a1b-be5f-4ed566852d9b">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItMy0xLTEtMA_ef2b8229-60fb-45e6-8f8c-c2b2081d6a5a">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItNS0xLTEtMA_a77ed023-b68d-4b44-81bd-4436095b41a4">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItNy0xLTEtMA_7edc41e2-117d-4d63-87f2-a151cc83fa26">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwOA_d3613aa3-cfc8-4624-ba2a-2fb3887cb1eb" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2020 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMC0xLTEtMS0w_3b31f111-7949-43b9-9867-7bc7db762c8d">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMS0xLTEtMS0w_28f6ef6f-468c-426b-be21-a70cad7a0b23">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMi0xLTEtMS0w_359c5e2d-3169-4cc8-b156-a197a046311f">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMy0xLTEtMS0w_2e041719-033b-43b5-be5c-d96cc3707103">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNC0xLTEtMS0w_c8fc04e7-d38b-4530-b2c4-230a0efa1ebb">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNi0xLTEtMS0w_5bcc2c45-39cb-4101-8427-cbc80bbf0ceb">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNy0xLTEtMS0w_17e465a7-3e01-404d-8582-325d5cd3d666">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfOC0xLTEtMS0w_3face530-b544-400b-9599-ba3bdfc320b9">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if43c117d09de4ff289c1029a77c923e4_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;<ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNzk1NA_188d8371-310b-4eaa-b792-1ddfe80696f5" continuedAt="ia6bea041e98b49b2ba71156ec9d4fa2b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia6bea041e98b49b2ba71156ec9d4fa2b" continuedAt="i8e5314be7e564bdfa8ce4051059620dd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Demand Notice</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015.&#160; The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested&#160;$<ix:nonFraction unitRef="usd" contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfMzA4_ba1388aa-21a0-4ce8-b963-2bb5cc94c9f0">3.0</ix:nonFraction> million&#160;in penalties, plus payment of the cost for certain raw materials.&#160;While the Company believed&#160; it had several defenses to the supplier's claim, the Company and the supplier negotiated an amicable resolution of the dispute.&#160; On July 31, 2020, the Company and the supplier entered into a settlement agreement, which released the Company from any penalties relating to annual minimums under the 2015 agreement, established new minimums under an amended supply agreement and required the Company to pay for certain raw materials with <ix:nonFraction unitRef="number" contextRef="id7bf20809ab9443ebd612edde24ebe08_D20200731-20200731" decimals="INF" name="rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfODYz_b96f333f-9bca-4ca8-815c-285c9b9456f1">50</ix:nonFraction>% of the cost to be paid upon execution of the settlement agreement and the remaining <ix:nonFraction unitRef="number" contextRef="i1d16d753feea42379fc36a6fc4802303_D20200801-20201231" decimals="INF" name="rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfOTUw_88bda84c-8d5c-4710-ae13-442414b5a989">50</ix:nonFraction>% to be paid no later than December 31, 2020. As of September 30, 2020, the Company has purchased <ix:nonFraction unitRef="number" contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930" decimals="INF" name="rmti:SupplyAgreementPercentageOfRawMaterialsPaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfMjc0ODc3OTA3NzcxOA_abcf0799-3b5d-4ab7-92e1-b95c1924461c">50</ix:nonFraction>% of the required raw materials under the settlement agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company&#8217;s&#160;quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8e5314be7e564bdfa8ce4051059620dd" continuedAt="ieda3aa58adc742d1877d02cfb07ac6b5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the status of the Company&#8217;s request to the Centers for Medicare &amp; Medicaid Services (the "CMS") for separate reimbursement status for Triferic Dialysate, the Company&#8217;s reserving methodology for expiring Triferic inventory, and the basis for the Board&#8217;s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC&#8217;s requests for documents and information.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Class Action Lawsuits</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company&#8217;s drug, Triferic, to quality for separate reimbursement status by the CMS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company&#8217;s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company&#8217;s proposal for separate reimbursement for Triferic; misstated reserves in the Company&#8217;s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company&#8217;s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company&#8217;s business were&#160;materially false and misleading.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ah Kit Too v. Rockwell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;securities class action with the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spock v. Rockwell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;securities class action.&#160; On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel.&#160; On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company&#8217;s securities between November 8, 2017 and June 26, 2018.&#160;&#160;On February 18, 2019, the Company answered the consolidated amended complaint.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action.&#160;&#160;Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $<ix:nonFraction unitRef="usd" contextRef="ic43d3fec43e04417ac3e08e63a74b5a6_D20190807-20190807" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNDc5NQ_eca07ff5-4c5e-4ced-8185-c00f43f00bc9">3.7</ix:nonFraction> million (the &#8220;Settlement Amount") in exchange for a full release of all liability as to all defendants.&#160;This resulted in a settlement expense of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ia36da30ff01749b28487000f6715ba77_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNDk0OQ_1465c7af-e31b-4f6c-b18c-e5f200422e5e">0.4</ix:nonFraction> million&#160;for the year ended&#160;December&#160;31, 2019. Of the Settlement Amount, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i71d9fbef3e73446cbd0ee3d7923afae2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNTA1NA_41385c44-37a0-4316-8aae-464e09921f30">0.1</ix:nonFraction> million, which represented the remaining retention amount under the Company&#8217;s director and officer liability insurance policy as of September&#160;30, 2020. The remainder of the settlement amount was funded by the Company&#8217;s director and officer insurance carrier. The settlement was approved by the court on February 26, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Derivative Actions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the &#8220;Derivative Complaints&#8221;) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company&#8217;s current and former directors (the &#8220;Individual Defendants&#8221;).&#160; The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.&#160; The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls.&#160; The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors&#8217; trading activities, restitution, and attorneys&#8217; fees. &#160;The cases were consolidated.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="text-align:justify;text-indent:36pt"><ix:continuation id="ieda3aa58adc742d1877d02cfb07ac6b5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. On May 18, 2020, the Company, the Individual Defendants and the Plaintiffs (the "Settling Parties") entered into a formal Stipulation of Settlement, which memorializes the terms of the Settling Parties' settlement of the Derivative Complaints.  A hearing occurred before the court on August 10, 2020 and the court issued a final order approving the settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's director and officer insurance carrier has funded the settlement  on behalf of the Company.</span></ix:continuation></div><div id="if43c117d09de4ff289c1029a77c923e4_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM4OTg_4f1136d0-7cdf-45ca-a2af-99645901faa0" continuedAt="i0642b39a572a4f6ca552a8aff747fd82" escape="true">Loan and Security Agreement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0642b39a572a4f6ca552a8aff747fd82" continuedAt="ibbc9d1351e584aefb0ed795067f0fb56"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzQzMg_a828bd05-e505-426a-9434-2a58acc3f4c7">35.0</ix:nonFraction> million (the "Term Loans"). Funding of the first $<ix:nonFraction unitRef="usd" contextRef="i74badfe283474cd495162707af80f4c0_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzQ3Ng_96f87b04-374e-4a68-8065-badd23cdeb73">22.5</ix:nonFraction> million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $<ix:nonFraction unitRef="usd" contextRef="i550d13f16af14526aa4aba8c018e3653_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzU4MA_f1f73619-3106-4cf6-a43c-7cf7ac8f88f4">5.0</ix:nonFraction> million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $<ix:nonFraction unitRef="usd" contextRef="id3bca046ce7d4f19a430c177d2515e64_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzc2Ng_42e541ce-dc8a-43bd-a33c-c0efb3881d27">7.5</ix:nonFraction> million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $<ix:nonFraction unitRef="usd" contextRef="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzkxNg_51e2ddf0-01ae-4e4d-8b9c-132600214b66">21.2</ix:nonFraction> million with closing costs of $<ix:nonFraction unitRef="usd" contextRef="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzk0MQ_ba6a714e-ecdf-49ce-bdfb-5e0a78e29771">1.3</ix:nonFraction> million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for <ix:nonNumeric contextRef="ied6c0e6eb376449797262cd45e197f26_D20200316-20200316" format="ixt-sec:durwordsen" name="rmti:DebtInstrumentPeriodOfInterestOnlyPayments" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEwMDc_6b3e6642-e85d-480e-b653-b60c83879441">thirty months</ix:nonNumeric>, or up to <ix:nonNumeric contextRef="iaa2795cf61054796b20b23bef364d55e_D20200316-20200316" format="ixt-sec:durwordsen" name="rmti:DebtInstrumentPeriodOfInterestOnlyPayments" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEwMjA_5073867e-b6b3-4b52-86c4-36972f872b90">thirty-six months</ix:nonNumeric> if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) <ix:nonFraction unitRef="number" contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyMDA_daafe7f9-48c2-4ead-8f7c-e0691e265196">4.75</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyMDk_b435670d-6901-464d-984a-864a9b582dfe">4.00</ix:nonFraction>% with an initial interest rate of <ix:nonFraction unitRef="number" contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyNDU_a7ce2f0e-7f2b-4dfc-bed1-b7ded2bc64fa">8.75</ix:nonFraction>% per annum and an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyOTI_e13d9c82-55dc-4e62-a592-d07b46f2886e">10.9</ix:nonFraction>%. The Company has the option, under certain circumstances, to add <ix:nonFraction unitRef="number" contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316" decimals="INF" name="rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEzNjA_530ed2c8-8476-4c4e-b9ce-7fa10790e193">1.00</ix:nonFraction>% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three and nine months ended September&#160;30, 2020, interest expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i7ad74bef55824ee587591169cd823d18_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzYwNDczMTM5NTY3MTU_285ea13a-8d0d-45cf-992d-ea861d141bc9">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id21bb6146027445a9e33a3043534e284_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzE2MzE_0ac40b8f-1933-426e-b150-1abfb857acae">1.3</ix:nonFraction> million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity. As of&#160;September&#160;30, 2020, the Company is in compliance with all the reporting and financial covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock equal to <ix:nonFraction unitRef="number" contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316" decimals="INF" name="rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI0NDg_a9703c63-cd1a-4efb-b94a-b8e9a1e9d4be">3.5</ix:nonFraction>% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#8217;s stock for the <ix:nonFraction unitRef="day" contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316" decimals="INF" name="rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI2NTI_235551a4-bdbb-4393-a812-35ac5ba10ae9">5</ix:nonFraction>-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="ic5bb31ec7a444c18904dfe090598b734_I20200316" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI5MzQ_11a29178-a735-4414-8ea7-b52242c20f3c">1.65</ix:nonFraction> per share or (ii) the volume weighted average closing price of the Company&#8217;s stock for the <ix:nonFraction unitRef="day" contextRef="i99be750d121e4bba9049423b4facb83d_D20200316-20200316" decimals="INF" name="rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzMwMjg_4513e475-f891-4221-8897-b4343d9a53c9">5</ix:nonFraction>-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="i74badfe283474cd495162707af80f4c0_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM2MDA_54a87674-f085-4351-b71c-e0bdd70676cb">477,273</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i74badfe283474cd495162707af80f4c0_I20200316" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM2NjQ_35b4af24-fdd7-4446-99a8-23e29bdf8f9c">1.65</ix:nonFraction> per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $<ix:nonFraction unitRef="usd" contextRef="i74badfe283474cd495162707af80f4c0_I20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI3NDg3NzkwODUyODE_bfd51b0d-ee38-4742-9cb7-c9e0f46d477a">0.5</ix:nonFraction>&#160;million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2020, the outstanding balance of the Term Loan was&#160;$<ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM3MzQ_1ca45d31-4a2a-4201-9519-64241ae4bb49">20.9</ix:nonFraction> million, net of unamortized issuance costs and unaccreted discount of&#160;$<ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM3OTk_e586739a-7d17-43e1-89e4-7b17830a5702">1.6</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="ibbc9d1351e584aefb0ed795067f0fb56"><ix:nonNumeric contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM4OTk_5cc6d0c1-f392-490e-9065-fd02adb59e1b" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of&#160;September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.385%"><tr><td style="width:1.0%"></td><td style="width:47.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzEtMS0xLTEtMA_39f79192-b167-4a4d-8303-7d8c0fefc97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzItMS0xLTEtMA_0b8ac8f7-b86c-4921-88cd-00ca4f23137b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzMtMS0xLTEtMA_38c032ff-fec3-44e6-bd7e-cf20056d1c04">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzQtMS0xLTEtMA_f54bea8b-94de-4e58-8dcd-4d7ae23f968b">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzUtMS0xLTEtMA_3797c983-6d2f-4f82-b6c5-dbc6c79d05ae">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzYtMS0xLTEtMA_66c31dde-58a4-47ba-9c72-f52b8783f9dc">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:0 1pt"></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzctMS0xLTEtMA_e791ed95-4090-432b-aec5-7a6956971a43">22,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in &#8220;Item 1. Condensed Consolidated Financial Statements&#8221;. References in this report to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; are references to Rockwell Medical,&#160;Inc. and its subsidiaries.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC.&#160;&#160;We may also make forward-looking statements in our press releases or other public or shareholder communications.&#160;&#160;Our forward-looking statements are subject to risks and uncertainties and include information about our expectations and possible or assumed future results of our operations.&#160;&#160;When we use words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our plans and ability to successfully commercialize our products; our ability to successfully launch FDA-approved Triferic AVNU; our ability to develop FPC for other indications; our ability to successfully execute on our business strategy and development of new indications; and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made.&#160;&#160;Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different.&#160;&#160;Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, &#8220;Item 1A &#8212; Risk Factors&#8221; in our Form&#160;10-K for the year ended December&#160;31, 2019 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position.&#160;&#160;There can be no assurance that future results will meet expectations.&#160;&#160;Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Developments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Rockwell Medical, Inc. and subsidiaries (collectively, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, or the &#8220;Company&#8221;), is a biopharmaceutical company dedicated to improving outcomes for patients with iron deficiency and iron-deficiency anemia,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate citrate (&#8220;FPC&#8221;) therapeutic platform. The first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients. We initiated commercial sales of Triferic Dialysate during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. Our lead indication is developing FPC for the treatment of iron deficiency anemia in patients undergoing home infusion therapy. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients&#8217; lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Substantially all of our sales have been concentrate products and ancillary items, though we initiated commercial sales of our proprietary therapeutic, Triferic Dialysate, during the second quarter of 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Triferic&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triferic is the Company&#8217;s first proprietary iron therapy from the FPC therapeutic platform that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. Triferic Dialysate was the first FDA approved product indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysis patients. On March 27, 2020, the FDA approved Triferic AVNU, a novel intravenous formulation of Triferic that would be used for the same indication. Descriptions of Triferic Dialysate and Triferic AVNU are set forth below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triferic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dialysate</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triferic Dialysate, our dialysate formulation of Triferic, received FDA approval in 2015 and remains the first FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Triferic Dialysate received a reimbursement J-code on January 1, 2016 from the Centers for Medicare &amp; Medicaid Services (the "CMS"), providing that Triferic Dialysate would be reimbursed for administration to dialysis patients within the existing fixed-price &#8220;bundle&#8221; of payments that CMS provides to dialysis providers.&#160;&#160;On April 26, 2019, pursuant to a request we submitted earlier in 2019, we were notified of a preliminary recommendation by CMS to grant our powder packet formulation of Triferic Dialysate a separate J-Code, which became effective on July 1, 2019. As a result, the Company changed its commercialization strategy to plan for the commercial launch of Triferic Dialysate with reimbursement within the bundle of payments to dialysis providers, while continuing to develop Triferic AVNU (discussed below). We commercially launched Triferic Dialysate in May 2019.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company determined, based on feedback provided from CMMI, that Triferic Dialysate was unlikely to obtain add-on reimbursement in the near term. As a result, the Company changed its commercialization strategy to plan for the commercial launch of Triferic Dialysate with reimbursement within the bundle of payments to dialysis providers, while continuing to develop Triferic AVNU (discussed below). We commercially launched Triferic Dialysate in May 2019.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triferic AVNU (formerly I.V. Triferic)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed Triferic AVNU, an intravenous injection formulation of Triferic, for use by hemodialysis clinics in the United States as well as international markets. On March 27, 2020, we received FDA approval for Triferic AVNU, with the same indications as the dialysate formulation (indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysis patients) and we began recruiting clinics for participation in a sample evaluation program for Triferic AVNU during the third quarter of 2020.  Due to a minor scheduling delay in the production of packaging for salable product, commercialization will likely be postponed until the first quarter of 2021. Like Triferic Dialysate, Triferic AVNU will be reimbursed within the existing fixed-price bundle of payments that CMS provides to dialysis providers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to market and sell Triferic Dialysate and Triferic AVNU directly in the United States, our international strategy is to partner with and license these products to established companies in other regions of the world to assist in the further development (primarily clinical trials and regulatory activities), if necessary, and commercialize in those regions. We continue to pursue international licensing opportunities in a number of countries and specific regions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dialysis Concentrates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture, sell, deliver and distribute hemodialysis concentrates, along with a line of ancillary dialysis products abroad.&#160;We sell directly to DaVita, Inc. and use Baxter as our exclusive marketer and distributor in the United States and in select foreign markets.&#160;Dialysate concentrates accounted for approximately 96% of our revenues for the nine months  September 30, 2020, with ancillary products and Triferic accounting for most of the remainder.&#160;&#160;We receive a pre-defined gross profit margin on our concentrate products sold pursuant to the Baxter Agreement, subject to an annual true-up of costs.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Triferic is approved for commercial sale in the United States, it is not approved for sale in other major markets globally.&#160;&#160;We have received regulatory guidance from the European Medicines Agency ("EMA") regarding the clinical studies that are needed to file for approval of Triferic AVNU in Europe.&#160;&#160;At the present time, we do not intend to commence these clinical studies without a development partner in Europe. In conjunction with our licensee in China, Wanbang Biopharmaceutical, Co., Ltd. ("Wanbang"), we completed two clinical pharmacology studies in China during 2019. We expect Wanbang to initiate an additional, pivotal, clinical study that is required to support a submission for regulatory approval in China. In addition, pursuant to the licensing agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), our licensee in India, meetings between Sun Pharma and the regulatory authorities in India have been initiated. Sun Pharma continues to follow </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up with the Indian regulatory authorities to determine the requirements for approval of Triferic in India. Lastly, pursuant to the licensing agreement with Jeil Pharmaceutical Co., Ltd ("Jeil Pharma"), our licensee in South Korea, meetings between Jeil Pharma and the regulatory authorities in South Korea will be initiated. Jeil Pharma has informed us they do not believe they would need to perform a clinical trial in advance of approval. We anticipate sales in South Korea to begin in early 2022. See "Item 1A &#8212; Risk Factors" below for a discussion of the potential impact of COVID-19 our overall business and such clinical studies.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a post-approval requirement under the Pediatric Research Equity Act, we are required to conduct a further clinical study of the effectiveness of Triferic in a pediatric patient population. We have reached agreement with the FDA and EMA on the design of this study.  We have engaged a contract research organization and are in process of selecting sites in the United States and selected EU countries. We expect the data from this study could be used as part of the overall clinical data package to support approval by the EMA, if and when we are able to complete the other clinical trials needed to support making such a filing. See "Item 1A &#8212; Risk Factors" below for a discussion of the potential impact of COVID-19 on such clinical studies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Opportunities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the third Quarter of 2020 we initiated our plan to leverage our development and regulatory experience with our FPC platform for use in other indications. We plan to meet with the FDA for a Type C meeting to discuss our plan for developing FPC for the treatment of iron deficiency anemia in patients undergoing home infusion therapy. Over 3.2 million patients are treated annually using home infusion therapy.  The incidence of iron deficiency is estimated to be as high as 60% in this patient population.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iron deficiency anemia is largely undertreated in part due to limitations of the currently available iron replacement drugs.  Due to concerns about hypersensitivity reactions, IV iron is infrequently prescribed as a home infusion therapy. This means that patients need to visit a physician office for an infusion which is costly and inconvenient. As a result, physicians are often hesitant to proactively treat iron deficiency and the majority of patients are left to deal with the disease on their own.   Those who become severely anemic are reactively given blood transfusions, which comes with significant risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to meet with FDA in 2021 to discuss our development plans for FPC to improve cardiac function in hospitalized acute congestive heart failure patients. More than a million patients are hospitalized each year with acute decompensated heart failure. Iron deficiency is a common co-morbidity in 50% to 70% of these patients. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there is increasing evidence regarding the positive impact of IV iron replacement therapy in the chronic ambulatory heart failure patient, the evidence in the acute population is scarce.  One limitation of currently available parenteral iron products is that the iron must be processed and stored in the liver before it is released and becomes available as a fuel for cardiac muscle energetics.  We believe FPC may be a significant advantage for the acute heart failure patient due to the fact that it provides 100% immediately bioavailable iron, which may mean it is faster acting and could make a meaningful impact within the context of the hospital stay.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the three months ended September 30, 2020 and 2019</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating results for the periods presented below (dollars in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit (Loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,135.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,690)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, our net sales were $15.3 million compared to net sales of $15.4 million during the three months ended September 30, 2019. The decrease of $0.1 million was primarily due to a decrease in international sales of dialysis concentrates products.  Triferic Dialysate net sales for the three months ended September 30, 2020 included approximately $0.2 million of Triferic Dialysate product sales to United States customers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales during the three months ended September 30, 2020 was $14.9 million, resulting in gross profit of $0.4 million during the three months ended September 30, 2020, compared to cost of sales of a $15.4 million and a gross loss of $17,000 during the three months ended September 30, 2019. Gross profit increased by $0.4 million in the third quarter of 2020 compared to the third quarter of 2019, due primarily to a large inventory reserved of $1.1 million recorded in the third quarter of 2019 compared to $0.3 million inventory reserve recorded in the third quarter of 2020; offset by an increase in labor and material costs $0.3 million to address protocols put in place from the ongoing COVID-19 pandemic. Gross profits are primarily related to our concentrates business at this time. The Company anticipates that potential future sales of Triferic will impact the mix of future gross profits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $1.7 million during the three months ended September 30, 2020, compared with $1.8 million during the three months ended September 30, 2019. The decrease of $0.1 million is primarily due to a decrease in marketing costs related to Triferic Dialysate offset by an increase in costs associated with the launch of Triferic AVNU, our new FDA-approved intravenous formula.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $3.6 million during the three months ended September 30, 2020,&#160;compared with $4.6 million during the three months ended September 30, 2019. The decrease of $1.0 million is due primarily to a decrease in stock compensation of $0.6 million, relating to a decrease in incentive compensation from forfeited equity awards associated with the departure of our former Chief Financial in July 2020; a decrease in consulting expense of $0.3 million, relating to strategic development; a decrease in accounting costs of $0.2 million , relating to a decrease in internal audit fees; and a decrease in legal expense of $0.1 million, relating to previous litigation that has since been resolved; partially offset by an increase of $0.3 million for increased training cost and severance pay related to our former President and Chief Executive Officer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Product Development Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and product development expenses were $1.7 million for the three months ended September 30, 2020, compared with $1.5 million during the three months ended September 30, 2019. The increase of $0.2 million was due primarily </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to increase in costs relating to our scientific programs. The Company is continuing to invest in its medical and scientific programs to support the global launch of Triferic and the advancement of our FPC technology platform.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the three months ended September 30, 2020 was $5,861, consisting of interest income of $1,767 and $4,094 of realized gains on investments. Other income for the three months ended September 30, 2019 was $103,386, consisting of $97,100 of interest income and $6,268 of realized gains on investments. Other expense for the three months ended September 30, 2020 was $0.7 million of interest expense related to our debt facility (see Note 15 for more information on our debt facility). Other expense for the three months ended September 30, 2019 was $16,365 of interest expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the nine months ended September 30, 2020 and 2019</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating results for the periods presented below (dollars in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement Expense, net of Reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,348)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, our net sales were $47.0 million compared to net sales of $45.8 million during the nine months ended September 30, 2019. The increase of $1.2 million was primarily due to higher domestic dialysis concentrate sales of  $0.8 million and an increase in Triferic Dialysate sales of approximately $0.4 million compared to the nine months ended September 30, 2019. Triferic was launched in the third quarter of 2019 via the sample evaluation program and there were nominal revenues for the same period in 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales during the nine months ended September 30, 2020 was $44.7 million, resulting in gross profit of $2.3 million during the nine months ended September 30, 2020, compared to cost of sales of $44.1 million and a gross profit of $1.7 million during the nine months ended September 30, 2019. Gross profit increased by $0.6 million during the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019. The increase was due primarily to a gross margin increase of $0.3 million in our Triferic Dialysate product in 2020. In comparison, the launch and sales of Triferic Dialysate occurred in the third quarter of 2019 and had no to minimal impact during the nine months ended September 30, 2019. Gross profits are primarily related to our concentrates business at this time.  The Company anticipates that potential future sales of Triferic will impact the mix of future gross profits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were&#160;$5.7 million during the nine months ended September 30, 2020, compared with $7.1 million during the nine months ended September 30, 2019. The decrease of $1.4 million is due primarily to the decrease in marketing costs of $2.2 million, partially offset by an increase in costs associated with hiring, training and educating new employees of $0.8 million. The fluctuation in these costs are mainly due to the timing of the Triferic Dialysate launch in the third quarter of 2019. We expect those costs to continue to level off quarter over quarter going forward.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $11.8 million during the nine months ended September 30, 2020, compared with $16.3 million during the nine months ended September 30, 2019. The $4.5 million decrease was driven primarily by decreases to stock compensation, legal, recruiting and consulting fees, partially offset by an increase in labor costs. The decrease in stock compensation primarily relate to the resignation of our former President and Chief Executive Officer in April 2020 and former Chief Financial Officer effective July 2020.&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Product Development Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and product development expenses was $5.2 million for the nine months ended September 30, 2020, compared with $4.9 million during the nine months ended September 30, 2019, an increase of $0.3 million. Research and product development expenses for the nine months ended September 30, 2020 included clinical trials and other product development expenses of $1.8 million for Triferic, compared to $1.4 million during the nine months ended September 30, 2019.&#160;The Company is continuing to invest in its medical and scientific programs to support the global launch of Triferic and the advancement of our FPC technology platform.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlement Expense, net of Reimbursement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement expense was nil for the nine months ended September 30, 2020, compared to $0.4 million in for the nine months ended September 30, 2019. Settlement expense for the nine months ended September 30, 2019 reflected the terms of the confidential settlement agreement and mutual release entered into in August 2018 relating to the Company&#8217;s former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the nine months ended September 30, 2020 was $247,682, consisting of interest income of $239,594 and $8,088 of realized gains on investments. Other income for the nine months ended September 30, 2019 was $313,393, consisting of $289,101 of interest income and $24,292 of realized gains on investments. Other expense for the nine months ended September 30, 2020 was $2.1 million, consisting of warrant modification expense of $0.8 million and interest expense of $1.3 million related to our debt facility (see Note 15 for more information on our debt facility). Other expense for the nine months ended September 30, 2019 was $16,365 of interest expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had approximately $67.3 million of cash, cash equivalents and investments available-for-sale, and working capital of $65.2 million. Net cash used in operating activities for the nine months ended September 30, 2020 was approximately $21.1 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell from time to time shares of the Company&#8217;s common stock through the Agent up to $40.0 million. As of December 31, 2019, the Company sold 1,840,443 shares of its common stock pursuant to the Sales Agreement for gross proceeds of approximately $5.4 million, at a weighted average selling price of approximately $2.92. The Company paid approximately $0.3 million in commissions and offering fees related to the sale of the common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company sold 1,128,608 of shares of its common stock pursuant to the Sales Agreement with the Agent for proceeds of $2.3 million, net of issuance costs. As of September 30, 2020, approximately $32.3 million remains available for sale under this facility. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co., as underwriter, pursuant to which the Company agreed to issue and sell up to 3,670,212 shares of its common stock, which included 478,723 shares optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share. On February&#160;19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the offering. The offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP (&#8220;Innovatus&#8221;), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the &#8220;Term Loans&#8221;). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specified date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-nine months if certain conditions are met. The Term Loans will mature on March 16, 2025 and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00%, with an initial interest rate of 8.75% per annum. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the nine months ended September 30, 2020 and 2019, interest expense amounted to $1.3 million and $16,000, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity. As of&#160;September 30, 2020, the Company was in compliance with all the reporting and financial covenants. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to maintain compliance with the reporting and financial covenants in the future, the Company could experience an event of default under the Loan Agreement, which would negatively impact the Company&#8217;s liquidity. For more information, see the risk factor entitled &#8220;Our Loan Agreement with Innovatus contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation. The occurrence of any of these events could cause a significant adverse impact on our business, prospects and share price.&#8221; in &#8220;Item 1A &#8212; Risk Factors.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2020, the Company entered into a Securities Purchase Agreement with certain purchasers named therein, pursuant to which the Company agreed to issue and sell to several institutional and accredited investors in a registered direct offering 21,818,544 shares of common stock and warrants to purchase up to 23,178,809 shares of common stock (the &#8220;Warrants&#8221;) at a combined purchase price equal to $1.51 per share. Each Warrant is exercisable for one share of common stock at an exercise price of $1.80 per share. The Warrants are immediately exercisable and will expire on September 25, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offered to certain purchasers pre-funded warrants to purchase up to an aggregate of 1,360,265 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of common stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is sold to the public in the offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants were exercised in conjunction with the issuance of common stock under the Securities Purchase Agreement. The Company received gross proceeds of approximately $35.0 million in connection with the offering, before deducting placement agent fees and related offering expenses of approximately $2.3 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the equity and debt financing described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the commercial launch and medical education programs of Triferic Dialysate and Triferic AVNU, and the further development of our FPC pipeline programs. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual amount of cash that we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial launch of Triferic Dialysate and Triferic AVNU; the timing and magnitude of cash received from drug product sales; and the timing and expenditures associated with the development of Triferic for international markets; the timing and expenditures associated with the development of further innovative administration techniques of Triferic for dialysis patients; the timing and expenditures associated with the development of our FPC technology for patients with iron-deficiency anemia in other disease states; and the costs associated with ongoing litigation and investigatory matters.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance that we will be able to secure additional capital or funding on acceptable terms, of if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the U.S., as well as potential combinations (including by merger or acquisition) or other corporate transactions.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to fund our activities in the long term will be highly dependent upon our ability to successfully launch Triferic Dialysate and Triferic AVNU. Our commercialization of Triferic Dialysate and Triferic AVNU is subject to significant risks and uncertainties, including risks we will be successful in the commercialization of Triferic in accordance with our plans. If our commercialization of Triferic Dialysate and/or Triferic AVNU should be delayed for any reason or not proceed in accordance with our plans, we may be forced to implement cost-saving measures that may potentially have a negative impact on our activities and potentially the results of our research and development programs. If our launch of Triferic Dialysate and/or Triferic AVNU is unsuccessful or our commercial launch does not proceed as planned, we may be unable to secure the additional capital that we will require to continue our research and development activities and operations, which could have a material adverse effect on our business. If we are unable to raise the required capital, we may be required to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders&#8217; interests and, in such event, the market price of our common stock may decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $21.1 million for the nine months ended September 30, 2020. The net loss for this period was higher than net cash used in operating activities by $1.1 million, which was primarily attributable to non-cash expenses of $2.8 million, consisting primarily of $1.1 million of amortization of the right to use assets, $0.8 million of warrant modification expense,&#160;$0.6 million of depreciation and amortization, ($0.3) million of stock-based compensation and a ($1.6) million net change in assets and liabilities.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.0 million for the nine months ended September 30, 2019. The net loss for this period was higher than net cash used in operating activities by $4.9 million, which was primarily attributable to non-cash expenses of $7.2 million, consisting of $3.9 million of stock-based compensation,&#160;$1.4 million of amortization of the right to use assets, $0.6 million of depreciation and amortization, and a ($2.3) million net change in assets and liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by (Used In) Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $2.6 million during the nine months ended September 30, 2020. The net cash provided was primarily due to the sales of our available-for-sale investments of $27.1 million, offset by $23.5 million used for the purchase of investments available-for-sale and $1.0 million for the purchase of equipment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net used in investing activities was $4.9 million during the nine months ended September 30, 2019. The cash used was primarily due to the purchase of our available-for-sale investments of $30.5 million, offset by $34.2 million provided by the sale of investments available-for-sale, $0.8 million for the purchase of research and development licenses acquired from a related party and $0.4 million for the purchase of equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $63.3 million during the nine months ended September 30, 2020. The net cash provided was primarily due to net proceeds of $21.2 million related to the Loan Agreement and $40.7 million and $2.3 million from the sale of our common stock,&#160;&#160;related to our public offerings and our at-the market offering, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $18.6 million during the nine months ended September 30, 2019. The net cash provided was primarily due to net proceeds of $17.3 million and $2.1 million from the sale of our common stock,&#160;related to our public offering and our at-the market offering, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Impact </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending on the severity of the impact on our sales and marketing efforts, the timing of our commercial launch of Triferic AVNU could be adjusted. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Judgments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Estimates</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2019. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, except for those subjects mentioned in the section of the notes to the condensed consolidated financial statements titled Adoption of Recent Accounting Pronouncements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued and adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 of the condensed consolidated financial statements at September 30, 2020.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per &#167;229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in &#167;229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure material information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management necessarily was required to apply its judgment in evaluating the cost&#8209;benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of and with the participation of our management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2020. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weaknesses related to change management and third-party management controls, user access security and segregation of duties as it relates to user access controls in our Information Technology General Controls ("ITGC"), described in our Annual Report on Form 10-K for the year ended December 31, 2019, have been remediated. The Company is still evaluating the design, implementation and operating effectiveness of the pervasive effect on other ITGC dependent business activity level internal control cycles, which has not been remediated. Notwithstanding the material weaknesses, the Company&#8217;s management, including the Chief Executive Officer and Chief Financial Officer (Principal Financial Officer), have concluded that the condensed consolidated financial statements as of September 30, 2020, are fairly stated, in all material respects, in accordance with generally accepted accounting principles in the United States for each of the periods presented herein.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pervasive effect of the ITGC material weaknesses, management has taken a number of steps with the intention of remediating the above control deficiencies. We continue to implement enhanced procedures and controls to remediate the pervasive impact of our material weaknesses in internal control over financial reporting.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. We maintain internal control over financial reporting designed to provide reasonable, but not absolute, assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to make further improvements to our internal controls over financial reporting, in addition to the improvements developed in 2019. During the quarter ended June 30, 2020, the Company remediated the ITGC control deficiencies in connection with change management and third-party management and enhanced evidentiary review and documentation of key ITGC controls and implemented new programs and policies to provide improved control over change management and third-party management controls to the ERP system. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2020, we continued our improvements by remediating the ITGC control deficiencies in connection with user access security and segregation of duties as it relates to user access controls.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continued to make progress on our 2020 audit program, utilizing a National Audit firm as our internal audit partner, which includes in-house remediation testing of the pervasive impact on other ITGC dependent business activity level internal control cycles.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remediation of the material weaknesses is among our highest priorities. Our Audit Committee continually assesses the progress and sufficiency of these initiatives and make adjustments as and when necessary. As of the date of this report, our management believes that our efforts, when completed, will remediate the material weaknesses in internal control over financial reporting. However, there can be no assurance that our efforts will result in remediation of the material weaknesses in internal control over financial reporting.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION </span></div><div id="if43c117d09de4ff289c1029a77c923e4_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure set forth above in Note 14 &#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to our unaudited condensed consolidated financial statements is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are involved in certain other legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims that are considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those set forth below, there have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019 under &#8220;Item 1A &#8212; Risk Factors.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited capital resources and will likely need additional funding before we are able to achieve profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capital resources, a cumulative deficit of approximately $328.7 million since inception and expect to incur further losses for the foreseeable future.&#160; As of September 30, 2020, we had approximately $67.3 million of cash, cash equivalents and investments available-for-sale, and working capital of $65.2 million. Net cash used in operating activities for the nine months ended September 30, 2020 was approximately $21.1 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell from time to time up to $40.0 million of shares of the Company&#8217;s common stock through the Agent. As of December 31, 2019, the Company sold 1,840,443 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5.4 million, at a weighted average selling price of approximately $2.92. The Company paid $0.3 million in commissions and offering fees related to the sales. During the nine months ended September&#160;30, 2020, the Company sold 1,128,608 of shares of its common stock pursuant to the Sales Agreement with the Agent for proceeds of $2.3 million, net of issuance costs. As of September 30, 2020, approximately $32.3 million remains available for sale under this facility. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the &#8220;Offering&#8221;). On February&#160;19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February&#160;21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP, as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specified date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. and contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity. As of September 30, 2020, the Company was in compliance with all reporting and financial covenants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2020, the Company entered into a Securities Purchase Agreement with certain purchasers named therein, pursuant to which the Company agreed to issue and sell to several institutional and accredited investors in a registered direct offering 21,818,544 shares of its common stock and warrants to purchase up to 23,178,809 shares of its common stock (the &#8220;Warrants&#8221;) at a combined purchase price equal to $1.51 per share. Each Warrant is exercisable for one share of common stock at an exercise price of $1.80 per share. The Warrants are immediately exercisable and will expire on September 25, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offered to certain purchasers pre-funded warrants to purchase up to an aggregate of 1,360,265 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of common stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is sold to the public in the offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants were exercised at the same time as the issuance of common stock under the Securities Purchase Agreement. The Company received gross proceeds of approximately $35.0 million in connection with the offering, before deducting placement agent fees and related offering expenses of approximately $2.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the equity offerings and the Loan Agreement described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the current launch of Triferic Dialysate and Triferic AVNU. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our near-term success depends substantially on the commercialization of Triferic Dialysate and Triferic AVNU. Although Triferic Dialysate and Triferic AVNU have been approved by the FDA, we may not be able to commercialize either product successfully.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triferic Dialysate launched commercially in the United States in May 2019 and Triferic AVNU was approved by the FDA in March 2020; however, it is possible that either version of Triferic will not gain market acceptance and that we will not be successful in the commercialization of these products. We do not know whether we will be able to successfully implement our commercialization strategy for Triferic Dialysate and Triferic AVNU or whether our new business strategy will ultimately be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both formulations of Triferic will be reimbursed &#8220;within the bundle,&#8221; which means that dialysis providers will not receive any additional amount of reimbursement from Medicare or Medicaid to compensate them for the cost of purchasing and administering Triferic. This reimbursement status may result in a slower rate of commercial adoption, as we must work to show dialysis providers that improved patient outcomes, the reduction of utilization in other therapies and the resulting savings offset the costs associated with Triferic. Additionally, Triferic competes against current anemia therapies (including intravenous iron and the ESA class of drugs) and possibly other future products. Additionally, it may be difficult to gain market acceptance from dialysis chains, anemia managers and nephrologists and such acceptance may be slower than expected, if at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance will depend on a number of factors, such as demonstration of Triferic Dialysate&#8217;s safety and efficacy, cost-effectiveness, and advantages over existing products. Other factors that may impact the commercial success and ultimate profitability of Triferic include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the rate of adoption of Triferic Dialysate and Triferic AVNU relative to the shelf life of the existing inventory that we have on hand and whether we can sell our existing inventory before it expires;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to manage inventory available for commercial sale;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the effectiveness of our marketing, sales and distribution strategies and operations for development and commercialization;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the impact of Triferic Dialysate and Triferic AVNU on established customer protocols, formularies, administration methods and operational practices;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">The ability and willingness of dialysis centers to adopt their protocols and utilize the drugs in a manner consistent with state regulatory agencies.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">reimbursement of either formulation of Triferic by government and commercial payors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to execute our marketing strategy without significant additional expenditures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our competitors&#8217; activities, including aggressive marketing and pricing practices and other tactics to retain their market share;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to successfully assert our patents against potential competitors who may seek to introduce generic versions of either formulation of Triferic;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to comply with ongoing regulatory requirements applicable to either formulation of Triferic and the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping applicable to Triferic;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the impact of certain royalties related to our sale of either formulation of Triferic paid by us based on the profitability of either formulation of Triferic;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to avoid third party patent interference or patent infringement claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">our ability to maintain a continued acceptable safety profile of either formulation of Triferic;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the discovery of previously unknown problems with either formulation of Triferic or with any third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the ability to successfully manufacture enough commercial product and successfully complete our commercialization planning to enable a launch of Triferic AVNU in 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse development with respect to any of the foregoing may have a material adverse effect on our ability to manufacture and market either formulation of Triferic. We cannot assure you that we will be able to generate meaningful and sustained revenues through the sale of either formulation of Triferic. If we are not successful in commercializing either formulation of Triferic, or are significantly delayed in doing so, our entire investment in Triferic may be of no value, our inventory of finished product may expire or become obsolete (resulting in write-offs of such inventory), our licensing rights could be materially adversely affected and the price of our common stock could substantially decline. Even if we are successful in commercializing either formulation of Triferic, since the market is highly concentrated with two significant suppliers, our continued success may depend on adoption of Triferic Dialysate by the limited number of existing dialysis providers.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may result in significant disruptions to our business operations, including the commercial launch of our Triferic products and our clinical trials, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and its operations, including but not limited to our sales and marketing efforts and our research and development activities, could be adversely affected by health epidemics in regions where we have business operations, and such health epidemics could cause significant disruption in the operations of third parties upon whom we rely. In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to other countries, including the United States, and has been declared a pandemic by the World Health Organization. In response to public health directives and orders related to COVID-19, we have implemented work-from-home policies for substantially all employees, excluding our essential manufacturing and distribution employees. The effects of executive and similar government orders, shelter-in-place orders and our work-from-home policies may negatively impact our growth and productivity, disrupt our business, including our sales and marketing activities, and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, may impact personnel at our manufacturing facilities and third-party manufacturing facilities in the United States, Europe and other countries, or the availability or cost of materials we use or require to conduct our business, including product development, which would disrupt our supply chain. If the COVID-19 pandemic were to negatively affect our manufacturing facilities, the costs related to such manufacturing may increase and the productivity of our facilities may decrease. Furthermore, some of our manufacturers and suppliers are in Europe and may be impacted by port closures and other restrictions resulting from the COVID-19 pandemic, which may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercially launched Triferic Dialysate in the United States in May 2019 and we began recruiting clinics to participate in a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch. Quarantines, shelter-in-place, executive and similar government orders, or changes in prospective customer practices in response to the COVID-19 outbreak, may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending on the severity of the impact on our sales and marketing efforts, the commercial launch of Triferic AVNU could be delayed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may face decreased demand if our dialysis patients are unable to travel to dialysis clinics or if dialysis clinics are unable to make additional protocol changes that are required for Triferic. In order to ensure the safety of patients and staff at the dialysis clinics that use our Triferic products, we expect the dialysis clinics will implement a number of changes to their safety procedures. In addition, the dialysis clinics may face challenges related to decreased staffing, if staff members are affected by COVID-19. Changes to safety procedures and/or staffing issues may impede the clinics&#8217; ability to make additional protocol changes that are required for Triferic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials and our partners&#8217; clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, Wanbang is our commercialization partner for both Triferic Dialysate and Triferic AVNU in China and we currently expect Wanbang to initiate additional clinical studies during 2020 that are necessary to support a submission for regulatory approval in China. Such clinical studies may be delayed to later in 2020 than previously expected. In addition, meetings between Sun Pharma and the regulatory authorities in India related to our Triferic products have been postponed due to government restrictions in India. Lastly, meetings between Jeil Pharma and the regulatory authorities in South Korea could be postponed due to potential government restrictions in South Korea. If COVID-19 continues to spread in the United States and elsewhere, we or our partners may experience additional disruptions that could severely impact our business and clinical trials, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving legalization documents from foreign embassies, which are required to allow our partners to direct activities on behalf of the Company in local markets;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring and data entry and verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the completeness and integrity of clinical trial data and, as a result, determine the outcomes of the trial;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will not be able to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from COVID-19;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials in affected geographies; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays to our clinical activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially affect our business and the value of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. However, any one or a combination of these events could have an adverse effect on the operation of and results from our clinical trials and on our other business operations, which could negatively impact our business, operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks related to the ongoing COVID-19 pandemic may amplify the other risk factors described in this &#8220;Item 1A &#8212; Risk Factors&#8221; and in the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Loan Agreement with Innovatus contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation. The occurrence of any of these events could cause a significant adverse impact on our business, prospects and share price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Loan Agreement, we have pledged substantially all of our assets and the assets of our subsidiary, Rockwell Transportation, Inc., and have agreed that we may not sell or assign rights to our patents and other intellectual property without the prior consent of Innovatus. Additionally, the Loan Agreement contains affirmative, including financial covenants related to liquidity and trailing twelve months sales of Triferic, and negative covenants that, among other things, restrict our ability to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional indebtedness;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">grant liens;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make distributions, including dividends;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into a merger or consolidation; </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">alter the business of the Company; or</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell all or a portion of the Company&#8217;s property, business or assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These terms of the Loan Agreement could prevent us from taking certain actions without the consent of our lenders, which may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders, placing us at a competitive disadvantage compared to our competitors who have less leverage and who therefore may be able to take advantage of opportunities that our leverage prevents us from exploiting. These covenants could also limit our ability to make needed capital expenditures or otherwise conduct necessary or desirable business activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement also includes customary events of default, including, among other things, a change of control or a failure to comply with certain of the covenants in the Loan Agreement. Upon the occurrence and continuation of an event of default, all amounts due under the Loan Agreement become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of Innovatus), immediately due and payable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default under the Loan Agreement should occur, we could be required to immediately repay the outstanding indebtedness. If we are unable to repay this debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Loan Agreement. Even if we are able to repay the indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned. The occurrence of any of these events could cause a significant adverse impact on our business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not paid any cash dividends on our common stock and do not anticipate paying such dividends in the foreseeable future. In addition, the terms of our Loan Agreement with Innovatus restrict our ability to pay dividends to limited circumstances. As a result, investors in our common stock may only receive a return if the market price of our common stock increases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of dividends is within the discretion of our Board of Directors, subject to the restrictions in the Loan Agreement, and depends upon our earnings, capital requirements, financial condition and requirements, future prospects, restrictions in future financing agreements, business conditions and other factors deemed relevant by the Board. We intend to retain earnings and any cash resources to finance our operations. Therefore, it is highly unlikely we will pay cash dividends.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if43c117d09de4ff289c1029a77c923e4_151"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT INDEX</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1041024/000110465920108972/tm2031704-1_8k.htm">Form of Warrant (filed with the SEC as Exhibit 4.1 to the Company's Form 8-K filed on September 25, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1041024/000110465920108972/tm2031704-1_8k.htm">Form of Pre-Funded Warrant (filed with the SEC as Exhibit 4.2 to the Company's Form 8-K filed on September 25, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1041024/000162828020013679/rmti-20200915.htm">Russell Skibsted Employment Agreement, dated September 15, 2020 (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Form 8-K filed on September 16, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1041024/000110465920108972/tm2031704-1_8k.htm">Securities Purchase Agreement dated September 23, 2020 (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Form 8-K filed on September 25, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20200930x10qex311.htm">Certification of Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20200930x10qex312.htm">Certification of Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1#**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20200930x10qex321.htm">Certification pursuant to 18 U.S.C. Section&#160;1350 and Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Database</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contracts or compensatory plans or arrangements.</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="if43c117d09de4ff289c1029a77c923e4_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROCKWELL MEDICAL,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 9, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Ellison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Ellison<br/>Chief Executive Officer (Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 9, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Skibsted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Skibsted<br/>Chief Financial Officer (Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>rmti-20200930x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icd239b4742f84722a232e447447f9dd0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE&#160;13a&#8209;14(a)</font></div><div style="margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Russell Ellison, certify that&#58;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">have reviewed this quarterly report on Form&#160;10&#8209;Q of Rockwell Medical, Inc.&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a&#8209;15(e) and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a&#8209;15(f) and 15d&#8209;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:465.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 9, 2020</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Russell Ellison<br>Russell Ellison<br>Chief Executive Officer</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>rmti-20200930x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6021f06352b447538a98977e3e523364_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE&#160;13a&#8209;14(a)</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Russell Skibsted, certify that&#58;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10&#8209;Q of Rockwell Medical, Inc.&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a&#8209;15(e) and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a&#8209;15(f) and 15d&#8209;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:465.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 9, 2020</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Russell Skibsted<br>Russell Skibsted<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>rmti-20200930x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic6eba2ceaeb54bdd8cf2bc6842b88c22_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Rockwell Medical, Inc. (the &#8220;Company&#8221;) on Form&#160;10&#8209;Q for the quarter ending September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Periodic Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Periodic Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:255.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:253.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Russell Ellison</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Ellison <br>Chief Executive Officer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Russell Skibsted</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Skibsted<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rmti-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://rockwellmed.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://rockwellmed.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResources" roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources">
        <link:definition>2102102 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResourcesDetails" roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails">
        <link:definition>2403401 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements">
        <link:definition>2104103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies">
        <link:definition>2205201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables">
        <link:definition>2306301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails">
        <link:definition>2407402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://rockwellmed.com/role/RevenueRecognition">
        <link:definition>2108104 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://rockwellmed.com/role/RevenueRecognitionTables">
        <link:definition>2309302 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNatureofGoodsandServicesDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails">
        <link:definition>2410403 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>2411404 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>2412405 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2413406 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSale" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale">
        <link:definition>2114105 - Disclosure - Investments - Available-for-Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleTables" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables">
        <link:definition>2315303 - Disclosure - Investments - Available-for-Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleDetails" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails">
        <link:definition>2416407 - Disclosure - Investments - Available-for-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://rockwellmed.com/role/Inventory">
        <link:definition>2117106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://rockwellmed.com/role/InventoryTables">
        <link:definition>2318304 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://rockwellmed.com/role/InventoryDetails">
        <link:definition>2419408 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://rockwellmed.com/role/PropertyAndEquipment">
        <link:definition>2120107 - Disclosure - Property And Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://rockwellmed.com/role/PropertyAndEquipmentTables">
        <link:definition>2321305 - Disclosure - Property And Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://rockwellmed.com/role/PropertyAndEquipmentDetails">
        <link:definition>2422409 - Disclosure - Property And Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://rockwellmed.com/role/AccruedLiabilities">
        <link:definition>2123108 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables">
        <link:definition>2324306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails">
        <link:definition>2425410 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenue" roleURI="http://rockwellmed.com/role/DeferredRevenue">
        <link:definition>2126109 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueDetails" roleURI="http://rockwellmed.com/role/DeferredRevenueDetails">
        <link:definition>2427411 - Disclosure - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://rockwellmed.com/role/StockholdersEquity">
        <link:definition>2128110 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://rockwellmed.com/role/StockholdersEquityDetails">
        <link:definition>2429412 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://rockwellmed.com/role/StockBasedCompensation">
        <link:definition>2130111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://rockwellmed.com/role/StockBasedCompensationTables">
        <link:definition>2331307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSharebasedcompensationexpenseDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails">
        <link:definition>2432413 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails">
        <link:definition>2433414 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails">
        <link:definition>2434415 - Disclosure - Stock-Based Compensation - Service Based Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails">
        <link:definition>2435416 - Disclosure - Stock-Based Compensation - Performance Based Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails">
        <link:definition>2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationServiceBasedStockOptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails">
        <link:definition>2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationServiceBasedStockOptionsOthersDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails">
        <link:definition>2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPerformanceBasedStockOptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails">
        <link:definition>2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://rockwellmed.com/role/RelatedPartyTransactions">
        <link:definition>2140112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://rockwellmed.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2441421 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://rockwellmed.com/role/Leases">
        <link:definition>2142113 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://rockwellmed.com/role/LeasesTables">
        <link:definition>2343308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails">
        <link:definition>2444422 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeasesDetails" roleURI="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails">
        <link:definition>2445423 - Disclosure - Leases - Summary of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails">
        <link:definition>2446424 - Disclosure - Leases - Future Minimum Rental Payments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1" roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1">
        <link:definition>2446424 - Disclosure - Leases - Future Minimum Rental Payments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://rockwellmed.com/role/CommitmentsandContingencies">
        <link:definition>2147114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://rockwellmed.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2448425 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansandSecurityAgreement" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement">
        <link:definition>2149115 - Disclosure - Loans and Security Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansandSecurityAgreementTables" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables">
        <link:definition>2350309 - Disclosure - Loans and Security Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansandSecurityAgreementNarrativeDetails" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails">
        <link:definition>2451426 - Disclosure - Loans and Security Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails">
        <link:definition>2452427 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rmti_SaleofStockRemainingSalesAmount" abstract="false" name="SaleofStockRemainingSalesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_JeilPharmaAgreementsMember" abstract="true" name="JeilPharmaAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ContractWithCustomerDeferredRevenueTextBlock" abstract="false" name="ContractWithCustomerDeferredRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" abstract="false" name="RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_SunPharmaAgreementsMember" abstract="true" name="SunPharmaAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" abstract="false" name="SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_TermLoanTrancheThreeMember" abstract="true" name="TermLoanTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_PerformanceBasedAwardsMember" abstract="true" name="PerformanceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ServiceBasedAwardsMember" abstract="true" name="ServiceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_LiquidityAndFinancialConditionAbstract" abstract="true" name="LiquidityAndFinancialConditionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" abstract="true" name="PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_PresidentandChiefExecutiveOfficerMember" abstract="true" name="PresidentandChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_PaymentsToAcquireAssets" abstract="false" name="PaymentsToAcquireAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_SettlementAgreementWithAllPartiesMember" abstract="true" name="SettlementAgreementWithAllPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" abstract="false" name="SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" abstract="false" name="ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_AveragePaymentTermOfCustomers" abstract="false" name="AveragePaymentTermOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmti_SaleOfEquityPlacementAgentFeeClearingFees" abstract="false" name="SaleOfEquityPlacementAgentFeeClearingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_NumberOfAdditionalAgreements" abstract="false" name="NumberOfAdditionalAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmti_OperatingLeaseRightOfUseAssetAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_RelatedPartyNumberOfInstallmentPayments" abstract="false" name="RelatedPartyNumberOfInstallmentPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmti_TrifericDialysateMember" abstract="true" name="TrifericDialysateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_DeferredRevenueBenefitPercentage" abstract="false" name="DeferredRevenueBenefitPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_CertainEmployeesMember" abstract="true" name="CertainEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_RevenueRecognitionTable" abstract="true" name="RevenueRecognitionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmti_ServiceBasedStockOptionAwardsMember" abstract="true" name="ServiceBasedStockOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" abstract="true" name="ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" abstract="false" name="SaleOfEquityPlacementAgentFeeNonAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_PartialRefund" abstract="false" name="PartialRefund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_AtthemarketOfferingMember" abstract="true" name="AtthemarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ConcentrateProductLicenseFeeMember" abstract="true" name="ConcentrateProductLicenseFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" abstract="false" name="RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_SalesAgreementThresholdSaleOfShares" abstract="false" name="SalesAgreementThresholdSaleOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" abstract="false" name="ResearchAndDevelopmentRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_AveragePaymentTermOfDistributors" abstract="false" name="AveragePaymentTermOfDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmti_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_TermLoanTrancheOneMember" abstract="true" name="TermLoanTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" abstract="false" name="SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_PerformanceBasedRestrictedStockAwardsMember" abstract="true" name="PerformanceBasedRestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_NumberOfDistributionAndLicenseAgreements" abstract="false" name="NumberOfDistributionAndLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" abstract="false" name="ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmti_BaxterHealthcareOrganizationMember" abstract="true" name="BaxterHealthcareOrganizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_DrugLicenseFeeMember" abstract="true" name="DrugLicenseFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_WanbangBiopharmaceuticalMember" abstract="true" name="WanbangBiopharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmti_InstallmentPaymentToRelatedParties" abstract="false" name="InstallmentPaymentToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" abstract="false" name="ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmti_ConcentrateProductsMember" abstract="true" name="ConcentrateProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_TermLoanTrancheTwoAndTrancheThreeMember" abstract="true" name="TermLoanTrancheTwoAndTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_AssetAcquisitionMilestonePayments" abstract="false" name="AssetAcquisitionMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" abstract="true" name="ExecutiveVicePresidentAndChiefScientificOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" abstract="false" name="SupplyAgreementPercentageOfRawMaterialsToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_TrifericAPIMember" abstract="true" name="TrifericAPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" abstract="false" name="ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_LiquidityAndFinancialConditionTextBlock" abstract="false" name="LiquidityAndFinancialConditionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_RevenueRecognitionLineItems" abstract="true" name="RevenueRecognitionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmti_LeaseFacilityTwoMember" abstract="true" name="LeaseFacilityTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" abstract="false" name="RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" abstract="false" name="DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_IncreaseDecreaseInOperatingLeaseLiabilites" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilites" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_RevenueRecognitionReceived" abstract="false" name="RevenueRecognitionReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_DrugProductSalesMember" abstract="true" name="DrugProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_LeaseFacilityOneMember" abstract="true" name="LeaseFacilityOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" abstract="false" name="SaleOfEquityAmountPayableForServicesRelatedToOffering" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_TermLoanTrancheTwoMember" abstract="true" name="TermLoanTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_DebtInstrumentPeriodOfInterestOnlyPayments" abstract="false" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmti_SupplyAgreementPercentageOfRawMaterialsPaid" abstract="false" name="SupplyAgreementPercentageOfRawMaterialsPaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" abstract="false" name="ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_CurrentAndNonCurrentInventory" abstract="false" name="CurrentAndNonCurrentInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" abstract="false" name="PaymentsOfStockIssuanceCostsAndCommissionsFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" abstract="false" name="AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" abstract="false" name="DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="rmti_ConcentrateProductSalesMember" abstract="true" name="ConcentrateProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_PerformanceBasedStockOptionAwardsMember" abstract="true" name="PerformanceBasedStockOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_MasterServicesAndIpAgreementMember" abstract="true" name="MasterServicesAndIpAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_WorkingCapitalNet" abstract="false" name="WorkingCapitalNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmti_DrugRevenueMember" abstract="true" name="DrugRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="rmti_TrifericInventoryMember" abstract="true" name="TrifericInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rmti-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="rmti-20200930.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_009884c0-d7ba-40dd-b413-94d187d15b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_AccountsPayableCurrent_009884c0-d7ba-40dd-b413-94d187d15b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_041bb424-0526-44b4-a463-8fd21f2d4049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_041bb424-0526-44b4-a463-8fd21f2d4049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_e995aafb-a949-468b-b450-6211f50f8c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_LitigationReserveCurrent_e995aafb-a949-468b-b450-6211f50f8c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8d17d18-4590-4318-8709-cdf1fc571207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8d17d18-4590-4318-8709-cdf1fc571207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_55848cf6-a07e-4b9e-ae38-903d371d8273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_NotesPayable_55848cf6-a07e-4b9e-ae38-903d371d8273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_f9880bce-b8a6-48b7-b294-c68edd9c9de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_f9880bce-b8a6-48b7-b294-c68edd9c9de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_84af970a-0ea3-4220-b7df-b905049d6601" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_84af970a-0ea3-4220-b7df-b905049d6601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1735def1-2e32-4b6a-ad16-32756e1fb5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a916976-bfe5-4ea7-bd91-0ffd501d1235" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1735def1-2e32-4b6a-ad16-32756e1fb5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38ab341f-4bca-47b0-936e-96c994935b32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38ab341f-4bca-47b0-936e-96c994935b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_104c52b3-af8b-4118-b01b-82a49a21a298" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_104c52b3-af8b-4118-b01b-82a49a21a298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2a093e73-6a06-4366-b87f-93300a792534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:to="loc_us-gaap_InventoryNet_2a093e73-6a06-4366-b87f-93300a792534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c4013ab-1fc7-4c80-a3a3-43b406929397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c4013ab-1fc7-4c80-a3a3-43b406929397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fab8c4f6-495b-4175-a717-0ea5db2106ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b2baf274-9c7b-46f2-9c50-002ee395be7d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fab8c4f6-495b-4175-a717-0ea5db2106ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0b9387ef-2604-451e-b0c6-079e14838625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1b467b8-8230-402b-94c1-21bc53fa95c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0b9387ef-2604-451e-b0c6-079e14838625" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1b467b8-8230-402b-94c1-21bc53fa95c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b2408b9f-289f-4b5a-b429-0eee28ea5fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0b9387ef-2604-451e-b0c6-079e14838625" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b2408b9f-289f-4b5a-b429-0eee28ea5fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4a850377-eb3b-4e2e-abee-e059b63d70e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0b9387ef-2604-451e-b0c6-079e14838625" xlink:to="loc_us-gaap_LiabilitiesCurrent_4a850377-eb3b-4e2e-abee-e059b63d70e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1b251b23-2929-434a-9105-7a69d3bdd208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0b9387ef-2604-451e-b0c6-079e14838625" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1b251b23-2929-434a-9105-7a69d3bdd208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fbc911cf-ac63-4976-939a-a871a85921c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fbc911cf-ac63-4976-939a-a871a85921c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8d3b7d00-9315-4257-9409-262390c7d17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_InventoryNoncurrent_8d3b7d00-9315-4257-9409-262390c7d17a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8db0a73f-6798-41a5-888e-d388d52af768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8db0a73f-6798-41a5-888e-d388d52af768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_881c0366-819b-4d36-9354-fa1878881915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_881c0366-819b-4d36-9354-fa1878881915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_29773bf7-0544-4406-acf1-03ba1746d55e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_Goodwill_29773bf7-0544-4406-acf1-03ba1746d55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_347f5e34-9246-4f2b-bd98-b417af2515ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3691bce2-455e-4367-9ee1-9fdfca6dc355" xlink:to="loc_us-gaap_AssetsCurrent_347f5e34-9246-4f2b-bd98-b417af2515ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_27145c57-03b2-49b0-a32a-0029292a9879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_27145c57-03b2-49b0-a32a-0029292a9879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a116d46-0f9c-4aad-a6aa-042eae6345ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a116d46-0f9c-4aad-a6aa-042eae6345ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d9ac60d1-edc4-46af-bb3d-b8b137a8c3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d9ac60d1-edc4-46af-bb3d-b8b137a8c3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_cd408944-72b9-43ec-af3d-67c3fb32ea7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_cd408944-72b9-43ec-af3d-67c3fb32ea7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0b61f399-2690-4e5d-8fd1-adc3344cbcdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58832e6b-a128-4eb8-acfe-07349f0645c3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0b61f399-2690-4e5d-8fd1-adc3344cbcdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88517ed9-2fe2-4811-9305-be42e74d05c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6f278e28-b9ef-4191-9b05-7702de83aae3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88517ed9-2fe2-4811-9305-be42e74d05c4" xlink:to="loc_us-gaap_Liabilities_6f278e28-b9ef-4191-9b05-7702de83aae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7276422-c613-4269-b940-833f3d01409b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88517ed9-2fe2-4811-9305-be42e74d05c4" xlink:to="loc_us-gaap_StockholdersEquity_c7276422-c613-4269-b940-833f3d01409b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_93d88090-8b2d-4c6e-8d87-ff02d8c11fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88517ed9-2fe2-4811-9305-be42e74d05c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_93d88090-8b2d-4c6e-8d87-ff02d8c11fe3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_beb0ac36-9edd-42ed-98bb-a2c574989ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f0faa4f6-b95e-4b49-8a8e-7d03a1fb50db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_beb0ac36-9edd-42ed-98bb-a2c574989ecd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f0faa4f6-b95e-4b49-8a8e-7d03a1fb50db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9d5eb3fc-412c-419b-9749-082d38684019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_beb0ac36-9edd-42ed-98bb-a2c574989ecd" xlink:to="loc_us-gaap_InterestExpense_9d5eb3fc-412c-419b-9749-082d38684019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7aaba472-6e4a-432c-b203-3a5718e71816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_beb0ac36-9edd-42ed-98bb-a2c574989ecd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7aaba472-6e4a-432c-b203-3a5718e71816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7d21cbc2-eb42-44ff-a615-e5fe8783c7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_beb0ac36-9edd-42ed-98bb-a2c574989ecd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7d21cbc2-eb42-44ff-a615-e5fe8783c7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c8004a4c-f870-4dd8-bb64-4dbf47d063e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33b13e1c-1e77-4abd-9733-c71f0d98752d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c8004a4c-f870-4dd8-bb64-4dbf47d063e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33b13e1c-1e77-4abd-9733-c71f0d98752d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4a919369-4f1a-47e5-a1d9-3a6c9f20362f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c8004a4c-f870-4dd8-bb64-4dbf47d063e5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4a919369-4f1a-47e5-a1d9-3a6c9f20362f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_236378ce-3bd2-4a74-97b1-f011464c1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5eee183b-df07-4200-9967-5acd2e4436de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_236378ce-3bd2-4a74-97b1-f011464c1c5f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5eee183b-df07-4200-9967-5acd2e4436de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af6ef866-0128-4f7b-8427-addd18ff5c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_236378ce-3bd2-4a74-97b1-f011464c1c5f" xlink:to="loc_us-gaap_OperatingIncomeLoss_af6ef866-0128-4f7b-8427-addd18ff5c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_46191b69-519c-48e3-b458-ba56c3585bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:to="loc_us-gaap_GrossProfit_46191b69-519c-48e3-b458-ba56c3585bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_65aefa05-363a-4b8d-88af-9613a8991603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_65aefa05-363a-4b8d-88af-9613a8991603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_418dcc89-b3ed-427e-a97d-de84f5c08584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_418dcc89-b3ed-427e-a97d-de84f5c08584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_e76ba673-4d54-4e3a-b349-2fc11b88e576" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:to="loc_us-gaap_LitigationSettlementExpense_e76ba673-4d54-4e3a-b349-2fc11b88e576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e923c929-fa07-49bf-9ad9-1ddeb38f7047" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a1bac53-c017-4b44-bb86-6dc5cd24bfa1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e923c929-fa07-49bf-9ad9-1ddeb38f7047" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_901150a1-fa70-47e4-b2b1-9f219e466f36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4c76082-9820-460f-a8f6-9df6c887724a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_901150a1-fa70-47e4-b2b1-9f219e466f36" xlink:to="loc_us-gaap_NetIncomeLoss_f4c76082-9820-460f-a8f6-9df6c887724a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ebaa3b6e-1008-42cb-83d7-f2fa8cb40650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_901150a1-fa70-47e4-b2b1-9f219e466f36" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ebaa3b6e-1008-42cb-83d7-f2fa8cb40650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c282fa-dcbb-45a4-b432-26fd06204a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_901150a1-fa70-47e4-b2b1-9f219e466f36" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c282fa-dcbb-45a4-b432-26fd06204a73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b381c70f-bd59-4809-91a2-28c80dbcf27f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_c08f10e3-8a3e-44c2-a4d5-a0f9ee1bf42d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b381c70f-bd59-4809-91a2-28c80dbcf27f" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_c08f10e3-8a3e-44c2-a4d5-a0f9ee1bf42d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3a6540f8-7e40-485c-962b-0c8b108b9c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b381c70f-bd59-4809-91a2-28c80dbcf27f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3a6540f8-7e40-485c-962b-0c8b108b9c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7ed60e3c-305f-4158-8ac4-0969df7314cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b381c70f-bd59-4809-91a2-28c80dbcf27f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7ed60e3c-305f-4158-8ac4-0969df7314cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b5854ee8-6871-451d-86c1-cb6ec4a4276c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b381c70f-bd59-4809-91a2-28c80dbcf27f" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b5854ee8-6871-451d-86c1-cb6ec4a4276c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1ceca0ca-a5b8-468d-98b7-c1397736e794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1ceca0ca-a5b8-468d-98b7-c1397736e794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_1e84d7a6-d106-4995-9df3-6d8bb748b736" xlink:href="rmti-20200930.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiabilites"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_1e84d7a6-d106-4995-9df3-6d8bb748b736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_044d7fa9-d426-4cd5-94bd-a4ba1ccb7b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_044d7fa9-d426-4cd5-94bd-a4ba1ccb7b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_dd2546b3-bc97-4ae4-a7a4-85749139dac6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_dd2546b3-bc97-4ae4-a7a4-85749139dac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f78da9e2-2337-4873-abef-951fa66e084e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f78da9e2-2337-4873-abef-951fa66e084e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a44aff94-9e68-4894-81f8-7ce3b4b1b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a44aff94-9e68-4894-81f8-7ce3b4b1b7b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_f7d905e7-d2f6-4069-ac8e-ac7d7447062b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_f7d905e7-d2f6-4069-ac8e-ac7d7447062b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b2aa0008-52a9-441c-871b-4f47b94bf1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b2aa0008-52a9-441c-871b-4f47b94bf1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_12da749d-739e-43b8-aa94-00ec77995089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7b6e7d16-8fdb-4176-abf1-5c2fa0e48de3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_12da749d-739e-43b8-aa94-00ec77995089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a846fd5c-9059-45ba-8cb1-f098091cf585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6547a16-ae72-4313-815d-14e35bee4f46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a846fd5c-9059-45ba-8cb1-f098091cf585" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6547a16-ae72-4313-815d-14e35bee4f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac2ddeac-c0c5-4261-997d-85be915a9e13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a846fd5c-9059-45ba-8cb1-f098091cf585" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac2ddeac-c0c5-4261-997d-85be915a9e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f98a52-d206-4d17-8a2d-e2dcadcf4384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a846fd5c-9059-45ba-8cb1-f098091cf585" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f98a52-d206-4d17-8a2d-e2dcadcf4384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea6c1fb3-448e-4a43-b8c9-1fd4068153cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_NetIncomeLoss_ea6c1fb3-448e-4a43-b8c9-1fd4068153cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_593ccbd5-4f86-49bf-921e-09ce4bb71498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_593ccbd5-4f86-49bf-921e-09ce4bb71498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c57d2acf-a10a-4d7b-8183-85cab5ef4e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_ShareBasedCompensation_c57d2acf-a10a-4d7b-8183-85cab5ef4e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_8fdc0c9b-970b-42c1-bb23-f8e093897efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_8fdc0c9b-970b-42c1-bb23-f8e093897efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_716ea334-fa96-4d31-bce2-5542e536121b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_716ea334-fa96-4d31-bce2-5542e536121b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_705a69de-f384-4e94-915e-da90afa1f120" xlink:href="rmti-20200930.xsd#rmti_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_705a69de-f384-4e94-915e-da90afa1f120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_932fbfda-b137-4e58-9bbd-6915913b06a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_932fbfda-b137-4e58-9bbd-6915913b06a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_129bd10b-d984-407f-8332-1d9fc2bf7724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_129bd10b-d984-407f-8332-1d9fc2bf7724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_33b39008-25f7-47a3-a71b-54b824ffc321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_33b39008-25f7-47a3-a71b-54b824ffc321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_fd0a0232-50b5-456e-a246-60259fa1fa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_fd0a0232-50b5-456e-a246-60259fa1fa8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_529b57ce-fb8b-4339-af02-f20299323191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb5c3ecc-aec2-4418-bdb6-12c30fbed29b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_529b57ce-fb8b-4339-af02-f20299323191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36df6255-32b7-49a5-b19c-8181cc8c0fca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_36df6255-32b7-49a5-b19c-8181cc8c0fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_31be805e-4ad7-4bc5-ab09-58f889d6fdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_31be805e-4ad7-4bc5-ab09-58f889d6fdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b5881c72-7892-48fe-b923-392f589a33ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b5881c72-7892-48fe-b923-392f589a33ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6fcfaa9-0f23-4024-8ec6-ae662e811c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6fcfaa9-0f23-4024-8ec6-ae662e811c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_37620fc9-37b8-4b38-ad6b-793cf3fd137e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_37620fc9-37b8-4b38-ad6b-793cf3fd137e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7b5d9bd0-3e6c-4f3a-8e8d-10e88c160578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7b5d9bd0-3e6c-4f3a-8e8d-10e88c160578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_bca6d1bf-6a8b-4922-8ce0-d0300145c543" xlink:href="rmti-20200930.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca7f55f3-c5dc-4d70-82b3-f5c18f82c992" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_bca6d1bf-6a8b-4922-8ce0-d0300145c543" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="rmti-20200930.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResources"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognition" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNatureofGoodsandServicesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSale"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/Inventory" xlink:type="simple" xlink:href="rmti-20200930.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_bfb82ce3-f2b9-43be-a4bd-c6a19c765a6f" xlink:href="rmti-20200930.xsd#rmti_CurrentAndNonCurrentInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_af385b6b-48a2-4411-9d1f-3c0c6b61333c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_bfb82ce3-f2b9-43be-a4bd-c6a19c765a6f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_af385b6b-48a2-4411-9d1f-3c0c6b61333c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_78c43180-5f50-4220-a7ee-4a33a3bc80b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_bfb82ce3-f2b9-43be-a4bd-c6a19c765a6f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_78c43180-5f50-4220-a7ee-4a33a3bc80b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a369fff5-85d0-4a71-b82c-94bd3084c0c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_bfb82ce3-f2b9-43be-a4bd-c6a19c765a6f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a369fff5-85d0-4a71-b82c-94bd3084c0c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_793dd759-eb2b-49ec-af2c-41578662679d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_656e9759-c3c0-44a0-ad1f-7a475a989dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_793dd759-eb2b-49ec-af2c-41578662679d" xlink:to="loc_us-gaap_InventoryGross_656e9759-c3c0-44a0-ad1f-7a475a989dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_413b5612-2af1-4d76-b97d-2feb8bda7b02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_793dd759-eb2b-49ec-af2c-41578662679d" xlink:to="loc_us-gaap_InventoryValuationReserves_413b5612-2af1-4d76-b97d-2feb8bda7b02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipment"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de319e53-d705-4f07-89e6-ee47e86c7145" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ad4df549-f803-4968-8757-a2bb2a08a514" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de319e53-d705-4f07-89e6-ee47e86c7145" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ad4df549-f803-4968-8757-a2bb2a08a514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_af70bca1-590c-48da-885b-93e729494e31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de319e53-d705-4f07-89e6-ee47e86c7145" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_af70bca1-590c-48da-885b-93e729494e31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilities"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_da0c1e0a-145f-42c8-8fd6-1a924681623e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_da0c1e0a-145f-42c8-8fd6-1a924681623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_926ecb47-aa54-4ff8-af46-4e261e1d0d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_926ecb47-aa54-4ff8-af46-4e261e1d0d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_7a6d61d5-a66d-443e-8d68-d660dafee30e" xlink:href="rmti-20200930.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:to="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_7a6d61d5-a66d-443e-8d68-d660dafee30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_feadf3e5-0571-4df6-b5ca-5d37661dc4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_feadf3e5-0571-4df6-b5ca-5d37661dc4b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4d30b690-c530-4eed-89b3-39df731d6cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c0255222-ca7d-4f47-ba7b-81552df8902b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4d30b690-c530-4eed-89b3-39df731d6cc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenue" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenue"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/DeferredRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationRestrictedStockAwardsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsOthersDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/Leases" xlink:type="simple" xlink:href="rmti-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesSummaryofOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_97aa1361-fcc5-4e24-b48d-a373842bbef0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_d320b73a-cb40-4f9b-bd45-b97e3abe7d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_97aa1361-fcc5-4e24-b48d-a373842bbef0" xlink:to="loc_us-gaap_ShortTermLeaseCost_d320b73a-cb40-4f9b-bd45-b97e3abe7d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9aba2d96-2b33-426c-b624-f59f71536922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_97aa1361-fcc5-4e24-b48d-a373842bbef0" xlink:to="loc_us-gaap_OperatingLeaseExpense_9aba2d96-2b33-426c-b624-f59f71536922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_cb6c9884-796c-4065-b205-2663e9d8265b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c88ffbb4-f2dc-4286-b31e-0185fe929ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_cb6c9884-796c-4065-b205-2663e9d8265b" xlink:to="loc_us-gaap_OperatingLeaseCost_c88ffbb4-f2dc-4286-b31e-0185fe929ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0838ce17-94c2-46ed-891c-a9de5bf9b620" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_cb6c9884-796c-4065-b205-2663e9d8265b" xlink:to="loc_us-gaap_VariableLeaseCost_0838ce17-94c2-46ed-891c-a9de5bf9b620" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc9a5138-4b3d-4697-b964-b78fcb9deafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c821a708-e730-47f0-8a63-4f1e41670724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc9a5138-4b3d-4697-b964-b78fcb9deafb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c821a708-e730-47f0-8a63-4f1e41670724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_436b2ad2-2411-4b7c-8a6d-2709d0cb90da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc9a5138-4b3d-4697-b964-b78fcb9deafb" xlink:to="loc_us-gaap_OperatingLeaseLiability_436b2ad2-2411-4b7c-8a6d-2709d0cb90da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_531c5771-dab8-4c49-a232-6b394a242cad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_531c5771-dab8-4c49-a232-6b394a242cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e4d3ec0-1948-4d1c-91da-53c513dba744" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e4d3ec0-1948-4d1c-91da-53c513dba744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f1a03db9-350a-4f19-859b-af020f9fb57a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f1a03db9-350a-4f19-859b-af020f9fb57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cdac03da-68bc-471d-94cd-f3a76e2d33fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cdac03da-68bc-471d-94cd-f3a76e2d33fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1ac4d588-4a79-428a-81b1-241e679747d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fe28420-65ba-45fe-b2eb-61c7d8c00267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1ac4d588-4a79-428a-81b1-241e679747d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreement"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementTables"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementNarrativeDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0cd38325-b5bd-4407-aac7-370b3c5b1e39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0cd38325-b5bd-4407-aac7-370b3c5b1e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5e2f2ebb-4e05-4842-9769-5c0a3c09c7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5e2f2ebb-4e05-4842-9769-5c0a3c09c7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e0942875-6120-4c67-9675-b1d7f084a549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e0942875-6120-4c67-9675-b1d7f084a549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bf798538-58e1-4f5e-b1f4-2a94094d6785" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bf798538-58e1-4f5e-b1f4-2a94094d6785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0e37814b-8901-4592-a5e3-e39429d40d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0e37814b-8901-4592-a5e3-e39429d40d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_c8640a17-5d25-41b8-97f2-225488758a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1fb7557-8a0d-4e90-878d-3e2af0a901c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_c8640a17-5d25-41b8-97f2-225488758a0e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rmti-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="rmti-20200930.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="extended" id="i3bc0c5d7bf4a46b584497674d483765d_DocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_42e4ee7c-9583-4493-8eca-1ab22653c347" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressAddressLine1_42e4ee7c-9583-4493-8eca-1ab22653c347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eccc54ce-4e7b-4c37-a18b-08c37d24125b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressCityOrTown_eccc54ce-4e7b-4c37-a18b-08c37d24125b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9eda44ef-7b2f-44c4-bda3-041e7293a9dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressStateOrProvince_9eda44ef-7b2f-44c4-bda3-041e7293a9dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bec4f5eb-b2ff-49a6-a861-7efd7b79d005" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressPostalZipCode_bec4f5eb-b2ff-49a6-a861-7efd7b79d005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_24083e93-597f-4532-b7bc-79473d9737a2_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:to="loc_dei_AddressTypeDomain_24083e93-597f-4532-b7bc-79473d9737a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:to="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_59cfcf97-eb2c-4bec-be80-cd8d578cd423" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:to="loc_dei_FormerAddressMember_59cfcf97-eb2c-4bec-be80-cd8d578cd423" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i877b22eccd384fe09a48b50b2ecbee4e_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ib81a25f933284653aab8fc35e514d968_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i80eebe46be914c9c8079a4b9f94c3f33_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="i05cbe85b073e459c92643226684386c8_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3936dd51cbe045cca2b6904f9130e9b9_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98d5ee68-4a5c-40be-b5ab-377ee2fbd4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98d5ee68-4a5c-40be-b5ab-377ee2fbd4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_711468a4-73a0-4fb7-b744-372e746c43e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockholdersEquity_711468a4-73a0-4fb7-b744-372e746c43e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc428779-dc22-42c2-91da-31c955209ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_NetIncomeLoss_bc428779-dc22-42c2-91da-31c955209ba2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_82f84c36-d79b-401a-bdf1-3ce802465e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_82f84c36-d79b-401a-bdf1-3ce802465e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7e87dde6-dc0e-41de-90ac-88b59b820c48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7e87dde6-dc0e-41de-90ac-88b59b820c48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1d50b663-4564-45de-8a19-be0bd0d652a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1d50b663-4564-45de-8a19-be0bd0d652a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b1105e1a-9b19-4911-9361-a4eea3ec4aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b1105e1a-9b19-4911-9361-a4eea3ec4aa5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e57b8acb-321b-4600-a227-27f95974d2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e57b8acb-321b-4600-a227-27f95974d2fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_aaa76e00-f32d-4889-9347-b3179c4217e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_aaa76e00-f32d-4889-9347-b3179c4217e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e0225e4c-09bb-4526-aa39-366ee7ec21e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e0225e4c-09bb-4526-aa39-366ee7ec21e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_88b85346-8b87-4cf0-87d0-98a6fe563c09" xlink:href="rmti-20200930.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_88b85346-8b87-4cf0-87d0-98a6fe563c09" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f399c52b-6e61-4eb6-bd3e-4dc036da01d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f399c52b-6e61-4eb6-bd3e-4dc036da01d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_2beb82d4-98bf-4766-bac4-81e3febd5aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_2beb82d4-98bf-4766-bac4-81e3febd5aa6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6267f5d2-50be-42dd-a30f-4676f4defaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6267f5d2-50be-42dd-a30f-4676f4defaa1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_01482760-c3a1-4964-8718-4a1437a0e8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e798c740-8fdc-4254-be08-5633b52c7827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:to="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee14b75e-fba4-4344-afbc-e5c47eff4eb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee14b75e-fba4-4344-afbc-e5c47eff4eb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_a98833a7-7ed5-420c-82b6-ce9a6f6df5d0" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:to="loc_rmti_PublicOfferingMember_a98833a7-7ed5-420c-82b6-ce9a6f6df5d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_f7f346b9-6853-4621-a74c-066c5b7f559e" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:to="loc_rmti_AtthemarketOfferingMember_f7f346b9-6853-4621-a74c-066c5b7f559e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:to="loc_us-gaap_EquityComponentDomain_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:to="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f258dff7-170a-4308-a437-2792d97142d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_CommonStockMember_f258dff7-170a-4308-a437-2792d97142d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ec00540-1e4a-47ef-995f-c01504acc206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ec00540-1e4a-47ef-995f-c01504acc206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc9cb637-73b0-4c34-af36-481c82ddb1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_RetainedEarningsMember_fc9cb637-73b0-4c34-af36-481c82ddb1d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_279c75bd-0b60-4912-a5f5-5bef496b1035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_279c75bd-0b60-4912-a5f5-5bef496b1035" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i7f2294c167ee4c109f659db212e8e568_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16be53dd-5a75-4abf-a0c2-e597b51be53a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_NetIncomeLoss_16be53dd-5a75-4abf-a0c2-e597b51be53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7584cb28-23c7-4c62-b8be-0b45f2b0cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7584cb28-23c7-4c62-b8be-0b45f2b0cb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_71463d54-3a89-45c9-ae8a-a80a61b21479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_ShareBasedCompensation_71463d54-3a89-45c9-ae8a-a80a61b21479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c7d9bed8-a750-4bc2-a4a6-28fdc19dec98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c7d9bed8-a750-4bc2-a4a6-28fdc19dec98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_c31f4b24-b61b-4e3e-810a-7b38405afbda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_c31f4b24-b61b-4e3e-810a-7b38405afbda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_6e421ab6-06a2-403a-b0b5-cfa96649c3e1" xlink:href="rmti-20200930.xsd#rmti_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_6e421ab6-06a2-403a-b0b5-cfa96649c3e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2a1c262-83bc-4721-947d-ba0845e73727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2a1c262-83bc-4721-947d-ba0845e73727" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c87159d2-f0cd-423f-8a17-25d97348d7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c87159d2-f0cd-423f-8a17-25d97348d7af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_771f1aa9-b2e1-40e8-9f77-1c6c13080ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_771f1aa9-b2e1-40e8-9f77-1c6c13080ae2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_724bf874-2593-44c1-8573-44b96ec77411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_724bf874-2593-44c1-8573-44b96ec77411" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ae2cf55-3675-4c12-9e54-aa67e2947ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ae2cf55-3675-4c12-9e54-aa67e2947ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_60528fcd-ccfd-4150-a971-438be1ad6208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_60528fcd-ccfd-4150-a971-438be1ad6208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ae0a0c5d-f9c2-4f0e-9b7b-2b0e0a5582b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ae0a0c5d-f9c2-4f0e-9b7b-2b0e0a5582b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c033b3c2-1b0a-407c-b197-bb7a7bedac03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c033b3c2-1b0a-407c-b197-bb7a7bedac03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebf01e7e-6735-4e3d-aa5a-1de208763659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebf01e7e-6735-4e3d-aa5a-1de208763659" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_011afeaa-2c89-4729-b57a-d7d04396c45e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_011afeaa-2c89-4729-b57a-d7d04396c45e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_55c0bbe8-44c1-4bc1-8a67-3f095b6b0a4d" xlink:href="rmti-20200930.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiabilites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_55c0bbe8-44c1-4bc1-8a67-3f095b6b0a4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9afeb038-d239-423a-bd84-99734a582487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9afeb038-d239-423a-bd84-99734a582487" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_30cf6af8-ec03-40ac-985c-0bc0a147dfec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_30cf6af8-ec03-40ac-985c-0bc0a147dfec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b0a523d1-9679-4a7b-b1a4-9a20be5d48d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b0a523d1-9679-4a7b-b1a4-9a20be5d48d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3aba84a8-7254-48b0-99a0-34ea19179d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3aba84a8-7254-48b0-99a0-34ea19179d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c2e09f96-9291-4891-bd93-4e90bdea67c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c2e09f96-9291-4891-bd93-4e90bdea67c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c28a4893-5e04-4d63-81a2-49b719398e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c28a4893-5e04-4d63-81a2-49b719398e3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_5a27d1bc-cf33-4f13-9245-aedfe8e6bf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_5a27d1bc-cf33-4f13-9245-aedfe8e6bf3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_12671773-075d-4a13-9dbf-f2028e088440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_12671773-075d-4a13-9dbf-f2028e088440" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b782b0c2-9c38-4420-9464-dc25369f759e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b782b0c2-9c38-4420-9464-dc25369f759e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c230bce6-f8d4-4a23-ba23-17bf7112ddb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c230bce6-f8d4-4a23-ba23-17bf7112ddb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dd7dc916-5a34-46ed-a494-fc83ac78d1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dd7dc916-5a34-46ed-a494-fc83ac78d1eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7981e25b-eaaf-4b06-aa72-97074a18d686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7981e25b-eaaf-4b06-aa72-97074a18d686" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c7e844d0-c53a-4f65-b34a-7b3a405cec1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c7e844d0-c53a-4f65-b34a-7b3a405cec1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc488ea1-411f-44ac-94ed-a848a596a8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc488ea1-411f-44ac-94ed-a848a596a8ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e5441105-181e-47df-9623-16309c75b1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e5441105-181e-47df-9623-16309c75b1e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_3d5003f9-6cc3-4152-b0be-ed83f0e20127" xlink:href="rmti-20200930.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_3d5003f9-6cc3-4152-b0be-ed83f0e20127" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f64710ea-0e6e-4c09-b467-91613ef9bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f64710ea-0e6e-4c09-b467-91613ef9bffd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_feeb7681-b4e6-4ce4-965f-d6d2bfbe4c32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_feeb7681-b4e6-4ce4-965f-d6d2bfbe4c32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d682491-3eb6-4862-a87e-18a15303d685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d682491-3eb6-4862-a87e-18a15303d685" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f3ad391-82f1-431c-9af5-4695fe6e5086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4ac053b1-51e2-40d2-8769-e1bb6d14f102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:to="loc_us-gaap_InterestPaidNet_4ac053b1-51e2-40d2-8769-e1bb6d14f102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_8d4bb622-56ce-4a48-9196-72406ac96c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_8d4bb622-56ce-4a48-9196-72406ac96c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1_51d8b2ed-63c0-44d3-be07-c9e7d4d3a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_NotesAssumed1_51d8b2ed-63c0-44d3-be07-c9e7d4d3a29c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_cf8e4df5-7a17-4a47-8b52-41ebc1abace2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_StockIssued1_cf8e4df5-7a17-4a47-8b52-41ebc1abace2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdb6002-918e-4512-b0b9-ce2b8d6dae27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdb6002-918e-4512-b0b9-ce2b8d6dae27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_93869684-7683-405d-93c1-3b3430991726" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:to="loc_rmti_PublicOfferingMember_93869684-7683-405d-93c1-3b3430991726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_5e096446-b3c7-49de-95ab-1e2c27bb675d" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:to="loc_rmti_AtthemarketOfferingMember_5e096446-b3c7-49de-95ab-1e2c27bb675d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="rmti-20200930.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="extended" id="i985b754e9854454cbe273e42b672e7e1_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResources"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="extended" id="i086a76ba352e4cf3aa3f38b0d47ccf58_LiquidityandCapitalResources"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended" id="i0b3a5506109445d2aa184767fa43cc03_LiquidityandCapitalResourcesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="extended" id="iaafc845cdfee4e97b8f2d8e4159418f1_BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="extended" id="i2237ee727c0744eca784b708c4cbe8df_BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="extended" id="i35cc9cba6927439a94253cf8945a9770_BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="extended" id="ie1e7dc09604745eb954c7d6755191aa5_BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f30a574b-8848-43ec-903a-224c073deb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f30a574b-8848-43ec-903a-224c073deb0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1790c4d6-5e3b-47a4-9379-5c2b4cf11343_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1790c4d6-5e3b-47a4-9379-5c2b4cf11343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a8acc8b-921c-43c2-a633-0a3af2f36508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a8acc8b-921c-43c2-a633-0a3af2f36508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ad0f3ed4-ad6a-483d-9600-6bf78343ff0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_RestrictedStockMember_ad0f3ed4-ad6a-483d-9600-6bf78343ff0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9c077a5-cf44-4d32-a516-5442e5c2018a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9c077a5-cf44-4d32-a516-5442e5c2018a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e3c688e9-9dc6-406d-be63-aa02f0733ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_WarrantMember_e3c688e9-9dc6-406d-be63-aa02f0733ce8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognition" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognition" xlink:type="extended" id="i759bb051386d459286b13b6f1172056e_RevenueRecognition"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="extended" id="if8b0b1c9b0fc4031b0773d9ce07d358e_RevenueRecognitionTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNatureofGoodsandServicesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="extended" id="i304a662b084e4dca8a3cc520d9c2aa6d_RevenueRecognitionNatureofGoodsandServicesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ie9a9142f43344268bbe6a05cc5513c66_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3c44ca19-668b-4af2-aeb8-69a86d1ce571" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3c44ca19-668b-4af2-aeb8-69a86d1ce571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_7d7e6442-aa64-4b15-97ca-462118598875_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_7d7e6442-aa64-4b15-97ca-462118598875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_b0db9857-1749-4dbd-a827-3eb8032d4d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_b0db9857-1749-4dbd-a827-3eb8032d4d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_70c6dcfc-be77-4b1a-a1ae-bb5d25a3ef93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:to="loc_us-gaap_TransferredOverTimeMember_70c6dcfc-be77-4b1a-a1ae-bb5d25a3ef93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1fbd1c19-f16a-416e-b87f-59afeb2762d8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:to="loc_srt_SegmentGeographicalDomain_1fbd1c19-f16a-416e-b87f-59afeb2762d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:to="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_02ffd365-8543-47aa-a8ed-23e1b3c3fd9a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:to="loc_country_US_02ffd365-8543-47aa-a8ed-23e1b3c3fd9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bd1a28de-b640-4308-9e2d-4eb3b3842b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:to="loc_us-gaap_NonUsMember_bd1a28de-b640-4308-9e2d-4eb3b3842b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3af1fe39-750b-46d8-91e8-d0e469e95c8b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:to="loc_srt_ProductsAndServicesDomain_3af1fe39-750b-46d8-91e8-d0e469e95c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:to="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:href="rmti-20200930.xsd#rmti_DrugRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:to="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember_7f850b36-a4b2-4f40-9f2c-f4727331cbd8" xlink:href="rmti-20200930.xsd#rmti_DrugProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:to="loc_rmti_DrugProductSalesMember_7f850b36-a4b2-4f40-9f2c-f4727331cbd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember_da89d555-04a2-4c4d-9748-b4567d87b011" xlink:href="rmti-20200930.xsd#rmti_DrugLicenseFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:to="loc_rmti_DrugLicenseFeeMember_da89d555-04a2-4c4d-9748-b4567d87b011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:to="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember_f25f2586-c9a0-4f4c-8abc-04e2606a8bb7" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:to="loc_rmti_ConcentrateProductSalesMember_f25f2586-c9a0-4f4c-8abc-04e2606a8bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember_0fb96492-266e-49ef-ba2f-9ead2f490899" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:to="loc_rmti_ConcentrateProductLicenseFeeMember_0fb96492-266e-49ef-ba2f-9ead2f490899" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended" id="i1a6953b85cd848e39afe70be76d4388f_RevenueRecognitionContractBalancesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="iff6b9ecc5af24311bacf84f082064dd1_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_eef2cddd-a3fa-4deb-a22c-74d1157e9043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_eef2cddd-a3fa-4deb-a22c-74d1157e9043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_70378e69-b879-4bcc-baef-64dcdd53ac20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_70378e69-b879-4bcc-baef-64dcdd53ac20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_b5b29153-b037-436d-8dd6-acab36dc3595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_b5b29153-b037-436d-8dd6-acab36dc3595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4d7e2727-8b6e-453a-92da-0848f8269b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4d7e2727-8b6e-453a-92da-0848f8269b6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:to="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6ca899a-293e-405c-860e-a3fae4a84c62_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6ca899a-293e-405c-860e-a3fae4a84c62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_0c86b6a9-9040-43cd-ab84-d19faf6aed4c" xlink:href="rmti-20200930.xsd#rmti_BaxterHealthcareOrganizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_0c86b6a9-9040-43cd-ab84-d19faf6aed4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:to="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:to="loc_srt_ProductsAndServicesDomain_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:to="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_d01fcdf0-e9c9-4757-9f02-1ccdc5520f29" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:to="loc_rmti_ConcentrateProductsMember_d01fcdf0-e9c9-4757-9f02-1ccdc5520f29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSale"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="extended" id="i8131574f123b4ab38402bb0953c6e918_InvestmentsAvailableforSale"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="extended" id="icbbdbd010a3a458a9f535499b3e9e9bd_InvestmentsAvailableforSaleTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended" id="i496bf602210243d2943e40c73f96071b_InvestmentsAvailableforSaleDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/Inventory" xlink:type="simple" xlink:href="rmti-20200930.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/Inventory" xlink:type="extended" id="i02337e4cc7d1456899047a5ab747b7c2_Inventory"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/InventoryTables" xlink:type="extended" id="ib29878ce52654cfbae4002b575bf5607_InventoryTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended" id="ia66b8b91b2e04ae99247c80591e65ba5_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70eb1451-0426-4673-b7e6-f286b001075e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70eb1451-0426-4673-b7e6-f286b001075e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd0511e0-6151-4217-b381-cabac962fed7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd0511e0-6151-4217-b381-cabac962fed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62fea76d-a487-4573-83a8-9936fa120922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62fea76d-a487-4573-83a8-9936fa120922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_f3e90265-f191-4530-bf8d-49702c9c12ab" xlink:href="rmti-20200930.xsd#rmti_CurrentAndNonCurrentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_rmti_CurrentAndNonCurrentInventory_f3e90265-f191-4530-bf8d-49702c9c12ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ef871946-1941-402d-b681-b45e98f3162b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryNoncurrent_ef871946-1941-402d-b681-b45e98f3162b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0eefea75-612c-48d9-bd8d-d560d8076a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryGross_0eefea75-612c-48d9-bd8d-d560d8076a14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_1aff2ebf-00df-43ba-8c9c-f60cafd238b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryValuationReserves_1aff2ebf-00df-43ba-8c9c-f60cafd238b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_073a4dfd-8735-452f-bee7-c2537021bc45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryNet_073a4dfd-8735-452f-bee7-c2537021bc45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_d147de1c-0293-45d6-9144-69d6752a3b22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_d147de1c-0293-45d6-9144-69d6752a3b22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:href="rmti-20200930.xsd#rmti_TrifericInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:to="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember_a8e57b6e-6035-41ac-8861-3517edf6f92a" xlink:href="rmti-20200930.xsd#rmti_TrifericDialysateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:to="loc_rmti_TrifericDialysateMember_a8e57b6e-6035-41ac-8861-3517edf6f92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember_890698c4-c4df-4ff8-939d-64accc853141" xlink:href="rmti-20200930.xsd#rmti_TrifericAPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:to="loc_rmti_TrifericAPIMember_890698c4-c4df-4ff8-939d-64accc853141" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipment"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="extended" id="id1bda592337449beb0c31f9100bb1212_PropertyAndEquipment"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="extended" id="i4f947068b74c46758b5925588f9a6bdf_PropertyAndEquipmentTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="extended" id="i268a8c0b5eee4d97b40a83f19ec8191e_PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_37f774d7-2518-48d0-a7da-b770b6c2cc98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_37f774d7-2518-48d0-a7da-b770b6c2cc98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0e73bfaf-c25a-464f-b50d-9be0977b5bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0e73bfaf-c25a-464f-b50d-9be0977b5bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_56678ad0-00de-435e-9b63-8824ed34ffa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_56678ad0-00de-435e-9b63-8824ed34ffa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_244d9f9d-13e6-4bb9-9dc7-e8c72d514cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_Depreciation_244d9f9d-13e6-4bb9-9dc7-e8c72d514cb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_996191a5-be53-4d0e-bb7e-a09afa383889_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_996191a5-be53-4d0e-bb7e-a09afa383889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7d43422c-0fe0-4524-bee5-2de263766b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7d43422c-0fe0-4524-bee5-2de263766b4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ca0f7082-4920-4724-9874-b9690a4b9394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ca0f7082-4920-4724-9874-b9690a4b9394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a5cef989-5413-4b30-a8b3-574bfe24758d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_OfficeEquipmentMember_a5cef989-5413-4b30-a8b3-574bfe24758d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_42a6c2f8-0ca9-4aba-aaba-f5acc07fc03a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_42a6c2f8-0ca9-4aba-aaba-f5acc07fc03a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilities"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="extended" id="i34ab91f394ec478da3d4624853816352_AccruedLiabilities"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="extended" id="ib2774b3452964420a062a715707ba819_AccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended" id="id265eefbe438419682bb0bcf5688cd4f_AccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenue" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenue"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/DeferredRevenue" xlink:type="extended" id="ia53e4e3fff194eb1ba17585a4e532310_DeferredRevenue"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="extended" id="i3c91e1119fc64eedb64f479a5694c8b5_DeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived_7f02a1e0-fbf9-4bfc-829c-e64b2ece9604" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_RevenueRecognitionReceived_7f02a1e0-fbf9-4bfc-829c-e64b2ece9604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_33d53968-7307-48d6-974b-c849ace1033c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_33d53968-7307-48d6-974b-c849ace1033c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3782e86a-f51a-4463-b37f-f940b8fa4426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3782e86a-f51a-4463-b37f-f940b8fa4426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredRevenueBenefitPercentage_a3e9aadc-db4c-4672-b62e-37d73231dd79" xlink:href="rmti-20200930.xsd#rmti_DeferredRevenueBenefitPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_DeferredRevenueBenefitPercentage_a3e9aadc-db4c-4672-b62e-37d73231dd79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PartialRefund_750ddaaa-56a7-4d68-a60c-f257e8e7decf" xlink:href="rmti-20200930.xsd#rmti_PartialRefund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_PartialRefund_750ddaaa-56a7-4d68-a60c-f257e8e7decf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:to="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e29dae9-fc9d-466b-a347-c587492de3b0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e29dae9-fc9d-466b-a347-c587492de3b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_90334684-1802-4cd8-accf-2ec475bf4bb3" xlink:href="rmti-20200930.xsd#rmti_BaxterHealthcareOrganizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_90334684-1802-4cd8-accf-2ec475bf4bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember_e8630fa8-c5cc-4788-be52-8460017ef893" xlink:href="rmti-20200930.xsd#rmti_WanbangBiopharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_WanbangBiopharmaceuticalMember_e8630fa8-c5cc-4788-be52-8460017ef893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember_1764e104-c9f0-488d-b809-615bbc74e827" xlink:href="rmti-20200930.xsd#rmti_SunPharmaAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_SunPharmaAgreementsMember_1764e104-c9f0-488d-b809-615bbc74e827" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember_c75d5dd1-64e4-4f5a-b59d-9114b474271a" xlink:href="rmti-20200930.xsd#rmti_JeilPharmaAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_JeilPharmaAgreementsMember_c75d5dd1-64e4-4f5a-b59d-9114b474271a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockholdersEquity" xlink:type="extended" id="i408dbe5cf16b4bcb9e91f93b0aa51a55_StockholdersEquity"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="extended" id="i416644d8f49a4e5bb4875c04e8ed609a_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f8ec5c4f-e546-4040-b857-80deabc1875e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f8ec5c4f-e546-4040-b857-80deabc1875e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7953e646-3d6f-4bae-97ce-1fff99dc991e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7953e646-3d6f-4bae-97ce-1fff99dc991e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d2737844-32c5-4866-a8c6-8a8bc5d4861b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d2737844-32c5-4866-a8c6-8a8bc5d4861b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_926c9051-6b49-42b1-8840-78031dfcd1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_926c9051-6b49-42b1-8840-78031dfcd1dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4791a45f-aec9-4f06-b1a7-f25d7cf37aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4791a45f-aec9-4f06-b1a7-f25d7cf37aaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_928245e2-02ae-4f7c-aaa9-23ad7062978d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_928245e2-02ae-4f7c-aaa9-23ad7062978d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_42398824-9a02-4b43-b6f5-b4fd17e9c46c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesIssued_42398824-9a02-4b43-b6f5-b4fd17e9c46c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_238b411d-b9d4-47b0-a69e-034f5f80e98c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_238b411d-b9d4-47b0-a69e-034f5f80e98c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares_7a7ab4a2-537e-4d9f-9b9c-243392b265db" xlink:href="rmti-20200930.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SalesAgreementThresholdSaleOfShares_7a7ab4a2-537e-4d9f-9b9c-243392b265db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39882ace-285a-4384-87d7-ea901887232c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39882ace-285a-4384-87d7-ea901887232c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_874ec90c-3bf2-437b-8a3e-5340e825a301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_874ec90c-3bf2-437b-8a3e-5340e825a301" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_85cfb972-2d5d-4304-b813-b07e5e26c372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_85cfb972-2d5d-4304-b813-b07e5e26c372" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b6d5739b-b118-44bc-83ac-33f7e0697cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b6d5739b-b118-44bc-83ac-33f7e0697cdb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_cdd9fe13-6b3c-456f-a4d7-ada5c03c0def" xlink:href="rmti-20200930.xsd#rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_cdd9fe13-6b3c-456f-a4d7-ada5c03c0def" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount_dab9e63b-6038-4990-b14c-f5b874224183" xlink:href="rmti-20200930.xsd#rmti_SaleofStockRemainingSalesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleofStockRemainingSalesAmount_dab9e63b-6038-4990-b14c-f5b874224183" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57b0891f-5496-4775-8d86-0f446bd249ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57b0891f-5496-4775-8d86-0f446bd249ca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_200162ac-48a6-4149-9f77-e75d8ea09daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_SharePrice_200162ac-48a6-4149-9f77-e75d8ea09daf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c678ae-8df5-401e-b26a-759f47fffe74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c678ae-8df5-401e-b26a-759f47fffe74" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b8fc7d36-4ec1-4fae-ad56-c67863c5018f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b8fc7d36-4ec1-4fae-ad56-c67863c5018f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0e0c87bc-cee9-4051-ab1d-16da8e16096d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0e0c87bc-cee9-4051-ab1d-16da8e16096d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_94bcd4c0-e50c-4366-98c7-0a11f5c410c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_94bcd4c0-e50c-4366-98c7-0a11f5c410c3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_0e19a430-c2c5-4b74-b369-64f78131eb86" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_0e19a430-c2c5-4b74-b369-64f78131eb86" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_4f47ce67-9fc0-427c-9060-01a23088e506" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_4f47ce67-9fc0-427c-9060-01a23088e506" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_10f8bc48-9e7b-48ce-8fe4-41e6845763b8" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_10f8bc48-9e7b-48ce-8fe4-41e6845763b8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_d9ebb99b-c8f0-4000-ab0d-b78b28e231d1" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_d9ebb99b-c8f0-4000-ab0d-b78b28e231d1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_2b081de9-dffd-4862-b6cf-663c56fb5861" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_2b081de9-dffd-4862-b6cf-663c56fb5861" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_b94c7718-c25e-4c20-9ff1-7b72bc3e93c4" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_b94c7718-c25e-4c20-9ff1-7b72bc3e93c4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_6e41368e-27a2-4adc-aa82-acc18ef2fc8a" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_6e41368e-27a2-4adc-aa82-acc18ef2fc8a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees_57f3882f-952d-4f94-8f4f-132f29043252" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeClearingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees_57f3882f-952d-4f94-8f4f-132f29043252" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_43012df2-64c2-47cc-bc7e-6cd5884261e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_43012df2-64c2-47cc-bc7e-6cd5884261e1" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_aa7e3ed2-1686-4228-9a1d-792f821a8331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_aa7e3ed2-1686-4228-9a1d-792f821a8331" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf988bfa-6d7e-4ae2-af00-337f0e676f74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf988bfa-6d7e-4ae2-af00-337f0e676f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_28d0ec73-2a06-4095-b7dd-70a4d7c85bea" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_AtthemarketOfferingMember_28d0ec73-2a06-4095-b7dd-70a4d7c85bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_a1ae0e8e-3362-4c4f-8cd1-56da3d8748a5" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_PublicOfferingMember_a1ae0e8e-3362-4c4f-8cd1-56da3d8748a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_073a078a-679c-45cf-8c53-b2049ff215de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_us-gaap_OverAllotmentOptionMember_073a078a-679c-45cf-8c53-b2049ff215de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RegisteredDirectOfferingMember_b6adc14d-cb99-4595-b521-dea6c7fd949d" xlink:href="rmti-20200930.xsd#rmti_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_RegisteredDirectOfferingMember_b6adc14d-cb99-4595-b521-dea6c7fd949d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56a6ca03-1312-4748-9003-0a734d5ec74a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:to="loc_srt_RangeMember_56a6ca03-1312-4748-9003-0a734d5ec74a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:to="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ade95bc4-b5c2-4d54-96ef-6b53f4171b1f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:to="loc_srt_MaximumMember_ade95bc4-b5c2-4d54-96ef-6b53f4171b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_80ff977c-2393-4b47-a869-cebd547184e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_80ff977c-2393-4b47-a869-cebd547184e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WarrantsMember_e9ba3d6a-f05d-4ff6-8c47-8e5742886b53" xlink:href="rmti-20200930.xsd#rmti_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:to="loc_rmti_WarrantsMember_e9ba3d6a-f05d-4ff6-8c47-8e5742886b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PreFundedWarrantsMember_e00e4999-ccd6-434a-a023-30d8080ee617" xlink:href="rmti-20200930.xsd#rmti_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:to="loc_rmti_PreFundedWarrantsMember_e00e4999-ccd6-434a-a023-30d8080ee617" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="extended" id="ibbf6aeb646144b2f8506d62872da435d_StockBasedCompensation"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="extended" id="i20e2235f32fa49ae9b00353e452286c4_StockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f38ff4e-73cb-47b0-85ad-aaab6da63755" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f38ff4e-73cb-47b0-85ad-aaab6da63755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_db3c5273-640e-465a-b599-6112c7dcc4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_db3c5273-640e-465a-b599-6112c7dcc4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_710b7750-6b41-4f21-a21d-752b9a1b4216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_710b7750-6b41-4f21-a21d-752b9a1b4216" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3357f5b2-2fad-4f58-8df0-454cc6db2ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3357f5b2-2fad-4f58-8df0-454cc6db2ba9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:to="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51140073-6db4-40b4-b941-776ccf215ad2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51140073-6db4-40b4-b941-776ccf215ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_e113cf94-68da-40da-87b4-2cbddf53ef0a" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_e113cf94-68da-40da-87b4-2cbddf53ef0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_11816f19-c468-4026-8790-e9d87c670cba" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_11816f19-c468-4026-8790-e9d87c670cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_b4ee3246-c92c-44a6-a815-de393dc1a678" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_b4ee3246-c92c-44a6-a815-de393dc1a678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_1bf6cc46-8c7f-4d04-b9d0-3d88002b5451" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_1bf6cc46-8c7f-4d04-b9d0-3d88002b5451" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended" id="i85dca76b212d4cf2b2567eab56a30c90_StockBasedCompensationSharebasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e40f2b7d-5111-44d5-899d-ae1b52a7c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e40f2b7d-5111-44d5-899d-ae1b52a7c32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:to="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56417d8-1c96-4818-bd0a-ba1e143b578d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56417d8-1c96-4818-bd0a-ba1e143b578d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:to="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_2841ae56-c34d-4164-a962-f80f8380a30d" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_2841ae56-c34d-4164-a962-f80f8380a30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_717acc2e-b0fb-4106-9127-003da7437936" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_717acc2e-b0fb-4106-9127-003da7437936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:to="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_271ed313-6e62-4b0d-8b85-c408ae20aed4" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_271ed313-6e62-4b0d-8b85-c408ae20aed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_f7c844f4-e40d-4932-aadc-a5d310b73c4c" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_f7c844f4-e40d-4932-aadc-a5d310b73c4c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationRestrictedStockAwardsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" id="i99988980827949f2ba0876f69c21d434_StockBasedCompensationRestrictedStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bc93ce1-5fd0-4687-9804-5ffde22e89c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bc93ce1-5fd0-4687-9804-5ffde22e89c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cc5d0f7-69de-4cd6-83d7-28db50798a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cc5d0f7-69de-4cd6-83d7-28db50798a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d153879a-0a9e-4715-b8e6-397ef7832f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d153879a-0a9e-4715-b8e6-397ef7832f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:to="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97b61bd6-98cf-4f42-a8bb-3e6a70236625_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97b61bd6-98cf-4f42-a8bb-3e6a70236625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_06f1c943-b4c3-44de-80f6-3e0af0755bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:to="loc_us-gaap_RestrictedStockMember_06f1c943-b4c3-44de-80f6-3e0af0755bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_8894a002-d24b-483c-b7c9-310c381f2c2e" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_8894a002-d24b-483c-b7c9-310c381f2c2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="extended" id="i12fccc54ec014e04afb99bad2ffd293f_StockBasedCompensationServiceBasedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4110d46f-14c9-4943-bd75-ed945b3e2cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4110d46f-14c9-4943-bd75-ed945b3e2cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39229e42-90d8-4b61-b472-6ba0cd4bfefb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39229e42-90d8-4b61-b472-6ba0cd4bfefb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04c2c9a5-e6af-443d-a75a-da97bb61c3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04c2c9a5-e6af-443d-a75a-da97bb61c3ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ebe22735-4300-43b3-9c8e-2bf07ccae5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ebe22735-4300-43b3-9c8e-2bf07ccae5c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5fd6e8c6-54c5-45af-9efe-3bf45478d6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8bfcd170-4c20-4611-b5bb-1d48fd1c751b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8bfcd170-4c20-4611-b5bb-1d48fd1c751b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64b95a97-ad90-4bc6-b6d7-eeceacf594d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64b95a97-ad90-4bc6-b6d7-eeceacf594d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_544abffa-9af3-44bf-a329-a64c630c54d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_544abffa-9af3-44bf-a329-a64c630c54d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02783abe-6f34-40a8-8a93-12c6a69c2aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02783abe-6f34-40a8-8a93-12c6a69c2aec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1cbf3dc-c591-4c05-ba58-ab4fef4f61d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c8b5e1a3-e7ef-46b9-8ca9-fd6253689321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c8b5e1a3-e7ef-46b9-8ca9-fd6253689321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b9df04c-35e2-4c02-861b-737b8432001a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b9df04c-35e2-4c02-861b-737b8432001a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6dcc75d1-d319-43f7-8f1d-2408dd2d936c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6dcc75d1-d319-43f7-8f1d-2408dd2d936c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66e82126-6423-4dec-b15d-eea265245c80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66e82126-6423-4dec-b15d-eea265245c80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_088d832f-91c5-40b8-8211-6f792198e4f6" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_088d832f-91c5-40b8-8211-6f792198e4f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2a734db6-e9df-48a0-a665-397073a8276b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2a734db6-e9df-48a0-a665-397073a8276b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_bf99defc-32fc-4b79-b7e6-2c3d7316582a" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_bf99defc-32fc-4b79-b7e6-2c3d7316582a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_2a19a7a3-3e1e-4618-a2f4-4e5c7d47cc8b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:to="loc_srt_ChiefFinancialOfficerMember_2a19a7a3-3e1e-4618-a2f4-4e5c7d47cc8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:to="loc_srt_RangeMember_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:to="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e228efef-9fd8-42aa-b2f0-5e26c0dacfaf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:to="loc_srt_MinimumMember_e228efef-9fd8-42aa-b2f0-5e26c0dacfaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_999f3276-c36d-4714-8269-7a45d7a63f5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:to="loc_srt_MaximumMember_999f3276-c36d-4714-8269-7a45d7a63f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_81bb62a4-177e-463b-be3b-e24eeca9a701" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_81bb62a4-177e-463b-be3b-e24eeca9a701" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="extended" id="iaf058c2e711e4a85a84d36a234916382_StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecdc1e48-e0cd-42ba-ae44-e3121671dd96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecdc1e48-e0cd-42ba-ae44-e3121671dd96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44a87a37-3e4c-48c9-8a20-43379e539c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44a87a37-3e4c-48c9-8a20-43379e539c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd4d1bc-4bd5-41e6-b56a-231354849ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6354c994-2e52-4ce4-a692-e57595e775c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6354c994-2e52-4ce4-a692-e57595e775c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_32aa1759-84c6-4659-8c69-0639671b47bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_32aa1759-84c6-4659-8c69-0639671b47bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_880b7cfa-100c-428c-a56a-c15e49591153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_183b8002-b21a-4d2e-8bd3-ec396492382f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_183b8002-b21a-4d2e-8bd3-ec396492382f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_50922f9a-f179-4303-80d5-4f8b226a2855" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_50922f9a-f179-4303-80d5-4f8b226a2855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_826a1c4a-f25f-4fe9-b546-bc85c866e735" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_826a1c4a-f25f-4fe9-b546-bc85c866e735" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:to="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_8a0e69b3-3cc3-4a53-8d51-6389f3b4eea8" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_8a0e69b3-3cc3-4a53-8d51-6389f3b4eea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:to="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fca6f144-c77e-4786-8e03-b77f2e01dad3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fca6f144-c77e-4786-8e03-b77f2e01dad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_95deceb5-4020-4a0a-8c17-79d77c676828" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_95deceb5-4020-4a0a-8c17-79d77c676828" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="extended" id="i0faa1c0e14b448e7854fb9b165670539_StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0b7a6a39-9731-4c95-9a9a-6b856db0e216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0b7a6a39-9731-4c95-9a9a-6b856db0e216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_48e4cbf3-ea5f-4391-b073-bb17d5f92e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_48e4cbf3-ea5f-4391-b073-bb17d5f92e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e1a07add-173c-455d-82a5-85c7f54ba035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e1a07add-173c-455d-82a5-85c7f54ba035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fb118163-9b66-4485-9b1e-36747eb436db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fb118163-9b66-4485-9b1e-36747eb436db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_25588fa1-431c-4238-b5f7-594efef37a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_25588fa1-431c-4238-b5f7-594efef37a73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f938ac12-f821-4aaf-a57e-2d5e5e0bdf12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f938ac12-f821-4aaf-a57e-2d5e5e0bdf12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:to="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e727dfe-8619-465c-9dc2-f2c5bf8200d6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:to="loc_srt_RangeMember_9e727dfe-8619-465c-9dc2-f2c5bf8200d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:to="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4548c03f-11b3-4c92-b688-c35ce57e2847" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:to="loc_srt_MinimumMember_4548c03f-11b3-4c92-b688-c35ce57e2847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_145c1158-938e-4d5c-937b-14c3405ba171" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:to="loc_srt_MaximumMember_145c1158-938e-4d5c-937b-14c3405ba171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:to="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91517d3a-2f16-4a33-b219-a41d88b55a76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91517d3a-2f16-4a33-b219-a41d88b55a76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_fd64985e-17b4-475c-81c4-cde7008d572a" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_fd64985e-17b4-475c-81c4-cde7008d572a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended" id="i23f52155694341c5aa41879187684439_StockBasedCompensationServiceBasedStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8fab633-38f3-42ba-b554-501e5c0192f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8fab633-38f3-42ba-b554-501e5c0192f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d9490251-bd5c-4510-8c1b-17392a18bbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d9490251-bd5c-4510-8c1b-17392a18bbcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c27d3b59-4ff4-42a4-a7a9-c31feb558667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c27d3b59-4ff4-42a4-a7a9-c31feb558667" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ca510bf-59d5-40f2-9059-8144295ecd66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ca510bf-59d5-40f2-9059-8144295ecd66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2b71e321-21a0-49ee-9045-8f2686389dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2b71e321-21a0-49ee-9045-8f2686389dfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7ed16628-65f5-4bf4-86da-3c59d2ef3c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30ed2d2f-2a1c-411e-8006-3f7b1830568f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30ed2d2f-2a1c-411e-8006-3f7b1830568f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_49a2e70e-af11-4875-bd2f-0e99e575ef73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_49a2e70e-af11-4875-bd2f-0e99e575ef73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5defbeee-0d93-4df0-be76-7e79accf4125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5defbeee-0d93-4df0-be76-7e79accf4125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01f17208-009a-439f-a653-49652d36e00b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01f17208-009a-439f-a653-49652d36e00b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80c48031-f95a-44ca-ad9f-f6f9b47308c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80c48031-f95a-44ca-ad9f-f6f9b47308c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_615a5178-22c4-4e77-9974-ab8e38003a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_615a5178-22c4-4e77-9974-ab8e38003a8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14e17ae5-dbe6-4ce5-8894-37639f7c1500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb3f2352-09a2-4474-b25d-310f32f52f69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb3f2352-09a2-4474-b25d-310f32f52f69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a5ad72b-36bf-457e-9d8e-0b973ae3d60e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a5ad72b-36bf-457e-9d8e-0b973ae3d60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_0f84eb9e-6cad-4322-b64a-3f58e408d56b" xlink:href="rmti-20200930.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_0f84eb9e-6cad-4322-b64a-3f58e408d56b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b20bfaa-b231-457b-8361-2a32c1748651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b20bfaa-b231-457b-8361-2a32c1748651" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d18f1622-7229-480c-8b3f-628926cdb491" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d18f1622-7229-480c-8b3f-628926cdb491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_5277046d-6833-4863-a3fd-16f7887d60ca" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_5277046d-6833-4863-a3fd-16f7887d60ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ffa5838-f949-4527-801b-c1e44a2bd98b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ffa5838-f949-4527-801b-c1e44a2bd98b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:to="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69aa105a-3819-42ed-86f2-4c02c61b99ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69aa105a-3819-42ed-86f2-4c02c61b99ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_bf2eb26d-2f72-4e91-86f2-10772d3df074" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_bf2eb26d-2f72-4e91-86f2-10772d3df074" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsOthersDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="extended" id="i4dd9f6fb05d14287adb49b362799eb0d_StockBasedCompensationServiceBasedStockOptionsOthersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c392e3fa-1ab1-47bf-8220-333683b70252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c392e3fa-1ab1-47bf-8220-333683b70252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9f3e3182-280e-4406-86c8-99d217e90391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9f3e3182-280e-4406-86c8-99d217e90391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b7340d17-527c-4f1b-9bbd-c07c7984b3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b7340d17-527c-4f1b-9bbd-c07c7984b3b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_49cf04b0-592e-4b31-99e9-66ed392fd146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_49cf04b0-592e-4b31-99e9-66ed392fd146" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_851e1077-9e7e-4b1f-ab3b-af9abad7c6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_851e1077-9e7e-4b1f-ab3b-af9abad7c6bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_3d6da65b-25be-409f-8968-7a48175be86d" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_3d6da65b-25be-409f-8968-7a48175be86d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2298bcca-e0a7-40ab-8070-3ab3858cb59c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2298bcca-e0a7-40ab-8070-3ab3858cb59c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:to="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cabd304c-b521-40c9-99ee-9a66cb624d5c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cabd304c-b521-40c9-99ee-9a66cb624d5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CertainEmployeesMember_0f5c5954-0d6d-4c73-8e6a-10708e06bc20" xlink:href="rmti-20200930.xsd#rmti_CertainEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_CertainEmployeesMember_0f5c5954-0d6d-4c73-8e6a-10708e06bc20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_2fd96e03-103e-4cdd-a28e-e66096fffc8e" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_2fd96e03-103e-4cdd-a28e-e66096fffc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_ea631b08-2656-4521-aec5-923f6b8c31df" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:to="loc_srt_ChiefFinancialOfficerMember_ea631b08-2656-4521-aec5-923f6b8c31df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_db6220d3-c0b0-4419-a409-54bc8ff1a084" xlink:href="rmti-20200930.xsd#rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_db6220d3-c0b0-4419-a409-54bc8ff1a084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:to="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd92ed07-02a1-4700-ad6a-77314d603310_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd92ed07-02a1-4700-ad6a-77314d603310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_a147ae08-cfaa-4a7c-80ce-3c1e39b2ce6f" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_a147ae08-cfaa-4a7c-80ce-3c1e39b2ce6f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended" id="iddba7a9277a74a2e8982c7ce6c2132bc_StockBasedCompensationPerformanceBasedStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f77c6c67-7326-4d31-9f90-a48a2e818391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f77c6c67-7326-4d31-9f90-a48a2e818391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52baa656-4d0f-476b-9629-c8268eaaa20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52baa656-4d0f-476b-9629-c8268eaaa20d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_432e7caa-0e9e-45f8-a898-524ede56f855" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_432e7caa-0e9e-45f8-a898-524ede56f855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3803fce0-0bf6-4c06-a797-7a29c81547b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8ffc59c8-82ab-4ae3-ac7d-6bf6ec3b4b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8ffc59c8-82ab-4ae3-ac7d-6bf6ec3b4b31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12c6e958-2182-4f30-a2a0-aa6759b86996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12c6e958-2182-4f30-a2a0-aa6759b86996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2d71a92-c66b-476d-9dd1-a4a400269120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2d71a92-c66b-476d-9dd1-a4a400269120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9729215-5f8d-4878-9dc4-390e7d16e618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9729215-5f8d-4878-9dc4-390e7d16e618" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5c4a40d-add1-4da9-bde8-30f3edcf5d95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6079e53d-fedb-4bd9-8f8f-54f4b296c440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6079e53d-fedb-4bd9-8f8f-54f4b296c440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8dfa737a-65db-45ec-b69c-fda77ead7c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8dfa737a-65db-45ec-b69c-fda77ead7c25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_78eb40bc-79f1-4478-a2d1-b5cfcb446508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_78eb40bc-79f1-4478-a2d1-b5cfcb446508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_d9f7a3af-df13-4903-86a2-11e76e553079" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_d9f7a3af-df13-4903-86a2-11e76e553079" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:to="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_972163b1-23c2-4598-8bcf-4dd3bff02449_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_972163b1-23c2-4598-8bcf-4dd3bff02449_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_466a145a-a176-4e2c-a205-79c24a3eeec6" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_466a145a-a176-4e2c-a205-79c24a3eeec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:to="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e61a7b-8fbb-4e5b-8180-79c029b76181_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e61a7b-8fbb-4e5b-8180-79c029b76181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_92489822-7f17-46b0-86e5-ab71ccc575b0" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_92489822-7f17-46b0-86e5-ab71ccc575b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="extended" id="i430e6e26d2a248f6ad50befc39de2cb2_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="idb7acf90b4b449d0bfd7260fa3b867af_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements_f246891e-2c97-4a4a-9dc1-46fbffd4714c" xlink:href="rmti-20200930.xsd#rmti_NumberOfAdditionalAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_NumberOfAdditionalAgreements_f246891e-2c97-4a4a-9dc1-46fbffd4714c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_711af8ca-084b-46fb-91de-b7a32cdb1965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_711af8ca-084b-46fb-91de-b7a32cdb1965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyNumberOfInstallmentPayments_6081561e-2812-4eda-99a1-debb5d6db2bc" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyNumberOfInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyNumberOfInstallmentPayments_6081561e-2812-4eda-99a1-debb5d6db2bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties_06095c2f-ae30-4b18-aef0-da4d375a7b5d" xlink:href="rmti-20200930.xsd#rmti_InstallmentPaymentToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_InstallmentPaymentToRelatedParties_06095c2f-ae30-4b18-aef0-da4d375a7b5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_3308162a-9608-4332-936e-b5ddef3b6a7c" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_3308162a-9608-4332-936e-b5ddef3b6a7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_1f43b9ac-9a80-4f78-9aa7-08b847810cb5" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_1f43b9ac-9a80-4f78-9aa7-08b847810cb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsToAcquireAssets_33d24889-1181-42b7-b373-b4d829d6feae" xlink:href="rmti-20200930.xsd#rmti_PaymentsToAcquireAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_PaymentsToAcquireAssets_33d24889-1181-42b7-b373-b4d829d6feae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AssetAcquisitionMilestonePayments_aa8591ad-fc23-47f2-b62e-d4eca4d118a0" xlink:href="rmti-20200930.xsd#rmti_AssetAcquisitionMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_AssetAcquisitionMilestonePayments_aa8591ad-fc23-47f2-b62e-d4eca4d118a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:to="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffb6accd-a659-400b-b395-d00d6d392bea_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffb6accd-a659-400b-b395-d00d6d392bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_61f2d744-2771-4cf3-9358-c88f6aacb434" xlink:href="rmti-20200930.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:to="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_61f2d744-2771-4cf3-9358-c88f6aacb434" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b86bc345-3185-47d6-b2f1-37e99cd89792_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b86bc345-3185-47d6-b2f1-37e99cd89792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_MasterServicesAndIpAgreementMember_b46a3a4d-8e77-4b56-81c0-870aa8847ada" xlink:href="rmti-20200930.xsd#rmti_MasterServicesAndIpAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:to="loc_rmti_MasterServicesAndIpAgreementMember_b46a3a4d-8e77-4b56-81c0-870aa8847ada" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/Leases" xlink:type="simple" xlink:href="rmti-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/Leases" xlink:type="extended" id="if948bb24c1b0424fa26309759a2e8366_Leases"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LeasesTables" xlink:type="extended" id="i3e674026c0fa48739ff285ebf7a274c3_LeasesTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i6338352d89014c0da9550679aa483c16_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9a287cf8-086b-45cf-b83b-84d16985f236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9a287cf8-086b-45cf-b83b-84d16985f236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_eb1fe268-ed0f-4ecf-9085-d93d6b90b50a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_eb1fe268-ed0f-4ecf-9085-d93d6b90b50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9132a828-0780-44ad-9bce-d5ac1eabf0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_OperatingLeaseLiability_9132a828-0780-44ad-9bce-d5ac1eabf0c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_404805a5-f527-4579-9b84-853f8076b3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_404805a5-f527-4579-9b84-853f8076b3c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41b77294-e922-4785-84a6-f8135ed66bbc_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:to="loc_srt_RangeMember_41b77294-e922-4785-84a6-f8135ed66bbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:to="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8137fa91-7c42-4c80-b8a7-fe3782fdbc43" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:to="loc_srt_MaximumMember_8137fa91-7c42-4c80-b8a7-fe3782fdbc43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80a6ac02-9b15-4a3d-b643-3b83981120d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80a6ac02-9b15-4a3d-b643-3b83981120d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityOneMember_abbf5b70-eab7-42cf-bd12-3f0175c3d69b" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:to="loc_rmti_LeaseFacilityOneMember_abbf5b70-eab7-42cf-bd12-3f0175c3d69b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityTwoMember_623fcf9f-2e31-45cf-9d45-da05277ba6a7" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:to="loc_rmti_LeaseFacilityTwoMember_623fcf9f-2e31-45cf-9d45-da05277ba6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a0506564-861c-4479-a377-056a0e851046_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:to="loc_srt_SegmentGeographicalDomain_a0506564-861c-4479-a377-056a0e851046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:to="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_c6480d89-65d0-48be-a3dc-57ad4b0bab82" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_MI_c6480d89-65d0-48be-a3dc-57ad4b0bab82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_d28c2f0d-dab9-42d6-9ffd-c62dea6109d5" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_TX_d28c2f0d-dab9-42d6-9ffd-c62dea6109d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_aae521f5-01da-4686-93f8-766fedb35b44" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_SC_aae521f5-01da-4686-93f8-766fedb35b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_509a9990-98b2-4b55-996e-930716ec3adc" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_NJ_509a9990-98b2-4b55-996e-930716ec3adc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesSummaryofOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="extended" id="iae0b816023fa44ad968fb2d924effef5_LeasesSummaryofOperatingLeasesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="extended" id="i6586cd92e5a1442abd506702137be000_LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="extended" id="idf9a1cc3d57f44708873bb8be4e19dcf_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ia676cdc18474491684238da774e1953b_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_f766b0b3-d2df-42dc-8d5b-46920829b587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_f766b0b3-d2df-42dc-8d5b-46920829b587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_58497ee8-f93a-4c50-bd06-8db9c71322db" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_58497ee8-f93a-4c50-bd06-8db9c71322db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_7263d271-441e-4f29-b679-79e62811be78" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_7263d271-441e-4f29-b679-79e62811be78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7c6e83e3-b7ec-425c-b969-4b31c2b52e07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7c6e83e3-b7ec-425c-b969-4b31c2b52e07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_38e659d4-031f-4634-9a3a-2466302c8fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LitigationSettlementExpense_38e659d4-031f-4634-9a3a-2466302c8fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:to="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cd2885bc-300e-478a-8637-788b7eb9c952" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:to="loc_srt_ScenarioForecastMember_cd2885bc-300e-478a-8637-788b7eb9c952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:to="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d15e709-bae6-4f3e-8cd7-0273328361c5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:to="loc_srt_LitigationCaseTypeDomain_2d15e709-bae6-4f3e-8cd7-0273328361c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:to="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SettlementAgreementWithAllPartiesMember_ffa03688-d8e0-4231-8155-b70a68a100f6" xlink:href="rmti-20200930.xsd#rmti_SettlementAgreementWithAllPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:to="loc_rmti_SettlementAgreementWithAllPartiesMember_ffa03688-d8e0-4231-8155-b70a68a100f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreement"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="extended" id="i7faf5d15a7834126b9fa6822181b647a_LoansandSecurityAgreement"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementTables"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="extended" id="i4260dc8e3f6943aca6eb45223fe03e3c_LoansandSecurityAgreementTables"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="extended" id="id0a14ae2a34a4163a90441dd17013773_LoansandSecurityAgreementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5e31bdf4-9ca6-47e9-bb7c-488e28018ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5e31bdf4-9ca6-47e9-bb7c-488e28018ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cde7963d-fa7c-47d8-aa4e-3ed1610626a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cde7963d-fa7c-47d8-aa4e-3ed1610626a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_fdc99f3e-9fcf-4689-9506-60af4808db9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_fdc99f3e-9fcf-4689-9506-60af4808db9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_d5a8ee51-c2ec-4b75-a68d-49671773ee70" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_d5a8ee51-c2ec-4b75-a68d-49671773ee70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e27384e6-fd2f-4162-9ca6-93d24794deac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e27384e6-fd2f-4162-9ca6-93d24794deac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4a997c47-b009-490c-ba95-1b951a28a9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4a997c47-b009-490c-ba95-1b951a28a9c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_178af8e8-e571-4909-8b64-d7eaa0d6fbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_178af8e8-e571-4909-8b64-d7eaa0d6fbe7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_52f303da-b055-4fd1-8d4b-0f5940c3182f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_52f303da-b055-4fd1-8d4b-0f5940c3182f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_12ecff56-3f13-4654-b980-315e78a14985" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_12ecff56-3f13-4654-b980-315e78a14985" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_35a55ae8-5c32-4685-8bd2-a3e9be38b2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_InterestExpenseDebt_35a55ae8-5c32-4685-8bd2-a3e9be38b2e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_107c1c4f-562e-497b-adfb-c1eda34c0b40" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_107c1c4f-562e-497b-adfb-c1eda34c0b40" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_c791f05c-dc02-45d7-be2a-f1c60fff5dc4" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_c791f05c-dc02-45d7-be2a-f1c60fff5dc4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ebe3291-7225-490b-b58b-5c43a0c3449e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ebe3291-7225-490b-b58b-5c43a0c3449e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_dced0f91-733a-4432-a604-6aa36f852f28" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_dced0f91-733a-4432-a604-6aa36f852f28" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20ef5c90-5261-4b02-a5b6-497611412c42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20ef5c90-5261-4b02-a5b6-497611412c42" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9165deaa-d07b-4a92-a3cb-1e9f6edbb189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9165deaa-d07b-4a92-a3cb-1e9f6edbb189" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_42bf07ac-cc72-4ef3-96c6-86d9c0322db7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_LongTermDebt_42bf07ac-cc72-4ef3-96c6-86d9c0322db7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88bbbdaa-217a-4e43-8306-f7df443d4ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88bbbdaa-217a-4e43-8306-f7df443d4ec9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6c35fc32-d002-493b-90a1-4596b6fccff5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6c35fc32-d002-493b-90a1-4596b6fccff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_af794d77-1871-42ec-8045-427a9c4d0b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:to="loc_us-gaap_MediumTermNotesMember_af794d77-1871-42ec-8045-427a9c4d0b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7d8acda-ab14-44e5-82bb-0412673db6e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7d8acda-ab14-44e5-82bb-0412673db6e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:href="rmti-20200930.xsd#rmti_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:to="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember_d6c669b1-1bd4-41a9-b115-29eccc681690" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:to="loc_rmti_TermLoanTrancheOneMember_d6c669b1-1bd4-41a9-b115-29eccc681690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:to="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember_bb2361b6-ef49-460a-a787-353ea674da61" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:to="loc_rmti_TermLoanTrancheTwoMember_bb2361b6-ef49-460a-a787-353ea674da61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember_23927c3e-3d62-44e1-a326-5a3b8f84ef59" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:to="loc_rmti_TermLoanTrancheThreeMember_23927c3e-3d62-44e1-a326-5a3b8f84ef59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72e4cbc1-8610-41f6-9420-b493d5f6f346_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:to="loc_srt_RangeMember_72e4cbc1-8610-41f6-9420-b493d5f6f346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:to="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0deb2db-04a8-4519-a4e6-2c30c4ef18ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:to="loc_srt_MinimumMember_d0deb2db-04a8-4519-a4e6-2c30c4ef18ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a6a7458-107a-4371-b7b0-5842ec48c713" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:to="loc_srt_MaximumMember_0a6a7458-107a-4371-b7b0-5842ec48c713" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended" id="i0bfbb5a28d6644439096feec5783a97d_LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6f7d21ac-f99d-40ff-8fce-f38ba25d5bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6f7d21ac-f99d-40ff-8fce-f38ba25d5bd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8fe6ad3e-b35e-4b55-8713-633eee475192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8fe6ad3e-b35e-4b55-8713-633eee475192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9db5e38e-9c3c-4345-8335-7ed034850887" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9db5e38e-9c3c-4345-8335-7ed034850887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_007345f0-0511-4e9d-ae3d-192c41a5c290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_007345f0-0511-4e9d-ae3d-192c41a5c290" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_fa902b3d-9720-459e-b5c3-7ba01f82e95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_fa902b3d-9720-459e-b5c3-7ba01f82e95b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4d04ddcc-f593-4ba0-bc14-d360e1bcce16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4d04ddcc-f593-4ba0-bc14-d360e1bcce16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_55bc7839-e405-4427-ac03-25a1139c9419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_55bc7839-e405-4427-ac03-25a1139c9419" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e1d5faa3-1946-4f06-a1bd-3f619c42adfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e1d5faa3-1946-4f06-a1bd-3f619c42adfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_8b65483a-33c5-417f-b8e8-eeaca19ab743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:to="loc_us-gaap_MediumTermNotesMember_8b65483a-33c5-417f-b8e8-eeaca19ab743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:to="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dae5b080-7751-408a-8072-7941ffbee1b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dae5b080-7751-408a-8072-7941ffbee1b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_7f9a7452-595d-4106-818d-8853beabcbe3" xlink:href="rmti-20200930.xsd#rmti_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:to="loc_rmti_TermLoanMember_7f9a7452-595d-4106-818d-8853beabcbe3" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rmti-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_36ef494a-c4c5-48e4-b1a8-b10b95986b58_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_AtthemarketOfferingMember_944e832d-5a19-4901-9ece-d8a93c421e2c_terseLabel_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market offering</link:label>
    <link:label id="lab_rmti_AtthemarketOfferingMember_label_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_rmti_AtthemarketOfferingMember_documentation_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AtthemarketOfferingMember" xlink:to="lab_rmti_AtthemarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aa84e3f3-d723-4314-8b6c-fd207a6cd00a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_f0f87e91-708e-496e-836f-f8d45848be8e_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greer, South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2f109730-2fac-45b6-8ecd-0a22fc500790_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_52667960-3278-4487-9689-67a7400c26be_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_534ea507-2210-4c88-ade0-44620a83de46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b3f421db-8678-42bb-b171-5aa8fb4e273c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_58fe040c-1fa3-4a9a-8d1f-2813f686a176_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e587081e-5db2-46d1-9708-bf3a5c5c36a1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f4c44025-3f18-4f54-8ecd-adf97ccb9268_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DrugProductSalesMember_64cb82b1-a4cc-40f7-8b3c-06f9e300d270_terseLabel_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product sales</link:label>
    <link:label id="lab_rmti_DrugProductSalesMember_label_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Sales [Member]</link:label>
    <link:label id="lab_rmti_DrugProductSalesMember_documentation_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember" xlink:href="rmti-20200930.xsd#rmti_DrugProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugProductSalesMember" xlink:to="lab_rmti_DrugProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e7f55cda-aec6-4dec-92ec-d235877888b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c8f19a7-555b-4ed1-9c15-58d1ef46da21_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8b5ba5c-8d5c-4eac-a886-21cc245c63cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c650f666-bf9e-4730-b285-018286c28a34_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c567d01-bd8e-47aa-aaa9-973140d8e190_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e67a14bd-1ca3-4a7a-b695-50e2b5e9b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2f80ac73-4e41-41ca-8dc8-3c74b3e36847_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7084aa4d-d7f7-4e86-9661-9be6c8acbfa2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b7cff199-6b01-4602-9e0c-55cc567f13a0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_60f31730-f2b7-4cc7-9e6b-7daeca492eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the Issuance of Common Stock / Public Offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_20112681-b962-4692-a7f4-2c3704582735_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_5a695980-074d-463c-be47-956ba24f90a1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Inventory Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_cab5ccaa-fe6e-4aa2-ac04-d9788ee205dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eb91dec0-13aa-4043-ba97-1371b1ce8eba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available for sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce7f84db-8b77-4ade-8ed8-af7546069976_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76d7880b-1410-4f00-b6cd-2b27f12bb360_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5b6d559f-ea5a-461d-bb7a-5eee6a25dc58_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_d5459962-09f6-4172-8c0a-775535184622_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_AveragePaymentTermOfCustomers_1a3b13fd-a7e0-4d02-b699-4804fb3fb66e_terseLabel_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers average payment term</link:label>
    <link:label id="lab_rmti_AveragePaymentTermOfCustomers_label_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Payment Term of Customers</link:label>
    <link:label id="lab_rmti_AveragePaymentTermOfCustomers_documentation_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average payment term of customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfCustomers" xlink:href="rmti-20200930.xsd#rmti_AveragePaymentTermOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AveragePaymentTermOfCustomers" xlink:to="lab_rmti_AveragePaymentTermOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6692fe9d-17c7-4aef-bcf6-0292943c9a70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized issuance costs and unaccreted discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8d3871d1-d3e2-461b-af8b-6f6e2684718b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a3df3f25-9559-42c1-bd66-64514a3ead82_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_5b338a81-1e66-4052-97df-d2af1092485c_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_532678e7-a31b-4aff-8e0b-729fe9fbbc00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db3dbfc-8037-4bc8-a956-11e9ba71d79f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, additional percentage added to base percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_ec962e54-0d1d-40c4-a325-d3970f284f2f_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief financial officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4741bdbe-4ac1-4aa6-bad6-4df991e196a7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98ac45ec-02f4-4466-9339-d48c509c1ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average selling price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0f6a1647-d945-4910-af3d-1fcb18309288_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3125ddc0-d9fb-46f2-8317-5862c3c02627_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_760d2de9-ba9b-417a-825a-29acd7e8bed4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_314eeb9d-adbb-4e73-bdee-52f29ffdce81_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_db856139-1262-4f8f-8aa1-c4f30bd78687_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_94440c5c-768f-4e55-8a8e-d4fc4328a4f9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_4971bb98-cb31-4f93-9824-6f3e1e11102c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_1b57f0d6-cc98-444f-9d67-48d7ce8b46df_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f3a54b4c-ed45-4d40-b966-98d7a68d45c3_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a6abe6f-945b-4561-9632-7f67df819b62_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_40ce8dc1-1480-4f93-85d4-dcb0ba71d3e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d5a5b012-6c3f-4498-ac44-b9dafe3175f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cf5213b4-b38d-40c3-9394-03b5ee4e184a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bef1ff6c-2535-4d30-8fda-e061e3578670_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets exchanged for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_e4c5b761-c240-4f60-b835-f6c6dc1ae7bd_terseLabel_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research&#160;&amp; Development Expense</link:label>
    <link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Related Liabilities, Current</link:label>
    <link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:href="rmti-20200930.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:to="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ba06b12a-c38f-468c-885d-7be9ac41b06f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_2275f980-3759-416c-89a9-b1245d98d5c9_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:to="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_WanbangBiopharmaceuticalMember_26848f54-868c-466c-a6c8-1bea1ac22df2_terseLabel_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wanbang Biopharmaceutical</link:label>
    <link:label id="lab_rmti_WanbangBiopharmaceuticalMember_label_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wanbang Biopharmaceutical [Member]</link:label>
    <link:label id="lab_rmti_WanbangBiopharmaceuticalMember_documentation_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (&#8220;Wanbang&#8221;) for the rights to commercialize the Triferic and Calcitriol drugs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember" xlink:href="rmti-20200930.xsd#rmti_WanbangBiopharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WanbangBiopharmaceuticalMember" xlink:to="lab_rmti_WanbangBiopharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_bc88fdf1-53e2-41b7-9ac6-a79a77b2d4c5_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - performance based awards</link:label>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_6a29bd4e-35f8-4e61-8b02-f9c99b4e6fa7_terseLabel_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of raw materials to be paid</link:label>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_label_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Percentage Of Raw Materials To Be Paid</link:label>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_documentation_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Percentage Of Raw Materials To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:to="lab_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ea46ccd2-3a66-448b-9663-e2c791c259d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_cfbf1f14-db82-4a3c-b563-e7eb5356e8bc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_CurrentAndNonCurrentInventory_ff3439bf-7bb6-495a-97c0-b747776a0117_totalLabel_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_rmti_CurrentAndNonCurrentInventory_label_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Non Current Inventory</link:label>
    <link:label id="lab_rmti_CurrentAndNonCurrentInventory_documentation_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of current and non-current inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory" xlink:href="rmti-20200930.xsd#rmti_CurrentAndNonCurrentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CurrentAndNonCurrentInventory" xlink:to="lab_rmti_CurrentAndNonCurrentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_39b33d63-dcba-41f1-b555-029ba6a3a622_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional debt discount recognized</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c4d78d0a-0e19-4c30-8e1a-3604104c2946_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4288abc7-f031-4809-b6b2-882e5dafb06c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6e7a6e88-cb74-4e94-95cf-b64f1db1ea35_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_19d04453-ba20-4fb6-8de2-0ae1582d8c47_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b70e0c9b-5aa2-4ae7-a0c3-5cf0ba53d356_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fae3868-c5ea-4232-b72a-df7fddca00e3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred License Revenue - Long-Term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PerformanceBasedAwardsMember_a8d3b79e-cde6-40d8-8d3c-b17de0fe0811_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based awards</link:label>
    <link:label id="lab_rmti_PerformanceBasedAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Awards [Member]</link:label>
    <link:label id="lab_rmti_PerformanceBasedAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to performance based awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedAwardsMember" xlink:to="lab_rmti_PerformanceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17ea6579-7f15-4de8-bacb-1a5679b1d02e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30ec3ec1-f67f-4445-9e7f-fc6344a9e03e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TrifericInventoryMember_8de47151-9402-453e-9812-97612be0184b_terseLabel_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory</link:label>
    <link:label id="lab_rmti_TrifericInventoryMember_label_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory [Member]</link:label>
    <link:label id="lab_rmti_TrifericInventoryMember_documentation_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember" xlink:href="rmti-20200930.xsd#rmti_TrifericInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericInventoryMember" xlink:to="lab_rmti_TrifericInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_68ddf4c8-dcf3-474f-8d43-cb2ed855b320_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bc5ef82d-e330-4ba8-b584-47d6d44008c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0c0e9534-11e4-4198-adb6-3f423612e3c2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6ba480be-7c46-491f-bb3c-a78279f9c7e6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cecd5abb-0bdb-4cb5-9158-e17f7bd383e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_AveragePaymentTermOfDistributors_c988c6a2-6200-4fad-8d8f-d1df55ec66cd_terseLabel_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributors average payment term</link:label>
    <link:label id="lab_rmti_AveragePaymentTermOfDistributors_label_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Payment Term of Distributors</link:label>
    <link:label id="lab_rmti_AveragePaymentTermOfDistributors_documentation_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average payment term of distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfDistributors" xlink:href="rmti-20200930.xsd#rmti_AveragePaymentTermOfDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AveragePaymentTermOfDistributors" xlink:to="lab_rmti_AveragePaymentTermOfDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_BaxterHealthcareOrganizationMember_d2f65ef9-9596-48ad-b819-ea78822492b3_terseLabel_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization</link:label>
    <link:label id="lab_rmti_BaxterHealthcareOrganizationMember_label_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization [Member]</link:label>
    <link:label id="lab_rmti_BaxterHealthcareOrganizationMember_documentation_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember" xlink:href="rmti-20200930.xsd#rmti_BaxterHealthcareOrganizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_BaxterHealthcareOrganizationMember" xlink:to="lab_rmti_BaxterHealthcareOrganizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0bf651be-09ab-4f8d-b7ba-16f2da9d2483_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_24b11f51-f964-47b0-ad1a-e5de39f0cc81_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_f19fa6f2-af9c-4a69-93e3-0563fe83173b_terseLabel_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of raw materials paid</link:label>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_label_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Percentage Of Raw Materials Paid</link:label>
    <link:label id="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_documentation_en-US" xlink:label="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Percentage Of Raw Materials Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:to="lab_rmti_SupplyAgreementPercentageOfRawMaterialsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_605f98c4-e186-4522-86c6-375aa6a0fb10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e6d17dd5-98d5-42bb-85b1-17d806654112_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_643dd936-d7f8-49c9-b612-c2bcace29e50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_8bd93a81-8c50-4e7c-b01f-5be4f9e3bf20_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_fbcd4939-d3db-4a3a-83c9-268916b28d94_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_9f7a6b30-2246-48c2-93da-2094d3319741_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount payable to financial advisory firm for services related to offering</link:label>
    <link:label id="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_label_en-US" xlink:label="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Amount Payable For Services Related To Offering</link:label>
    <link:label id="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Amount Payable For Services Related To Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:to="lab_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_df86be99-74d0-4e3c-be76-1ff8e2d8b098_terseLabel_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for which company is entitled to make interest-only payments</link:label>
    <link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_label_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest-Only Payments</link:label>
    <link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_documentation_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest-Only Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:to="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bd2b41f1-fe77-4b11-a17c-5e6556414edf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_70a7ba82-27a0-4261-adeb-622936238915_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1d2341f-6620-4407-a685-9bf06b7189ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_ec2dabef-e6be-43b1-823e-4b32d2b5dc6a_terseLabel_en-US" xlink:label="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Income</link:label>
    <link:label id="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:href="rmti-20200930.xsd#rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:to="lab_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_aaa4b9c8-8cdd-4903-bf48-c41b121b1b7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, which are included in "Trade and other receivables"</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_db397f9d-02a9-44cc-9657-430619985f4c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_28d7c7f6-d0c1-4d0e-a740-abee798c5df6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_688271fe-f6e0-45be-b02e-9a0246027d27_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_8e3a9cd6-3ef4-4c2e-9417-1c787c93c8ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_76562703-0584-4872-9a49-99a114ca503b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5f3fc860-1d42-4dfa-8218-4b418ffc5351_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_8c11214f-b64c-4365-b4be-3b35ecf6af9f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a43e9537-9a1d-4370-8acc-478b07804439_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_467cad90-1cc9-48c8-9b63-bd4a7dc17644_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d13b1ab2-0c96-4919-9c8a-cae9460df106_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eda210b1-a6ae-4632-a8c0-a7b5a7567f63_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5686625-3a7b-4576-8af7-c7920fb62ef6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleofStockRemainingSalesAmount_9d6cd24f-20b4-42f2-b6c0-4e05cbab437b_terseLabel_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount available for sale</link:label>
    <link:label id="lab_rmti_SaleofStockRemainingSalesAmount_label_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Remaining Sales Amount</link:label>
    <link:label id="lab_rmti_SaleofStockRemainingSalesAmount_documentation_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Remaining Sales Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount" xlink:href="rmti-20200930.xsd#rmti_SaleofStockRemainingSalesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleofStockRemainingSalesAmount" xlink:to="lab_rmti_SaleofStockRemainingSalesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3190992b-9f95-4ac2-950f-b974d6829336_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9207483b-9097-4848-882a-6d934e4f7733_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_CertainEmployeesMember_65a14f4d-6609-4705-b9e2-8bfee48e7ebd_terseLabel_en-US" xlink:label="lab_rmti_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_rmti_CertainEmployeesMember_label_en-US" xlink:label="lab_rmti_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Employees [Member]</link:label>
    <link:label id="lab_rmti_CertainEmployeesMember_documentation_en-US" xlink:label="lab_rmti_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This represents information pertaining to certain employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CertainEmployeesMember" xlink:href="rmti-20200930.xsd#rmti_CertainEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CertainEmployeesMember" xlink:to="lab_rmti_CertainEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_fbbf9797-eef6-4598-95eb-ff53fb4b4646_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_38cee320-9dfa-4bc7-8c31-86c6ce64b4d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_b01910a7-dd4e-406e-a42b-8d0cb6acfe4a_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:to="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab1a70a9-e32e-4c25-9ee5-739bdbe42f88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_34150a6f-5e7c-4075-bad2-d968486c5204_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a94c124f-7e62-4e81-9e18-cec6a66d6b77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_51850b58-6b5c-43b3-81b4-d516bf520661_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grapevine, Texas</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_2485b3a2-f721-4665-bec6-dff787c0c5e3_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales &#8211; Point-in-time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_e4d611cc-29ca-4075-ba1d-879ac4062c0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PreFundedWarrantsMember_a7ce47ac-58d3-44ae-90a1-4fcaa80bed33_terseLabel_en-US" xlink:label="lab_rmti_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_rmti_PreFundedWarrantsMember_label_en-US" xlink:label="lab_rmti_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_rmti_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_rmti_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PreFundedWarrantsMember" xlink:href="rmti-20200930.xsd#rmti_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PreFundedWarrantsMember" xlink:to="lab_rmti_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8f9180c-939d-4030-8b53-7d21039a98e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Assets and Liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_114cc5d5-8f1c-41ee-9ab2-6739104aa0a0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ca424351-e585-4489-b2d7-b1f32210138f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fd58a909-219e-4e40-ac2b-4c3536befe56_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_78043eb2-d3e8-41cf-a8cd-0748581d0c5e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_109111fc-ea9a-44b2-b304-d796d0761b31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_28a08838-ca03-4397-8a67-a9f482a2389d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_10722440-3b1f-495f-81b2-9d4f36c3c12e_terseLabel_en-US" xlink:label="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and offering fees paid</link:label>
    <link:label id="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_label_en-US" xlink:label="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs And Commissions Fees</link:label>
    <link:label id="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_documentation_en-US" xlink:label="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs And Commissions Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:href="rmti-20200930.xsd#rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:to="lab_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_da41d2d0-4ebc-4fbd-9793-db5d9bc14cf3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f525f255-6fa2-4297-af6a-8e6e67823720_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4b4787a0-90fd-481c-9624-e77486d6a372_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5495ffb4-b6ee-48c2-b793-6807599a132b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock each warrant is exercisable for (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_MasterServicesAndIpAgreementMember_815e8797-96fa-4b6a-8da7-598572869e3f_terseLabel_en-US" xlink:label="lab_rmti_MasterServicesAndIpAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master services and IP agreements</link:label>
    <link:label id="lab_rmti_MasterServicesAndIpAgreementMember_label_en-US" xlink:label="lab_rmti_MasterServicesAndIpAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services And Ip Agreement [Member]</link:label>
    <link:label id="lab_rmti_MasterServicesAndIpAgreementMember_documentation_en-US" xlink:label="lab_rmti_MasterServicesAndIpAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Master services and Ip agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_MasterServicesAndIpAgreementMember" xlink:href="rmti-20200930.xsd#rmti_MasterServicesAndIpAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_MasterServicesAndIpAgreementMember" xlink:to="lab_rmti_MasterServicesAndIpAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_23eebd56-9692-45cb-a057-6de3639b00c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (Gain) on Disposal of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_e5f96ef2-720c-4e86-8ff6-58a157dbc347_terseLabel_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TermLoanTrancheThreeMember_f85be286-7050-4579-8206-6698493d8b1c_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, third tranche</link:label>
    <link:label id="lab_rmti_TermLoanTrancheThreeMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Three [Member]</link:label>
    <link:label id="lab_rmti_TermLoanTrancheThreeMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheThreeMember" xlink:to="lab_rmti_TermLoanTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e3dafcce-7b42-44dd-8108-9eaed4c8c6dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03649ef9-1f82-4d60-aad6-f5ab30c2e4a6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_db963b40-5301-4c50-ab12-f0f702a20a07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of major classes of property and equipment, stated at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cf2d1d80-14e5-43f6-b644-358d239e0104_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RevenueRecognitionReceived_61ef3f29-3946-4ab6-a933-b9cf50af6f4b_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_rmti_RevenueRecognitionReceived_label_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Received</link:label>
    <link:label id="lab_rmti_RevenueRecognitionReceived_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of consideration received during the period for the milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionReceived" xlink:to="lab_rmti_RevenueRecognitionReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_51497e85-2df0-4e13-84e2-be28628dd2da_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7ddc5b3d-9e01-4600-bfe3-7f1a53b3f216_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_54e4ba32-86cb-4e4f-b2b3-6283c7898337_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_4f5cb29d-a61b-4e80-b651-a8205a3f65cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2fee1e39-b499-4fe0-a58f-72c75ef1044e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_eda36170-2912-4d47-9e6f-5dd4aba59574_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_937d1121-118f-4474-b81d-45489a2eaf81_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_7af079d1-b8c9-40ee-bdbe-0f1ab3ff76db_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b399c0a7-4661-4bc9-b120-e980f25fbaed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c404275a-b5d2-4559-a74d-e71accc77c87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_2c398a0d-a53e-4d75-8fc3-832012b90c4a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_efad9bf8-998b-4ac4-b92c-b6888468ce84_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease rent expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e8bb695-75d3-4b16-ac9a-70c8d94c5859_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1b954edb-d306-468d-ac71-05a1bb189b30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de4287fe-882f-406e-8809-cc2bda33c67e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of employee stock options, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b9a9820-67aa-40b0-8f98-688a6a649c50_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6c2244e2-9bc0-473c-af6e-0bcb93d0af79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_fad7e95a-b4b9-46bf-8342-2ea1221945c5_terseLabel_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Lease Liability</link:label>
    <link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_label_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Operating Lease Liabilites</link:label>
    <link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_documentation_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:href="rmti-20200930.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiabilites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:to="lab_rmti_IncreaseDecreaseInOperatingLeaseLiabilites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4b437398-c889-4825-97fb-5023c190a1eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0d023852-d3b1-4fcb-8da4-141064a6e168_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_0a69222f-89cf-4911-b102-a4885b9928ea_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:to="lab_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_6534eb05-5829-4b4e-911a-3b94a919fd9a_terseLabel_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions, accrued reimbursement of legal expenses</link:label>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_label_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Accrued Reimbursement of Legal Expenses</link:label>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_documentation_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of related party transactions accrued reimbursement of legal expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:to="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TrifericAPIMember_d4271184-ae81-494e-9236-edcdd4f10d2b_terseLabel_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API</link:label>
    <link:label id="lab_rmti_TrifericAPIMember_label_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API [Member]</link:label>
    <link:label id="lab_rmti_TrifericAPIMember_documentation_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember" xlink:href="rmti-20200930.xsd#rmti_TrifericAPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericAPIMember" xlink:to="lab_rmti_TrifericAPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RelatedPartyNumberOfInstallmentPayments_23ffe3d4-0f78-44ee-a264-d2606ccea0f6_terseLabel_en-US" xlink:label="lab_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installment payments</link:label>
    <link:label id="lab_rmti_RelatedPartyNumberOfInstallmentPayments_label_en-US" xlink:label="lab_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Number Of Installment Payments</link:label>
    <link:label id="lab_rmti_RelatedPartyNumberOfInstallmentPayments_documentation_en-US" xlink:label="lab_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Number Of Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyNumberOfInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:to="lab_rmti_RelatedPartyNumberOfInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ba00882b-9478-452a-999a-c52351e3fdc1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a5b74ae1-8b2f-48fc-8b4d-647bcd0b74f8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_75ccc41d-d59d-4560-92ba-ec9a0d9d2c5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Loss on Marketable Securities Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_14156415-bde0-4fb7-b706-14cdf62b7e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the Exercise of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c98dd42d-4366-4ffa-8677-89770d23839e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9bb303f8-76c6-46ef-8d47-c808e0149113_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_f59dbfc9-2c90-4ea4-a5a6-5ee2782473f1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_208bb04a-ae8b-49a6-93d4-be2797524092_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd3409f-af9a-43ac-a4a6-3fe102cc7cd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b117b80-34f3-4d6e-9e79-eda85bcdc4bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0fac23a0-fdd5-45b1-aeb8-6199410e764e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1ad836bb-4836-4f72-87e1-d6ef49609935_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Financing Costs and Accretion of Debt Discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_91c307fc-2130-4de1-9b02-c3accbde51ce_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a5610ba5-fefd-4980-ab9a-bd4d88eaed26_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_8f7e7ef2-8fe4-4114-a7eb-aa1f6cbda162_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent, cash fee, percentage of aggregate gross proceeds raised in Offering</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_label_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:to="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_d6527a32-ec26-41f3-a0bc-d85bb6e6cf5f_terseLabel_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions, accrued reimbursement of IP expenses and sublicense royalty fees</link:label>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_label_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</link:label>
    <link:label id="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_documentation_en-US" xlink:label="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:to="lab_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4cba61ab-9e51-4754-a353-1885526daca8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dda188a4-108c-4b7a-98bf-a838ffa9429c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_f7a38758-3086-4478-8e14-44c960449e2f_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards - service based awards</link:label>
    <link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Stock Option Awards [Member]</link:label>
    <link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedStockOptionAwardsMember" xlink:to="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_964098d3-dcf6-4770-8f2f-1886ab550184_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d05e0a30-41a0-4c16-be23-913e075fb143_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_09bff7aa-f76c-4eb9-8eab-9e3afd9c2641_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8e822285-a800-48eb-ac9f-ea801be147be_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ConcentrateProductsMember_d4e7cbb9-64ec-4e3f-9839-addcd006e80c_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products</link:label>
    <link:label id="lab_rmti_ConcentrateProductsMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products [Member]</link:label>
    <link:label id="lab_rmti_ConcentrateProductsMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductsMember" xlink:to="lab_rmti_ConcentrateProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_343dd3c7-d487-4430-a5a0-1d7346c75eff_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_LeaseFacilityOneMember_6d9ae6cf-c5a3-478f-8945-cd33ba4536ef_terseLabel_en-US" xlink:label="lab_rmti_LeaseFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease facility one</link:label>
    <link:label id="lab_rmti_LeaseFacilityOneMember_label_en-US" xlink:label="lab_rmti_LeaseFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facility One [Member]</link:label>
    <link:label id="lab_rmti_LeaseFacilityOneMember_documentation_en-US" xlink:label="lab_rmti_LeaseFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Lease facility one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityOneMember" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LeaseFacilityOneMember" xlink:to="lab_rmti_LeaseFacilityOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_90153fea-de55-4396-b511-307ed597e7b8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_70acdd79-84fe-47c9-99c5-0edca95b936e_terseLabel_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_label_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity And Financial Condition [Text Block]</link:label>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_documentation_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of liquidity position and financial conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionTextBlock" xlink:href="rmti-20200930.xsd#rmti_LiquidityAndFinancialConditionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LiquidityAndFinancialConditionTextBlock" xlink:to="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3a7bcc14-fbff-4340-9a35-1feb32125bbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability - Long-Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_27c366e8-fb8a-4256-a811-2dec9c0cab69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b6e7a042-53e9-475a-a35b-e78b33ea1f80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_dcd5e0b9-2010-4892-bb64-24fc1d8817e0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_cbc4c064-f07b-45c1-9d31-5702c094453b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_acb1a5dc-194e-4001-aa35-2fde0ae2bc56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SunPharmaAgreementsMember_8618dc12-644c-4976-8c63-bc9c8accf8e4_terseLabel_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements</link:label>
    <link:label id="lab_rmti_SunPharmaAgreementsMember_label_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements [Member]</link:label>
    <link:label id="lab_rmti_SunPharmaAgreementsMember_documentation_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember" xlink:href="rmti-20200930.xsd#rmti_SunPharmaAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SunPharmaAgreementsMember" xlink:to="lab_rmti_SunPharmaAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_83be6e4a-d94d-4c40-83d6-20b4f1a69b65_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_fd177fa8-9db3-4d00-b919-5e9e3b85f745_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_103f5d57-5a8d-46c8-912c-977b3bb48761_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6ddce5d2-ee4a-4aaf-846d-24575a5b3a59_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Investments Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2119c1d1-4282-4895-af8b-3709c07d7f1a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_119fd00f-3b91-4630-90bf-4ba9e767aa87_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9a73ed29-472c-4a30-8980-37f90633c9c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain on Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_62f0b270-e80b-406d-9a2a-633a0b3239e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2a92febb-8045-4f1b-ba44-f0629ad5472e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock for which warrant is exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_NumberOfAdditionalAgreements_bbfe2b88-8e2f-4a1f-9f57-526009e772eb_terseLabel_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional agreements</link:label>
    <link:label id="lab_rmti_NumberOfAdditionalAgreements_label_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional agreements</link:label>
    <link:label id="lab_rmti_NumberOfAdditionalAgreements_documentation_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of additional agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements" xlink:href="rmti-20200930.xsd#rmti_NumberOfAdditionalAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_NumberOfAdditionalAgreements" xlink:to="lab_rmti_NumberOfAdditionalAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_57edc8ec-55ed-4db0-abdd-04d533ef1b74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a2964355-e5ba-464e-ad45-bd7822634239_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_e983d4e0-0822-478a-8726-2a7d03755ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net draw down proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_e7cf0c4a-9000-4961-87a4-4629ee068804_verboseLabel_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - service based awards</link:label>
    <link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_760de048-56a4-4d4a-9f2b-53d938cbc265_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - service based awards</link:label>
    <link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_WarrantsMember_b5f1e1ac-2a5f-47e7-8cc9-7bb7ab1651b6_terseLabel_en-US" xlink:label="lab_rmti_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_rmti_WarrantsMember_label_en-US" xlink:label="lab_rmti_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_rmti_WarrantsMember_documentation_en-US" xlink:label="lab_rmti_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WarrantsMember" xlink:href="rmti-20200930.xsd#rmti_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WarrantsMember" xlink:to="lab_rmti_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_99216647-9ee7-4d05-9639-4c8f09183631_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fc8940d4-2722-427b-b945-1cd3134ee077_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_92992de7-1927-4c81-8718-26527823fb44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_12e9b283-fd80-4429-ad8f-92247c3e3bcd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63202ed6-56fa-44a2-a052-2e8df42c0387_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b11de013-198e-4b59-9e44-25b22101914a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_1ab0d8da-6811-477a-9589-e1a095f2d384_terseLabel_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_label_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_documentation_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_dbc1e7ff-17ec-40e7-956e-336acc435740_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of any warrants issued in the offering from the exercise of warrants during the remainder term of such warrants</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_label_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:to="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6bf64b67-3650-49b3-91d8-35ff3704b29b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_862d335e-709e-43f1-b5f2-f3c0f26c88d1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_85eb5dd9-6749-4fcc-80ba-ac650e50f475_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8434a7bf-f458-413b-a394-de843b466f3b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_70296b68-aa6a-41c2-b48f-b408b249d640_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_16343f78-217b-44a1-99a1-a0f093856196_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_c27fb8bb-bdba-4a2c-86c7-f117796146cb_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee &#8211; Over time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_9ed19a80-893d-4abd-9c01-138050416e90_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payable</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6d6470bd-923f-4f6a-add8-75498c15cad6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_ac5b3b6e-49ff-436c-8cb6-40f559b81ebe_terseLabel_en-US" xlink:label="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President, chief executive officer, and chief financial officer</link:label>
    <link:label id="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_label_en-US" xlink:label="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President, Chief Executive Officer, And Chief Financial Officer [Member]</link:label>
    <link:label id="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_documentation_en-US" xlink:label="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President, Chief Executive Officer, And Chief Financial Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:to="lab_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense_20092ed3-b2b3-4c79-b6d5-8b0dcb10f2dc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:to="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7e24bed3-3781-45bb-bd69-c536c1a0d85c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_938468c6-af78-4887-bc2b-f3871c734386_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Investments Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a04a3c25-80c7-4fce-9593-674df5a7ae8a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_885453b3-0b17-4bca-af5a-d10cd797df0c_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_77e558da-03cb-423c-bb9f-6ffebe3456e3_negatedLabel_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of Common Stock to Pay Employee Withholding Taxes</link:label>
    <link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_label_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Of Common Shares To Pay Employee Withholding Taxes</link:label>
    <link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_documentation_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares to pay employee withholding taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:href="rmti-20200930.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:to="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dc4c0381-d3e9-431f-9937-d81a0b59c99f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_057e55d4-75dd-481c-99eb-5bbaaec88d6b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_3fa43925-250b-4cce-a674-63248a3b5dd8_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hackensack, New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3719bcec-bbec-494d-bb26-8870461f7b49_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc30779d-6e75-409d-a658-c72580084fd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_517c025e-6bc1-459e-a25c-8a217de8ce9a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of penalties sought from supplier</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3ec4d0c1-b3e6-4824-bdba-7707bbc9b073_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_36e4b25d-ee3e-4cc3-a5ff-bb4a23a1e996_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_35a70374-400a-4976-8cc8-4466c06f3ab7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_f526e3f7-2b5a-40cb-ad89-8acbe2b6f651_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ee8ac233-9e02-421c-b500-6f0062db8b63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1266f0df-239e-4336-befa-81ba5d6f61d5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_01983a9a-3f9a-4f7e-8a27-3e5627850b22_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_ba41eb24-a177-4403-b766-267159163c8c_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards - performance based</link:label>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Awards [Member]</link:label>
    <link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:to="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_89ab0f41-1526-440b-bd9e-5d094b912228_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_64362718-cb08-472b-a8fd-68c3dcc3025c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e9940050-d36d-4d8b-8edc-d56b5900bec8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MI_3781aa73-13c2-4168-8be4-160d72cac864_terseLabel_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan</link:label>
    <link:label id="lab_stpr_MI_label_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MICHIGAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MI" xlink:to="lab_stpr_MI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_521cffc4-071c-47d8-a1b1-9c937c2b897c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_d14777df-0e98-477a-867c-89ea8934203f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_831ea800-3683-49bd-a27d-2d940a23b527_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_2bc37b93-463c-4ab2-882a-1e848092e501_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ca968fdb-233d-4527-b08d-c089d5c1864b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_800b9ad0-4d02-4a99-b048-e9c639f3591b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_9fc42a2d-32ae-4398-8814-488aa43c608f_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_9edd7941-3628-4f09-bfc3-1e921dfd53c6_terseLabel_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive vice president and chief scientific officer</link:label>
    <link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_label_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Vice President And Chief Scientific Officer [Member]</link:label>
    <link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_documentation_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Executive Vice President and Chief Scientific Officer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:href="rmti-20200930.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:to="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f620460c-5a17-42de-a169-8e5f84d3fce1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_81fa61a5-f993-4b56-b97f-f747640a276f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Research and Development Licenses (Related Party)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b2c85cef-de5a-4b07-9034-d05839936057_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_c8961c7b-1f59-40df-814e-c099a8a0e801_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bc62dd04-c269-4dd7-8990-1336808dab58_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PresidentandChiefExecutiveOfficerMember_6841a80a-658a-4316-a550-0f07bc78fcf9_terseLabel_en-US" xlink:label="lab_rmti_PresidentandChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and chief executive officer</link:label>
    <link:label id="lab_rmti_PresidentandChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_rmti_PresidentandChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer [Member]</link:label>
    <link:label id="lab_rmti_PresidentandChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_rmti_PresidentandChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PresidentandChiefExecutiveOfficerMember" xlink:to="lab_rmti_PresidentandChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_4ab55ffa-9d34-421a-9897-f80359713fea_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d19a54-ddc8-47c6-aa38-f9ed87ba6d55_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_750d13e8-c285-49dc-afb7-da5b10662f97_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6fb28b61-6cbd-4251-ba16-2e75cff8c0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1d48ffbe-861b-4215-abc2-f34df5cd8b53_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided By Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_LeaseFacilityTwoMember_3f28cb19-2243-47c5-878c-6b5a893328df_terseLabel_en-US" xlink:label="lab_rmti_LeaseFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease facility two</link:label>
    <link:label id="lab_rmti_LeaseFacilityTwoMember_label_en-US" xlink:label="lab_rmti_LeaseFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facility Two [Member]</link:label>
    <link:label id="lab_rmti_LeaseFacilityTwoMember_documentation_en-US" xlink:label="lab_rmti_LeaseFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Lease facility two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityTwoMember" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LeaseFacilityTwoMember" xlink:to="lab_rmti_LeaseFacilityTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02eaf060-be5f-418a-8440-fe509babcc8b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c1ed1849-78d5-4d2b-b565-9ed6042ad125_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2b9dc78e-ec31-491a-ba7f-3ccd78c07744_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e7ae535f-0fec-403d-af34-b05141334baf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_84392f85-12d2-4aea-87ba-d0a37aca82b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_2e999af8-bd24-47c0-babd-5f4643c404ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e83841e6-3439-4f9f-8d1a-cbccb3bf9c81_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_2c1b203f-30c9-43e9-b241-7edbd83c21eb_terseLabel_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales agreement, threshold sale of shares</link:label>
    <link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_label_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement, Threshold Sale Of Shares</link:label>
    <link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_documentation_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of threshold offering or sale of shares under the sales agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares" xlink:href="rmti-20200930.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SalesAgreementThresholdSaleOfShares" xlink:to="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1e7a801b-b1b0-446f-82c1-1120ec37cbda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_JeilPharmaAgreementsMember_3e045b08-f47b-4cb5-8de5-acf2f3da17bf_terseLabel_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements</link:label>
    <link:label id="lab_rmti_JeilPharmaAgreementsMember_label_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements [Member]</link:label>
    <link:label id="lab_rmti_JeilPharmaAgreementsMember_documentation_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember" xlink:href="rmti-20200930.xsd#rmti_JeilPharmaAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_JeilPharmaAgreementsMember" xlink:to="lab_rmti_JeilPharmaAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_526b8cab-515b-4f3b-bcad-299c928b53c3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Prepaid and Other Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5659ab9d-1a27-48b0-bf58-c11e3d97e499_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_20505781-e9aa-4981-a706-c709aae9d754_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8211ef7c-5d09-46e3-b44b-cf1be75f45f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (up to) (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b5a5320e-a432-41e5-a6c2-cc6d7535a26d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DrugRevenueMember_5fedcbec-0502-424a-92d2-599c8210feb2_terseLabel_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug products</link:label>
    <link:label id="lab_rmti_DrugRevenueMember_label_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Revenue [Member]</link:label>
    <link:label id="lab_rmti_DrugRevenueMember_documentation_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember" xlink:href="rmti-20200930.xsd#rmti_DrugRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugRevenueMember" xlink:to="lab_rmti_DrugRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ServiceBasedAwardsMember_60f6f823-d637-4528-890a-21e1c60647ab_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service based awards</link:label>
    <link:label id="lab_rmti_ServiceBasedAwardsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Awards [Member]</link:label>
    <link:label id="lab_rmti_ServiceBasedAwardsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to service based awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedAwardsMember" xlink:to="lab_rmti_ServiceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAssumed1_f5ff508a-cb53-4949-9649-126c5dac7852_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesAssumed1_label_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAssumed1" xlink:to="lab_us-gaap_NotesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_6963e7dd-301f-45b4-a985-481225a081ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e92398e6-62c1-4e77-b3a0-3837e59d20f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum rental payments under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b97b311e-1612-4ffb-a328-d25777b3c838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_da3ef943-dc0d-4fff-a9f9-8a6bb2ad8509_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_664a96b9-05c7-46f8-8973-13707811fc59_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c16c51a5-ee27-4ee2-8cad-a1a303ac0935_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd4b09d7-10cb-4204-ba04-9c7e0e94215a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6030f64a-f775-4cd2-a47a-6de38ba42011_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ccf16f50-bea6-4f45-b280-77ac1b6085d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term &#8211; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_3be5153f-db5d-460c-8d65-82f9ea6b82ea_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6e9e15b2-b609-4d02-845f-296ed1a5b013_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a52256fc-a083-480d-8304-016a14beaca1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0f5ac455-6134-48ad-b2a2-edcb1b989bb7_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount due</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3d1c792c-c98b-4209-8e93-97eed6b624ba_terseLabel_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic Value</link:label>
    <link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dd81a173-926a-4114-ae2a-daa622e0a8e2_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_810cd719-657d-4b10-bd61-6798a0550bb4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value assumptions:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_1bfe36b9-901d-42dd-b486-5d2970ff8dc9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ee9fe7c7-3810-4d4c-9f27-1d566d825dc6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_503c3499-beae-4253-9917-b08580646ff5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Settlement Payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_960a20d8-0615-4038-b418-713b9ec1e64b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_94e24128-4a3e-444c-9e7a-d27b2a8d1cd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_bb35b666-3d59-4d8e-a72c-5434dcf230b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of principal payments on term loan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e22993a5-21e5-4217-9480-28e047fd6d13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b54c2aa1-8b0a-40e1-84e5-69aceb1c8c86_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5385601c-692a-4385-b8b0-50806c2118be_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_13841780-c1d2-40c9-9359-d44041bd5b00_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_864a004b-9850-4e36-8234-c83454dc651a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d3c52b32-ecb5-483e-b6bc-1fc6e11aff30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate &#8211; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_2713c128-f242-484b-a76e-1e2d7d2210cf_terseLabel_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_label_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Deferred Revenue [Text Block]</link:label>
    <link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_documentation_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Deferred Revenue [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:href="rmti-20200930.xsd#rmti_ContractWithCustomerDeferredRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:to="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ea1ac752-a310-4058-9da4-0a1256f6220d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_122d387c-c5ab-4899-88cb-4e46925e19aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_7049504c-c94a-48f3-920c-9ee2dd62c9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_434fabcd-200e-4d33-a2f6-d5a29a4efd70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1e1bcf0-8ba1-4200-a7e6-46e391c04c51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_908ad61f-8fe2-4ed7-9a6e-4be896e65ca5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_59024f22-4128-4e5c-959b-752a43f17177_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_5a1a6b46-981c-423f-ab91-606c37af2a67_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3ceeb151-cd29-4355-bee7-a0f22425b36c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2890bcda-dab5-4052-9497-e851a71e8f90_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fd84964d-060b-4dba-9ef4-b714e14ee508_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b8800016-0ed3-431c-818f-e94992a45145_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a7ac2c27-b6b3-4cfb-be3f-c0b780cad367_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4b971daf-6cb8-4932-88bb-767c859db2eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_6d5fbe5a-18ad-43a6-95b0-9744fa15eada_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Non-Current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_06f9da29-4d21-4905-8c9d-0286b98380ed_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_4cf3deeb-4590-47f2-86f3-2c9772018f61_terseLabel_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distribution and license agreements</link:label>
    <link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_label_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Distribution and License Agreements</link:label>
    <link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_documentation_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of distribution and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfDistributionAndLicenseAgreements" xlink:href="rmti-20200930.xsd#rmti_NumberOfDistributionAndLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_NumberOfDistributionAndLicenseAgreements" xlink:to="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_bf8d177a-3650-4691-91a5-460d1cfb1602_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and Security Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_df768d40-bdc9-4ad8-b2c0-9a7535f14a82_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_2bd4c720-9c1a-4dfb-96bf-7e281ab22911_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7b45b8cd-0212-46cb-8c59-b5889c4b4458_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_89457730-21a4-4b6a-8eff-e5735b8f7a19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_986564a5-ad6b-40e3-aa60-6733b5a049ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c592aa53-b14d-4c85-9f55-8249ce01f963_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33fc2d1e-11e3-4e0a-a769-9ae06ce26615_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_81c7eb4e-699f-4fc6-ab29-300a8d2eae78_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_38f0bd3a-7208-453c-8ccf-f45f7bbdbc38_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2e54dbcf-ebc3-44ba-b981-7834781eab66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cbd4ab3c-0695-47cf-a749-8348fda732fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability - Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_8d7bad31-1f21-494a-9dcb-a154e2f68202_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards - performance based awards</link:label>
    <link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Stock Option Awards [Member]</link:label>
    <link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedStockOptionAwardsMember" xlink:to="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_204e1416-8208-43b8-8844-e0c7c3234e4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Net of Issuance Costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_98c41442-131c-40ab-90d3-6de600750a54_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ee619ad6-8fea-4982-b9c9-f42f00f314d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ee2af0bf-24bf-467e-8302-c004e48a0f96_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_28683b5a-6d7b-43c5-8653-1c56e147842d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs from the Issuance of Common Stock / Public Offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_46d4800d-9405-4862-b8b3-4bc3ca510711_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_94bc9897-3ddc-420e-bb6b-4a968e866482_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation and Benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2c8165c2-3ad2-4863-bd99-0bb8b86e59b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2020 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_9e1aea9f-f9bd-4349-8e36-8bc9f0725c2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ac37c08e-98d1-4f48-b0a9-0833949b839f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PaymentsToAcquireAssets_4f2dea83-7ee5-43d2-af54-299469026f3e_terseLabel_en-US" xlink:label="lab_rmti_PaymentsToAcquireAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire assets</link:label>
    <link:label id="lab_rmti_PaymentsToAcquireAssets_label_en-US" xlink:label="lab_rmti_PaymentsToAcquireAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Assets</link:label>
    <link:label id="lab_rmti_PaymentsToAcquireAssets_documentation_en-US" xlink:label="lab_rmti_PaymentsToAcquireAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount paid to acquire assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsToAcquireAssets" xlink:href="rmti-20200930.xsd#rmti_PaymentsToAcquireAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PaymentsToAcquireAssets" xlink:to="lab_rmti_PaymentsToAcquireAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_02994dee-b246-4809-97e0-48d0a4bd8b81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f47877df-41b5-4f82-b7e5-0133066a1713_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_fc983dce-2e5e-49a4-99b4-6c056e741953_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:to="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6a1d3ef5-693c-4522-86a0-47e620c2fb38_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_914c94f3-b978-4fdf-ba48-ef3a6305952d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6e30d05c-49fe-4be0-91f2-71133c100568_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5d5a7d4a-7f27-4ee5-9699-51dde671f21f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a865030-a7c9-46ce-8b38-f1f853b8cd21_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d8eca872-ab3d-457a-b3c9-4f78e93f2127_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bfc53b8c-365f-4612-bef6-ad7d04d30200_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_021832d4-fcd1-4b6f-b7be-4278f9ee5747_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_6a6d8797-d186-456b-8a00-3c36b548d0dd_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_ae372494-3969-4f65-b70b-81ae64bc8ead_terseLabel_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</link:label>
    <link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_documentation_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:href="rmti-20200930.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d1c0f0e-6f0a-4042-b594-735bf257c022_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_b9fb9285-9018-4533-99d5-97e5eac3bb07_terseLabel_en-US" xlink:label="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief executive officer, chief financial officer, and director</link:label>
    <link:label id="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_label_en-US" xlink:label="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer, Chief Financial Officer, And Director [Member]</link:label>
    <link:label id="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_documentation_en-US" xlink:label="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer, Chief Financial Officer, And Director</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:href="rmti-20200930.xsd#rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:to="lab_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_77b05c81-35cd-4599-8139-13746634f6c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, net of unamortized issuance costs and unaccreted discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_25485acf-aa79-4d19-b24a-0ee5de92cfed_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_FormerAddressMember_2d011793-54a4-4f72-9fba-d162ce760251_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_15e04b44-64a8-403a-921f-ef85cb6e5bc0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TermLoanTrancheOneMember_89f05d97-4397-4e64-a03b-6c2c602e6d6b_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, first tranche</link:label>
    <link:label id="lab_rmti_TermLoanTrancheOneMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche One [Member]</link:label>
    <link:label id="lab_rmti_TermLoanTrancheOneMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheOneMember" xlink:to="lab_rmti_TermLoanTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6b7a3832-d770-4a9e-804e-ba54f16325b6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Term Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e6d1e0d0-5139-4c13-b41f-6427e69050b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_2bdfda28-5ede-46fb-ab85-5799f7b61e3c_terseLabel_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
    <link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_label_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Modification Expense</link:label>
    <link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_documentation_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Modification Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:href="rmti-20200930.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:to="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_43badbf5-70db-4f95-af29-a907b5e09163_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d2d8e79e-990e-4bc3-9f71-9cf250048fac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27fd374f-b385-40e4-89e7-a18943cb4721_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_628885cc-7823-4795-8838-ab6a136a4406_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, weighted average remaining term (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e6e6e0d4-e454-47ae-a838-ae4f63f71497_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_785a8448-0113-4180-bad2-1bcfc8dff4e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ce6bbaaf-f510-4a86-a51e-4a82599bd811_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_839227c5-db9e-4cd9-8865-dfbff47f6eca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_5bd802a9-71dd-4d40-a333-3ffa5499444f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Insurance Receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Settlements Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2f27109b-98a1-4146-b512-e083f6498c71_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7556e570-3372-49d3-adcc-0675e9ee9942_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TrifericDialysateMember_66f1b627-2c6d-4186-a255-554da41b6fd9_terseLabel_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate</link:label>
    <link:label id="lab_rmti_TrifericDialysateMember_label_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate [Member]</link:label>
    <link:label id="lab_rmti_TrifericDialysateMember_documentation_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember" xlink:href="rmti-20200930.xsd#rmti_TrifericDialysateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericDialysateMember" xlink:to="lab_rmti_TrifericDialysateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_190acfea-8f27-47e2-9618-49f5c6a530e4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ConcentrateProductSalesMember_b05bb12d-4909-44c4-a484-0a84849b6b26_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate product sales</link:label>
    <link:label id="lab_rmti_ConcentrateProductSalesMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product Sales [Member]</link:label>
    <link:label id="lab_rmti_ConcentrateProductSalesMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductSalesMember" xlink:to="lab_rmti_ConcentrateProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_603c07cf-4a4a-4c72-aa27-dc43a673cc94_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_85d9aaa7-e35b-42c1-8344-5b0c606d34a7_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of warrants issued to investors</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_label_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:to="lab_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_36915ba5-c613-41ff-ae44-c2ccc1387bbc_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized (Gain) on Sale of Investments Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1cbd5d4e-474a-47db-913e-4c554ef69560_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of Restricted Stock Units Issued, net of taxes withheld</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8f47cd3-bec4-4c9a-816b-5dde8898b924_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, base percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_98e56657-9aed-4389-8d87-9c5cb1b79cb8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d3c6c894-377c-4577-9d92-face116ff872_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7ffb5b69-5793-45c3-a7f8-2c784fed7908_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f9911c4c-e3a7-460b-9ead-fb285bb50a94_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bbd43f0d-ffb8-4a90-a427-9d63f3c8bc0f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_dfd5064b-701b-424a-b207-416209b60105_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bc6251f1-a0af-4ee0-a3ac-86e82c45e7a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees_a447b600-3874-4c45-a224-1ca356c39761_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent fee, clearing fees</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees_label_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Clearing Fees</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Clearing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeClearingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:to="lab_rmti_SaleOfEquityPlacementAgentFeeClearingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_56ab6cf5-96b2-4431-a754-50717139dcd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on Short Term Note Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a12c428e-1328-42e7-976f-9b0111e2617f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided By (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e35850ca-c843-4684-8385-b4f53d75e6d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrants related to Debt Financing</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_5d08a9af-146e-408e-b467-b15d57b4257f_verboseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility sqft.</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_ad2bdd0f-6b4b-46ac-a6e9-6a921e4e52de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_OperatingLeaseRightOfUseAssetAmortization_ef76cf9d-b258-4c81-b4b6-6c39baa9692c_terseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Right of Use Asset</link:label>
    <link:label id="lab_rmti_OperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Asset Amortization</link:label>
    <link:label id="lab_rmti_OperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:href="rmti-20200930.xsd#rmti_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_rmti_OperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_21154abd-2fa0-499f-98c6-34488a6032b1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a68bddd7-efe6-4915-b9b8-ce1dc29500ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PartialRefund_53afac8b-a5cd-47e6-b732-09a5da5721bb_terseLabel_en-US" xlink:label="lab_rmti_PartialRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial refund</link:label>
    <link:label id="lab_rmti_PartialRefund_label_en-US" xlink:label="lab_rmti_PartialRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Refund</link:label>
    <link:label id="lab_rmti_PartialRefund_documentation_en-US" xlink:label="lab_rmti_PartialRefund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Refund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PartialRefund" xlink:href="rmti-20200930.xsd#rmti_PartialRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PartialRefund" xlink:to="lab_rmti_PartialRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_PublicOfferingMember_74a3d295-dd4a-4819-b800-97910bf6699d_terseLabel_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_rmti_PublicOfferingMember_label_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_rmti_PublicOfferingMember_documentation_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PublicOfferingMember" xlink:to="lab_rmti_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_3512baad-23e8-4455-a6e7-35f01b447a10_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate product license fee</link:label>
    <link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product License Fee [Member]</link:label>
    <link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product License Fee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductLicenseFeeMember" xlink:to="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8f32900e-8344-436c-9eec-a4495a122bc1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_12d63cb6-25e1-4282-9546-c1e5cc38cb1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_51380c86-3725-4ca5-8f43-17c581a58d80_terseLabel_en-US" xlink:label="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</link:label>
    <link:label id="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_label_en-US" xlink:label="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs</link:label>
    <link:label id="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:href="rmti-20200930.xsd#rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:to="lab_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_622e35cc-08d4-4e21-8b66-fe5f03712d55_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_cf6c11e5-3750-460c-a65d-c67d488d09de_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Deposits</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_13e98d7c-145f-4a56-8c85-722731ec84c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8c0960a3-8616-4447-8ee0-9d53c6805538_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3fe7cdd3-c4d6-468e-8cdd-3b5f425a0867_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ba268882-8bd4-4f7a-bde2-722aa7a46c9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4d435a3e-130b-4a15-b91b-e7a08f786209_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5912b9bb-f571-4148-80e6-23f6fec2f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0c4afb85-371a-4ee7-8fc0-15f3e31f20f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_40939bb0-44e0-4edd-9f06-11b40827369b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1c9fabc-dede-4d44-bd17-cda07035910f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_efcf81dd-393b-44a4-b388-230975bb59e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_adabffd7-d543-474c-953f-f33c1e321925_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_86b56e42-1d76-4f06-b474-ed04f70428f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_06a4ba46-12b1-4ea3-8167-498476029879_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_10e32392-f09e-446c-a050-e9ccbac8fb5d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_06e157d2-e663-4589-af9e-b886dbb05f33_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_89ae18ec-9e45-48f4-a6df-44937baaca95_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_045c624a-12cc-47ec-95d1-dd981bf2565c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_96c88777-7db8-4f40-9742-f8d727560d09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4ffb929c-8e23-47df-8511-07e44b755ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70c3710d-7ebd-4e2e-aaee-58d47743837e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8bcf0a86-aaa8-4130-aedf-c2975ff21647_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e77dfede-1630-45c4-9f6e-183cc64a6f65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7c2588f-793f-47f4-a676-9f93f75dc92e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d25141a1-e873-4868-8d39-98863b650cc9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_03062beb-d1d8-4892-8947-321db76f1ef8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eee7cc95-b3a9-4280-a870-0d9ef69a777b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_0671e7c1-1082-45be-a46b-974d1c52379c_terseLabel_en-US" xlink:label="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated expense reduction in stock compensation expense related to forfeited stock awards</link:label>
    <link:label id="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_label_en-US" xlink:label="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</link:label>
    <link:label id="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_documentation_en-US" xlink:label="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:to="lab_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TermLoanMember_de5441f2-6875-4fb6-8f5b-b5b39400fae3_terseLabel_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_rmti_TermLoanMember_label_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_rmti_TermLoanMember_documentation_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember" xlink:href="rmti-20200930.xsd#rmti_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanMember" xlink:to="lab_rmti_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_71c4dfa7-545b-437d-92b5-3b278cd5348d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_747bfdf1-8099-478e-9c5e-36d9fc65f15b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Product Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_02ce5e1c-e136-4f43-95ba-5f9234cc9774_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e13bb83f-2310-4b30-b267-f118e8b9b92e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_da2383b8-3e05-403f-a265-a51ffc88a343_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_64f4a1ce-0f6b-418a-a55f-ca70a4d9177c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) Decrease in Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e63b12f3-c758-4a90-a003-2971dc16e72e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c2032ca-d8ff-4532-8c73-3d7190d09087_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_59addaab-fd10-4f47-bf35-cda227986fa3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_33b4bce9-3db9-42b8-9896-ade4b1187fd1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Employee Stock Options, Net of Tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DrugLicenseFeeMember_cc327b41-b5a6-4fc0-9c43-76be02e40492_terseLabel_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug license fee</link:label>
    <link:label id="lab_rmti_DrugLicenseFeeMember_label_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug License Fee [Member]</link:label>
    <link:label id="lab_rmti_DrugLicenseFeeMember_documentation_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug License Fee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember" xlink:href="rmti-20200930.xsd#rmti_DrugLicenseFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugLicenseFeeMember" xlink:to="lab_rmti_DrugLicenseFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cd2ab8fe-c5c0-4966-a3d3-d519959159dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use Assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6773209e-2d24-47a1-9cd9-9b8aac3feff2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9a1747c6-2f23-43e3-be8b-0c9f9fb30bb4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af2114a1-1223-40f2-961d-e3d6cc58ec36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RevenueRecognitionTable_918c8732-4cb5-4449-afd8-48535b230d6c_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
    <link:label id="lab_rmti_RevenueRecognitionTable_label_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
    <link:label id="lab_rmti_RevenueRecognitionTable_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionTable" xlink:to="lab_rmti_RevenueRecognitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7c802a12-e24d-4b0d-b42d-ea40af4867be_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2eff1bee-a398-4896-ae7c-7220651555c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_403a1034-e3fc-4721-8e5a-d021c9669daa_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b2fc707d-2d71-4407-95c3-fd0df539a7de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_500bc61a-163c-4d92-b881-6f8d6396fdb8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TermLoanTrancheTwoMember_f7ca9d07-9920-42d6-803a-34072bda224e_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, second tranche</link:label>
    <link:label id="lab_rmti_TermLoanTrancheTwoMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two [Member]</link:label>
    <link:label id="lab_rmti_TermLoanTrancheTwoMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheTwoMember" xlink:to="lab_rmti_TermLoanTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64ff8f68-8f4f-468a-9139-fd3a9560f7b8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_fe1f3cc4-d5b2-4264-bc62-94795501bc06_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred License Revenue - Current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_2ffb72f6-b1c1-4f64-b176-895281babfee_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c487aa19-a367-4be0-93d0-2bcc891f9151_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_54a64085-fda5-49b0-a325-e1108a72406c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ee81fde2-dd04-465a-b785-15a96b99e5d7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c5a81cf7-5199-420e-90cd-55cb8305f210_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c245ce8b-06cc-4838-990b-5c44e5fe53c6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_11a55c68-1af9-4bce-87a5-7cc714ca92e7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_1c774587-3530-4866-ada3-dba08935a7c6_terseLabel_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage</link:label>
    <link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_label_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</link:label>
    <link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_documentation_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:to="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RevenueRecognitionLineItems_a11e254f-60fe-48af-a6bc-3e54083f81aa_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
    <link:label id="lab_rmti_RevenueRecognitionLineItems_label_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
    <link:label id="lab_rmti_RevenueRecognitionLineItems_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionLineItems" xlink:to="lab_rmti_RevenueRecognitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_df8755d2-e7ad-43aa-b9d3-977f3ad77a26_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_a2237955-7927-4f9e-8467-20a0047cb01a_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_1e9c90fe-5b95-4dd3-90cb-afaf1b632b0c_terseLabel_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent fee, non-accountable expenses</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_label_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses</link:label>
    <link:label id="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_documentation_en-US" xlink:label="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:to="lab_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_f5e14664-078e-4bc9-b170-dc57fe4ff6f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrants issued related to Debt Financing</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b21979f-f65e-4ea4-84a9-95bd849432e6_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from diluted loss per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_c2ef1f44-a205-4e49-926a-59737d21b2c4_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability - Related Party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d1b3a58c-c571-4ce7-bb0a-b20c425747e6_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, second and third tranches</link:label>
    <link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two And Tranche Three [Member]</link:label>
    <link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two And Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:to="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f78f84d7-69f9-4ff8-94d7-60f89da270d0_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5cc69689-cde3-4155-9cea-2ee2e51081a4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_AssetAcquisitionMilestonePayments_6aeb4296-4229-4994-982a-d98f869a964d_terseLabel_en-US" xlink:label="lab_rmti_AssetAcquisitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_rmti_AssetAcquisitionMilestonePayments_label_en-US" xlink:label="lab_rmti_AssetAcquisitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Milestone Payments</link:label>
    <link:label id="lab_rmti_AssetAcquisitionMilestonePayments_documentation_en-US" xlink:label="lab_rmti_AssetAcquisitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of milestone payments related to asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AssetAcquisitionMilestonePayments" xlink:href="rmti-20200930.xsd#rmti_AssetAcquisitionMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AssetAcquisitionMilestonePayments" xlink:to="lab_rmti_AssetAcquisitionMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d2dfd737-e00b-40bc-891b-0e952040b686_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_RegisteredDirectOfferingMember_72d374f2-654d-4503-8df0-5ea6197dfa95_terseLabel_en-US" xlink:label="lab_rmti_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_rmti_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_rmti_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_rmti_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_rmti_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RegisteredDirectOfferingMember" xlink:href="rmti-20200930.xsd#rmti_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RegisteredDirectOfferingMember" xlink:to="lab_rmti_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f351a9f2-a060-4c7b-b5e9-28ec278a5e76_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_30247981-9984-4263-b0eb-24040aae00ab_netLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8caf4fd3-d52e-4cfa-825d-fd384e415f22_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d6b3437-67bc-4ab3-8de1-786d8164230a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Used In Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_dec12b12-ed65-4b62-9ab8-614beaf9313d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a3eae9d-e02a-4e9b-950e-b39cdee18560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_DeferredRevenueBenefitPercentage_326f3d88-679e-47ad-8a6a-da593e5ec45b_terseLabel_en-US" xlink:label="lab_rmti_DeferredRevenueBenefitPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund eligible for, percent of upfront fee</link:label>
    <link:label id="lab_rmti_DeferredRevenueBenefitPercentage_label_en-US" xlink:label="lab_rmti_DeferredRevenueBenefitPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Benefit Percentage</link:label>
    <link:label id="lab_rmti_DeferredRevenueBenefitPercentage_documentation_en-US" xlink:label="lab_rmti_DeferredRevenueBenefitPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Benefit Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredRevenueBenefitPercentage" xlink:href="rmti-20200930.xsd#rmti_DeferredRevenueBenefitPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DeferredRevenueBenefitPercentage" xlink:to="lab_rmti_DeferredRevenueBenefitPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_92da0b15-734c-4c41-abd9-ad2302f53b16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_edb2aa6a-2562-4925-bc79-ef9b30d67ac7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a398ea97-6cb8-477e-b8bd-5c1331977b38_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Deferred License Revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_WorkingCapitalNet_1d4aca22-b082-4c1e-ba27-f76cbce8c01d_terseLabel_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital net</link:label>
    <link:label id="lab_rmti_WorkingCapitalNet_label_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Net</link:label>
    <link:label id="lab_rmti_WorkingCapitalNet_documentation_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the monetary amount of working capital, as of the indicated date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WorkingCapitalNet" xlink:href="rmti-20200930.xsd#rmti_WorkingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WorkingCapitalNet" xlink:to="lab_rmti_WorkingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_fc7d8213-9d6d-4a20-94c1-6a9c368c284b_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants, at holder's option upon issuance</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise</link:label>
    <link:label id="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:to="lab_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_3328e15f-f9c2-4f98-8b54-91114331558d_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Technology&#160;&amp; Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_301408e0-3900-4a87-b918-552ffbedbe7e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_0bb6b65e-38be-44a8-a524-9ace97f5bf3d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,573,165 and 65,378,890 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_f0fcc609-7aa2-4da9-8e27-edece3e27ae0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount allocated to common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_08c71b5b-3e09-4f6b-ac5a-b9600c8f9525_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_c8d22ea1-caef-47c9-ae09-d62afd263665_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_SettlementAgreementWithAllPartiesMember_39808826-899f-42bb-bc3c-ac1ae36742ea_terseLabel_en-US" xlink:label="lab_rmti_SettlementAgreementWithAllPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement with all parties</link:label>
    <link:label id="lab_rmti_SettlementAgreementWithAllPartiesMember_label_en-US" xlink:label="lab_rmti_SettlementAgreementWithAllPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement With All Parties [Member]</link:label>
    <link:label id="lab_rmti_SettlementAgreementWithAllPartiesMember_documentation_en-US" xlink:label="lab_rmti_SettlementAgreementWithAllPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent information relating to settlement agreement with all parties to the class action.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SettlementAgreementWithAllPartiesMember" xlink:href="rmti-20200930.xsd#rmti_SettlementAgreementWithAllPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SettlementAgreementWithAllPartiesMember" xlink:to="lab_rmti_SettlementAgreementWithAllPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9f3332b1-4fef-424e-9148-b05cb1094455_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_21a88a8a-af41-4247-a1c9-d672f77d0538_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_InstallmentPaymentToRelatedParties_832f889f-492d-49aa-a57a-36d3a83371fc_terseLabel_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment paid</link:label>
    <link:label id="lab_rmti_InstallmentPaymentToRelatedParties_label_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment paid</link:label>
    <link:label id="lab_rmti_InstallmentPaymentToRelatedParties_documentation_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow associated with installment payment to related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties" xlink:href="rmti-20200930.xsd#rmti_InstallmentPaymentToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_InstallmentPaymentToRelatedParties" xlink:to="lab_rmti_InstallmentPaymentToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionAbstract_7d4b6204-7764-488b-8e2c-293c9e1beea2_terseLabel_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionAbstract_label_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_rmti_LiquidityAndFinancialConditionAbstract_documentation_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionAbstract" xlink:href="rmti-20200930.xsd#rmti_LiquidityAndFinancialConditionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract" xlink:to="lab_rmti_LiquidityAndFinancialConditionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rmti-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c1885d05-9eba-4bcc-b6cc-c3a122fafec9,g:eccff102-f67e-41ab-8e4e-dc76dc74a21f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="rmti-20200930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_782d1ee5-4b29-4753-8229-994dfe58e024" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentType_782d1ee5-4b29-4753-8229-994dfe58e024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_746ed998-133b-40c5-b54d-02d3461e81d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentQuarterlyReport_746ed998-133b-40c5-b54d-02d3461e81d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5598ee27-58fd-4cb5-bc5c-7d2084bbc255" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentPeriodEndDate_5598ee27-58fd-4cb5-bc5c-7d2084bbc255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0d3242ee-a7e9-48a7-a856-fd9c9dabac14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentTransitionReport_0d3242ee-a7e9-48a7-a856-fd9c9dabac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4d2664bd-d4e3-4637-b21f-03eee4ee5460" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityFileNumber_4d2664bd-d4e3-4637-b21f-03eee4ee5460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_20775e80-524e-4961-bd1a-ff7a29e52830" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityRegistrantName_20775e80-524e-4961-bd1a-ff7a29e52830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_25308ba6-958e-42f5-a910-29f6784bba02" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_25308ba6-958e-42f5-a910-29f6784bba02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8e907d59-f542-4e1a-b4c6-92a0fd3b2006" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityTaxIdentificationNumber_8e907d59-f542-4e1a-b4c6-92a0fd3b2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_24083e93-597f-4532-b7bc-79473d9737a2" xlink:to="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_59cfcf97-eb2c-4bec-be80-cd8d578cd423" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_82731108-73b3-4229-a8e4-a56dfab9091b" xlink:to="loc_dei_FormerAddressMember_59cfcf97-eb2c-4bec-be80-cd8d578cd423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_fc32c9a0-01f4-4d40-8400-16e17a74a87c" xlink:to="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_42e4ee7c-9583-4493-8eca-1ab22653c347" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressAddressLine1_42e4ee7c-9583-4493-8eca-1ab22653c347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eccc54ce-4e7b-4c37-a18b-08c37d24125b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressCityOrTown_eccc54ce-4e7b-4c37-a18b-08c37d24125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9eda44ef-7b2f-44c4-bda3-041e7293a9dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressStateOrProvince_9eda44ef-7b2f-44c4-bda3-041e7293a9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bec4f5eb-b2ff-49a6-a861-7efd7b79d005" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_212fd6d2-0701-4c1f-9336-b71f32eddff9" xlink:to="loc_dei_EntityAddressPostalZipCode_bec4f5eb-b2ff-49a6-a861-7efd7b79d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eed4a8c4-018d-45e8-9f75-485f770389f8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_CityAreaCode_eed4a8c4-018d-45e8-9f75-485f770389f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a0af205-e87d-47cb-a2b3-a2d7fa003024" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_LocalPhoneNumber_4a0af205-e87d-47cb-a2b3-a2d7fa003024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d35fe879-e9f6-467d-8d95-768bb3bdf074" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityCurrentReportingStatus_d35fe879-e9f6-467d-8d95-768bb3bdf074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1113b306-8ec2-4b3e-80b7-2ef336bdc572" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityInteractiveDataCurrent_1113b306-8ec2-4b3e-80b7-2ef336bdc572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a44ed892-e1c3-4a85-a931-4146aff0d6ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityFilerCategory_a44ed892-e1c3-4a85-a931-4146aff0d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7360888a-e99c-438e-a06c-5335693c0cf5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntitySmallBusiness_7360888a-e99c-438e-a06c-5335693c0cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c2c717a5-ee2c-413a-8ab7-23bb7cb0f18f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityEmergingGrowthCompany_c2c717a5-ee2c-413a-8ab7-23bb7cb0f18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5eea5380-bbb1-4c93-b31c-199491b73cd3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityShellCompany_5eea5380-bbb1-4c93-b31c-199491b73cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fe7e5341-65ff-4b8c-b057-6be5f4d3788d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_Security12bTitle_fe7e5341-65ff-4b8c-b057-6be5f4d3788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_74ed2404-e1d7-4705-a43b-32784a7c500e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_TradingSymbol_74ed2404-e1d7-4705-a43b-32784a7c500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5ac67129-8b55-493c-b414-e96a9e5aac4b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_SecurityExchangeName_5ac67129-8b55-493c-b414-e96a9e5aac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dc211f04-04bc-4355-a0e2-9d8f565f5af8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dc211f04-04bc-4355-a0e2-9d8f565f5af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c1d5f191-3713-4772-beda-cbee79650193" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_EntityCentralIndexKey_c1d5f191-3713-4772-beda-cbee79650193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_59914d74-0cd0-406c-a490-ea439d2a7836" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_AmendmentFlag_59914d74-0cd0-406c-a490-ea439d2a7836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9b1915ab-3d5f-4ab5-9221-ef7e06f6cbaf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_CurrentFiscalYearEndDate_9b1915ab-3d5f-4ab5-9221-ef7e06f6cbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e2e369e6-0e3e-4834-b92b-47212de04931" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentFiscalYearFocus_e2e369e6-0e3e-4834-b92b-47212de04931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5fda4cb0-3ae3-4791-ac7e-8a3d4d23538e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4a8bdbe-5a12-4f68-bcba-622ada4a7db8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5fda4cb0-3ae3-4791-ac7e-8a3d4d23538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_06b7e4a7-afb3-4930-8b02-7b2a3a60f31e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_06b7e4a7-afb3-4930-8b02-7b2a3a60f31e" xlink:to="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ef91738-7137-422f-b92c-98e71f070f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ef91738-7137-422f-b92c-98e71f070f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33acb048-2b44-4cc0-ba9e-22e74a5c4ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33acb048-2b44-4cc0-ba9e-22e74a5c4ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d67fa773-42b7-4076-b688-098c64051126" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d67fa773-42b7-4076-b688-098c64051126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6acd2504-d515-41fc-aa82-81384e7e7a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_InventoryNet_6acd2504-d515-41fc-aa82-81384e7e7a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419d286c-9e11-40bb-bc7b-49ef268aa625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419d286c-9e11-40bb-bc7b-49ef268aa625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e10137e8-7fd5-4c81-a442-58a3ce2987c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_AssetsCurrent_e10137e8-7fd5-4c81-a442-58a3ce2987c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9234bb9b-4d73-4361-a61b-0142a6093e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9234bb9b-4d73-4361-a61b-0142a6093e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_48afdf17-351b-4c89-b69e-982c5b3129f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_InventoryNoncurrent_48afdf17-351b-4c89-b69e-982c5b3129f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_63906b70-81fa-4f6b-a8a4-07af37ee0616" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_63906b70-81fa-4f6b-a8a4-07af37ee0616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_76b84925-821a-4003-b829-ccfbca824904" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_Goodwill_76b84925-821a-4003-b829-ccfbca824904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75b3beb1-f12a-4bbb-9815-78dcea0dbff3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75b3beb1-f12a-4bbb-9815-78dcea0dbff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_50518fbe-8b76-4f1a-ab21-8ec6af1f41db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d78458b7-cb02-4f12-8ce4-032e1db5c541" xlink:to="loc_us-gaap_Assets_50518fbe-8b76-4f1a-ab21-8ec6af1f41db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_06b7e4a7-afb3-4930-8b02-7b2a3a60f31e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_28a62160-15da-4e30-877d-b9734ac3dc42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_AccountsPayableCurrent_28a62160-15da-4e30-877d-b9734ac3dc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_98ace7a2-1239-4e23-a372-2866693f6f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_98ace7a2-1239-4e23-a372-2866693f6f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_564516e7-85a6-4ed1-ae56-8707faa9e9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_LitigationReserveCurrent_564516e7-85a6-4ed1-ae56-8707faa9e9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_668cf4ac-1cb8-4599-8788-04597c2d9926" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_668cf4ac-1cb8-4599-8788-04597c2d9926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2a54203-2c0d-44ff-a5e0-5c5b9b2a112b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2a54203-2c0d-44ff-a5e0-5c5b9b2a112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_55f70e49-1cc3-4456-aa84-018e7e3a8e95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_NotesPayable_55f70e49-1cc3-4456-aa84-018e7e3a8e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_9cdecfb7-b2bb-4faf-81d3-ab3b97ee408a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_9cdecfb7-b2bb-4faf-81d3-ab3b97ee408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_4fba3a9e-9673-4e7e-a661-274f1d17b620" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_4fba3a9e-9673-4e7e-a661-274f1d17b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c49016aa-8e3d-497a-88a5-1bacb504ee4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_LiabilitiesCurrent_c49016aa-8e3d-497a-88a5-1bacb504ee4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fb424551-8284-434b-a457-4ec136868d63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fb424551-8284-434b-a457-4ec136868d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e27c501d-e8be-4c0c-8a55-af10478a8d58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e27c501d-e8be-4c0c-8a55-af10478a8d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a48e6d7a-5484-4daa-b60d-9156b3c05381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a48e6d7a-5484-4daa-b60d-9156b3c05381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b473ade3-d2ce-49fc-8435-14060141a871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_Liabilities_b473ade3-d2ce-49fc-8435-14060141a871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b709451d-281c-4aab-93a5-f1dfe7dce016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b709451d-281c-4aab-93a5-f1dfe7dce016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_ab77b452-22a3-476e-9f93-b1828f86da42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_ab77b452-22a3-476e-9f93-b1828f86da42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d08685a2-3cb5-489f-bcb3-a34f8697f237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d08685a2-3cb5-489f-bcb3-a34f8697f237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fa70c028-847f-47e2-a4d1-9875ca280496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fa70c028-847f-47e2-a4d1-9875ca280496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_119ffc68-5d4b-40a5-96de-ed00fb43ca35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_119ffc68-5d4b-40a5-96de-ed00fb43ca35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ac4cd940-53da-4123-9cfc-7f7427fea465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ac4cd940-53da-4123-9cfc-7f7427fea465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25ac79fc-75a4-42eb-805e-a00dafc4c818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b6245aab-db24-4270-9d89-74518b9876d3" xlink:to="loc_us-gaap_StockholdersEquity_25ac79fc-75a4-42eb-805e-a00dafc4c818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_986d4643-1056-4401-9e2b-866369dc4e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7fd3c005-1149-4f5d-80a9-acde92901b19" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_986d4643-1056-4401-9e2b-866369dc4e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rmti-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_086aa1e9-e547-4954-a12d-538c9cbafeb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_086aa1e9-e547-4954-a12d-538c9cbafeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_aa7d2390-96fc-4789-8cdc-18199f2d1994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_aa7d2390-96fc-4789-8cdc-18199f2d1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1c1a98d7-185f-4cd5-b798-bcde0b1702a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1c1a98d7-185f-4cd5-b798-bcde0b1702a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_361d1d98-4b67-4d9f-a8cc-ec6a8a02ed3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_361d1d98-4b67-4d9f-a8cc-ec6a8a02ed3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b946eb65-e083-4394-8bbb-dbff0abc751c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b946eb65-e083-4394-8bbb-dbff0abc751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_720eddba-c819-4b44-ada2-1be5ccfb7f90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_720eddba-c819-4b44-ada2-1be5ccfb7f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b8e1f8d4-3d8c-49ef-8619-bc45da1ee9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_CommonStockSharesIssued_b8e1f8d4-3d8c-49ef-8619-bc45da1ee9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_da39eb3b-53c0-4b66-a53f-a6301128e1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bf4489b-419e-4566-ac90-54434bcbf10f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_da39eb3b-53c0-4b66-a53f-a6301128e1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e83aaae7-0c57-4c1d-963b-f8cb27cd077d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e83aaae7-0c57-4c1d-963b-f8cb27cd077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_62583283-4018-4606-b435-ac3aad82161c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_62583283-4018-4606-b435-ac3aad82161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_465c3579-d1a0-4c5a-8ff7-1a1f1f02f93f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_GrossProfit_465c3579-d1a0-4c5a-8ff7-1a1f1f02f93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_305a3484-ea19-4109-b78e-a13fa9b3f3df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_SellingAndMarketingExpense_305a3484-ea19-4109-b78e-a13fa9b3f3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e5e2141a-8bc0-487c-9b89-be1f7e9a56f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e5e2141a-8bc0-487c-9b89-be1f7e9a56f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_57161204-6a9b-4a8a-bea2-80f55987cd94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_LitigationSettlementExpense_57161204-6a9b-4a8a-bea2-80f55987cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62006c45-e081-4108-a9ae-556ee3f0f7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62006c45-e081-4108-a9ae-556ee3f0f7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_758e0c66-c350-458c-8cd3-b595e4c15e15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_OperatingIncomeLoss_758e0c66-c350-458c-8cd3-b595e4c15e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_ba79a9b6-f25b-447b-a891-fdd714bb5f16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_ba79a9b6-f25b-447b-a891-fdd714bb5f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6078e306-ba62-4c9c-ae22-b54b0fc4fb04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6078e306-ba62-4c9c-ae22-b54b0fc4fb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_246199c8-bb30-4860-82e9-2d508b79c80b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:to="loc_us-gaap_InterestExpense_246199c8-bb30-4860-82e9-2d508b79c80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4d294b40-bb48-4090-a8f3-f16e839353cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4d294b40-bb48-4090-a8f3-f16e839353cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c1309bc0-1ee1-4503-8e40-8c875385ae0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a08c572e-fa4c-4a75-b392-169f6cfbf996" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c1309bc0-1ee1-4503-8e40-8c875385ae0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e055ff2-4db1-4744-98ea-03f22f830ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_NetIncomeLoss_6e055ff2-4db1-4744-98ea-03f22f830ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_056e82c7-fdee-47a6-a056-31e6ff44c207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_056e82c7-fdee-47a6-a056-31e6ff44c207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2a92becf-e916-44b8-a98d-6e2be391ebe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cbbaf376-f636-411e-b3bc-9acc097bc8ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2a92becf-e916-44b8-a98d-6e2be391ebe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b686278f-c0ef-4779-b525-c990aa14c5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_242a5f6f-ae02-41f8-aa77-c052a6b29b13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b686278f-c0ef-4779-b525-c990aa14c5eb" xlink:to="loc_us-gaap_NetIncomeLoss_242a5f6f-ae02-41f8-aa77-c052a6b29b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f18abff6-d33c-408e-b77c-a38ccb0b1eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b686278f-c0ef-4779-b525-c990aa14c5eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f18abff6-d33c-408e-b77c-a38ccb0b1eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e48d23f-ebc8-485d-96a6-dcd670720cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b686278f-c0ef-4779-b525-c990aa14c5eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e48d23f-ebc8-485d-96a6-dcd670720cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f87da3d-9e4a-4550-9b3b-8360c4793b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b686278f-c0ef-4779-b525-c990aa14c5eb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f87da3d-9e4a-4550-9b3b-8360c4793b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd2f1c0f-abb1-4742-92c5-53937442c8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd2f1c0f-abb1-4742-92c5-53937442c8fe" xlink:to="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee14b75e-fba4-4344-afbc-e5c47eff4eb6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_a98833a7-7ed5-420c-82b6-ce9a6f6df5d0" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:to="loc_rmti_PublicOfferingMember_a98833a7-7ed5-420c-82b6-ce9a6f6df5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_f7f346b9-6853-4621-a74c-066c5b7f559e" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6f0e1cc-8f4e-48f8-ab67-3c322a5188b9" xlink:to="loc_rmti_AtthemarketOfferingMember_f7f346b9-6853-4621-a74c-066c5b7f559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3cda625-f9bb-4fad-bb8d-ae8995c90e1b" xlink:to="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f258dff7-170a-4308-a437-2792d97142d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_CommonStockMember_f258dff7-170a-4308-a437-2792d97142d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ec00540-1e4a-47ef-995f-c01504acc206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ec00540-1e4a-47ef-995f-c01504acc206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc9cb637-73b0-4c34-af36-481c82ddb1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_RetainedEarningsMember_fc9cb637-73b0-4c34-af36-481c82ddb1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_279c75bd-0b60-4912-a5f5-5bef496b1035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d22018d-7873-4a19-ba95-5ac5eb283e91" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_279c75bd-0b60-4912-a5f5-5bef496b1035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79aae60d-8262-4c69-87ee-bd50e1806ecd" xlink:to="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8207bcdf-96fe-4f3f-9fa3-e6a08d5d2179" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98d5ee68-4a5c-40be-b5ab-377ee2fbd4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98d5ee68-4a5c-40be-b5ab-377ee2fbd4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_711468a4-73a0-4fb7-b744-372e746c43e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockholdersEquity_711468a4-73a0-4fb7-b744-372e746c43e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc428779-dc22-42c2-91da-31c955209ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_NetIncomeLoss_bc428779-dc22-42c2-91da-31c955209ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_82f84c36-d79b-401a-bdf1-3ce802465e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_82f84c36-d79b-401a-bdf1-3ce802465e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7e87dde6-dc0e-41de-90ac-88b59b820c48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7e87dde6-dc0e-41de-90ac-88b59b820c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1d50b663-4564-45de-8a19-be0bd0d652a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1d50b663-4564-45de-8a19-be0bd0d652a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b1105e1a-9b19-4911-9361-a4eea3ec4aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b1105e1a-9b19-4911-9361-a4eea3ec4aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e57b8acb-321b-4600-a227-27f95974d2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e57b8acb-321b-4600-a227-27f95974d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_aaa76e00-f32d-4889-9347-b3179c4217e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_aaa76e00-f32d-4889-9347-b3179c4217e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e0225e4c-09bb-4526-aa39-366ee7ec21e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e0225e4c-09bb-4526-aa39-366ee7ec21e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_88b85346-8b87-4cf0-87d0-98a6fe563c09" xlink:href="rmti-20200930.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_88b85346-8b87-4cf0-87d0-98a6fe563c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f399c52b-6e61-4eb6-bd3e-4dc036da01d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f399c52b-6e61-4eb6-bd3e-4dc036da01d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_2beb82d4-98bf-4766-bac4-81e3febd5aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_2beb82d4-98bf-4766-bac4-81e3febd5aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6267f5d2-50be-42dd-a30f-4676f4defaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6267f5d2-50be-42dd-a30f-4676f4defaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_01482760-c3a1-4964-8718-4a1437a0e8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_01482760-c3a1-4964-8718-4a1437a0e8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e798c740-8fdc-4254-be08-5633b52c7827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d68f7282-b907-43c6-8873-2d193882db37" xlink:to="loc_us-gaap_StockholdersEquity_e798c740-8fdc-4254-be08-5633b52c7827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20200930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_13b4f0cb-59ee-4cd5-a2b7-30d69082eaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13b4f0cb-59ee-4cd5-a2b7-30d69082eaa7" xlink:to="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcdb6002-918e-4512-b0b9-ce2b8d6dae27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_93869684-7683-405d-93c1-3b3430991726" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:to="loc_rmti_PublicOfferingMember_93869684-7683-405d-93c1-3b3430991726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_5e096446-b3c7-49de-95ab-1e2c27bb675d" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f36eeb2-3920-43c5-b133-2d9a52b094e9" xlink:to="loc_rmti_AtthemarketOfferingMember_5e096446-b3c7-49de-95ab-1e2c27bb675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b7905e16-b09a-4efb-8c17-5e735b6c38d2" xlink:to="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16be53dd-5a75-4abf-a0c2-e597b51be53a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_NetIncomeLoss_16be53dd-5a75-4abf-a0c2-e597b51be53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7584cb28-23c7-4c62-b8be-0b45f2b0cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7584cb28-23c7-4c62-b8be-0b45f2b0cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_71463d54-3a89-45c9-ae8a-a80a61b21479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_ShareBasedCompensation_71463d54-3a89-45c9-ae8a-a80a61b21479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c7d9bed8-a750-4bc2-a4a6-28fdc19dec98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c7d9bed8-a750-4bc2-a4a6-28fdc19dec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_c31f4b24-b61b-4e3e-810a-7b38405afbda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_c31f4b24-b61b-4e3e-810a-7b38405afbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_6e421ab6-06a2-403a-b0b5-cfa96649c3e1" xlink:href="rmti-20200930.xsd#rmti_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_rmti_OperatingLeaseRightOfUseAssetAmortization_6e421ab6-06a2-403a-b0b5-cfa96649c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2a1c262-83bc-4721-947d-ba0845e73727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2a1c262-83bc-4721-947d-ba0845e73727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c87159d2-f0cd-423f-8a17-25d97348d7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c87159d2-f0cd-423f-8a17-25d97348d7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_771f1aa9-b2e1-40e8-9f77-1c6c13080ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_771f1aa9-b2e1-40e8-9f77-1c6c13080ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_724bf874-2593-44c1-8573-44b96ec77411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_724bf874-2593-44c1-8573-44b96ec77411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a91afa-f86b-4b12-9b5d-1865d3ca9883" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ae2cf55-3675-4c12-9e54-aa67e2947ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ae2cf55-3675-4c12-9e54-aa67e2947ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_60528fcd-ccfd-4150-a971-438be1ad6208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_60528fcd-ccfd-4150-a971-438be1ad6208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ae0a0c5d-f9c2-4f0e-9b7b-2b0e0a5582b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ae0a0c5d-f9c2-4f0e-9b7b-2b0e0a5582b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c033b3c2-1b0a-407c-b197-bb7a7bedac03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c033b3c2-1b0a-407c-b197-bb7a7bedac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebf01e7e-6735-4e3d-aa5a-1de208763659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebf01e7e-6735-4e3d-aa5a-1de208763659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_011afeaa-2c89-4729-b57a-d7d04396c45e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_011afeaa-2c89-4729-b57a-d7d04396c45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_55c0bbe8-44c1-4bc1-8a67-3f095b6b0a4d" xlink:href="rmti-20200930.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiabilites"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiabilites_55c0bbe8-44c1-4bc1-8a67-3f095b6b0a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9afeb038-d239-423a-bd84-99734a582487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9afeb038-d239-423a-bd84-99734a582487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_30cf6af8-ec03-40ac-985c-0bc0a147dfec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_30cf6af8-ec03-40ac-985c-0bc0a147dfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b0a523d1-9679-4a7b-b1a4-9a20be5d48d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33db63a6-1023-47e2-bd6a-787a6ee4c565" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b0a523d1-9679-4a7b-b1a4-9a20be5d48d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3aba84a8-7254-48b0-99a0-34ea19179d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b36e7d4f-f912-4bfd-82f7-ba93c68a34cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3aba84a8-7254-48b0-99a0-34ea19179d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c2e09f96-9291-4891-bd93-4e90bdea67c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c2e09f96-9291-4891-bd93-4e90bdea67c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c28a4893-5e04-4d63-81a2-49b719398e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c28a4893-5e04-4d63-81a2-49b719398e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_5a27d1bc-cf33-4f13-9245-aedfe8e6bf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_5a27d1bc-cf33-4f13-9245-aedfe8e6bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_12671773-075d-4a13-9dbf-f2028e088440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_12671773-075d-4a13-9dbf-f2028e088440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b782b0c2-9c38-4420-9464-dc25369f759e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f472cc-6c50-40f6-ba9e-5b0827f91a64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b782b0c2-9c38-4420-9464-dc25369f759e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c230bce6-f8d4-4a23-ba23-17bf7112ddb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c230bce6-f8d4-4a23-ba23-17bf7112ddb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dd7dc916-5a34-46ed-a494-fc83ac78d1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dd7dc916-5a34-46ed-a494-fc83ac78d1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7981e25b-eaaf-4b06-aa72-97074a18d686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7981e25b-eaaf-4b06-aa72-97074a18d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c7e844d0-c53a-4f65-b34a-7b3a405cec1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c7e844d0-c53a-4f65-b34a-7b3a405cec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc488ea1-411f-44ac-94ed-a848a596a8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc488ea1-411f-44ac-94ed-a848a596a8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e5441105-181e-47df-9623-16309c75b1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e5441105-181e-47df-9623-16309c75b1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_3d5003f9-6cc3-4152-b0be-ed83f0e20127" xlink:href="rmti-20200930.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_3d5003f9-6cc3-4152-b0be-ed83f0e20127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f64710ea-0e6e-4c09-b467-91613ef9bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8336649a-544d-4585-8e16-c1eb221008a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f64710ea-0e6e-4c09-b467-91613ef9bffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_feeb7681-b4e6-4ce4-965f-d6d2bfbe4c32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_feeb7681-b4e6-4ce4-965f-d6d2bfbe4c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d682491-3eb6-4862-a87e-18a15303d685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d682491-3eb6-4862-a87e-18a15303d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f3ad391-82f1-431c-9af5-4695fe6e5086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f3ad391-82f1-431c-9af5-4695fe6e5086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4ac053b1-51e2-40d2-8769-e1bb6d14f102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58787cd6-c456-41e0-a2b0-38f70c659644" xlink:to="loc_us-gaap_InterestPaidNet_4ac053b1-51e2-40d2-8769-e1bb6d14f102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df73dd27-6410-4161-9617-e720c13d1bed" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_8d4bb622-56ce-4a48-9196-72406ac96c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_8d4bb622-56ce-4a48-9196-72406ac96c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1_51d8b2ed-63c0-44d3-be07-c9e7d4d3a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_NotesAssumed1_51d8b2ed-63c0-44d3-be07-c9e7d4d3a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_cf8e4df5-7a17-4a47-8b52-41ebc1abace2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c319fa7c-8cc2-4936-8dba-a7780bc51375" xlink:to="loc_us-gaap_StockIssued1_cf8e4df5-7a17-4a47-8b52-41ebc1abace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="rmti-20200930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0c72776-8190-4433-a43e-c3d366e653c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e23278dc-4618-4388-9407-73283a18c037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0c72776-8190-4433-a43e-c3d366e653c0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e23278dc-4618-4388-9407-73283a18c037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResources"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionAbstract_91249dd3-cc46-43ed-af72-ed2ca7e1fb6e" xlink:href="rmti-20200930.xsd#rmti_LiquidityAndFinancialConditionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionTextBlock_c5b32d2b-f602-409f-8b21-8a1cbfd6be63" xlink:href="rmti-20200930.xsd#rmti_LiquidityAndFinancialConditionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_91249dd3-cc46-43ed-af72-ed2ca7e1fb6e" xlink:to="loc_rmti_LiquidityAndFinancialConditionTextBlock_c5b32d2b-f602-409f-8b21-8a1cbfd6be63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:href="rmti-20200930.xsd#rmti_LiquidityAndFinancialConditionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a85d5fd1-83f4-4ddb-a86f-2f61cfb6b0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a85d5fd1-83f4-4ddb-a86f-2f61cfb6b0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f6bf6b68-cc6f-4051-90af-83c1b39ece95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f6bf6b68-cc6f-4051-90af-83c1b39ece95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WorkingCapitalNet_7c737077-ebb6-4a7b-b821-5a5bdf05dc29" xlink:href="rmti-20200930.xsd#rmti_WorkingCapitalNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_rmti_WorkingCapitalNet_7c737077-ebb6-4a7b-b821-5a5bdf05dc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef6c597e-88d2-4d65-ae53-58bfe4d3ed0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef6c597e-88d2-4d65-ae53-58bfe4d3ed0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1178646-096b-4d1e-836e-33ca7dafb41c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1178646-096b-4d1e-836e-33ca7dafb41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_463a7273-91ee-4f13-89ef-45bb0454b7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_463a7273-91ee-4f13-89ef-45bb0454b7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_0d67cf79-d216-4af5-b7b5-d5507bf20231" xlink:href="rmti-20200930.xsd#rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_0d67cf79-d216-4af5-b7b5-d5507bf20231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_e0111315-007b-42e2-9c5a-81d2a552b2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_e0111315-007b-42e2-9c5a-81d2a552b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount_f1ecfaf3-3dc1-41d0-933d-407f14fd30cf" xlink:href="rmti-20200930.xsd#rmti_SaleofStockRemainingSalesAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndFinancialConditionAbstract_c9bebc95-f94c-4877-b302-9109aded6662" xlink:to="loc_rmti_SaleofStockRemainingSalesAmount_f1ecfaf3-3dc1-41d0-933d-407f14fd30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8c958e9-155d-4b5f-89b1-fbad33a10a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5e6198bd-145d-4d25-87a7-911e847ee4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8c958e9-155d-4b5f-89b1-fbad33a10a5d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5e6198bd-145d-4d25-87a7-911e847ee4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_37c2d2df-7bdb-4d4d-aef2-b5b7913928c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_37c2d2df-7bdb-4d4d-aef2-b5b7913928c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b140f1fd-9bd7-4d4b-b4e8-75c0739fa627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:to="loc_us-gaap_UseOfEstimates_b140f1fd-9bd7-4d4b-b4e8-75c0739fa627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ccec58fa-aa94-439b-8a63-bb77b4cb39c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ccec58fa-aa94-439b-8a63-bb77b4cb39c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f5e6e6a8-517d-4e68-96e2-3702a62c8539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f5e6e6a8-517d-4e68-96e2-3702a62c8539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5a48b1bd-6b04-4e89-8a6d-709e304d8942" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_295d7751-940b-4bb3-a2bb-9966c1f45fa0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5a48b1bd-6b04-4e89-8a6d-709e304d8942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e0758d15-c51b-4842-8721-d2f85b5371c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4cfde707-9c9d-4a3f-9dad-5d8debd09f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0758d15-c51b-4842-8721-d2f85b5371c0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4cfde707-9c9d-4a3f-9dad-5d8debd09f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2e5c3f2-5c91-4056-b032-80171e1b1e69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2e5c3f2-5c91-4056-b032-80171e1b1e69" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1790c4d6-5e3b-47a4-9379-5c2b4cf11343" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a8acc8b-921c-43c2-a633-0a3af2f36508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a8acc8b-921c-43c2-a633-0a3af2f36508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ad0f3ed4-ad6a-483d-9600-6bf78343ff0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_RestrictedStockMember_ad0f3ed4-ad6a-483d-9600-6bf78343ff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9c077a5-cf44-4d32-a516-5442e5c2018a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9c077a5-cf44-4d32-a516-5442e5c2018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e3c688e9-9dc6-406d-be63-aa02f0733ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_84516fd8-7188-407e-a63e-6f1cc2a7ef66" xlink:to="loc_us-gaap_WarrantMember_e3c688e9-9dc6-406d-be63-aa02f0733ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0816f67-7a92-4417-8955-1845c244f6c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f30a574b-8848-43ec-903a-224c073deb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0707ac8e-ac7b-4fe1-91c5-31e0f1fe35cd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f30a574b-8848-43ec-903a-224c073deb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognition" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_72f7e7b5-ed45-4859-a7da-54308087eadf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5c16e700-12a2-40fb-83e3-f9ebe2ba53b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_72f7e7b5-ed45-4859-a7da-54308087eadf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5c16e700-12a2-40fb-83e3-f9ebe2ba53b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_610344e5-9923-42a3-aa84-12604b6935a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_36881b99-f089-4ffe-b72c-857572e30b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_610344e5-9923-42a3-aa84-12604b6935a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_36881b99-f089-4ffe-b72c-857572e30b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05eec5b6-2740-40a8-b93c-03d0564b1bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_610344e5-9923-42a3-aa84-12604b6935a3" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05eec5b6-2740-40a8-b93c-03d0564b1bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNatureofGoodsandServicesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4abcc49d-a21f-4785-b26c-5bb222721608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfDistributionAndLicenseAgreements_7520b939-3d2c-4c6d-b698-52c95b4a01ba" xlink:href="rmti-20200930.xsd#rmti_NumberOfDistributionAndLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4abcc49d-a21f-4785-b26c-5bb222721608" xlink:to="loc_rmti_NumberOfDistributionAndLicenseAgreements_7520b939-3d2c-4c6d-b698-52c95b4a01ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfCustomers_9eb62e16-58f8-4041-9181-765f5d4b97fc" xlink:href="rmti-20200930.xsd#rmti_AveragePaymentTermOfCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4abcc49d-a21f-4785-b26c-5bb222721608" xlink:to="loc_rmti_AveragePaymentTermOfCustomers_9eb62e16-58f8-4041-9181-765f5d4b97fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfDistributors_ea16c6e1-834a-4a11-8580-24dfd3a083b4" xlink:href="rmti-20200930.xsd#rmti_AveragePaymentTermOfDistributors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4abcc49d-a21f-4785-b26c-5bb222721608" xlink:to="loc_rmti_AveragePaymentTermOfDistributors_ea16c6e1-834a-4a11-8580-24dfd3a083b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b730ccc5-da0b-4dfd-b7c9-90bb326ca3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b730ccc5-da0b-4dfd-b7c9-90bb326ca3b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7d7e6442-aa64-4b15-97ca-462118598875" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_b0db9857-1749-4dbd-a827-3eb8032d4d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_b0db9857-1749-4dbd-a827-3eb8032d4d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_70c6dcfc-be77-4b1a-a1ae-bb5d25a3ef93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_d07bebfc-b144-41e9-bc62-bc73a21f93de" xlink:to="loc_us-gaap_TransferredOverTimeMember_70c6dcfc-be77-4b1a-a1ae-bb5d25a3ef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1fbd1c19-f16a-416e-b87f-59afeb2762d8" xlink:to="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_02ffd365-8543-47aa-a8ed-23e1b3c3fd9a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:to="loc_country_US_02ffd365-8543-47aa-a8ed-23e1b3c3fd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bd1a28de-b640-4308-9e2d-4eb3b3842b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4816f716-426a-4b27-a295-96b3a758b44a" xlink:to="loc_us-gaap_NonUsMember_bd1a28de-b640-4308-9e2d-4eb3b3842b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3af1fe39-750b-46d8-91e8-d0e469e95c8b" xlink:to="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:href="rmti-20200930.xsd#rmti_DrugRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:to="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember_7f850b36-a4b2-4f40-9f2c-f4727331cbd8" xlink:href="rmti-20200930.xsd#rmti_DrugProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:to="loc_rmti_DrugProductSalesMember_7f850b36-a4b2-4f40-9f2c-f4727331cbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember_da89d555-04a2-4c4d-9748-b4567d87b011" xlink:href="rmti-20200930.xsd#rmti_DrugLicenseFeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_DrugRevenueMember_dd982edb-544a-4039-81c4-4d2b5c52ba95" xlink:to="loc_rmti_DrugLicenseFeeMember_da89d555-04a2-4c4d-9748-b4567d87b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_472671e4-9ba3-4100-9ada-567c5a6addb9" xlink:to="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember_f25f2586-c9a0-4f4c-8abc-04e2606a8bb7" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:to="loc_rmti_ConcentrateProductSalesMember_f25f2586-c9a0-4f4c-8abc-04e2606a8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember_0fb96492-266e-49ef-ba2f-9ead2f490899" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ConcentrateProductsMember_74aa91bb-7b39-4d5e-a0dc-9c96280a36fa" xlink:to="loc_rmti_ConcentrateProductLicenseFeeMember_0fb96492-266e-49ef-ba2f-9ead2f490899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e1d3127-798a-4798-bcd3-9122f82ff0b4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3c44ca19-668b-4af2-aeb8-69a86d1ce571" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e53df9eb-9251-4d73-ad54-1abd9ee391fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3c44ca19-668b-4af2-aeb8-69a86d1ce571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d9cec3b-95dd-4f5b-ae04-c5384d1152d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_58281765-0494-4d8f-bce7-58201d334f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d9cec3b-95dd-4f5b-ae04-c5384d1152d9" xlink:to="loc_us-gaap_OtherReceivables_58281765-0494-4d8f-bce7-58201d334f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1ac691f3-5073-4288-ba67-ea89d3df743e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d9cec3b-95dd-4f5b-ae04-c5384d1152d9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1ac691f3-5073-4288-ba67-ea89d3df743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c64b49be-e26f-4e93-8882-f510703bf6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c64b49be-e26f-4e93-8882-f510703bf6c9" xlink:to="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:to="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a6ca899a-293e-405c-860e-a3fae4a84c62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_0c86b6a9-9040-43cd-ab84-d19faf6aed4c" xlink:href="rmti-20200930.xsd#rmti_BaxterHealthcareOrganizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936128b9-01ac-4e0f-9645-c62f1e8d31d6" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_0c86b6a9-9040-43cd-ab84-d19faf6aed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:to="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b54a7a7f-a52d-4a80-8e11-8eedfeb2dce1" xlink:to="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_d01fcdf0-e9c9-4757-9f02-1ccdc5520f29" xlink:href="rmti-20200930.xsd#rmti_ConcentrateProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b04add4-200b-49dd-85ca-8df37bbe2aa7" xlink:to="loc_rmti_ConcentrateProductsMember_d01fcdf0-e9c9-4757-9f02-1ccdc5520f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_9cb2c1c2-586f-472b-8f03-8f86545710fd" xlink:to="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_eef2cddd-a3fa-4deb-a22c-74d1157e9043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_eef2cddd-a3fa-4deb-a22c-74d1157e9043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_70378e69-b879-4bcc-baef-64dcdd53ac20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_70378e69-b879-4bcc-baef-64dcdd53ac20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_b5b29153-b037-436d-8dd6-acab36dc3595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_b5b29153-b037-436d-8dd6-acab36dc3595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4d7e2727-8b6e-453a-92da-0848f8269b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_570236fd-fd8d-454c-bdca-2660b2199704" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4d7e2727-8b6e-453a-92da-0848f8269b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSale"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7401885-eccb-4781-ace6-a75a45bf23ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_eb5ba97c-c897-497a-a35a-df46fcbec240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7401885-eccb-4781-ace6-a75a45bf23ab" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_eb5ba97c-c897-497a-a35a-df46fcbec240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0d509ca-172f-4842-9bde-381412c959ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3a7384d3-2114-4a2e-8035-89b8dae65ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0d509ca-172f-4842-9bde-381412c959ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3a7384d3-2114-4a2e-8035-89b8dae65ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InvestmentsAvailableforSaleDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e6a187db-9eb6-4389-9d59-579350420f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e6a187db-9eb6-4389-9d59-579350420f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2feb33c3-d00f-4948-8e73-271c3c04e231" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2feb33c3-d00f-4948-8e73-271c3c04e231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d053f20c-a6e4-4b83-8df2-caba30791562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d053f20c-a6e4-4b83-8df2-caba30791562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_24cb80fa-05a9-44bd-8288-5b2b3691a53a" xlink:href="rmti-20200930.xsd#rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:to="loc_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_24cb80fa-05a9-44bd-8288-5b2b3691a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_07e7c007-4b2d-4882-832a-c98a88cff0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ce25e76-794c-4fa4-801c-610bcebfd9ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_07e7c007-4b2d-4882-832a-c98a88cff0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/Inventory" xlink:type="simple" xlink:href="rmti-20200930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5db795e4-6828-4f8b-b9db-97ab9ca66316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e500c9bc-0f9a-4359-9c8e-81f83cf88a27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5db795e4-6828-4f8b-b9db-97ab9ca66316" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e500c9bc-0f9a-4359-9c8e-81f83cf88a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_43cf1e60-b56b-4f27-ac61-717c038fb590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_260d1f82-254d-4c54-8a56-b5901caf8380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_43cf1e60-b56b-4f27-ac61-717c038fb590" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_260d1f82-254d-4c54-8a56-b5901caf8380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a5b117a4-9137-4f2d-b02b-9ba99699e922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a5b117a4-9137-4f2d-b02b-9ba99699e922" xlink:to="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d147de1c-0293-45d6-9144-69d6752a3b22" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:href="rmti-20200930.xsd#rmti_TrifericInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_df1bbd21-d6ef-4e29-83c7-5c22c3931697" xlink:to="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember_a8e57b6e-6035-41ac-8861-3517edf6f92a" xlink:href="rmti-20200930.xsd#rmti_TrifericDialysateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:to="loc_rmti_TrifericDialysateMember_a8e57b6e-6035-41ac-8861-3517edf6f92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember_890698c4-c4df-4ff8-939d-64accc853141" xlink:href="rmti-20200930.xsd#rmti_TrifericAPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TrifericInventoryMember_f1fc9b07-10ee-45ef-9733-7266b387eb67" xlink:to="loc_rmti_TrifericAPIMember_890698c4-c4df-4ff8-939d-64accc853141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_03426443-6ced-4158-b6bd-f4dc79190e7a" xlink:to="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70eb1451-0426-4673-b7e6-f286b001075e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70eb1451-0426-4673-b7e6-f286b001075e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd0511e0-6151-4217-b381-cabac962fed7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd0511e0-6151-4217-b381-cabac962fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62fea76d-a487-4573-83a8-9936fa120922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_62fea76d-a487-4573-83a8-9936fa120922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_f3e90265-f191-4530-bf8d-49702c9c12ab" xlink:href="rmti-20200930.xsd#rmti_CurrentAndNonCurrentInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_rmti_CurrentAndNonCurrentInventory_f3e90265-f191-4530-bf8d-49702c9c12ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ef871946-1941-402d-b681-b45e98f3162b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryNoncurrent_ef871946-1941-402d-b681-b45e98f3162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0eefea75-612c-48d9-bd8d-d560d8076a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryGross_0eefea75-612c-48d9-bd8d-d560d8076a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_1aff2ebf-00df-43ba-8c9c-f60cafd238b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryValuationReserves_1aff2ebf-00df-43ba-8c9c-f60cafd238b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_073a4dfd-8735-452f-bee7-c2537021bc45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_247c38c5-6c52-4314-a88d-38ad397c6258" xlink:to="loc_us-gaap_InventoryNet_073a4dfd-8735-452f-bee7-c2537021bc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipment"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2a9d2f45-d33d-4b11-a5a8-739b39f934a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_98afc747-7416-484c-b956-5a2e0175ef78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2a9d2f45-d33d-4b11-a5a8-739b39f934a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_98afc747-7416-484c-b956-5a2e0175ef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a682f528-4999-485d-ba08-80c04ccd386b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6d56c9a0-92f9-4c9a-b052-decb896d5b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a682f528-4999-485d-ba08-80c04ccd386b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6d56c9a0-92f9-4c9a-b052-decb896d5b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#PropertyAndEquipmentDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6c5813d6-8f60-42a1-80f4-d4803e4f2e76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6c5813d6-8f60-42a1-80f4-d4803e4f2e76" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_996191a5-be53-4d0e-bb7e-a09afa383889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7d43422c-0fe0-4524-bee5-2de263766b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7d43422c-0fe0-4524-bee5-2de263766b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ca0f7082-4920-4724-9874-b9690a4b9394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ca0f7082-4920-4724-9874-b9690a4b9394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a5cef989-5413-4b30-a8b3-574bfe24758d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_OfficeEquipmentMember_a5cef989-5413-4b30-a8b3-574bfe24758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_42a6c2f8-0ca9-4aba-aaba-f5acc07fc03a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84bde283-0ed3-4845-a7a4-d46db4f5c8a7" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_42a6c2f8-0ca9-4aba-aaba-f5acc07fc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_54a4ebc0-eeba-4a91-8d8e-1f4787ca7ba1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_37f774d7-2518-48d0-a7da-b770b6c2cc98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_37f774d7-2518-48d0-a7da-b770b6c2cc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0e73bfaf-c25a-464f-b50d-9be0977b5bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0e73bfaf-c25a-464f-b50d-9be0977b5bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_56678ad0-00de-435e-9b63-8824ed34ffa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_56678ad0-00de-435e-9b63-8824ed34ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_244d9f9d-13e6-4bb9-9dc7-e8c72d514cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1cce8b8d-a09d-4051-a2dc-2e28e177efc5" xlink:to="loc_us-gaap_Depreciation_244d9f9d-13e6-4bb9-9dc7-e8c72d514cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_475bf17c-3e27-4998-b05c-c8c2efd83e31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ab390589-1494-4515-84cf-559fb5cfdc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_475bf17c-3e27-4998-b05c-c8c2efd83e31" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ab390589-1494-4515-84cf-559fb5cfdc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1ed5a197-87a9-4669-8139-15038547e92e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bdebd155-aaaf-4ff4-86d6-9cf6efafc063" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1ed5a197-87a9-4669-8139-15038547e92e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bdebd155-aaaf-4ff4-86d6-9cf6efafc063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_6009a94a-0326-4ec1-afae-e9af6def8d35" xlink:href="rmti-20200930.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_6009a94a-0326-4ec1-afae-e9af6def8d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a1913322-bde5-4336-a815-e4304695bb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a1913322-bde5-4336-a815-e4304695bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a287dcda-8958-4299-9e0c-3eaadf628112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a287dcda-8958-4299-9e0c-3eaadf628112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_d1222694-a80e-4e3a-8a46-ae659f463611" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_d1222694-a80e-4e3a-8a46-ae659f463611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_429d3486-b4d7-4e24-ac64-6be91e5f88d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_429d3486-b4d7-4e24-ac64-6be91e5f88d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6afb4af2-8a85-4bb6-8686-61fb225260e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8dee2bfc-3cbd-4379-b172-524a7820930f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6afb4af2-8a85-4bb6-8686-61fb225260e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenue" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenue"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/DeferredRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_09ad091e-dd48-4ac4-b71a-34a26a81577d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock_ff772b50-1b3b-418b-9da8-e2c00abd7c08" xlink:href="rmti-20200930.xsd#rmti_ContractWithCustomerDeferredRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_09ad091e-dd48-4ac4-b71a-34a26a81577d" xlink:to="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock_ff772b50-1b3b-418b-9da8-e2c00abd7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#DeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c173b696-8de1-4a4c-8917-113c5285297b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c173b696-8de1-4a4c-8917-113c5285297b" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:to="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3e29dae9-fc9d-466b-a347-c587492de3b0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_90334684-1802-4cd8-accf-2ec475bf4bb3" xlink:href="rmti-20200930.xsd#rmti_BaxterHealthcareOrganizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_90334684-1802-4cd8-accf-2ec475bf4bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember_e8630fa8-c5cc-4788-be52-8460017ef893" xlink:href="rmti-20200930.xsd#rmti_WanbangBiopharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_WanbangBiopharmaceuticalMember_e8630fa8-c5cc-4788-be52-8460017ef893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember_1764e104-c9f0-488d-b809-615bbc74e827" xlink:href="rmti-20200930.xsd#rmti_SunPharmaAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_SunPharmaAgreementsMember_1764e104-c9f0-488d-b809-615bbc74e827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember_c75d5dd1-64e4-4f5a-b59d-9114b474271a" xlink:href="rmti-20200930.xsd#rmti_JeilPharmaAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5dcb0bc-0d2d-40ab-aa18-5bca28927d42" xlink:to="loc_rmti_JeilPharmaAgreementsMember_c75d5dd1-64e4-4f5a-b59d-9114b474271a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9f3cdb7b-9973-4bbd-ae8d-ebfce5cbe4f4" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived_7f02a1e0-fbf9-4bfc-829c-e64b2ece9604" xlink:href="rmti-20200930.xsd#rmti_RevenueRecognitionReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_RevenueRecognitionReceived_7f02a1e0-fbf9-4bfc-829c-e64b2ece9604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_33d53968-7307-48d6-974b-c849ace1033c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_33d53968-7307-48d6-974b-c849ace1033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3782e86a-f51a-4463-b37f-f940b8fa4426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3782e86a-f51a-4463-b37f-f940b8fa4426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredRevenueBenefitPercentage_a3e9aadc-db4c-4672-b62e-37d73231dd79" xlink:href="rmti-20200930.xsd#rmti_DeferredRevenueBenefitPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_DeferredRevenueBenefitPercentage_a3e9aadc-db4c-4672-b62e-37d73231dd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PartialRefund_750ddaaa-56a7-4d68-a60c-f257e8e7decf" xlink:href="rmti-20200930.xsd#rmti_PartialRefund"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_06648b35-ccd5-420c-8ea0-b21a17b16cd0" xlink:to="loc_rmti_PartialRefund_750ddaaa-56a7-4d68-a60c-f257e8e7decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0400168b-20d6-4a2b-a59b-550d0dfdcbb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b1e007af-6c79-42cd-bf7c-b8c9e9c4def4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0400168b-20d6-4a2b-a59b-550d0dfdcbb9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b1e007af-6c79-42cd-bf7c-b8c9e9c4def4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa3875f0-5ed0-4122-87fa-ff8c429914ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa3875f0-5ed0-4122-87fa-ff8c429914ea" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf988bfa-6d7e-4ae2-af00-337f0e676f74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_28d0ec73-2a06-4095-b7dd-70a4d7c85bea" xlink:href="rmti-20200930.xsd#rmti_AtthemarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_AtthemarketOfferingMember_28d0ec73-2a06-4095-b7dd-70a4d7c85bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_a1ae0e8e-3362-4c4f-8cd1-56da3d8748a5" xlink:href="rmti-20200930.xsd#rmti_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_PublicOfferingMember_a1ae0e8e-3362-4c4f-8cd1-56da3d8748a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_073a078a-679c-45cf-8c53-b2049ff215de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_us-gaap_OverAllotmentOptionMember_073a078a-679c-45cf-8c53-b2049ff215de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RegisteredDirectOfferingMember_b6adc14d-cb99-4595-b521-dea6c7fd949d" xlink:href="rmti-20200930.xsd#rmti_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91abdf3a-c3e2-46d8-8c95-96fb83a9d738" xlink:to="loc_rmti_RegisteredDirectOfferingMember_b6adc14d-cb99-4595-b521-dea6c7fd949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56a6ca03-1312-4748-9003-0a734d5ec74a" xlink:to="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ade95bc4-b5c2-4d54-96ef-6b53f4171b1f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3d319e4f-687e-4c86-bfa3-2561a2502385" xlink:to="loc_srt_MaximumMember_ade95bc4-b5c2-4d54-96ef-6b53f4171b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80ff977c-2393-4b47-a869-cebd547184e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_WarrantsMember_e9ba3d6a-f05d-4ff6-8c47-8e5742886b53" xlink:href="rmti-20200930.xsd#rmti_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:to="loc_rmti_WarrantsMember_e9ba3d6a-f05d-4ff6-8c47-8e5742886b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PreFundedWarrantsMember_e00e4999-ccd6-434a-a023-30d8080ee617" xlink:href="rmti-20200930.xsd#rmti_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c48260ea-5288-4568-8fcb-5cca8338e7b1" xlink:to="loc_rmti_PreFundedWarrantsMember_e00e4999-ccd6-434a-a023-30d8080ee617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3838ac9e-a41d-4f99-a551-83ccdbf764ad" xlink:to="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f8ec5c4f-e546-4040-b857-80deabc1875e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f8ec5c4f-e546-4040-b857-80deabc1875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7953e646-3d6f-4bae-97ce-1fff99dc991e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7953e646-3d6f-4bae-97ce-1fff99dc991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d2737844-32c5-4866-a8c6-8a8bc5d4861b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d2737844-32c5-4866-a8c6-8a8bc5d4861b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_926c9051-6b49-42b1-8840-78031dfcd1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_926c9051-6b49-42b1-8840-78031dfcd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4791a45f-aec9-4f06-b1a7-f25d7cf37aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4791a45f-aec9-4f06-b1a7-f25d7cf37aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_928245e2-02ae-4f7c-aaa9-23ad7062978d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_928245e2-02ae-4f7c-aaa9-23ad7062978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_42398824-9a02-4b43-b6f5-b4fd17e9c46c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesIssued_42398824-9a02-4b43-b6f5-b4fd17e9c46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_238b411d-b9d4-47b0-a69e-034f5f80e98c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_238b411d-b9d4-47b0-a69e-034f5f80e98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares_7a7ab4a2-537e-4d9f-9b9c-243392b265db" xlink:href="rmti-20200930.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SalesAgreementThresholdSaleOfShares_7a7ab4a2-537e-4d9f-9b9c-243392b265db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39882ace-285a-4384-87d7-ea901887232c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39882ace-285a-4384-87d7-ea901887232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_874ec90c-3bf2-437b-8a3e-5340e825a301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_874ec90c-3bf2-437b-8a3e-5340e825a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_85cfb972-2d5d-4304-b813-b07e5e26c372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_85cfb972-2d5d-4304-b813-b07e5e26c372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b6d5739b-b118-44bc-83ac-33f7e0697cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b6d5739b-b118-44bc-83ac-33f7e0697cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_cdd9fe13-6b3c-456f-a4d7-ada5c03c0def" xlink:href="rmti-20200930.xsd#rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees_cdd9fe13-6b3c-456f-a4d7-ada5c03c0def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount_dab9e63b-6038-4990-b14c-f5b874224183" xlink:href="rmti-20200930.xsd#rmti_SaleofStockRemainingSalesAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleofStockRemainingSalesAmount_dab9e63b-6038-4990-b14c-f5b874224183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57b0891f-5496-4775-8d86-0f446bd249ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57b0891f-5496-4775-8d86-0f446bd249ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_200162ac-48a6-4149-9f77-e75d8ea09daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_SharePrice_200162ac-48a6-4149-9f77-e75d8ea09daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c678ae-8df5-401e-b26a-759f47fffe74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c678ae-8df5-401e-b26a-759f47fffe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b8fc7d36-4ec1-4fae-ad56-c67863c5018f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b8fc7d36-4ec1-4fae-ad56-c67863c5018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0e0c87bc-cee9-4051-ab1d-16da8e16096d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0e0c87bc-cee9-4051-ab1d-16da8e16096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_94bcd4c0-e50c-4366-98c7-0a11f5c410c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_94bcd4c0-e50c-4366-98c7-0a11f5c410c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_0e19a430-c2c5-4b74-b369-64f78131eb86" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise_0e19a430-c2c5-4b74-b369-64f78131eb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_4f47ce67-9fc0-427c-9060-01a23088e506" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise_4f47ce67-9fc0-427c-9060-01a23088e506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_10f8bc48-9e7b-48ce-8fe4-41e6845763b8" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering_10f8bc48-9e7b-48ce-8fe4-41e6845763b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_d9ebb99b-c8f0-4000-ab0d-b78b28e231d1" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering_d9ebb99b-c8f0-4000-ab0d-b78b28e231d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_2b081de9-dffd-4862-b6cf-663c56fb5861" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors_2b081de9-dffd-4862-b6cf-663c56fb5861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_b94c7718-c25e-4c20-9ff1-7b72bc3e93c4" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants_b94c7718-c25e-4c20-9ff1-7b72bc3e93c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_6e41368e-27a2-4adc-aa82-acc18ef2fc8a" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses_6e41368e-27a2-4adc-aa82-acc18ef2fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees_57f3882f-952d-4f94-8f4f-132f29043252" xlink:href="rmti-20200930.xsd#rmti_SaleOfEquityPlacementAgentFeeClearingFees"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_rmti_SaleOfEquityPlacementAgentFeeClearingFees_57f3882f-952d-4f94-8f4f-132f29043252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_43012df2-64c2-47cc-bc7e-6cd5884261e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_43012df2-64c2-47cc-bc7e-6cd5884261e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_aa7e3ed2-1686-4228-9a1d-792f821a8331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_658dcaa1-61cc-492a-905c-4f2c482ade1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_aa7e3ed2-1686-4228-9a1d-792f821a8331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e670407-11cc-47b0-832a-8460f698daec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5c6dfcdb-26dd-4e44-9c8a-354a29d4706f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e670407-11cc-47b0-832a-8460f698daec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5c6dfcdb-26dd-4e44-9c8a-354a29d4706f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9ec386e-af20-481b-9bd1-cd8629475408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9ec386e-af20-481b-9bd1-cd8629475408" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:to="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_51140073-6db4-40b4-b941-776ccf215ad2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_e113cf94-68da-40da-87b4-2cbddf53ef0a" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_e113cf94-68da-40da-87b4-2cbddf53ef0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_11816f19-c468-4026-8790-e9d87c670cba" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_11816f19-c468-4026-8790-e9d87c670cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_b4ee3246-c92c-44a6-a815-de393dc1a678" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_b4ee3246-c92c-44a6-a815-de393dc1a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_1bf6cc46-8c7f-4d04-b9d0-3d88002b5451" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e73e6132-f20d-46c4-b93f-30e25a090eeb" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_1bf6cc46-8c7f-4d04-b9d0-3d88002b5451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08d36f15-aba3-4dea-b0ff-e90a6a030120" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f38ff4e-73cb-47b0-85ad-aaab6da63755" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f38ff4e-73cb-47b0-85ad-aaab6da63755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_db3c5273-640e-465a-b599-6112c7dcc4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_db3c5273-640e-465a-b599-6112c7dcc4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_710b7750-6b41-4f21-a21d-752b9a1b4216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_710b7750-6b41-4f21-a21d-752b9a1b4216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3357f5b2-2fad-4f58-8df0-454cc6db2ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a785598-4537-4dea-81e2-b734c2d000cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3357f5b2-2fad-4f58-8df0-454cc6db2ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c3e7dd7-8afb-459f-b980-83d517c27daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c3e7dd7-8afb-459f-b980-83d517c27daa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:to="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d56417d8-1c96-4818-bd0a-ba1e143b578d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:to="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_2841ae56-c34d-4164-a962-f80f8380a30d" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_2841ae56-c34d-4164-a962-f80f8380a30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_717acc2e-b0fb-4106-9127-003da7437936" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ServiceBasedAwardsMember_a142672b-65c8-4b18-a767-f856f39929ef" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_717acc2e-b0fb-4106-9127-003da7437936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1250b477-4c41-4cac-94aa-aef876d005fe" xlink:to="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_271ed313-6e62-4b0d-8b85-c408ae20aed4" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_271ed313-6e62-4b0d-8b85-c408ae20aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_f7c844f4-e40d-4932-aadc-a5d310b73c4c" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PerformanceBasedAwardsMember_d1dab4b4-9071-48d8-a01b-7873b8cf733c" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_f7c844f4-e40d-4932-aadc-a5d310b73c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d6d1df8-35ed-43f1-92ce-a2c265696ab0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e40f2b7d-5111-44d5-899d-ae1b52a7c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d6704a0-e6ea-4351-9afd-9ce415b1dd00" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e40f2b7d-5111-44d5-899d-ae1b52a7c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationRestrictedStockAwardsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc47d226-55c2-4f08-9426-e653f08ef2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc47d226-55c2-4f08-9426-e653f08ef2bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:to="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_97b61bd6-98cf-4f42-a8bb-3e6a70236625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_06f1c943-b4c3-44de-80f6-3e0af0755bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:to="loc_us-gaap_RestrictedStockMember_06f1c943-b4c3-44de-80f6-3e0af0755bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_8894a002-d24b-483c-b7c9-310c381f2c2e" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9428b166-75a8-4a07-8a04-c6e70d21ac0c" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_8894a002-d24b-483c-b7c9-310c381f2c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb445278-4182-4c4a-ac00-ed8548d78ba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bc93ce1-5fd0-4687-9804-5ffde22e89c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6dffe0c7-a029-44e5-b3c5-c3a475829489" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bc93ce1-5fd0-4687-9804-5ffde22e89c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cc5d0f7-69de-4cd6-83d7-28db50798a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2382085-fdc9-480e-8049-57a03c974e26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cc5d0f7-69de-4cd6-83d7-28db50798a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d153879a-0a9e-4715-b8e6-397ef7832f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f19e2ba1-6222-42a2-a73f-0728e86007d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d153879a-0a9e-4715-b8e6-397ef7832f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69338ce0-26ce-40f5-a937-0e4c0414d47d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69338ce0-26ce-40f5-a937-0e4c0414d47d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2a734db6-e9df-48a0-a665-397073a8276b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_56c2db90-b23d-48a6-ba89-d7f79ac1665e" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_bf99defc-32fc-4b79-b7e6-2c3d7316582a" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_bf99defc-32fc-4b79-b7e6-2c3d7316582a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_2a19a7a3-3e1e-4618-a2f4-4e5c7d47cc8b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_a19f5ed6-6609-4af7-9717-10dc5676dd65" xlink:to="loc_srt_ChiefFinancialOfficerMember_2a19a7a3-3e1e-4618-a2f4-4e5c7d47cc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46f6d013-63d4-4fd1-8b5f-0c686f5d2fee" xlink:to="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e228efef-9fd8-42aa-b2f0-5e26c0dacfaf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:to="loc_srt_MinimumMember_e228efef-9fd8-42aa-b2f0-5e26c0dacfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_999f3276-c36d-4714-8269-7a45d7a63f5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_679bae40-65c4-4527-9c91-1e01294aa6d6" xlink:to="loc_srt_MaximumMember_999f3276-c36d-4714-8269-7a45d7a63f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0f6f176e-2ea2-4fab-9db4-a293d8d7b24b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_81bb62a4-177e-463b-be3b-e24eeca9a701" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a2a338a-9ad2-422b-ae57-648f19de0bf8" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_81bb62a4-177e-463b-be3b-e24eeca9a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c830f36d-ba52-4bed-902b-b5970fa133d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4110d46f-14c9-4943-bd75-ed945b3e2cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4110d46f-14c9-4943-bd75-ed945b3e2cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39229e42-90d8-4b61-b472-6ba0cd4bfefb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39229e42-90d8-4b61-b472-6ba0cd4bfefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04c2c9a5-e6af-443d-a75a-da97bb61c3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04c2c9a5-e6af-443d-a75a-da97bb61c3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ebe22735-4300-43b3-9c8e-2bf07ccae5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ebe22735-4300-43b3-9c8e-2bf07ccae5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5fd6e8c6-54c5-45af-9efe-3bf45478d6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b542c017-6ee8-4cab-af20-1ebb2b58007f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5fd6e8c6-54c5-45af-9efe-3bf45478d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8bfcd170-4c20-4611-b5bb-1d48fd1c751b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8bfcd170-4c20-4611-b5bb-1d48fd1c751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64b95a97-ad90-4bc6-b6d7-eeceacf594d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64b95a97-ad90-4bc6-b6d7-eeceacf594d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_544abffa-9af3-44bf-a329-a64c630c54d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_544abffa-9af3-44bf-a329-a64c630c54d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02783abe-6f34-40a8-8a93-12c6a69c2aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02783abe-6f34-40a8-8a93-12c6a69c2aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1cbf3dc-c591-4c05-ba58-ab4fef4f61d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_481aa58a-7f14-459b-b661-9275a0f8bc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1cbf3dc-c591-4c05-ba58-ab4fef4f61d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c8b5e1a3-e7ef-46b9-8ca9-fd6253689321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c8b5e1a3-e7ef-46b9-8ca9-fd6253689321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b9df04c-35e2-4c02-861b-737b8432001a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b9df04c-35e2-4c02-861b-737b8432001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6dcc75d1-d319-43f7-8f1d-2408dd2d936c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6dcc75d1-d319-43f7-8f1d-2408dd2d936c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66e82126-6423-4dec-b15d-eea265245c80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66e82126-6423-4dec-b15d-eea265245c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_088d832f-91c5-40b8-8211-6f792198e4f6" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48e182ea-e955-4dec-996c-80c4c6ec82f4" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_088d832f-91c5-40b8-8211-6f792198e4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c49486bd-f8fc-4191-8945-6f9e846225f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c49486bd-f8fc-4191-8945-6f9e846225f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:to="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a6b40c1e-a7f0-40cd-8ae5-ed1483c12893" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_8a0e69b3-3cc3-4a53-8d51-6389f3b4eea8" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_043834fd-9d89-424d-92fe-2b7e30657693" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_8a0e69b3-3cc3-4a53-8d51-6389f3b4eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:to="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fca6f144-c77e-4786-8e03-b77f2e01dad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_95deceb5-4020-4a0a-8c17-79d77c676828" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0786af80-4422-403d-bd93-96fdb7a27654" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_95deceb5-4020-4a0a-8c17-79d77c676828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a96154a-0829-4f08-8945-223b1fa7f544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecdc1e48-e0cd-42ba-ae44-e3121671dd96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecdc1e48-e0cd-42ba-ae44-e3121671dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44a87a37-3e4c-48c9-8a20-43379e539c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44a87a37-3e4c-48c9-8a20-43379e539c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd4d1bc-4bd5-41e6-b56a-231354849ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5ccc563-201c-4ea1-8e89-e11101ae1aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd4d1bc-4bd5-41e6-b56a-231354849ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6354c994-2e52-4ce4-a692-e57595e775c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6354c994-2e52-4ce4-a692-e57595e775c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_32aa1759-84c6-4659-8c69-0639671b47bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_32aa1759-84c6-4659-8c69-0639671b47bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_880b7cfa-100c-428c-a56a-c15e49591153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da9cf054-4442-474d-b0c9-d44c3518b724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_880b7cfa-100c-428c-a56a-c15e49591153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_183b8002-b21a-4d2e-8bd3-ec396492382f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_183b8002-b21a-4d2e-8bd3-ec396492382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_50922f9a-f179-4303-80d5-4f8b226a2855" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_283da748-1ea9-40d6-99d2-3a79ba7068d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_50922f9a-f179-4303-80d5-4f8b226a2855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_826a1c4a-f25f-4fe9-b546-bc85c866e735" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9ffb52c-44cc-4d69-a400-facc109444a6" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_826a1c4a-f25f-4fe9-b546-bc85c866e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c38af7d0-0729-4cf9-960d-85803ba0ba7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c38af7d0-0729-4cf9-960d-85803ba0ba7a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:to="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9e727dfe-8619-465c-9dc2-f2c5bf8200d6" xlink:to="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4548c03f-11b3-4c92-b688-c35ce57e2847" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:to="loc_srt_MinimumMember_4548c03f-11b3-4c92-b688-c35ce57e2847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_145c1158-938e-4d5c-937b-14c3405ba171" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_debeb764-b349-4b5d-8973-a7982dfeaa39" xlink:to="loc_srt_MaximumMember_145c1158-938e-4d5c-937b-14c3405ba171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:to="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_91517d3a-2f16-4a33-b219-a41d88b55a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_fd64985e-17b4-475c-81c4-cde7008d572a" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19cce4e4-a64a-4616-be2c-b8acb5fce4a4" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_fd64985e-17b4-475c-81c4-cde7008d572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342f0cfb-1426-42e1-8d20-2e6d8c6a420b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0b7a6a39-9731-4c95-9a9a-6b856db0e216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0b7a6a39-9731-4c95-9a9a-6b856db0e216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_48e4cbf3-ea5f-4391-b073-bb17d5f92e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_48e4cbf3-ea5f-4391-b073-bb17d5f92e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e1a07add-173c-455d-82a5-85c7f54ba035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e1a07add-173c-455d-82a5-85c7f54ba035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fb118163-9b66-4485-9b1e-36747eb436db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fb118163-9b66-4485-9b1e-36747eb436db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_25588fa1-431c-4238-b5f7-594efef37a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_25588fa1-431c-4238-b5f7-594efef37a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f938ac12-f821-4aaf-a57e-2d5e5e0bdf12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7c542f0-9880-43b1-8a0a-5a5f3aec8b61" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f938ac12-f821-4aaf-a57e-2d5e5e0bdf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0d56284-104b-467c-812e-02f8402c060a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0d56284-104b-467c-812e-02f8402c060a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:to="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_69aa105a-3819-42ed-86f2-4c02c61b99ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_bf2eb26d-2f72-4e91-86f2-10772d3df074" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b424da3-e16c-4166-ab57-ea89afeeed49" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_bf2eb26d-2f72-4e91-86f2-10772d3df074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a821d070-6651-42f6-8e01-3dfc0f8f10a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8fab633-38f3-42ba-b554-501e5c0192f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8fab633-38f3-42ba-b554-501e5c0192f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d9490251-bd5c-4510-8c1b-17392a18bbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d9490251-bd5c-4510-8c1b-17392a18bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c27d3b59-4ff4-42a4-a7a9-c31feb558667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c27d3b59-4ff4-42a4-a7a9-c31feb558667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ca510bf-59d5-40f2-9059-8144295ecd66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ca510bf-59d5-40f2-9059-8144295ecd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2b71e321-21a0-49ee-9045-8f2686389dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2b71e321-21a0-49ee-9045-8f2686389dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7ed16628-65f5-4bf4-86da-3c59d2ef3c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7ed16628-65f5-4bf4-86da-3c59d2ef3c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30ed2d2f-2a1c-411e-8006-3f7b1830568f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1497b42f-338e-4b1a-8b14-4494d21d5998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30ed2d2f-2a1c-411e-8006-3f7b1830568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_49a2e70e-af11-4875-bd2f-0e99e575ef73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_49a2e70e-af11-4875-bd2f-0e99e575ef73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5defbeee-0d93-4df0-be76-7e79accf4125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5defbeee-0d93-4df0-be76-7e79accf4125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01f17208-009a-439f-a653-49652d36e00b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01f17208-009a-439f-a653-49652d36e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80c48031-f95a-44ca-ad9f-f6f9b47308c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80c48031-f95a-44ca-ad9f-f6f9b47308c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_615a5178-22c4-4e77-9974-ab8e38003a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_615a5178-22c4-4e77-9974-ab8e38003a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14e17ae5-dbe6-4ce5-8894-37639f7c1500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14e17ae5-dbe6-4ce5-8894-37639f7c1500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb3f2352-09a2-4474-b25d-310f32f52f69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4d671493-f467-49e0-819e-13c4a69290a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb3f2352-09a2-4474-b25d-310f32f52f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a5ad72b-36bf-457e-9d8e-0b973ae3d60e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a5ad72b-36bf-457e-9d8e-0b973ae3d60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_0f84eb9e-6cad-4322-b64a-3f58e408d56b" xlink:href="rmti-20200930.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_0f84eb9e-6cad-4322-b64a-3f58e408d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b20bfaa-b231-457b-8361-2a32c1748651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_58384d16-176f-4fac-9c94-2a66d4fbd07d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b20bfaa-b231-457b-8361-2a32c1748651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20ae804e-7e27-4b76-a1b4-a862cf425252" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d18f1622-7229-480c-8b3f-628926cdb491" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d18f1622-7229-480c-8b3f-628926cdb491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_5277046d-6833-4863-a3fd-16f7887d60ca" xlink:href="rmti-20200930.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_5277046d-6833-4863-a3fd-16f7887d60ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ffa5838-f949-4527-801b-c1e44a2bd98b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a83c2c10-f81b-4cc6-9700-4faa43ddd04a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ffa5838-f949-4527-801b-c1e44a2bd98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationServiceBasedStockOptionsOthersDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bded2e8b-e45e-4ce8-b826-e0978b3f810b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bded2e8b-e45e-4ce8-b826-e0978b3f810b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:to="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cabd304c-b521-40c9-99ee-9a66cb624d5c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_CertainEmployeesMember_0f5c5954-0d6d-4c73-8e6a-10708e06bc20" xlink:href="rmti-20200930.xsd#rmti_CertainEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_CertainEmployeesMember_0f5c5954-0d6d-4c73-8e6a-10708e06bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:href="rmti-20200930.xsd#rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_2fd96e03-103e-4cdd-a28e-e66096fffc8e" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_2fd96e03-103e-4cdd-a28e-e66096fffc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_ea631b08-2656-4521-aec5-923f6b8c31df" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember_9cb03211-89ea-4131-ab2c-72acd74f11ba" xlink:to="loc_srt_ChiefFinancialOfficerMember_ea631b08-2656-4521-aec5-923f6b8c31df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_db6220d3-c0b0-4419-a409-54bc8ff1a084" xlink:href="rmti-20200930.xsd#rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3ed15fa5-7a7d-40ad-be1c-00b95cb56bd8" xlink:to="loc_rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember_db6220d3-c0b0-4419-a409-54bc8ff1a084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:to="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd92ed07-02a1-4700-ad6a-77314d603310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_a147ae08-cfaa-4a7c-80ce-3c1e39b2ce6f" xlink:href="rmti-20200930.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6db562b-c5ea-4013-84c8-7993a7467d36" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_a147ae08-cfaa-4a7c-80ce-3c1e39b2ce6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e03e5363-ec03-43b6-b4f8-a58fbfee446c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c392e3fa-1ab1-47bf-8220-333683b70252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c392e3fa-1ab1-47bf-8220-333683b70252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9f3e3182-280e-4406-86c8-99d217e90391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9f3e3182-280e-4406-86c8-99d217e90391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b7340d17-527c-4f1b-9bbd-c07c7984b3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b7340d17-527c-4f1b-9bbd-c07c7984b3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_49cf04b0-592e-4b31-99e9-66ed392fd146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_49cf04b0-592e-4b31-99e9-66ed392fd146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_851e1077-9e7e-4b1f-ab3b-af9abad7c6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_851e1077-9e7e-4b1f-ab3b-af9abad7c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_3d6da65b-25be-409f-8968-7a48175be86d" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_3d6da65b-25be-409f-8968-7a48175be86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2298bcca-e0a7-40ab-8070-3ab3858cb59c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_642491e4-5e97-41e8-8754-93a888c4f173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2298bcca-e0a7-40ab-8070-3ab3858cb59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#StockBasedCompensationPerformanceBasedStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e04abb8-8e1f-4e96-b5fa-314ba982d4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e04abb8-8e1f-4e96-b5fa-314ba982d4c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:to="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_972163b1-23c2-4598-8bcf-4dd3bff02449" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PresidentandChiefExecutiveOfficerMember_466a145a-a176-4e2c-a205-79c24a3eeec6" xlink:href="rmti-20200930.xsd#rmti_PresidentandChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5911845a-6127-425f-9780-43725e15713f" xlink:to="loc_rmti_PresidentandChiefExecutiveOfficerMember_466a145a-a176-4e2c-a205-79c24a3eeec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:to="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c6e61a7b-8fbb-4e5b-8180-79c029b76181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_92489822-7f17-46b0-86e5-ab71ccc575b0" xlink:href="rmti-20200930.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995f4f35-aaaf-411c-aad6-c4621c8f20ed" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_92489822-7f17-46b0-86e5-ab71ccc575b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1516ba7e-3010-4c47-b591-ccf8ecd2a94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f77c6c67-7326-4d31-9f90-a48a2e818391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f77c6c67-7326-4d31-9f90-a48a2e818391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52baa656-4d0f-476b-9629-c8268eaaa20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52baa656-4d0f-476b-9629-c8268eaaa20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_432e7caa-0e9e-45f8-a898-524ede56f855" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_432e7caa-0e9e-45f8-a898-524ede56f855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3803fce0-0bf6-4c06-a797-7a29c81547b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3803fce0-0bf6-4c06-a797-7a29c81547b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8ffc59c8-82ab-4ae3-ac7d-6bf6ec3b4b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a1fa03dd-04da-45e7-8b44-90329848c0e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8ffc59c8-82ab-4ae3-ac7d-6bf6ec3b4b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12c6e958-2182-4f30-a2a0-aa6759b86996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12c6e958-2182-4f30-a2a0-aa6759b86996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2d71a92-c66b-476d-9dd1-a4a400269120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2d71a92-c66b-476d-9dd1-a4a400269120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9729215-5f8d-4878-9dc4-390e7d16e618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9729215-5f8d-4878-9dc4-390e7d16e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5c4a40d-add1-4da9-bde8-30f3edcf5d95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5c4a40d-add1-4da9-bde8-30f3edcf5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6079e53d-fedb-4bd9-8f8f-54f4b296c440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c50cbac8-429f-4fd9-81f9-30815c616d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6079e53d-fedb-4bd9-8f8f-54f4b296c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8dfa737a-65db-45ec-b69c-fda77ead7c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8dfa737a-65db-45ec-b69c-fda77ead7c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_78eb40bc-79f1-4478-a2d1-b5cfcb446508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_78eb40bc-79f1-4478-a2d1-b5cfcb446508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_d9f7a3af-df13-4903-86a2-11e76e553079" xlink:href="rmti-20200930.xsd#rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89783bbb-6023-4634-81f3-6bc3b01ac070" xlink:to="loc_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures_d9f7a3af-df13-4903-86a2-11e76e553079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c1ee24be-586a-46d2-b719-c26fbbefef6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0873fc61-72a4-444d-bce2-fd10170de009" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c1ee24be-586a-46d2-b719-c26fbbefef6a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0873fc61-72a4-444d-bce2-fd10170de009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b3e38ce0-eae5-4ad9-aba1-9cc0f8a39e03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b3e38ce0-eae5-4ad9-aba1-9cc0f8a39e03" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:to="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ffb6accd-a659-400b-b395-d00d6d392bea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_61f2d744-2771-4cf3-9358-c88f6aacb434" xlink:href="rmti-20200930.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccf7d545-dff4-4c3b-b419-9b522cacead9" xlink:to="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_61f2d744-2771-4cf3-9358-c88f6aacb434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b86bc345-3185-47d6-b2f1-37e99cd89792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_MasterServicesAndIpAgreementMember_b46a3a4d-8e77-4b56-81c0-870aa8847ada" xlink:href="rmti-20200930.xsd#rmti_MasterServicesAndIpAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_216aeea4-451e-490f-b1c0-c60160c109ec" xlink:to="loc_rmti_MasterServicesAndIpAgreementMember_b46a3a4d-8e77-4b56-81c0-870aa8847ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7299a363-6ba3-4822-a039-6984ed1a0e2f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements_f246891e-2c97-4a4a-9dc1-46fbffd4714c" xlink:href="rmti-20200930.xsd#rmti_NumberOfAdditionalAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_NumberOfAdditionalAgreements_f246891e-2c97-4a4a-9dc1-46fbffd4714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_711af8ca-084b-46fb-91de-b7a32cdb1965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_711af8ca-084b-46fb-91de-b7a32cdb1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyNumberOfInstallmentPayments_6081561e-2812-4eda-99a1-debb5d6db2bc" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyNumberOfInstallmentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyNumberOfInstallmentPayments_6081561e-2812-4eda-99a1-debb5d6db2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties_06095c2f-ae30-4b18-aef0-da4d375a7b5d" xlink:href="rmti-20200930.xsd#rmti_InstallmentPaymentToRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_InstallmentPaymentToRelatedParties_06095c2f-ae30-4b18-aef0-da4d375a7b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_3308162a-9608-4332-936e-b5ddef3b6a7c" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses_3308162a-9608-4332-936e-b5ddef3b6a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_1f43b9ac-9a80-4f78-9aa7-08b847810cb5" xlink:href="rmti-20200930.xsd#rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_1f43b9ac-9a80-4f78-9aa7-08b847810cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_PaymentsToAcquireAssets_33d24889-1181-42b7-b373-b4d829d6feae" xlink:href="rmti-20200930.xsd#rmti_PaymentsToAcquireAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_PaymentsToAcquireAssets_33d24889-1181-42b7-b373-b4d829d6feae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_AssetAcquisitionMilestonePayments_aa8591ad-fc23-47f2-b62e-d4eca4d118a0" xlink:href="rmti-20200930.xsd#rmti_AssetAcquisitionMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0838a2d3-eaee-495d-b973-ed7a7f9bf552" xlink:to="loc_rmti_AssetAcquisitionMilestonePayments_aa8591ad-fc23-47f2-b62e-d4eca4d118a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/Leases" xlink:type="simple" xlink:href="rmti-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c266ae1f-4ea0-4e33-ba69-f5928fe123bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_3b6e09e0-4758-4c0a-ab87-f52ff326baf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c266ae1f-4ea0-4e33-ba69-f5928fe123bf" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_3b6e09e0-4758-4c0a-ab87-f52ff326baf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_17af7d2b-49fc-4909-a9af-a94a6553fb43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_8ebb6aee-ca86-4ef5-b172-8fc0d98c8139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_17af7d2b-49fc-4909-a9af-a94a6553fb43" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_8ebb6aee-ca86-4ef5-b172-8fc0d98c8139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5a88bb22-8696-453d-8ef8-b90cee82e869" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_17af7d2b-49fc-4909-a9af-a94a6553fb43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5a88bb22-8696-453d-8ef8-b90cee82e869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b132fef0-baac-41b4-bb26-63b9cff4282f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b132fef0-baac-41b4-bb26-63b9cff4282f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41b77294-e922-4785-84a6-f8135ed66bbc" xlink:to="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8137fa91-7c42-4c80-b8a7-fe3782fdbc43" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cf13ef30-19c2-4756-897b-c681ec44e525" xlink:to="loc_srt_MaximumMember_8137fa91-7c42-4c80-b8a7-fe3782fdbc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80a6ac02-9b15-4a3d-b643-3b83981120d4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityOneMember_abbf5b70-eab7-42cf-bd12-3f0175c3d69b" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:to="loc_rmti_LeaseFacilityOneMember_abbf5b70-eab7-42cf-bd12-3f0175c3d69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_LeaseFacilityTwoMember_623fcf9f-2e31-45cf-9d45-da05277ba6a7" xlink:href="rmti-20200930.xsd#rmti_LeaseFacilityTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19512334-4289-42fd-8bf2-5d80c2260b3e" xlink:to="loc_rmti_LeaseFacilityTwoMember_623fcf9f-2e31-45cf-9d45-da05277ba6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a0506564-861c-4479-a377-056a0e851046" xlink:to="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MI_c6480d89-65d0-48be-a3dc-57ad4b0bab82" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_MI_c6480d89-65d0-48be-a3dc-57ad4b0bab82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_d28c2f0d-dab9-42d6-9ffd-c62dea6109d5" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_TX_d28c2f0d-dab9-42d6-9ffd-c62dea6109d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_aae521f5-01da-4686-93f8-766fedb35b44" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_SC_aae521f5-01da-4686-93f8-766fedb35b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_509a9990-98b2-4b55-996e-930716ec3adc" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_15cfa98f-808e-4fa7-922c-5e278fdfb21a" xlink:to="loc_stpr_NJ_509a9990-98b2-4b55-996e-930716ec3adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a71704ca-4837-40d3-bbba-d3b405fc0ef8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9a287cf8-086b-45cf-b83b-84d16985f236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9a287cf8-086b-45cf-b83b-84d16985f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_eb1fe268-ed0f-4ecf-9085-d93d6b90b50a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_eb1fe268-ed0f-4ecf-9085-d93d6b90b50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9132a828-0780-44ad-9bce-d5ac1eabf0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_OperatingLeaseLiability_9132a828-0780-44ad-9bce-d5ac1eabf0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_404805a5-f527-4579-9b84-853f8076b3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e2130cbd-5601-41cc-907e-1901ed5b0a1b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_404805a5-f527-4579-9b84-853f8076b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesSummaryofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8e7ae147-f7ed-48fc-aa91-f13794f09934" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_OperatingLeaseCost_8e7ae147-f7ed-48fc-aa91-f13794f09934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_67e4765a-0c6d-4f7d-b598-2cf7a6943d19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_VariableLeaseCost_67e4765a-0c6d-4f7d-b598-2cf7a6943d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_d63f42da-64f3-40ad-81d1-16f0e9ff1e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_OperatingLeaseExpense_d63f42da-64f3-40ad-81d1-16f0e9ff1e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c92d5c23-1466-4e58-8421-7ec6a1c7ceba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_ShortTermLeaseCost_c92d5c23-1466-4e58-8421-7ec6a1c7ceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9c670aaf-6bb2-4e28-8d73-7ae45df3cb46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_LeaseCost_9c670aaf-6bb2-4e28-8d73-7ae45df3cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_81bd7f92-2235-48da-85be-ac2993eca10e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_OperatingLeasePayments_81bd7f92-2235-48da-85be-ac2993eca10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9ce3f9a5-7776-4302-b999-1a870e13c272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9ce3f9a5-7776-4302-b999-1a870e13c272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_14fe056d-9610-42ee-97a3-d91b7d13607f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_14fe056d-9610-42ee-97a3-d91b7d13607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_368f3355-29ce-4b31-9a52-48cdaba665c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3670be71-c1c7-47d1-9f26-a495570cda00" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_368f3355-29ce-4b31-9a52-48cdaba665c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_39d48949-bd44-4f11-9616-6cfcade29c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_39d48949-bd44-4f11-9616-6cfcade29c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b5a1876-6320-406e-9b65-27ae8eb3caae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b5a1876-6320-406e-9b65-27ae8eb3caae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7155f80d-b4ed-49dc-8061-aec0b12cb818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7155f80d-b4ed-49dc-8061-aec0b12cb818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_509fa574-8a3b-4a7a-93e3-73d1e10aabfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_509fa574-8a3b-4a7a-93e3-73d1e10aabfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e979a371-e540-46f2-b0c2-18f77a3fae0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e979a371-e540-46f2-b0c2-18f77a3fae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02d09d11-b970-449c-941c-38fa7cf10863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02d09d11-b970-449c-941c-38fa7cf10863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b07bffff-8c5c-46da-b3f2-7439ddbacdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b07bffff-8c5c-46da-b3f2-7439ddbacdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f409d79-fbd9-48d2-874e-ffdb0461d603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873bd156-33bb-40cd-908d-54992ba5af89" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f409d79-fbd9-48d2-874e-ffdb0461d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1" xlink:type="simple" xlink:href="rmti-20200930.xsd#LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_789b83f4-a7a5-4b8d-a657-158484f08e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b7487197-7143-48f0-ac28-558fd8ab6cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_789b83f4-a7a5-4b8d-a657-158484f08e42" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b7487197-7143-48f0-ac28-558fd8ab6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b8cebc-311b-41c5-914c-337a1d0212e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b8cebc-311b-41c5-914c-337a1d0212e5" xlink:to="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:to="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9b0d12ff-7b0e-4507-99f9-3a5eabebbe06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cd2885bc-300e-478a-8637-788b7eb9c952" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7a48e548-b9fc-44af-bf28-c21da41f7b59" xlink:to="loc_srt_ScenarioForecastMember_cd2885bc-300e-478a-8637-788b7eb9c952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:to="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2d15e709-bae6-4f3e-8cd7-0273328361c5" xlink:to="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SettlementAgreementWithAllPartiesMember_ffa03688-d8e0-4231-8155-b70a68a100f6" xlink:href="rmti-20200930.xsd#rmti_SettlementAgreementWithAllPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_902ef0b7-ada6-4fff-98f4-ecac557089ab" xlink:to="loc_rmti_SettlementAgreementWithAllPartiesMember_ffa03688-d8e0-4231-8155-b70a68a100f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b1de492e-5559-499f-9f62-16aec58452f6" xlink:to="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_f766b0b3-d2df-42dc-8d5b-46920829b587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_f766b0b3-d2df-42dc-8d5b-46920829b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_58497ee8-f93a-4c50-bd06-8db9c71322db" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid_58497ee8-f93a-4c50-bd06-8db9c71322db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_7263d271-441e-4f29-b679-79e62811be78" xlink:href="rmti-20200930.xsd#rmti_SupplyAgreementPercentageOfRawMaterialsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_rmti_SupplyAgreementPercentageOfRawMaterialsPaid_7263d271-441e-4f29-b679-79e62811be78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7c6e83e3-b7ec-425c-b969-4b31c2b52e07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7c6e83e3-b7ec-425c-b969-4b31c2b52e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_38e659d4-031f-4634-9a3a-2466302c8fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_22a1b021-9043-4a6b-a6e5-bbd7b4585c02" xlink:to="loc_us-gaap_LitigationSettlementExpense_38e659d4-031f-4634-9a3a-2466302c8fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreement"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_82e64ffc-2e65-4539-9b75-1b27cf137d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_92c2f298-5852-4d8f-8ca3-e454ea109380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_82e64ffc-2e65-4539-9b75-1b27cf137d0a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_92c2f298-5852-4d8f-8ca3-e454ea109380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementTables"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c0dc17d2-12ac-47a6-a676-ef3302d3a2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5148d5a9-6768-4fc6-baec-0f9a8630cda2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c0dc17d2-12ac-47a6-a676-ef3302d3a2df" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5148d5a9-6768-4fc6-baec-0f9a8630cda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3fc92f67-f7f9-410c-852a-b836c5c91d83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3fc92f67-f7f9-410c-852a-b836c5c91d83" xlink:to="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c35fc32-d002-493b-90a1-4596b6fccff5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_af794d77-1871-42ec-8045-427a9c4d0b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15f46d7-b587-4de2-a2ab-aaacdbe25e36" xlink:to="loc_us-gaap_MediumTermNotesMember_af794d77-1871-42ec-8045-427a9c4d0b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7d8acda-ab14-44e5-82bb-0412673db6e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:href="rmti-20200930.xsd#rmti_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6deb7cd7-4ecb-4c95-adb0-c37ac8e22041" xlink:to="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember_d6c669b1-1bd4-41a9-b115-29eccc681690" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:to="loc_rmti_TermLoanTrancheOneMember_d6c669b1-1bd4-41a9-b115-29eccc681690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanMember_72b0cbf8-61dd-44e9-8ba6-2c1b8143e90b" xlink:to="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember_bb2361b6-ef49-460a-a787-353ea674da61" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:to="loc_rmti_TermLoanTrancheTwoMember_bb2361b6-ef49-460a-a787-353ea674da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember_23927c3e-3d62-44e1-a326-5a3b8f84ef59" xlink:href="rmti-20200930.xsd#rmti_TermLoanTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_85b84a95-e339-4ea0-9daf-90fc47f877f6" xlink:to="loc_rmti_TermLoanTrancheThreeMember_23927c3e-3d62-44e1-a326-5a3b8f84ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_72e4cbc1-8610-41f6-9420-b493d5f6f346" xlink:to="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0deb2db-04a8-4519-a4e6-2c30c4ef18ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:to="loc_srt_MinimumMember_d0deb2db-04a8-4519-a4e6-2c30c4ef18ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a6a7458-107a-4371-b7b0-5842ec48c713" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc081073-aad6-4869-b44a-6a45a70a8b08" xlink:to="loc_srt_MaximumMember_0a6a7458-107a-4371-b7b0-5842ec48c713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9937112b-6793-4cf7-9ebc-971d372417ec" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5e31bdf4-9ca6-47e9-bb7c-488e28018ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5e31bdf4-9ca6-47e9-bb7c-488e28018ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cde7963d-fa7c-47d8-aa4e-3ed1610626a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cde7963d-fa7c-47d8-aa4e-3ed1610626a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_fdc99f3e-9fcf-4689-9506-60af4808db9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_fdc99f3e-9fcf-4689-9506-60af4808db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_d5a8ee51-c2ec-4b75-a68d-49671773ee70" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_d5a8ee51-c2ec-4b75-a68d-49671773ee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e27384e6-fd2f-4162-9ca6-93d24794deac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e27384e6-fd2f-4162-9ca6-93d24794deac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4a997c47-b009-490c-ba95-1b951a28a9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4a997c47-b009-490c-ba95-1b951a28a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_178af8e8-e571-4909-8b64-d7eaa0d6fbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_178af8e8-e571-4909-8b64-d7eaa0d6fbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_52f303da-b055-4fd1-8d4b-0f5940c3182f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_52f303da-b055-4fd1-8d4b-0f5940c3182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_12ecff56-3f13-4654-b980-315e78a14985" xlink:href="rmti-20200930.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_12ecff56-3f13-4654-b980-315e78a14985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_35a55ae8-5c32-4685-8bd2-a3e9be38b2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_InterestExpenseDebt_35a55ae8-5c32-4685-8bd2-a3e9be38b2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_107c1c4f-562e-497b-adfb-c1eda34c0b40" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_107c1c4f-562e-497b-adfb-c1eda34c0b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_c791f05c-dc02-45d7-be2a-f1c60fff5dc4" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_c791f05c-dc02-45d7-be2a-f1c60fff5dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ebe3291-7225-490b-b58b-5c43a0c3449e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ebe3291-7225-490b-b58b-5c43a0c3449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_dced0f91-733a-4432-a604-6aa36f852f28" xlink:href="rmti-20200930.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_dced0f91-733a-4432-a604-6aa36f852f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20ef5c90-5261-4b02-a5b6-497611412c42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20ef5c90-5261-4b02-a5b6-497611412c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9165deaa-d07b-4a92-a3cb-1e9f6edbb189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9165deaa-d07b-4a92-a3cb-1e9f6edbb189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_42bf07ac-cc72-4ef3-96c6-86d9c0322db7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_LongTermDebt_42bf07ac-cc72-4ef3-96c6-86d9c0322db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88bbbdaa-217a-4e43-8306-f7df443d4ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7551e41-44ed-4c9f-a96b-246a79bb0b38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88bbbdaa-217a-4e43-8306-f7df443d4ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20200930.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_99312edc-83af-41fd-a5dd-dd43227859d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_99312edc-83af-41fd-a5dd-dd43227859d3" xlink:to="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e1d5faa3-1946-4f06-a1bd-3f619c42adfe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_8b65483a-33c5-417f-b8e8-eeaca19ab743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_911b849a-fd24-4ae9-9cb8-0be283fa2804" xlink:to="loc_us-gaap_MediumTermNotesMember_8b65483a-33c5-417f-b8e8-eeaca19ab743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:to="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dae5b080-7751-408a-8072-7941ffbee1b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_7f9a7452-595d-4106-818d-8853beabcbe3" xlink:href="rmti-20200930.xsd#rmti_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e13aa4d-4be8-4c4f-9042-720de155314c" xlink:to="loc_rmti_TermLoanMember_7f9a7452-595d-4106-818d-8853beabcbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_630dd19d-ca7c-446a-a2ab-4e39a082ca9b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6f7d21ac-f99d-40ff-8fce-f38ba25d5bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6f7d21ac-f99d-40ff-8fce-f38ba25d5bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8fe6ad3e-b35e-4b55-8713-633eee475192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8fe6ad3e-b35e-4b55-8713-633eee475192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9db5e38e-9c3c-4345-8335-7ed034850887" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9db5e38e-9c3c-4345-8335-7ed034850887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_007345f0-0511-4e9d-ae3d-192c41a5c290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_007345f0-0511-4e9d-ae3d-192c41a5c290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_fa902b3d-9720-459e-b5c3-7ba01f82e95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_fa902b3d-9720-459e-b5c3-7ba01f82e95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4d04ddcc-f593-4ba0-bc14-d360e1bcce16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4d04ddcc-f593-4ba0-bc14-d360e1bcce16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_55bc7839-e405-4427-ac03-25a1139c9419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_233a7763-42b0-4c26-8600-0828db4daeac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_55bc7839-e405-4427-ac03-25a1139c9419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>rmti-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rmti="http://rockwellmed.com/20200930"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rmti-20200930.xsd" xlink:type="simple"/>
    <context id="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4edbeec154354697ac72b6c4e6eeaac5_I20201106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2020-11-06</instant>
        </period>
    </context>
    <context id="ibfa2ec5c25ac44e496b725edbf06211d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad39fc18340148d88260925cf2c71125_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2b30bbe1b55344bba8275550c225febe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86da6c4fcadb41b5ba4b5da76c54ba82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbd1887cf65f41b2b3d36bbd39db4838_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i770863e42a2a48b4a60892bc1e12c8e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5894f7b1235408b9757424526f72c51_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i70104b9963d5482b955d81352e01cba0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9edaf9e76a1545639356ff49ed8463fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie97de709080c4090915c065a4968de18_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc6c114819494195977381d6b0db0dea_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i75307b6d43bf458db7da774b1cf7e073_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i613f46abca3040f28bb46ad26bea4e91_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0fb4d607639d417e882b6b1325d73420_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ice592ffedeac499c8ffccc365e8a2547_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i94fd4f38167e440080bf667eae2b6adc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i668ce7c09fd243489fd8aa0744ebe327_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73fc87614fb147bcab7ea2ebc4329b29_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib2c0d288358b418e8a8e6005137b98d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibdc60d8ab5c84122b3c9526037d9fbbf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie7aeab489a5041d3971baf867a877f96_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibb47d4544bfe478d982c81e288fe8773_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5c2321752f47434c87f33cf993521b05_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i158adda0535d4568a317d0212af41201_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d75f31ec2c24f38ae359072561380f1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b6868d13e9543fb9846f82e219eb2d8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d1c76ded1ff4405a15cfd8dec9de35e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie513e505eaa642a0ba67d4d26a26bc6f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b7c8b7f5c8a4cd9a5e31c6ce7907dc2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3c8e35d265294eb3abef852d48f6016b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8327e54a894540d387fb1c21d05a7962_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90da80b5c0294f05980472837370ff77_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i32f5bee8a4224cc9bb993e924ffa5275_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic1b70d7f95f940b99b2e2d713e8c2e9c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1a91033410234d9b93822df743ab2cd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iffceb5a770d1470989b074fcb3ce1c72_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id350ff27398e46e386d5e77a30fd2dcd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iaf404915f16f48298abfdbae0b2660b1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="icf9d133aad0c4316be6655984efa94c8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iddf8c061dd424cdabc54af0c6e572255_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i69e28682b96b4df0b51ff9264ab162b4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iba6687bd6e9d42cf8aa0d9cbc3831aa7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2eb0f9c17c8145e8885d3c5be256df8f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0a806c9950844789a211562273ac4bd5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i669cbdb570ec462e90fee94d26485af7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i870c6dec364a4c55b84f57f46e3d3d59_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1c5a6d1ecfac490aa90fc495766c743e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifa01447503b345c3a703ee4cff530762_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i55eb32ecc0864f59969698ad4c39091f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i75ed909e37eb4f2d80b62754e1ac5a7d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1d3225f700f14b8eaa7dae5e7b000ccd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iad981cf655894d8b8f4cb43bc0028978_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib1303e4f07304f0ea1c7de0894409f16_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3554a067052149da9e0237073b75129d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i785da024692147b885c403a33b86064c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i21f6b8ee17a940baa698ca9d3509e8c2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib86aa439c9264e91b122ec5e8b121f23_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i584df65c9c7541bfbca2050c1a065f5e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3b182882e4024d7293ceaabba4bd8ccb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2261e4d5acc643928364085bf274f5eb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2275794073f343e286251f69c0725483_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1587de2669b493e879da7e102635c4b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idec8a2522d62421e89cd4c2750585635_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i988157eb43c948b0b48c71a792211e1c_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-09-23</startDate>
            <endDate>2020-09-23</endDate>
        </period>
    </context>
    <context id="ib8980a286d764741a6a0535b98f103cb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib149f28b57b5455b83b33022698763a7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3001b9e27cde4f58a61cf8c157040421_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ea41dcc63ed476d8dbece309c6ad63e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73ec1516b6ae4e118fa7217f2aa0bd68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc89f567f4234735a146c9ace53adbb1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae5349e0526343b290ff0221f6aed37a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3c484a5d97547fb92216812c28b5a52_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia771c78851094cf0b22dcaa46810686b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5917e109c9e540b5b6b275de9b444283_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb07690b76f1481ebb6c2909fa5e7323_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4464409c4ae443058ce462975a7634db_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3ff30259c1441b2a0a4f0b559884a2f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i05e0725267804eca91f6f04b1aba0ed8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i062b8ca84b4145329ac1a0509078f58f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic39fc677e9a549b382f949b298ba067b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d8fb70070b246648e8f8997628ff47a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1095befdd04d445e80654a04a53cabdb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icad9123b89e14db8adc3fd5832999d21_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief873247bf6b42c0ab6113a99352b4a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i697255d93ed5459aac6fe8eef560cb51_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74bba929d51d492abd362e87e6ba9825_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a16aafd4b73410cb11d551d736d5525_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i663f506330f048d4a93e2d6cc47aa6d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i754bf852083a492293cd350270a1a844_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6675c9f60fba4ff7b0a180e9cf9b6f2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i285b58ffd3fc4e8b92453fe7ecc0598e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf229f34c7b64e8bb5ea23ba69e5fd1f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96af2b1201d74f70a53001fcf34f9ffc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e93fcfaef8544759969602319623bfd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2130d942bd5e454aac8d0d51dac98817_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieeaeac98cba349d5b79b6b44e11381b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id737660a634e4a9c9bdbe80a2a316639_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icccc5ba795194400bf9c6a11150113a9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee231374be0442fb8029ebfdc1a3e6c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b06e779ddd644c9a0b0ff6c7875bd45_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d53e2964d824b1d90da68f8b963d64d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cc0c1d935564e1a813e0e93ec99c70a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8795859a4344592a375c53c2fe649cf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0c9575f496b407abf0680d511ae8619_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia261e596f7ae4be4a6bfacfd41985358_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i117b1cfaa32c4e209267190df3a1d335_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d6d5deee8c245e59ff7998cea9f8e8c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iadc5f4e7510d42e78b5fcd4d6ca0877d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7f0fc5632f44fa892279e11d3f5f64a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67baf02b08254808bd4df548744d90af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief6af98eb7bd4e238f6b0b2894b4556f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if3a805e442db408f92e45e37dfa077e0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d19f7511cb04600801f9d98fef26b60_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i482a8f6c3a59419eb4648b61db88d5db_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i15fbd0feab424ce1bcc0b1fb2ec36625_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic4437cf163a249a1b01639218fdce4af_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida40c86298494cfd939804f4adf6c2c7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab7b126708c34e6d8b8b6e745bac3bdb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i22a80d3ff4034599a93526645efcf37d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ade2e7c43f8418e9e161bca2328cc73_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6a93ba8c220648ca851f5aecd304d30c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b41310bebe843d3905f65a72974bd97_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45c343d1a1ad409c88aaec6888f258d7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifaeb1dae1cf94b168309faa699ac9f94_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50342dbb79e5499b9df2cb4e61d5be82_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id37b023ab7a5491390c1523729301141_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf1e2dfcd2804d95882c57e1cd29577d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0f56a098641f4adabdbc54bd9bf3cebd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib36cb5fa1a574affb0e19d405b184779_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85a4ecd57bc74263aa9d096516b7427a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6a70e4d101944330a1355aa4af4afef6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1db5ea92241540b2a00b5cc4513365e7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i95bbeb2e83814978a01e4b5de1f38535_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if1c1e6721d294667908c33dbde50345a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i444bb9b794c448cfbeb71eeb7d6b7942_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2a21751e445646ee893fa1935f34c449_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic68dd4e2cc7543f086a97c70aee4f3fd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d2ce83af8934687a4f96e799ec9b7dd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i32bbacc3c3f74215a538c3cb78cdda7d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id68098fe4a9b439eaacc7f7d0c5bcbdd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e195e8a16b54620a94c67cd6bc415f3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98cefbf199d9465dae391afe67bf6d55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3adad74f372a48a99515a279dafd740f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9fbfc3f90f54f06aa5a33e2c9b0418c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7264bcffa714400896107154c6920431_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib7e656f96253442ab7ee60c4d60cfdfc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieede3c5dcc3a49f1b95a145c32e7e7bd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1439b9bc31504073b9a6b6f1af0e5f94_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i521d8220c1444234b7c2ff570a6a0903_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i47777114a06c45f2824489ae3e94ab1a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16e371b1d2074f71ae9ec6f96bf78fc3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e5eda16ab0e411eb51123b3346dcd32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if75c9d8788794de588ddd02a124be433_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9c760a1961f04f77a2e3c6497a544e0c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib11597e3775d4b5f9e6494de29d10293_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericDialysateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5bd74d8095764a1eb76ef37b3b5b33ae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericAPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia59f19af41fc488a9449247c776c5edd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i490ec924f1484c5ab8de1f20a08eac2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09ea955020dc4aeda5d463477492921f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i724d030ef47645d9b041ce7ef4a3f9fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7e7800000fe40fdb031acb81db02074_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idcdae022f9c94d2cacaaf617ee81281b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icaf6b93155d0417884bb4a768fae1f99_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ied2d61a12cde4716914c1b6f8b1a5984_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="ic9ae312db51145cc9a83894a56a1cbb5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id517adcb738e4b869a1855cf0dc6e89c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbd0e24d44954042a9d519b591fd1314_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52774d95e2b2417085a873bc7c2ef34f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib51e33cf4bfd4008b1b122e6683c1a98_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ie0427b48c8964f40b6989681e03bf46d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i259025889eae4268ae9b6e57e34ee6d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if9668e4db871491a984f75bb8da0189f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic51b254d9485419498fa51735863171b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie89138f962f14daa953625c2f528ae33_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4bdc1b8fe88f47298e47838b329a17c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f8d7d55df774d63a47aea6d31334501_D20200114-20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-14</startDate>
            <endDate>2020-01-14</endDate>
        </period>
    </context>
    <context id="if753017f31704051a4c4bf411897fbe2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49ae4f19c274445bb160007dae42042b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4718c450d0ef47158d07ef1e72752de0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i91abe0affe46442896b337be936db0c0_D20200907-20200907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-07</startDate>
            <endDate>2020-09-07</endDate>
        </period>
    </context>
    <context id="i8ccd6e7c5ec24a5893a434fbdcebfbb4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0eeaf45b733e4e779dfcac83f1129f11_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice0831beb2ab467c80a2cd6478135fd1_D20190322-20190322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-22</startDate>
            <endDate>2019-03-22</endDate>
        </period>
    </context>
    <context id="if133411b23494ef4a52b411a10736bc0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f2b087a0e4f4228929a2c5ee622983c_I20200204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-04</instant>
        </period>
    </context>
    <context id="i05c8a3f51c2d4520bd74c294ecf97017_I20200204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-04</instant>
        </period>
    </context>
    <context id="i041fa2ada3f74f73bd7d90fb6dfb76f2_D20200206-20200206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-06</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="if132963a047b41d2a24b8a07ea731b8b_I20200206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="ib5508c49bd924868bbf229130f33ee19_I20200219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-19</instant>
        </period>
    </context>
    <context id="iab29bf3438904c79b711f873e3ceeb8c_I20200219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-19</instant>
        </period>
    </context>
    <context id="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="ia502bbba04754e9aba66622648340936_I20200923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-23</instant>
        </period>
    </context>
    <context id="i486841c65b234f6cbf7712dbae65542d_I20200923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rmti:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-23</instant>
        </period>
    </context>
    <context id="i782ec4f251e84caf91c4d307a48529b0_I20200923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rmti:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-23</instant>
        </period>
    </context>
    <context id="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-23</startDate>
            <endDate>2020-09-23</endDate>
        </period>
    </context>
    <context id="i1fae665e3ecf4ecaa260ed16b9864327_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib79801249b974542a7353d5d96850c6d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9942ba6c87d84e62962ab243afb9c8b2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1198ab5b58240dbb1f5bfeca60211a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie7fd1a1eeb924cc5b1b07ab373a25223_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if383605b1d784fb1a8ff6c886fb8e59d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c7e169bbaa94542ac7a76cb79b52918_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1daf26803ee746bc8aea3bb5e7e6adef_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id854eccd72ff423c94105e0747d833e3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i62e59b988f854af6a2f19b812a92527f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb4dad30bf674f2b81a41e72d5349c55_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i87ac32bf162f4c268157cf1641fa843a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6646233751964c4fb0aa59ba0eda8b5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f27d81d3cfe41f691685d6efd73d522_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icaba2c2351e144d5bcab77648873bd5f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6551685fb24049b682909f7a5086db3f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i10f9f4004419417e9412857f5acd3c8b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icf4a248d9fbf4a9dbd4e6806f7db82dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5579dd55e4b6461ba7c91e665d52fee3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a801e210d094fa18659b7a2f0a4f400_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="idcb8a240bd284c4e9463f5dd7b8a6c70_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i6efe4199c6e74202909ae855d11ce621_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i909683c4233b4a22804c27ebf1e6c92b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i515e2b0a4fef415196a45d1b5751f530_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i564592058228420b94ffbc322e7090c4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6606daf6bf13495a89c4cb1a8572fecf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0c9890f223334395a55787fcbfde8291_D20200417-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ie0fd29e788d64550b340302d86755201_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51825a238efa425a9b7252dd4452dcdd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibfccd25c8636494a85d9d1d3f1d09ba3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2b5bdfb4ab9b4caa9c0806d213fcfb9a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e2d2e0642bf45b09fe5f2a6bfa06696_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i07d733cb7a0441e9ae832f027f97a0a6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f601d2948df4553b7179e093cc01b77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1282277c8624ede8e591db387da49dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if1fe840a7dd542c2836bd0373f092156_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i744dc4048e2e4f8794db00508bd3d7b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7b33a9d825ac4f1abca98c67b705a726_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6cc0b7d956b44d84a62ad0c4ec9b6942_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaed2b90c22864608b60a3b3225ad1530_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i6bb2ee2e447941fdb9ab2c2d6386827c_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i40d39c6c2580451195d91bed252a4a52_D20200417-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i885bcca89a364caf8262446d9b98366c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i72f1121abfa849c8b1387a55992b3591_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b9db72d78c14bd0bafdf4d133155def_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:PresidentandChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2018-10-07</startDate>
            <endDate>2018-10-07</endDate>
        </period>
    </context>
    <context id="i8b2db876957c441ca0969f774801ddfa_I20181007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-07</instant>
        </period>
    </context>
    <context id="i2362cb7d4e704216966ce8696c3475f7_D20181007-20181007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-07</startDate>
            <endDate>2018-10-07</endDate>
        </period>
    </context>
    <context id="i759a54d69ef1425aa8087f8817c5243c_I20181015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="i2cc86daf3763428e93f171eb558edf4a_I20190115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-15</instant>
        </period>
    </context>
    <context id="i9b5fafdd17b044d38ca4687c5c170b5b_I20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="id6a755fb188b4af39fd3307f039573d2_I20190415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-15</instant>
        </period>
    </context>
    <context id="i79757255bddd4b608922f96cd3af93ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79863bdc8a984b328ab874faf1c4b1cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b7cf56169344015943de2cc62f7eab3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:MasterServicesAndIpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2985ad7b6c3459abea9cf473c3ffba0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:MasterServicesAndIpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfd4514ac70647b48f7ba3276ef1d345_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3145caf8d4884ddf8790d54cebdc6132_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iffda10ef89254fc8b784470695ac1a39_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1a68746f2fdd4216add87ba69b052f3f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idc4ac606416e4e319806c6b97ba5e4a9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if68138705a9e4ae8b0ad29ba0248671c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rmti:LeaseFacilityTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i656a4eb3707c4c909af7978cd89b8b65_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id7bf20809ab9443ebd612edde24ebe08_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i1d16d753feea42379fc36a6fc4802303_D20200801-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic43d3fec43e04417ac3e08e63a74b5a6_D20190807-20190807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">rmti:SettlementAgreementWithAllPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-07</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="ia36da30ff01749b28487000f6715ba77_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71d9fbef3e73446cbd0ee3d7923afae2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">rmti:SettlementAgreementWithAllPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i918e1ec310cd4501850ee5a1d190849e_I20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="i74badfe283474cd495162707af80f4c0_I20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="i550d13f16af14526aa4aba8c018e3653_I20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="id3bca046ce7d4f19a430c177d2515e64_I20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="ied6c0e6eb376449797262cd45e197f26_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="iaa2795cf61054796b20b23bef364d55e_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="i7ad74bef55824ee587591169cd823d18_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id21bb6146027445a9e33a3043534e284_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5bb31ec7a444c18904dfe090598b734_I20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="i99be750d121e4bba9049423b4facb83d_D20200316-20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="ia2342dabfb994ca9b8cabed424b37ce7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="agreement">
        <measure>rmti:agreement</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>rmti:installment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="day">
        <measure>rmti:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl80LTEtMS0xLTA_4f08180e-301e-4347-9193-6614b26b5018">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl83LTEtMS0xLTA_9fb2a8ea-dd6a-4198-b354-71d169b2e05f">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl84LTEtMS0xLTA_05a12cc7-017e-4687-ac81-49a30b7845ec">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl8xNi0xLTEtMS0w_369ea955-1ed6-4e74-a109-2a1b78e98001">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80L2ZyYWc6NjE1ZGQ3ZmMzYjE2NDYxMGI3ZTYzY2Y5YmU1MDljZTUvdGFibGU6MWE2NDdmYzdhMDNjNDUzYmFiNmQzZjdmNGQzZDk3MjYvdGFibGVyYW5nZToxYTY0N2ZjN2EwM2M0NTNiYWI2ZDNmN2Y0ZDNkOTcyNl8xNy0xLTEtMS0w_38c8bf57-ba04-41f6-8fa0-40ffa2e93f91">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEy_e07b7f43-62c9-45ca-9b45-75fc1edb41d1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6NzJkYjlmMzk4MjFjNDdiOGExMmZmYzU1ZjcxZGVlZDEvdGFibGVyYW5nZTo3MmRiOWYzOTgyMWM0N2I4YTEyZmZjNTVmNzFkZWVkMV8wLTAtMS0xLTA_78bc75c9-fe51-4000-9b8b-99df3d5636ff">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8xODY_b10146fa-8703-425a-a4d6-5d6feeea859e">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6OTlmNzVlMzZhMzk2NDM4YTg5NTdjMDU5MGY1MWNhMzIvdGFibGVyYW5nZTo5OWY3NWUzNmEzOTY0MzhhODk1N2MwNTkwZjUxY2EzMl8wLTAtMS0xLTA_e87a356b-7cca-41bb-b650-3e6df795e135">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEz_ec1f85b8-8ccd-420e-907d-000804d2728f">000-23661</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA2_deb64334-533a-43cd-a323-8f5e4c5565ca">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8wLTAtMS0xLTA_78153657-8149-4e30-b940-f8c98d3addd3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8wLTMtMS0xLTA_a82a4fee-9ac7-4570-8347-229361471a1b">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NDkz_ed193788-3f29-4fd0-94d0-a693429184d7">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NTE4_4f11f56a-7835-4507-a61e-8e9d33e200cd">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTY1MzkxZWQ5Njk0YmY1OGI4ODk1ZjZjZTY1NzgwNl8yNzQ4Nzc5MDY5NTI5_faf2815e-e7bf-47b6-a12a-905a0e93c449">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6N2JkNmQwZGRkNTQ5NDlmOTg4ZGZmZDczMTk4MGFmMDgvdGFibGVyYW5nZTo3YmQ2ZDBkZGQ1NDk0OWY5ODhkZmZkNzMxOTgwYWYwOF8yLTMtMS0xLTA_d0265eeb-a1ad-49b9-9644-a0b849020e9e">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA3_0007e7b7-936a-4df5-81cd-404d53c8206f">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA4_4f8b495c-908d-4ec1-8881-e871a9d566ac">960-9009</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcx_60bcefa7-2e1e-4bb0-b1f8-6a106bfe222b">411 Hackensack Avenue, Suite 501</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcy_ab5c2e1b-b28f-4b1e-a747-d58786f5f3db">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjcz_9caa5c9e-a969-40f8-af8d-865c9ff8f2e9">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5968b4798cfc4b3c915160c624c35344_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yNzQ4Nzc5MDcxNjc1_9e4bd5dc-9dfd-4b2b-96a9-2dbca62a094a">07601</dei:EntityAddressPostalZipCode>
    <dei:EntityCurrentReportingStatus
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTA5_1db1bb6f-5061-43fd-8673-3c8b8e5174c2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEw_f7f02d6a-e73d-4a6e-89e3-e3951c2175bb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8wLTItMS0xLTA_35d3518e-1afa-40ce-9633-01a38ee0e4ca">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8xLTMtMS0xLTA_e130e5ab-fc56-4425-b5fe-6a7b4ea89969">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6ZGUwOTUyMjk3ZGFhNDFmZmI5OGM2ODMyMDFkZWVhZmEvdGFibGVyYW5nZTpkZTA5NTIyOTdkYWE0MWZmYjk4YzY4MzIwMWRlZWFmYV8yLTMtMS0xLTA_97385001-a01d-4d56-85ca-82a73d31da5f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTEx_423edbeb-0629-4301-82b0-2184e441ac2b">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTAtMS0xLTA_7a2891c8-b2a3-49df-9c86-fbf0ab808b68">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTItMS0xLTA_7958c794-3437-452b-8d38-ae836e2e17a6">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGFibGU6MjhkOGZhY2EwMzQ5NDNmODg1YjJiMGUyNWYxMmE0ODMvdGFibGVyYW5nZToyOGQ4ZmFjYTAzNDk0M2Y4ODViMmIwZTI1ZjEyYTQ4M18xLTQtMS0xLTA_df3ae346-81cc-4b4e-8f6f-0399869037e4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4edbeec154354697ac72b6c4e6eeaac5_I20201106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xL2ZyYWc6ZTk1MzEyZmNiZGU4NGUyZWFlZTEyNmM2NTQ1MTg5NDEvdGV4dHJlZ2lvbjplOTUzMTJmY2JkZTg0ZTJlYWVlMTI2YzY1NDUxODk0MV8yMTAx_91d02ae9-f98e-48e5-8c74-3b6721e27e24"
      unitRef="shares">93573165</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMy0xLTEtMS0w_7ff17067-ea1f-4c72-96c4-97ffcb215340"
      unitRef="usd">56614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMy0zLTEtMS0w_d2491536-01ca-44de-b6cf-c047c768c54d"
      unitRef="usd">11794000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNC0xLTEtMS0w_87f9f49d-2bb1-47e6-9c36-6cbb0b229cad"
      unitRef="usd">10702000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNC0zLTEtMS0w_e28a4ba7-2299-4550-aeb7-8c2d4bc0b514"
      unitRef="usd">14250000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNS0xLTEtMS0w_0292a2d4-ea71-43e8-9ae6-04d185f45a6f"
      unitRef="usd">4129000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNS0zLTEtMS0w_dcb21e67-e60b-48a7-951e-6b0aa3af8020"
      unitRef="usd">4203000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNy0xLTEtMS0w_e6a531d5-5c9e-4afa-b65c-31c98aa011e1"
      unitRef="usd">3877000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNy0zLTEtMS0w_e23875a4-f434-4059-a8af-6af8a8e0d257"
      unitRef="usd">3647000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOC0xLTEtMS0w_d8ed525b-7c76-4b46-a591-3aef8b34ae03"
      unitRef="usd">2621000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOC0zLTEtMS0w_efc5d897-8185-44af-8e8f-3bf8f45af281"
      unitRef="usd">2980000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOS0xLTEtMS0w_0bea495a-32ee-4796-875a-0368f3861739"
      unitRef="usd">77943000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfOS0zLTEtMS0w_9f084993-ddef-45dd-85b8-f1f535b39c30"
      unitRef="usd">36874000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTAtMS0xLTEtMA_afb240ca-3912-4135-a83f-9c7652c1cd79"
      unitRef="usd">2785000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTAtMy0xLTEtMA_ad9d57c0-5003-477e-b03c-9a4e4115eb64"
      unitRef="usd">2433000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryNoncurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTEtMS0xLTEtMA_a7b48273-05c1-44de-8b16-db3c718adddb"
      unitRef="usd">859000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTEtMy0xLTEtMA_08e1c409-c36f-444e-94d4-9cd31c3f11fd"
      unitRef="usd">441000</us-gaap:InventoryNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTItMS0xLTEtMA_62cb2eb3-3c04-43fc-8abe-bc10ebe01f48"
      unitRef="usd">2099000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTItMy0xLTEtMA_4ffcaae0-e227-4804-a972-802917223856"
      unitRef="usd">3213000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTMtMS0xLTEtMA_3378a75f-63b0-4634-8ab6-b3d46669b9cc"
      unitRef="usd">921000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTMtMy0xLTEtMA_1904ac1b-610e-4d05-aa34-c7f77fa39ad0"
      unitRef="usd">921000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTQtMS0xLTEtMA_93c009a3-4199-4209-92f5-15e725096259"
      unitRef="usd">629000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTQtMy0xLTEtMA_6b0091ad-2617-4f4c-a58a-15f27528cae4"
      unitRef="usd">435000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTUtMS0xLTEtMA_3f288a42-dc45-4b34-b683-405088916195"
      unitRef="usd">85236000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTUtMy0xLTEtMA_a3f10b2d-82d5-4237-bfc1-d684870f8dc5"
      unitRef="usd">44317000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTctMS0xLTEtMA_da346131-5f65-43af-8efb-c9f952452f13"
      unitRef="usd">4190000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTctMy0xLTEtMA_9da97838-c0ad-44f8-99f2-2c32e6f0cb69"
      unitRef="usd">3018000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTgtMS0xLTEtMA_6adbc6b8-df04-4158-ba25-78ea5545b38d"
      unitRef="usd">4968000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTgtMy0xLTEtMA_88f12186-9401-44b0-aa17-3365e567a4fa"
      unitRef="usd">4518000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTktMS0xLTEtMA_ef266eaf-a3be-4886-a963-df80020d3cef"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMTktMy0xLTEtMA_4fb35f1e-a856-4cf4-90fb-502e4da4a6b6"
      unitRef="usd">104000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjAtMS0xLTEtMA_0cc19fe2-d84a-45c3-8813-c9b281c1316b"
      unitRef="usd">1155000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjAtMy0xLTEtMA_1fd00f77-5ae5-4e5b-a694-174ef6eece6c"
      unitRef="usd">1493000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjEtMS0xLTEtMA_db898287-02eb-4bda-b67b-6525ed33799d"
      unitRef="usd">2180000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjEtMy0xLTEtMA_4b3ce81a-e634-4ef5-be6a-13b8b85d5b0e"
      unitRef="usd">2234000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayable
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjItMS0xLTEtMA_477fda52-2785-4ce7-b123-ffb0559215c7"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjItMy0xLTEtMA_25654c3a-2c4b-4658-ada1-963da96ea5fa"
      unitRef="usd">763000</us-gaap:NotesPayable>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjMtMS0xLTEtMA_38fe4e7e-dba1-4877-9cca-23386a6eba9d"
      unitRef="usd">73000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjMtMy0xLTEtMA_236ffb08-e911-4ee5-a9ea-b69dbdb4166b"
      unitRef="usd">55000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjQtMS0xLTEtMA_ac8837f0-4324-4e78-ab38-1218ee8dcb9b"
      unitRef="usd">142000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjQtMy0xLTEtMA_be3249f3-ea83-45db-9710-7e4c900543d7"
      unitRef="usd">188000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjUtMS0xLTEtMA_266a4d00-6027-4c16-b7b2-c2837cfed183"
      unitRef="usd">12708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjUtMy0xLTEtMA_d01e2f79-1de1-4f47-9cbf-4bf427c754f9"
      unitRef="usd">12373000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjctMS0xLTEtMA_40c26c91-38f8-4fc2-a334-a5ac3c671c39"
      unitRef="usd">1039000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjctMy0xLTEtMA_68ab30cf-9f7b-4523-9f95-97fa40b0be3d"
      unitRef="usd">1781000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjgtMS0xLTEtMA_60aac1e2-10ff-4139-a370-45a604d4f5be"
      unitRef="usd">20856000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjgtMy0xLTEtMA_a619a4a6-897c-4db4-af45-527430c8d6de"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjktMS0xLTEtMA_d8295abd-f5a2-4ebe-ad3a-5f19ab287719"
      unitRef="usd">8558000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMjktMy0xLTEtMA_bdb6cd76-8d1b-4a3e-ba0e-1272f3a8af13"
      unitRef="usd">9843000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzAtMS0xLTEtMA_8b7a3f0b-f984-4b22-a5fd-1fb32ff902c1"
      unitRef="usd">43161000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzAtMy0xLTEtMA_9af9e765-413b-4916-9b83-f52ec1cdf501"
      unitRef="usd">23997000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzItMS0xLTEtMA_76469328-4ae3-4324-988c-9820d3ae4d16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzItMy0xLTEtMA_1ce9e05c-afce-48d6-a2a3-94c99df9121b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1ODc_c2c0db0f-ef53-4bbe-9fd4-d5acaae71654"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1ODc_d3307e1a-ff4b-48be-a7ac-3362f7190703"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1OTk_62a9eacf-117b-475e-80f9-ecdae81e5d62"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk1OTk_ffeb870e-028d-41be-925f-32386c8bfcee"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_208eb3a3-03f7-4d65-b03e-2c79a978f159"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_33a0d1b1-9336-436b-903e-e6d1c9b19373"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_46c05ecf-13d2-4813-9ae2-00a945ed75c0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQzOWE2ZTkxMjQyMjRkMTliODZmZjM4ZmQ5YjJjNzk1XzI3NDg3NzkwNjk2MDQ_4b6e24b5-31eb-41cc-b660-06ab820d9676"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMS0xLTEtMA_d09e6b90-ba0a-44af-acb7-0afa4c8a3471"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzUtMy0xLTEtMA_1e79c432-84ec-4af0-8809-6ac5caf65625"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2MjM_242c1fc6-efaf-4583-98c4-074eacbbe5b7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2MjM_54a09952-506e-4fb1-a1cb-bd7386543eba"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2Mzc_79b1ecc8-3782-4cff-81b2-e419b7485f75"
      unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2Mzc_96074e2c-07d0-4993-b908-5f5874d42511"
      unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NTI_08086c21-0419-46f3-8abd-7c758c5f9f33"
      unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NTI_8834268b-a848-459a-a555-26bffc9244d6"
      unitRef="shares">93573165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NjU_83fff684-49bd-4205-ab79-d2e74c156e72"
      unitRef="shares">65378890</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjJhMmM3ZWEyMDRjNjRmNjQ4NWZkMmJmYTZlYTFmZDVhXzI3NDg3NzkwNjk2NjU_b142312f-668b-4209-8b5f-6fef734aebca"
      unitRef="shares">65378890</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMS0xLTEtMA_80c19a09-fc98-4bea-8643-1f52b8b0e33e"
      unitRef="usd">9000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzYtMy0xLTEtMA_4b601ded-362b-4532-8039-6df5588fd388"
      unitRef="usd">7000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzctMS0xLTEtMA_7866b1e9-6bd6-4898-bbbc-9913d579d5c2"
      unitRef="usd">370760000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzctMy0xLTEtMA_c3f1c9dc-d264-4081-9bab-255560edc562"
      unitRef="usd">326777000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzgtMS0xLTEtMA_32f0f087-85e7-477c-b72d-fdb370334d39"
      unitRef="usd">-328743000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzgtMy0xLTEtMA_b95ab015-c489-4283-a2d0-30d073663170"
      unitRef="usd">-306516000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzktMS0xLTEtMA_9a7eae2b-2295-47d4-b9d9-f896bd286568"
      unitRef="usd">49000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfMzktMy0xLTEtMA_1a8651f8-4b5a-44ec-9558-9d017a54c7d8"
      unitRef="usd">52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDAtMS0xLTEtMA_54f5e6dd-2e28-4c64-a9b9-b8429be22ba5"
      unitRef="usd">42075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDAtMy0xLTEtMA_024598f7-dc01-4afa-9474-7bbb9e5b4ac2"
      unitRef="usd">20320000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDEtMS0xLTEtMA_0f586496-a43b-4961-a014-b461796b70a6"
      unitRef="usd">85236000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xNi9mcmFnOmZhZWY1MDIwYmQ5YzRmNGQ4NzdjYjhlY2EyY2I5NDQzL3RhYmxlOjc1MmJjOGY0YzU3YzQ0NDNiYzA4NDc0ODM1YzIzOTZmL3RhYmxlcmFuZ2U6NzUyYmM4ZjRjNTdjNDQ0M2JjMDg0NzQ4MzVjMjM5NmZfNDEtMy0xLTEtMA_ab14574a-1447-47d6-8fd1-abad69566914"
      unitRef="usd">44317000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi0xLTEtMS0w_f3ec7c29-ab80-45a0-97b8-5f9fd4789e27"
      unitRef="usd">15280000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi0zLTEtMS0w_1f9d633a-e235-4a61-b498-d407a407bb17"
      unitRef="usd">15407000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi01LTEtMS0w_f716290f-e01a-48ab-90d8-f7df76bd4dc8"
      unitRef="usd">47033000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMi03LTEtMS0w_ac559955-7e91-4847-8e2c-898ffeaf2046"
      unitRef="usd">45812000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy0xLTEtMS0w_5e69e40f-c23c-42e3-94a9-19f6f0b5169e"
      unitRef="usd">14934000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy0zLTEtMS0w_12ef22bf-ba52-47af-a45c-eb6d284918e3"
      unitRef="usd">15424000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy01LTEtMS0w_5fc50af0-db01-4a9f-a750-cf3b265b30ba"
      unitRef="usd">44693000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMy03LTEtMS0w_31023278-0c4f-4113-96c9-31447aac70a6"
      unitRef="usd">44085000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC0xLTEtMS0w_290ca396-6f81-4228-a44b-43324890d71b"
      unitRef="usd">346000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC0zLTEtMS0w_7f536514-13b2-483a-a09e-9c74267d5b12"
      unitRef="usd">-17000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC01LTEtMS0w_05af3146-9456-4bf5-8cd6-886704462d01"
      unitRef="usd">2340000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNC03LTEtMS0w_09dc8b84-e995-4c54-979f-f978de4dc52a"
      unitRef="usd">1727000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS0xLTEtMS0w_8217ba02-889d-4554-a7e3-4279a3dba91d"
      unitRef="usd">1669000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS0zLTEtMS0w_a2586a45-fe75-4430-a0ce-eb2fc0c73a25"
      unitRef="usd">1827000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS01LTEtMS0w_61b739ef-3d1d-4e11-ac42-fc53de56d237"
      unitRef="usd">5738000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNS03LTEtMS0w_0c933087-be97-499a-99bc-bc0ad7f885e8"
      unitRef="usd">7149000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi0xLTEtMS0w_c518a801-f1e3-4973-89b4-317a0900e3b7"
      unitRef="usd">3622000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi0zLTEtMS0w_cfe3bb05-c2cb-4a8b-a9a0-6eb3ccb91bd6"
      unitRef="usd">4623000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi01LTEtMS0w_347a40e8-07f5-43e3-9334-e633c373bdaf"
      unitRef="usd">11767000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNi03LTEtMS0w_90a73ae8-c984-41ac-a0d5-17ef00ac1fcb"
      unitRef="usd">16341000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy0xLTEtMS0w_74c20570-5202-43df-9ab4-89aa49d365d5"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy0zLTEtMS0w_5e925ad8-eb79-4047-b823-cfe75ff827bc"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy01LTEtMS0w_c0309a93-4cc1-44c7-883c-91194fc89aa4"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfNy03LTEtMS0w_2957a03d-ffd3-4d09-8616-36faa68bf91a"
      unitRef="usd">430000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC0xLTEtMS0w_1ce80426-bd30-4235-bbba-2f8499b02b7d"
      unitRef="usd">1745000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC0zLTEtMS0w_71a5f5b8-3295-41cd-9196-eeae08dfc092"
      unitRef="usd">1475000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC01LTEtMS0w_656c48d9-3e58-409e-8aef-66d99542cfaf"
      unitRef="usd">5183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOC03LTEtMS0w_ff2705d8-c893-4fce-82e1-6e5080b64123"
      unitRef="usd">4930000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS0xLTEtMS0w_93b1e5fa-ef85-4656-b211-d4cefa429a92"
      unitRef="usd">-6690000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS0zLTEtMS0w_00f858c3-21b9-4fb2-b3c4-aa93b0a9c9bc"
      unitRef="usd">-7942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS01LTEtMS0w_a608dfe8-574c-48df-98b0-328bdbb0a040"
      unitRef="usd">-20348000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfOS03LTEtMS0w_a2083582-e7de-422d-9b3d-0c54b8ee24eb"
      unitRef="usd">-27123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItMS0xLTEtMA_f0613f47-5dad-44ee-9580-0d0dd2f66f47"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItMy0xLTEtMA_8c3af980-2f18-4d76-864d-892872a692b1"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItNS0xLTEtMA_45148139-2c1b-468d-bf6f-ce1a2c8b36f3"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTItNy0xLTEtMA_3d443216-553a-4676-9a57-1334d8856aba"
      unitRef="usd">24000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtMS0xLTEtMA_89232b44-cddf-45e9-b864-844927afa1f1"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtMy0xLTEtMA_3d4d4cfa-131d-49c3-9d9e-814811c0e4f4"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtNS0xLTEtMA_d435a884-1f08-4d94-b2b9-5bcfdfe93b60"
      unitRef="usd">837000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTMtNy0xLTEtMA_85afd1e9-97c8-4bd9-85fc-51f314900d21"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtMS0xLTEtMA_993b3653-f5e3-444a-bcc7-3d67781d57a8"
      unitRef="usd">666000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtMy0xLTEtMA_fb4ef9c7-1fbd-4da0-ba03-aeec24614250"
      unitRef="usd">16000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtNS0xLTEtMA_37aaa3a6-dd8c-4e38-9392-df4381cc6131"
      unitRef="usd">1289000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTQtNy0xLTEtMA_3cafc109-d922-4a12-8ec1-e6a0ec73d0f1"
      unitRef="usd">16000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtMS0xLTEtMA_3496005c-1d2e-43a2-b61e-d893f092e016"
      unitRef="usd">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtMy0xLTEtMA_cce5988f-7a34-42e1-a05c-da800b42c621"
      unitRef="usd">97000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtNS0xLTEtMA_004bf35f-eea7-4d2a-a61f-3a04ba2c7f8b"
      unitRef="usd">239000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTUtNy0xLTEtMA_eed45fbc-1b5a-4fa3-8579-cbb15d99fde9"
      unitRef="usd">289000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtMS0xLTEtMA_7a320300-5e03-4cb9-9b18-41fbbd393c0b"
      unitRef="usd">-660000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtMy0xLTEtMA_3bc526bc-854a-4c35-90f7-de07d0083bc2"
      unitRef="usd">87000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtNS0xLTEtMA_3a835a0b-91a0-4a99-a770-6643188ddcc4"
      unitRef="usd">-1879000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTYtNy0xLTEtMA_36da26a7-1755-43da-a9c8-376988335578"
      unitRef="usd">297000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtMS0xLTEtMA_5bfdf19e-02ca-4ec6-855a-fce7c3d13ff6"
      unitRef="usd">-7350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtMy0xLTEtMA_98dcd546-3110-4165-9187-ddc7a29682e7"
      unitRef="usd">-7855000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtNS0xLTEtMA_10a7fa07-6488-4844-b594-f01b4d6d9c06"
      unitRef="usd">-22227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMTgtNy0xLTEtMA_be4e9cc5-5464-4556-82d0-e3ac1c289ee6"
      unitRef="usd">-26826000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtMS0xLTEtMA_13bde4a6-c57d-4aa0-9a2f-f2bc866ce5bc"
      unitRef="usdPerShare">-100</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtMy0xLTEtMA_583554ce-db9a-4632-982f-2be993428e32"
      unitRef="usdPerShare">-120</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtNS0xLTEtMA_b64eea50-92fb-44ed-9e4b-119cd3878bf3"
      unitRef="usdPerShare">-320</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjAtNy0xLTEtMA_6a76e8b9-398f-4850-a0de-356c882fee22"
      unitRef="usdPerShare">-450</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtMS0xLTEtMA_a09987c6-5e0d-4b36-876b-d586329b541d"
      unitRef="shares">71811322000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtMy0xLTEtMA_a1efaf54-c924-4f79-9a4b-b9dfd039ecce"
      unitRef="shares">63796723000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtNS0xLTEtMA_b1569074-05a3-44e4-9584-a088a72c2272"
      unitRef="shares">69594167000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yMi9mcmFnOmMzNjk1NWE3ZTQ1ZTQwMTZiYjcxZWQ0ZWYzZTBmZjA5L3RhYmxlOjk0NmRhMzc3NzQyMjQwMzc5YzYzMWNjOTMyZDgyMThjL3RhYmxlcmFuZ2U6OTQ2ZGEzNzc3NDIyNDAzNzljNjMxY2M5MzJkODIxOGNfMjEtNy0xLTEtMA_368daf0d-1e06-499c-b52b-4f7f9833e70d"
      unitRef="shares">59728446000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi0xLTEtMS0w_6d1c78bc-846b-447e-8367-e3bfe7e010c7"
      unitRef="usd">-7350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi0zLTEtMS0w_c23ced00-a846-42dc-8895-0f4398010172"
      unitRef="usd">-7855000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi01LTEtMS0w_58fb9a71-adf7-4e9b-84f7-3027cd8800d1"
      unitRef="usd">-22227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMi03LTEtMS0w_c71eeb7b-ef2f-4fac-aec9-a42d4f8c56ff"
      unitRef="usd">-26826000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy0xLTEtMS0w_ddd3093e-1b8b-4f2a-bd02-dc43cdcf3048"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy0zLTEtMS0w_421de530-31ff-4a0b-947d-7aee8a730e8a"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy01LTEtMS0w_7cda7a81-4391-4c4e-bcee-55fe345d9a2d"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfMy03LTEtMS0w_8d1f3de0-4dce-4c8d-b6e5-b498fb9a0f4f"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC0xLTEtMS0w_cc9eb18c-6508-41a5-8b7b-41f34e70d261"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC0zLTEtMS0w_2752600c-33f9-40cd-be9a-5ae3e9d55b2d"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC01LTEtMS0w_df7a324e-aef1-49ff-b085-841eb7a763a1"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNC03LTEtMS0w_82c1df07-fbb9-4d41-8b6b-e21e6ded5d79"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS0xLTEtMS0w_87843695-1b06-4475-8ca6-e45792aef8ad"
      unitRef="usd">-7347000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS0zLTEtMS0w_623f4dba-1d61-44a8-939c-3859393c4833"
      unitRef="usd">-7850000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS01LTEtMS0w_13ae6864-b632-4472-8391-d20eaf05c61b"
      unitRef="usd">-22230000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yNS9mcmFnOmY5ZTIxZmQ2MGY4ZDRiNzRiZTVkMzkyN2YwZWYxOWJkL3RhYmxlOjAxZjIwN2RmNDJlOTQ2ZTA4MmVkYWE2ODZiMWIzMGFmL3RhYmxlcmFuZ2U6MDFmMjA3ZGY0MmU5NDZlMDgyZWRhYTY4NmIxYjMwYWZfNS03LTEtMS0w_d121b007-e7e6-403a-bec2-606c67288309"
      unitRef="usd">-26817000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b30bbe1b55344bba8275550c225febe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0xLTEtMS0w_7bc7089c-dc6e-4a37-a874-d4e3fab4db60"
      unitRef="shares">65378890</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b30bbe1b55344bba8275550c225febe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0zLTEtMS0w_394b45d6-6938-4d02-925f-8a79ada6074f"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86da6c4fcadb41b5ba4b5da76c54ba82_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi01LTEtMS0w_495c2d24-5714-41ab-a305-bd4427e124ff"
      unitRef="usd">326777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibbd1887cf65f41b2b3d36bbd39db4838_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi03LTEtMS0w_df0211c7-b666-425b-99c0-dcc7e2e1ee86"
      unitRef="usd">-306516000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i770863e42a2a48b4a60892bc1e12c8e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi05LTEtMS0w_129275ca-f5e8-4940-8734-dd7f7d8053b0"
      unitRef="usd">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMi0xMS0xLTEtMA_5654f23c-6e1a-496d-a020-501e9e6c94f4"
      unitRef="usd">20320000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie5894f7b1235408b9757424526f72c51_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMy03LTEtMS0w_7e905127-560f-4557-8afb-b39d869b756e"
      unitRef="usd">-7984000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMy0xMS0xLTEtMA_fea0e366-8036-4e79-bdc7-38fdce6460ec"
      unitRef="usd">-7984000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i70104b9963d5482b955d81352e01cba0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNC05LTEtMS0w_1c5dd92e-6e0c-49d8-9dab-aa425c416aee"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNC0xMS0xLTEtMA_b615ca12-a3da-4464-b351-95ec40717837"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i70104b9963d5482b955d81352e01cba0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNS05LTEtMS0w_ea8f9e4a-7a03-4e5f-b67d-ea8fd74290b2"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNS0xMS0xLTEtMA_ee91490a-ab3d-488f-80d7-750058449fd8"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0xLTEtMS0w_f829dee6-24a9-4c1b-aa34-a1d2153c631a"
      unitRef="shares">3670212</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8e9b2ee88f404b69a5a079651964a06b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0zLTEtMS0w_c79103c1-30a3-48dd-baf7-76dd6a656a92"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9edaf9e76a1545639356ff49ed8463fe_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi01LTEtMS0w_67054cfd-78f5-4525-befe-2115aa310036"
      unitRef="usd">8003000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie97de709080c4090915c065a4968de18_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNi0xMS0xLTEtMA_a4dd1f46-eea3-40c0-a26d-cf520d8655e4"
      unitRef="usd">8003000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNy01LTEtMS0w_a04ff76c-b97e-46b9-8263-37f3f34f8426"
      unitRef="usd">501000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfNy0xMS0xLTEtMA_b40ea7bd-8c78-484d-b1c8-dc5e96a6029a"
      unitRef="usd">501000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i7e72db3d65f54e66bd15166a04edb193_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOC01LTEtMS0w_b1a7b84a-c0e7-4e08-b1c1-27e8743106b7"
      unitRef="usd">935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i73e7816826ae4af2818b37eb6f0a3e14_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOC0xMS0xLTEtMA_f4e40a85-9dce-427c-8a38-ee64363ad454"
      unitRef="usd">935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icc6c114819494195977381d6b0db0dea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0xLTEtMS0w_3e6849f2-06da-4b42-9d60-755c7cbea592"
      unitRef="shares">69049102</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icc6c114819494195977381d6b0db0dea_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0zLTEtMS0w_542ce200-038f-42db-ae24-7ef442c78843"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75307b6d43bf458db7da774b1cf7e073_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS01LTEtMS0w_97e30b6f-3117-4367-966f-4df9cc3fd635"
      unitRef="usd">336216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i613f46abca3040f28bb46ad26bea4e91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS03LTEtMS0w_e559bc5a-ef4c-40db-bbf3-187c6c385fcf"
      unitRef="usd">-314500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fb4d607639d417e882b6b1325d73420_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS05LTEtMS0w_a081ba08-7125-4ea3-87ab-4a95d86fc73f"
      unitRef="usd">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice592ffedeac499c8ffccc365e8a2547_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfOS0xMS0xLTEtMA_24d75056-c6c2-4463-a112-40357018e7e6"
      unitRef="usd">21774000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i94fd4f38167e440080bf667eae2b6adc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTAtNy0xLTEtMA_0b8e681f-5b30-432e-9568-7efbfae97c63"
      unitRef="usd">-6893000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTAtMTEtMS0xLTA_3130b617-ac51-41ed-a945-a2f530f07b39"
      unitRef="usd">-6893000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTEtOS0xLTEtMA_e5ea5fad-fe80-4185-ae79-8c48e30e47db"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTEtMTEtMS0xLTA_c2d923c9-ca86-442b-9e34-cc0893d106b3"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic1421174b6b7498fa93a3f36866f0dbc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTItOS0xLTEtMA_bc1ddbb9-9326-4e38-873c-fb7247c944e0"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTItMTEtMS0xLTA_39d750dd-1a2f-4ce8-a353-024a2e87aad9"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMS0xLTEtMA_b62237d2-0188-437e-8e14-91c72eebd055"
      unitRef="shares">987716</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i020b89778d3542d98d2b6635aad35a59_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMy0xLTEtMA_55973cfe-ceb4-453c-87c1-221fd8edd068"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i668ce7c09fd243489fd8aa0744ebe327_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtNS0xLTEtMA_79bfc99e-f1a7-438f-a994-b2a79a00c70a"
      unitRef="usd">1978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i73fc87614fb147bcab7ea2ebc4329b29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTMtMTEtMS0xLTA_57267280-9438-4351-92bd-d66280c9ae4a"
      unitRef="usd">1978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMS0xLTEtMA_bcf8cbe8-7323-4fde-8d52-1cc0923af549"
      unitRef="shares">120104</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i28d4ac2ed898496d8523dc895340bf1b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMy0xLTEtMA_d407b707-08f6-4373-ac0b-9bb8a7aa7afc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtNS0xLTEtMA_45e11bc6-74d9-4026-a7a9-087bb23252c7"
      unitRef="usd">-19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTQtMTEtMS0xLTA_db01795c-5f70-4698-a280-9d1c5e2fd8a5"
      unitRef="usd">-19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense
      contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTUtNS0xLTEtMA_3772a580-a10a-4633-a33d-288fba7be39f"
      unitRef="usd">837000</rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense>
    <rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTUtMTEtMS0xLTA_e87a0628-09d2-4622-8eac-7abd13e014fb"
      unitRef="usd">837000</rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i254a86d0c7bd40c5b206376a0ffa3af6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTYtNS0xLTEtMA_9bdd366d-eefc-4cd6-a1eb-f0f98eb8be04"
      unitRef="usd">-1461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ib2345c5c16114cc2be493f592db1d38e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTYtMTEtMS0xLTA_bebae314-f429-44d1-95e1-3c8961b53d11"
      unitRef="usd">-1461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib2c0d288358b418e8a8e6005137b98d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMS0xLTEtMA_0c057ec3-2a52-4db5-b679-f71ef3f0807b"
      unitRef="shares">70156922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib2c0d288358b418e8a8e6005137b98d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMy0xLTEtMA_fd1c1243-ffdf-4c77-8e6d-1701ca1924a3"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdc60d8ab5c84122b3c9526037d9fbbf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctNS0xLTEtMA_5d18c0a3-d26e-4d06-a3cf-173698e5e0f0"
      unitRef="usd">337551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7aeab489a5041d3971baf867a877f96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctNy0xLTEtMA_bfea0e51-f2cc-406c-a453-0ae0c9bd0e3c"
      unitRef="usd">-321393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb47d4544bfe478d982c81e288fe8773_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctOS0xLTEtMA_d573e027-8d2a-4bc3-96ea-4d2acfa7fa35"
      unitRef="usd">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c2321752f47434c87f33cf993521b05_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTctMTEtMS0xLTA_65f8cd4f-3f5e-4452-b95b-f7932a9f4c85"
      unitRef="usd">16211000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i158adda0535d4568a317d0212af41201_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTgtNy0xLTEtMzI1_42f3914f-97e4-47b5-b9d7-c0bc55d09927"
      unitRef="usd">-7350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTgtMTEtMS0xLTMyNQ_4b7e334c-6bf0-4858-b7ca-f1c66c519998"
      unitRef="usd">-7350000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTktOS0xLTEtMzI1_7124270a-50ce-47db-b369-5c51d478f242"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMTktMTEtMS0xLTMyNQ_fb7ebfa9-41d1-4455-9c58-74264c831cf1"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iacf2fe7da7c64bb1a63245f8adc90e7c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjAtOS0xLTEtMzI1_92cedce7-32c2-49ea-b42b-fc79d0f2f6bc"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjAtMTEtMS0xLTMyNQ_2ef4e357-d164-4495-99a4-cfe706bcfe6f"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMS0xLTEtMzMy_5a534353-4a9d-4679-b6c7-7de9ad53c590"
      unitRef="shares">23178809</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i57816a187fe34ab19f9c3dce771d771a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMy0xLTEtMzM3_febc4ae5-976f-4e6e-a9b1-5c11ee596773"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d75f31ec2c24f38ae359072561380f1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtNS0xLTEtMzQy_5d1feb95-e24e-41a0-b774-17035e4a6305"
      unitRef="usd">32675000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7b6868d13e9543fb9846f82e219eb2d8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjEtMTEtMS0xLTM1Nw_07557b71-50d9-4c0f-98f7-e420be36eb1c"
      unitRef="usd">32677000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMS0xLTEtMzI3_c6dcdb76-ec2f-4302-ba88-e389d3283b01"
      unitRef="shares">140892</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4c1ffa8177546348d1ceef53a76f931_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMy0xLTEtMzI3_180bdcb0-3cba-4a0c-980a-5a0fb38cdabf"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2d1c76ded1ff4405a15cfd8dec9de35e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItNS0xLTEtMzI3_05caabd6-4593-4efc-afb4-0a87889933aa"
      unitRef="usd">284000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie513e505eaa642a0ba67d4d26a26bc6f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjItMTEtMS0xLTM1Nw_29f4e4fe-9a20-47ff-8c91-2eae0c9134d1"
      unitRef="usd">284000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMS0xLTEtMzMy_0a8712f5-66f5-4dad-840e-02dd03105479"
      unitRef="shares">96542</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idff159780bc24c1dbb4e7634bae3f896_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMy0xLTEtMzM3_e17dbe49-97dc-449b-a216-01d64c22082a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjMtMTEtMS0xLTM1Nw_0271e878-f805-4c73-b2de-bff89a5c4409"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i7b7c8b7f5c8a4cd9a5e31c6ce7907dc2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjQtNS0xLTEtMzQy_82e4404e-c872-49bf-b7bf-fcade0b626af"
      unitRef="usd">250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjQtMTEtMS0xLTM1Nw_2c7bf9d4-7fd1-40f9-b671-98a956f25caf"
      unitRef="usd">250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMS0xLTEtMzI3_e1064730-3357-43f2-b8e4-ad20edaa0b87"
      unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0b0fe70b8dd64f1ab0e8b84055d68fb9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMy0xLTEtMzI3_4ad53af1-7139-4908-8d14-ba66adbaecc9"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c8e35d265294eb3abef852d48f6016b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtNS0xLTEtMzI3_a0adb378-b8f7-42a2-8c9a-64b9eaf3e076"
      unitRef="usd">370760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8327e54a894540d387fb1c21d05a7962_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtNy0xLTEtMzI3_bbbd6a60-5f52-4774-a037-26a7e6f80686"
      unitRef="usd">-328743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90da80b5c0294f05980472837370ff77_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtOS0xLTEtMzI3_7115074b-b463-4755-ae5a-0e58c52e4440"
      unitRef="usd">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOjE0ZDY0OTM4MzQ3NzRlNmViN2UzMjk5ZjA1NjJkYjY5L3RhYmxlcmFuZ2U6MTRkNjQ5MzgzNDc3NGU2ZWI3ZTMyOTlmMDU2MmRiNjlfMjUtMTEtMS0xLTMyNw_9b180337-5b90-40cc-905c-da6c151328fb"
      unitRef="usd">42075000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i32f5bee8a4224cc9bb993e924ffa5275_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0xLTEtMS0w_4d487fde-bf02-4d75-ac34-d1217fbe72e1"
      unitRef="shares">57034154</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i32f5bee8a4224cc9bb993e924ffa5275_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0zLTEtMS0w_7412770a-38dd-4084-9073-beec706bc4d5"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1b70d7f95f940b99b2e2d713e8c2e9c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi01LTEtMS0w_b849e31a-9677-4f21-a2e5-b7c9109840f3"
      unitRef="usd">299596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a91033410234d9b93822df743ab2cd9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi03LTEtMS0w_b9a5790d-bbfa-4e99-ad45-022e36155338"
      unitRef="usd">-272388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffceb5a770d1470989b074fcb3ce1c72_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi05LTEtMS0w_e4c2e6a0-7945-4451-9fae-825fd523fdc0"
      unitRef="usd">63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id350ff27398e46e386d5e77a30fd2dcd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMi0xMS0xLTEtMA_7e6e647f-2ca5-47c9-ba04-a3112792aef2"
      unitRef="usd">27277000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMy03LTEtMS0w_35d55239-dfe2-44f0-99ca-332a6f2227eb"
      unitRef="usd">-8679000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMy0xMS0xLTEtMA_44a37f58-5aa0-4b05-8e21-2cd66f4d3dd0"
      unitRef="usd">-8679000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNC05LTEtMS0w_11a5bf1b-5df3-42d5-acfa-741095c44cc2"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNC0xMS0xLTEtMA_31fc4df3-9871-41e0-9ec6-d6134dec3392"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id95f5ababe884561ba3acf9411d881a3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNS05LTEtMS0w_5da49076-37dc-4ece-98df-0680f298770f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNS0xMS0xLTEtMA_d3191f35-8125-4725-9d62-7a156e967777"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0xLTEtMS0w_93ac05de-dd3c-46cf-a2c2-46832cb2a8d2"
      unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
      contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0zLTEtMS0w_a716f623-2611-4202-8ada-5cb3cea2dc14"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
      contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi01LTEtMS0w_71c39c66-c1f9-40ae-b165-f5e5b2202157"
      unitRef="usd">148000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNi0xMS0xLTEtMA_ee54c8e2-a758-4a80-a961-ad783efed4ef"
      unitRef="usd">148000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0xLTEtMS0w_87f82780-f7cb-489d-8ee5-b7990e9c5230"
      unitRef="shares">64173</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icd5e9e6c75264de7a4db956210a7fe7c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0zLTEtMS0w_206e13e6-0c3e-4c38-b5d7-9fa59757aae4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy01LTEtMS0w_78fa009e-b35d-4dd0-a794-abb630127490"
      unitRef="usd">-95000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfNy0xMS0xLTEtMA_0104dc50-1f30-4c0b-888c-8d1a230b2035"
      unitRef="usd">-95000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ida8ffc9d88f44e76b1080eed5d1b67cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOC01LTEtMS0w_2af259dd-d2f9-4164-81ca-9702aa786004"
      unitRef="usd">1517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ifd4b77c71f9240179098869d0d38110b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOC0xMS0xLTEtMA_2fe723dd-776d-43bb-a8aa-bb8395cd6992"
      unitRef="usd">1517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0xLTEtMS0w_f321e6fb-df9b-4761-bd97-bce7bb563971"
      unitRef="shares">57128327</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3fb9798df29d40d5bdb52edba7d6c2b9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0zLTEtMS0w_bdf31753-ad4f-4445-bdb2-ee63e52f3e5d"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf404915f16f48298abfdbae0b2660b1_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS01LTEtMS0w_d4008e4d-5df3-480b-9b4d-179994099b29"
      unitRef="usd">301166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf9d133aad0c4316be6655984efa94c8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS03LTEtMS0w_90eab165-ac52-4934-8142-3957c2617036"
      unitRef="usd">-281067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iddf8c061dd424cdabc54af0c6e572255_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS05LTEtMS0w_ffd30dcf-da17-450b-8112-3dccac6d96c4"
      unitRef="usd">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69e28682b96b4df0b51ff9264ab162b4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfOS0xMS0xLTEtMA_db9abb1b-2e30-4fa9-aa93-fa7503b2ae66"
      unitRef="usd">20161000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iba6687bd6e9d42cf8aa0d9cbc3831aa7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTAtNy0xLTEtMA_b3737ff1-5d4f-4885-83a3-d782f78159a9"
      unitRef="usd">-10292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTAtMTEtMS0xLTA_a667882d-59df-4ef7-91fd-80586ee7c8f3"
      unitRef="usd">-10292000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTEtOS0xLTEtMA_cd962b5e-65d1-457f-b941-b5968b9b58dd"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTEtMTEtMS0xLTA_82efd651-effc-4431-a386-53313cf2d07d"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i08c3670bd6af498b8d2bab745be5adf4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTItOS0xLTEtMA_a511ecfe-4b88-40a8-a27d-9c88d92004b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTItMTEtMS0xLTA_0da0a461-015a-468d-bbed-06548491147a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMS0xLTEtMA_a2b99c0f-d425-450e-bda3-4a184f3afe10"
      unitRef="shares">5833334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1dbe4c55b7e347c1ad56c3b658b99329_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMy0xLTEtMA_e00359d9-7a6f-494e-a952-6ed64d4cd030"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2eb0f9c17c8145e8885d3c5be256df8f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtNS0xLTEtMA_71ca4253-f2d3-4199-b817-91be456f7684"
      unitRef="usd">16120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a806c9950844789a211562273ac4bd5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTMtMTEtMS0xLTA_a765c8d2-2173-4d13-abe6-06ef21a11a44"
      unitRef="usd">16120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMS0xLTEtMA_c5ef1239-99dc-4e8a-8400-b771648f2775"
      unitRef="shares">437043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6a73f73923ea41e8b16c0c56000c443d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMy0xLTEtMA_dee620dd-f4b0-4c2b-89f2-019357ec7415"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i669cbdb570ec462e90fee94d26485af7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtNS0xLTEtMA_aaa43f35-287f-46c7-a183-35a54134c41d"
      unitRef="usd">2089000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i870c6dec364a4c55b84f57f46e3d3d59_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTQtMTEtMS0xLTA_323b0ab8-5077-4a5d-a2c3-d08c42b1d5a5"
      unitRef="usd">2089000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i1c5a6d1ecfac490aa90fc495766c743e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTUtNS0xLTEtMA_48ac7176-65fd-4a08-b35b-dc83d51d8b23"
      unitRef="usd">1502000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i6861a9d643654992a3e661b8bcbc867f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTUtMTEtMS0xLTA_04e0f4c2-5a99-47a0-8483-befd12648a76"
      unitRef="usd">1502000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifa01447503b345c3a703ee4cff530762_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMS0xLTEtMA_0a2a15b9-3eb1-419e-8ac2-fa735a5b6075"
      unitRef="shares">63398704</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifa01447503b345c3a703ee4cff530762_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMy0xLTEtMA_f73447cb-3402-40c2-9bad-8e0310a5218f"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55eb32ecc0864f59969698ad4c39091f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtNS0xLTEtMA_c8410d62-4e9c-4463-8ed6-38d5d350b506"
      unitRef="usd">320877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75ed909e37eb4f2d80b62754e1ac5a7d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtNy0xLTEtMA_0b00baa0-239e-4b1c-b928-86a4e88aa7c3"
      unitRef="usd">-291359000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d3225f700f14b8eaa7dae5e7b000ccd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtOS0xLTEtMA_460baabb-c7ef-480e-91b9-01a67a79f644"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad981cf655894d8b8f4cb43bc0028978_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTYtMTEtMS0xLTA_a4e70a30-468c-4c7a-8ceb-d2729a72d2ab"
      unitRef="usd">29592000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib1303e4f07304f0ea1c7de0894409f16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTctNy0xLTEtMzIx_f76d0b15-6960-48ae-a8a4-42519016dcf0"
      unitRef="usd">-7855000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTctMTEtMS0xLTMyMQ_1ffe6d0c-057c-4093-a617-0f0e5f07af17"
      unitRef="usd">-7855000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTgtOS0xLTEtMzIx_68516f03-23a7-438b-9d7b-bb12baeaa64c"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTgtMTEtMS0xLTMyMQ_84bedcfc-432e-44c2-826b-ff4d3368f94f"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie8e856eda26040ec92a312ad282d2f09_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTktOS0xLTEtMzIz_70c6930d-b12d-4034-a692-91ecb208e2f9"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMTktMTEtMS0xLTMyMw_928fbfb1-44b8-4a27-a6f0-2e203bce3d6a"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMS0xLTEtMzIz_f1430ec0-1a14-4e53-931e-de33c54db16e"
      unitRef="shares">62800</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibc10bd83bfb545d5a228800b0e5a0095_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMy0xLTEtMzIz_8f0264e7-4cc8-4c0d-b8c0-1368afcf9dbb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3554a067052149da9e0237073b75129d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtNS0xLTEtMzIz_3a073a88-8100-4716-b94e-ac1e93167be2"
      unitRef="usd">-85000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjAtMTEtMS0xLTMyMw_ec854161-e465-4cfc-b3ff-66a42861f2b1"
      unitRef="usd">-85000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i785da024692147b885c403a33b86064c_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMS0xLTEtMzIz_a4a78ea5-8cfc-4a42-af76-dddc9684a45a"
      unitRef="shares">425880</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i785da024692147b885c403a33b86064c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMy0xLTEtMzIz_6a4ba0e5-0a82-4a42-bff9-017985a42616"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i21f6b8ee17a940baa698ca9d3509e8c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtNS0xLTEtMzIz_c414b9cf-afae-4179-97bb-9432a8fec50c"
      unitRef="usd">1169000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib86aa439c9264e91b122ec5e8b121f23_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjEtMTEtMS0xLTMyMw_ac19e8fa-3c92-492b-8fc3-43f437dec1f6"
      unitRef="usd">1169000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i3554a067052149da9e0237073b75129d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjItNS0xLTEtMzIz_0d1ba29e-64ff-4ed9-b912-3010fea0e1b8"
      unitRef="usd">876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjItMTEtMS0xLTMyMw_2a6dc790-9cd3-4611-9da7-866641b2e30f"
      unitRef="usd">876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i584df65c9c7541bfbca2050c1a065f5e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMS0xLTEtMzIz_8dfe58fd-c68e-454f-847b-1aef7c56788f"
      unitRef="shares">63887384</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i584df65c9c7541bfbca2050c1a065f5e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMy0xLTEtMzIz_468e633a-f439-4d50-8ec3-1aa653347499"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b182882e4024d7293ceaabba4bd8ccb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtNS0xLTEtMzIz_e37f2eb6-358c-42d2-90ff-06bab9d9612d"
      unitRef="usd">322837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2261e4d5acc643928364085bf274f5eb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtNy0xLTEtMzIz_733a444b-8a68-4d00-acfd-cddb0af8c989"
      unitRef="usd">-299214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2275794073f343e286251f69c0725483_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtOS0xLTEtMzIz_6306327f-b934-46d8-82ff-59ec3370d233"
      unitRef="usd">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8yOC9mcmFnOjY4ZDA4Mjc3Y2Y4NzQ4ZGE4NTJhZWI3MWFhY2NlY2E1L3RhYmxlOmJhZmU5ZDJkYmJiNTQ0MzdiYTYwNTYxYTk4MWJjY2QzL3RhYmxlcmFuZ2U6YmFmZTlkMmRiYmI1NDQzN2JhNjA1NjFhOTgxYmNjZDNfMjMtMTEtMS0xLTMyMw_6938141b-8e5d-4430-bf78-01993249646e"
      unitRef="usd">23702000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMy0xLTEtMS0w_217ff6f0-4b22-4542-883c-d25870047f48"
      unitRef="usd">-22227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMy0zLTEtMS0w_7abf426a-2f48-42c0-ab13-02da63af571b"
      unitRef="usd">-26826000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNS0xLTEtMS0w_16719d27-f249-417c-be9f-490a39fd2924"
      unitRef="usd">614000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNS0zLTEtMS0w_97165700-da1e-4c0c-addf-ac9aa3e3ead7"
      unitRef="usd">582000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNi0xLTEtMS0w_84a712b4-5b7c-4d66-aaa4-f81185b0422c"
      unitRef="usd">-276000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNi0zLTEtMS0w_0d2c8773-4cc9-4896-b0f1-de294851f01a"
      unitRef="usd">3895000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNy0xLTEtMS0w_d2b31c92-25ab-4165-a4b3-8c53cd594c61"
      unitRef="usd">837000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNy0zLTEtMS0w_515e3bcc-c68b-4e3b-9819-bec28fa34478"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOC0xLTEtMS0w_7c89f2a6-7049-4b8c-b4f3-a77524bc6d10"
      unitRef="usd">305000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOC0zLTEtMS0w_68ba6a11-8c53-4da9-ba98-89780fbeae91"
      unitRef="usd">1271000</us-gaap:InventoryLIFOReservePeriodCharge>
    <rmti:OperatingLeaseRightOfUseAssetAmortization
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOS0xLTEtMS0w_6f42f6d3-55a5-4172-9177-cb6a868e613a"
      unitRef="usd">1090000</rmti:OperatingLeaseRightOfUseAssetAmortization>
    <rmti:OperatingLeaseRightOfUseAssetAmortization
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfOS0zLTEtMS0w_7fcd0a4b-b1b9-4d0d-b892-e66e81e95e71"
      unitRef="usd">1430000</rmti:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTAtMS0xLTEtMA_fbc57e5b-1be3-49e1-b9a0-3c22861e85a8"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTAtMy0xLTEtMA_db560217-38a2-4d00-bf1d-8697997ca178"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTEtMS0xLTEtMA_574bb06d-f8f9-488a-9f66-10923a66a991"
      unitRef="usd">-7000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTEtMy0xLTEtMA_c952c57a-2f55-4b8b-add7-1055c0fdb89c"
      unitRef="usd">1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTItMS0xLTEtMA_ef313abb-d94e-40f4-88c3-9a5fe8167d0d"
      unitRef="usd">8000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTItMy0xLTEtMA_8f084526-8f9f-43bd-8b98-a80faa70b483"
      unitRef="usd">24000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTMtMS0xLTEtMA_1efc23fd-db46-4afe-8284-ddbc83256202"
      unitRef="usd">-7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTMtMy0xLTEtMA_8b691736-0726-4ddb-814d-08d01245c89e"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTUtMS0xLTEtMA_bc4052c1-8012-4015-9ae6-79499bd86a24"
      unitRef="usd">-74000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTUtMy0xLTEtMA_bf4d422b-d9d2-4cee-9619-ac654730e4bf"
      unitRef="usd">-1857000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTYtMS0xLTEtMA_7da24aa9-4f65-448c-be5c-dbcb5a1d6aa4"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
    <us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTYtMy0xLTEtMA_1d74e76c-d97b-4477-b832-b18dc8aafcc2"
      unitRef="usd">-371000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTctMS0xLTEtMA_84b6209a-8bf6-459b-a37e-d4f8b1dab624"
      unitRef="usd">953000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTctMy0xLTEtMA_c78c9186-5f30-4085-a00f-cb8607553127"
      unitRef="usd">-293000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTgtMS0xLTEtMA_20b9b243-420d-45d2-bd0d-0f5085391bbd"
      unitRef="usd">-161000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTgtMy0xLTEtMA_bc2782c0-fffc-4e59-aba5-812766c298a2"
      unitRef="usd">-931000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTktMS0xLTEtMA_522be999-a977-4e57-9901-ea4facd3c83c"
      unitRef="usd">1172000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMTktMy0xLTEtMA_c893041c-0aff-426c-9c81-84beecb498bd"
      unitRef="usd">-1298000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjAtMS0xLTEtMA_d9899276-bfb0-4f73-9518-3fa8949754da"
      unitRef="usd">-104000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjAtMy0xLTEtMA_d8531b31-bb28-4988-bbbe-c8c6dc29debc"
      unitRef="usd">-147000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <rmti:IncreaseDecreaseInOperatingLeaseLiabilites
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjEtMS0xLTEtMA_5c69676c-727d-458e-a7cc-4d9d976d5d99"
      unitRef="usd">-1056000</rmti:IncreaseDecreaseInOperatingLeaseLiabilites>
    <rmti:IncreaseDecreaseInOperatingLeaseLiabilites
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjEtMy0xLTEtMA_003416ac-0dfe-4d15-80ab-fc06551c0017"
      unitRef="usd">-1369000</rmti:IncreaseDecreaseInOperatingLeaseLiabilites>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjItMS0xLTEtMA_2fad458d-a16e-429c-add4-7d3bad3fc940"
      unitRef="usd">423000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjItMy0xLTEtMA_c5921c8c-e952-4671-9fb6-b10c87387e0e"
      unitRef="usd">-1229000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjMtMS0xLTEtMA_109c50b5-9e0c-477a-9cee-c521990f0deb"
      unitRef="usd">-1338000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjMtMy0xLTEtMA_55116eb1-5d20-42f1-9b9c-e2cd13570a10"
      unitRef="usd">-1690000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjQtMS0xLTEtMA_48b18595-17ba-4799-8a0a-93532be7f25e"
      unitRef="usd">1621000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjQtMy0xLTEtMA_8e9da7ca-7416-4842-835a-7640f632b0b7"
      unitRef="usd">2281000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjUtMS0xLTEtMA_adf9458f-6646-42e6-8ab1-3e0b20678e0a"
      unitRef="usd">-21072000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjUtMy0xLTEtMA_59372a96-7d4d-40c6-ad16-3f8f2471cf93"
      unitRef="usd">-21954000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjctMS0xLTEtMA_922abe59-b599-443d-b50e-8fb9a3386939"
      unitRef="usd">23531000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjctMy0xLTEtMA_9769364f-ab80-4f91-8f12-935d920fb7ff"
      unitRef="usd">34202000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjgtMS0xLTEtMA_9a91e8a4-53bc-47d4-b218-5b9747b94381"
      unitRef="usd">27076000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjgtMy0xLTEtMA_d28f5519-7e43-47d0-8d62-5d8a90f626ec"
      unitRef="usd">30479000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjktMS0xLTEtMA_52a94caa-d96c-4807-b52c-387130bd8f09"
      unitRef="usd">970000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMjktMy0xLTEtMA_524821fa-e4e8-4efd-b763-132fd80d8a76"
      unitRef="usd">449000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzAtMS0xLTEtMA_2619029b-0513-4462-8ccc-477426c27459"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzAtMy0xLTEtMA_744036d5-ca3a-4075-b9c3-63fc7f0ff120"
      unitRef="usd">750000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzEtMS0xLTEtMA_142e1dc1-beeb-404f-9fbd-385ebe9d1557"
      unitRef="usd">2575000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzEtMy0xLTEtMA_77da4753-01b8-4403-bea5-7b6e32ed2c3f"
      unitRef="usd">-4922000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzMtMS0xLTEtMA_885b7622-c7d0-4403-872a-5f12486d8f48"
      unitRef="usd">22500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzMtMy0xLTEtMA_a69da893-5a43-4922-b4f5-7ece7e867333"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzQtMS0xLTEtMA_24f0d18b-d967-4b59-b5ac-757bd97fce37"
      unitRef="usd">1343000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzQtMy0xLTEtMA_d29982e7-a205-4134-83f7-4bfba1f2f463"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzUtMS0xLTEtMA_c954db60-b965-4c1c-9aaa-51a2b6fed5bf"
      unitRef="usd">763000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzUtMy0xLTEtMA_1fd38609-41eb-448d-9582-a64d92cb38d9"
      unitRef="usd">763000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzYtMS0xLTEtMA_43e86993-3e1c-4537-864f-3b6194aa7f5a"
      unitRef="usd">43148000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia1587de2669b493e879da7e102635c4b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzYtMy0xLTEtMA_aa6ca036-aec2-48e0-9d8d-9470f7c2877e"
      unitRef="usd">18777000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2e750277bf3a4798a3c724b65660f106_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzctMS0xLTEtMA_0a647ea5-35da-443b-8524-069db610711e"
      unitRef="usd">2469000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia1587de2669b493e879da7e102635c4b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzctMy0xLTEtMA_28aba756-f939-40a1-b016-12d76c53c5f7"
      unitRef="usd">1488000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzgtMS0xLTEtMA_019ff18e-f2e2-4c45-8c33-6e56fb2fe79e"
      unitRef="usd">2325000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idec8a2522d62421e89cd4c2750585635_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzgtMy0xLTEtMA_d1e26b0f-2924-4e37-a54e-8cedef43daaf"
      unitRef="usd">2296000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzktMS0xLTEtMA_c085f22b-2800-4e11-b42c-d9bbf3e320df"
      unitRef="usd">63000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idec8a2522d62421e89cd4c2750585635_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfMzktMy0xLTEtMA_b11505bd-ab91-484b-a96c-f99640617be7"
      unitRef="usd">207000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDAtMS0xLTEtMA_c47ec6b5-a262-419e-8ad7-65f09fad1a7f"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDAtMy0xLTEtMA_7c5b7a54-167a-4d1b-9bc9-8f39833284fe"
      unitRef="usd">148000</us-gaap:ProceedsFromStockOptionsExercised>
    <rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDEtMS0xLTEtMA_7fbad686-4fac-4d54-851a-dd8595b9a8ee"
      unitRef="usd">18000</rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes>
    <rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDEtMy0xLTEtMA_d94cbd6d-8c0c-446a-a72e-3cee4357b9bc"
      unitRef="usd">180000</rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDItMS0xLTEtMA_9dd518be-8916-4ef2-85ea-4e60539566c1"
      unitRef="usd">63317000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDItMy0xLTEtMA_7ab34b84-d679-4ac7-b3b1-f32ff9ab6780"
      unitRef="usd">18583000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDQtMS0xLTEtMA_f085c756-ed51-4b3a-a30d-a25301571530"
      unitRef="usd">44820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDQtMy0xLTEtMA_6895e4aa-2577-4d5a-be21-85f4ff026415"
      unitRef="usd">-8293000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDUtMS0xLTEtMA_81ffb11c-9a90-452b-aadc-08f0949de4d2"
      unitRef="usd">11794000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id350ff27398e46e386d5e77a30fd2dcd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDUtMy0xLTEtMA_39879fcb-b1b3-46c0-8708-28880fa9c807"
      unitRef="usd">22714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDYtMS0xLTEtMA_508d531d-2619-4dd6-8c2d-df6334e2befd"
      unitRef="usd">56614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDYtMy0xLTEtMA_cea43af6-228a-4c8b-b5a3-8e1a19532d14"
      unitRef="usd">14421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDktMS0xLTEtMA_2dc00775-ef2f-41c3-b31f-7327a944b9b2"
      unitRef="usd">906000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNDktMy0xLTEtMA_ac6c8907-0e92-4dab-a76b-9fc08c02b605"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTEtMS0xLTEtMA_8d08faaf-49a4-4768-91d2-7b46ea0307b9"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTEtMy0xLTEtMA_b08b3c28-5626-4a15-a60d-cdced841323b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:NotesAssumed1
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTMtMS0xLTEtMA_3376d4c9-f759-4e7d-a33c-5b203d45f5ae"
      unitRef="usd">0</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTMtMy0xLTEtMA_6b7cae94-ac3f-4ec8-b0d7-d80d1d72e03e"
      unitRef="usd">1145000</us-gaap:NotesAssumed1>
    <us-gaap:StockIssued1
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTUtMS0xLTEtMA_7687e808-98e3-40ee-bc8b-1e1e0bca8a79"
      unitRef="usd">501000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zMS9mcmFnOmQxYTE5YzIwMDEwMzRkZmNiYzI3ZTYwYzE2YWJkOTIxL3RhYmxlOmE2Yjc1MWZlNDRiNTQ2ZmQ5NzMyNGIyZjc1YTY2ZjZkL3RhYmxlcmFuZ2U6YTZiNzUxZmU0NGI1NDZmZDk3MzI0YjJmNzVhNjZmNmRfNTUtMy0xLTEtMA_827ad139-1905-4663-95fb-131e0a533f4c"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8zNy9mcmFnOmVmOTAxNDhkMDUzNzQzODM4NTRiYmQ2ZTNjYmY0OTg3L3RleHRyZWdpb246ZWY5MDE0OGQwNTM3NDM4Mzg1NGJiZDZlM2NiZjQ5ODdfMTY4Mw_11a0581f-1e0c-4de2-a6b5-219a01d50187">Description of Business&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rockwell Medical, Inc. and subsidiaries (collectively, &#x201c;we&#x201d;, &#x201c;our&#x201d;, &#x201c;us&#x201d;, or the &#x201c;Company&#x201d;), is a biopharmaceutical company dedicated to improving outcomes for patients with iron deficiency and iron-deficiency anemia,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate citrate (&#x201c;FPC&#x201d;) therapeutic platform. The first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients.&#160;We initiated commercial sales of Triferic Dialysate during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. Our lead indication is developing FPC for the treatment of iron deficiency anemia in patients undergoing home infusion therapy. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients&#x2019; lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Triferic&#xae;&#160;is a registered trademark of Rockwell Medical, Inc.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <rmti:LiquidityAndFinancialConditionTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMzQ1NQ_befb70e1-e0d6-4976-8075-524095515b4c">Liquidity and Capital Resources&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had approximately $56.6 million of cash and cash equivalents, $10.7 million of investments available-for-sale, working capital of $65.2 million and an accumulated deficit of $328.7 million. Net cash used in operating activities for the nine months ended September&#160;30, 2020 was approximately $21.1 million. Management evaluated the Company&#x2019;s ability to continue as going concern for at least the next 12 months from the filing of this report. Based on the currently available working capital, capital raise and debt financing described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company sold 3,670,212 shares of its common stock for proceeds of $8.0 million, net of issuance costs. On March 16, 2020, the Company closed a debt financing transaction with net proceeds at closing of approximately $21.2 million, net of fees and expenses (See Note 15 for further detail). On September 23, 2020, the Company sold 23,178,809 shares of its common stock for proceeds of $32.7&#160;million, net of issuance costs (see Note 10 for further detail).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020, the Company sold 1,128,608 shares of its common stock as part of its sales agreement with Cantor Fitzgerald &amp;amp; Co. for proceeds of $2.3 million, net of issuance costs. Approximately $32.3 million remains available for sale under this facility. See Note 10 for further detail.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the commercialization of Triferic Dialysate and Triferic AVNU,  executing upon our plans for enhancing Triferic's medical capabilities, generating additional data for Triferic and developing Triferic for new therapeutic indications. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing.&#160;If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company is subject to certain covenants and cure provisions under our Loan Agreement with Innovatus.  As of the date of this report, the Company believes that it will either be able to satisfy such covenants or, in the event of  a breached covenant, exercise cure provisions to avoid an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity (See Note 15 for further detail).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Our international business development activities may also be negatively impacted by COVID-19, especially with the recent surge in infections and resulting quarantines or shelter-in-place orders. Depending on the severity of the impact on our sales and marketing efforts, the timing of our commercial launch of Triferic AVNU could be delayed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic, the recent domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.&lt;/span&gt;&lt;/div&gt;</rmti:LiquidityAndFinancialConditionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfODE_015b53d1-727e-4a47-8f82-2fcc98ae0bce"
      unitRef="usd">56600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTE0_0123e024-279e-4c98-ad7c-4e405b467a43"
      unitRef="usd">10700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <rmti:WorkingCapitalNet
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTcx_deca2a15-1e64-4b5a-a1ff-bd5104be1039"
      unitRef="usd">65200000</rmti:WorkingCapitalNet>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMjA0_7c6ad8bb-cf75-4063-aebc-e89a04292679"
      unitRef="usd">-328700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMjkx_a7c7f092-372e-4591-bd2a-ee3f58a0a0cf"
      unitRef="usd">-21100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzQ1_aec888e9-0702-4b2f-9a51-44d8a886a4d4"
      unitRef="shares">3670212</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzkx_c2257c58-5b5b-4866-ab3d-5e44d39129da"
      unitRef="usd">8000000.0</rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i988157eb43c948b0b48c71a792211e1c_D20200316-20200316"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfOTMx_33584fca-9b6a-47c4-b355-f900412cbc17"
      unitRef="usd">21200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzE0NjgyNTU4NDIwOA_7a7090ba-075d-405b-ad99-0fcf135e0f8d"
      unitRef="shares">23178809</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="i1a89e7ca5ddb47dfb780cbe4fd2892cc_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfNzE0NjgyNTU4NDIyMA_15d18d5f-0d49-4bc1-bcc9-e2973c8f15ce"
      unitRef="usd">32700000</rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTA1NQ_ea8669df-1830-4420-8703-b35a875e947e"
      unitRef="shares">1128608</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTE2MQ_31ebf2f7-238d-42cd-a94d-3dd6d60aadfd"
      unitRef="usd">2300000</rmti:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <rmti:SaleofStockRemainingSalesAmount
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80MC9mcmFnOjFkMGVhMTc2YTI0NTQzZDdiZmU1NTQxNjdiNjdlZWE4L3RleHRyZWdpb246MWQwZWExNzZhMjQ1NDNkN2JmZTU1NDE2N2I2N2VlYThfMTIwMg_cd355f18-e2e0-4cab-9e23-383dbb6ed7c1"
      unitRef="usd">32300000</rmti:SaleofStockRemainingSalesAmount>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4Nw_81be22bd-b259-4504-bdd6-4b9b5359c286">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (&#x201c;U.S.&#x201d;) of America (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and on the same basis as the Company prepares its annual audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet at September&#160;30, 2020, condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and condensed consolidated statement of changes in shareholder&#x2019;s equity for the three and nine months ended September&#160;30, 2020 and 2019 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020 or for any future interim period. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2019 and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 as filed with the SEC on Form 10-K on March 17, 2020. The Company&#x2019;s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires dual presentation of basic and diluted earnings per share (&#x201c;EPS&#x201d;), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income&#160;per share in the future that were not included in the computation of diluted loss per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,682,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,170,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,324,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,426,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,770,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,501,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,412,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company&#x2019;s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company&#x2019;s consolidated financial statements properly reflect the change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2017, the FASB issued ASU No. 2017-11, &#x201c;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#x201d; (&#x201c;ASU 2017-11&#x201d;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company as adopted on January 1, 2020, and did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4OA_f2638519-38e4-47bd-b114-18dc7c9e3d68">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4OQ_a8fe242e-026e-4598-9e24-ee329e6562c0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5MA_f34c1108-3a3a-4459-852b-5dc458259195">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5Mg_8c729a7b-85ce-4a3e-9324-fe912daf13f0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires dual presentation of basic and diluted earnings per share (&#x201c;EPS&#x201d;), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.&lt;/span&gt;&lt;/div&gt;Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk5Mw_f8a6410b-064d-4350-8987-06b771e9ac46">Securities that could potentially dilute net income&#160;per share in the future that were not included in the computation of diluted loss per share were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,682,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,170,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,324,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,426,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,770,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,501,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,412,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib8980a286d764741a6a0535b98f103cb_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMi0xLTEtMS0w_9c4810c1-378a-4f1c-bef1-c095ad822374"
      unitRef="shares">6682192</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib149f28b57b5455b83b33022698763a7_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMi0zLTEtMS0w_a82c16ae-bca2-445c-a1d0-ad1e148145b6"
      unitRef="shares">8170382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3001b9e27cde4f58a61cf8c157040421_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMy0xLTEtMS0w_c9c8753b-bb38-412b-88dd-86aa95e83de0"
      unitRef="shares">146800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ea41dcc63ed476d8dbece309c6ad63e_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfMy0zLTEtMS0w_792b2350-5b02-4bcc-8ad5-c996e762e467"
      unitRef="shares">146800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73ec1516b6ae4e118fa7217f2aa0bd68_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNC0xLTEtMS0w_36328ce6-6e98-46e7-8337-b479632b98f6"
      unitRef="shares">245405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc89f567f4234735a146c9ace53adbb1_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNC0zLTEtMS0w_dcfd644e-f58d-443e-af3f-e116b40da14f"
      unitRef="shares">1324172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae5349e0526343b290ff0221f6aed37a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNS0xLTEtMS0w_cad2985d-468e-4b6b-a0fb-c84556fde95f"
      unitRef="shares">26426863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3c484a5d97547fb92216812c28b5a52_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNS0zLTEtMS0w_3c9150dd-1504-484b-b354-0119ff3ab29e"
      unitRef="shares">2770781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNi0xLTEtMS0w_530808dd-c105-4349-a506-97bde9e26a07"
      unitRef="shares">33501260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RhYmxlOjE4MDBkNzdkYTA0YzQzOThiOWExNzk2OTYxZjcyOWQ5L3RhYmxlcmFuZ2U6MTgwMGQ3N2RhMDRjNDM5OGI5YTE3OTY5NjFmNzI5ZDlfNi0zLTEtMS0w_51983327-be52-4311-99a1-6557ac6cbaec"
      unitRef="shares">12412135</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80My9mcmFnOjc0ZmJlYjQwOGQxMTQxMzBhZThkZWU4ZDE3ZDAwZTgzL3RleHRyZWdpb246NzRmYmViNDA4ZDExNDEzMGFlOGRlZThkMTdkMDBlODNfNTk4Ng_2ca9a456-29e7-4460-a892-195ba38b906a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company&#x2019;s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company&#x2019;s consolidated financial statements properly reflect the change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2017, the FASB issued ASU No. 2017-11, &#x201c;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#x201d; (&#x201c;ASU 2017-11&#x201d;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company as adopted on January 1, 2020, and did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxMw_a4b92eee-76fe-4892-830f-8ee170a0db90">Revenue Recognition&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Step 1: Identify the contract with the customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Step 2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Step 3: Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Step 5: Recognize revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Nature of goods and services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of principal activities from which the Company generates its revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.&#160;&#160;For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.&#160;&#160;In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received upfront fees under four distribution and license agreements that have been deferred as a contract liability.&#160;&#160;The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (&#x201c;Wanbang&#x201d;) and Sun Pharmaceutical Industries Ltd. ("Sun Pharma") and amounts to be received Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.&#160;&#160;The amounts received from Baxter Healthcare Corporation (&#x201c;Baxter&#x201d;), are recognized as revenue at the point in time that the estimated product sales under the agreement occur.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the business under the Company&#x2019;s distribution agreement with Baxter (the &#x201c;Baxter Agreement&#x201d;), and for the majority of the Company&#x2019;s international customers, the Company recognizes revenue at the shipping point, which is generally the Company&#x2019;s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products By Geographic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Drug Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products By Geographic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Drug Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, which are included in "Trade and other receivables"&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material losses recognized related to any receivables arising from the Company&#x2019;s contracts with customers for the three and nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020 and September&#160;30, 2019, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September&#160;30, 2020 and December&#160;31, 2019.&#160;&#160;The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of September&#160;30, 2020 or December&#160;31, 2019.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020, revenue recognized from performance obligations related to prior periods was not material.&lt;/span&gt;&lt;/div&gt;Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $10.7 million as of September&#160;30, 2020. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $7.7 million as of September 30, 2020, which is being amortized ratably through expiration of the Baxter Agreement on October 2, 2024.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <rmti:NumberOfDistributionAndLicenseAgreements
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfMjk1NQ_b16c07a4-d292-4984-8ac0-ff214027aee8"
      unitRef="agreement">4</rmti:NumberOfDistributionAndLicenseAgreements>
    <rmti:AveragePaymentTermOfCustomers
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDQxMg_0cd6a551-1d8a-4aa3-8cca-7f4306920da6">P30D</rmti:AveragePaymentTermOfCustomers>
    <rmti:AveragePaymentTermOfDistributors
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDQ1Ng_c1604845-79fc-464b-9046-a2210db26aa9">P45D</rmti:AveragePaymentTermOfDistributors>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxNA_9a4219d0-b9c2-48f5-bd07-fdd4ca4d266e">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products By Geographic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Drug Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products By Geographic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Drug Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Sales &#x2013; Point-in-time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Fee &#x2013; Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Concentrate Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia771c78851094cf0b22dcaa46810686b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0xLTEtMS0w_7bd61b34-e7e9-4a72-a741-a91e044738b9"
      unitRef="usd">228000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5917e109c9e540b5b6b275de9b444283_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0zLTEtMS0w_81add3e4-2488-4088-8aa0-f99151d5d9b1"
      unitRef="usd">228000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibb07690b76f1481ebb6c2909fa5e7323_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy01LTEtMS0w_41d33c57-8cd6-42a5-a250-ec9a488d3b14"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4464409c4ae443058ce462975a7634db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy03LTEtMS0w_b8be65a3-698f-490d-880c-d86404529b11"
      unitRef="usd">609000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib3ff30259c1441b2a0a4f0b559884a2f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy05LTEtMS0w_3a88aaeb-0b56-4526-90dc-6eec4253522e"
      unitRef="usd">609000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i05e0725267804eca91f6f04b1aba0ed8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMy0xMS0xLTEtMA_bcd2ea57-2d31-47da-aaac-3853802ee26b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i062b8ca84b4145329ac1a0509078f58f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0xLTEtMS0w_9fad2641-410a-4706-abe6-391fe9525072"
      unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic39fc677e9a549b382f949b298ba067b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0zLTEtMS0w_ed1be790-1b79-4949-836f-df7ed031931b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6d8fb70070b246648e8f8997628ff47a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC01LTEtMS0w_5dce488e-7a4a-4a5a-814d-00d52ded30d5"
      unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1095befdd04d445e80654a04a53cabdb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC03LTEtMS0w_f05a68c8-0d53-4939-885e-ea490ac94527"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icad9123b89e14db8adc3fd5832999d21_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC05LTEtMS0w_a0857a6a-2b9c-413f-acc8-685a122024ae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ief873247bf6b42c0ab6113a99352b4a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNC0xMS0xLTEtMA_ff3ba592-78ae-406c-a2b8-963698b5f569"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0xLTEtMS0w_22d826b7-5b25-4a0a-b63c-af2830cca80a"
      unitRef="usd">284000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i697255d93ed5459aac6fe8eef560cb51_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0zLTEtMS0w_82421fea-e519-455a-ab25-74303a94e3a9"
      unitRef="usd">228000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i74bba929d51d492abd362e87e6ba9825_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS01LTEtMS0w_f6d6b384-c9ff-4025-871c-92739602f281"
      unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5a16aafd4b73410cb11d551d736d5525_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS03LTEtMS0w_8c58034b-a92f-46c0-b544-79e60355316f"
      unitRef="usd">776000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i663f506330f048d4a93e2d6cc47aa6d9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS05LTEtMS0w_471b165a-f1ee-439e-a890-1c0e64d39396"
      unitRef="usd">609000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i754bf852083a492293cd350270a1a844_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNS0xMS0xLTEtMA_98662ead-02d4-45ab-94ca-b7a5fcbe0e9b"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6675c9f60fba4ff7b0a180e9cf9b6f2b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0xLTEtMS0w_840d92cd-fb68-45f3-bcdb-30b5ddbc7b11"
      unitRef="usd">14506000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i285b58ffd3fc4e8b92453fe7ecc0598e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0zLTEtMS0w_dae40942-873f-4ac5-9367-7fe001b7edf8"
      unitRef="usd">13470000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibf229f34c7b64e8bb5ea23ba69e5fd1f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy01LTEtMS0w_8a6da72b-498a-4ec0-9776-0ea1ff378987"
      unitRef="usd">1036000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i96af2b1201d74f70a53001fcf34f9ffc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy03LTEtMS0w_ccd23600-77c9-44e3-af90-0c50700d998a"
      unitRef="usd">44786000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5e93fcfaef8544759969602319623bfd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy05LTEtMS0w_b1d2ffd2-f84b-4551-a110-848958999b3a"
      unitRef="usd">40295000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2130d942bd5e454aac8d0d51dac98817_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfNy0xMS0xLTEtMA_4e340139-1496-4879-905d-36423a1a1d16"
      unitRef="usd">4491000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieeaeac98cba349d5b79b6b44e11381b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0xLTEtMS0w_b968a3b4-f49c-4e7b-afea-d8dbd969a583"
      unitRef="usd">490000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id737660a634e4a9c9bdbe80a2a316639_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0zLTEtMS0w_0702d56e-d13f-4889-9172-a2011ac3d902"
      unitRef="usd">490000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icccc5ba795194400bf9c6a11150113a9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC01LTEtMS0w_289b510c-993d-45a3-ae4a-83ad38a0c8f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iee231374be0442fb8029ebfdc1a3e6c8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC03LTEtMS0w_52580b5a-a315-4cae-9653-f704ecc9c5d7"
      unitRef="usd">1471000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5b06e779ddd644c9a0b0ff6c7875bd45_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC05LTEtMS0w_e4141752-78f5-4b4f-986b-1c28a629c77d"
      unitRef="usd">1471000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4d53e2964d824b1d90da68f8b963d64d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOC0xMS0xLTEtMA_72c98bb7-63c3-4d36-beb1-e3411f36015f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8cc0c1d935564e1a813e0e93ec99c70a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0xLTEtMS0w_a072ca68-f8d6-4d69-9435-279fb6361869"
      unitRef="usd">14996000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia8795859a4344592a375c53c2fe649cf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0zLTEtMS0w_27e05bca-e5eb-4a0c-b038-65fd7727112d"
      unitRef="usd">13960000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id0c9575f496b407abf0680d511ae8619_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS01LTEtMS0w_98743b17-7b89-4dd5-8068-9044bbb80b98"
      unitRef="usd">1036000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia261e596f7ae4be4a6bfacfd41985358_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS03LTEtMS0w_60ebd675-c0e0-4f1e-8159-9a282f991aa6"
      unitRef="usd">46257000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i117b1cfaa32c4e209267190df3a1d335_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS05LTEtMS0w_1e3a6d5d-ef9a-42e6-aade-3fe93ff8b64c"
      unitRef="usd">41766000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4d6d5deee8c245e59ff7998cea9f8e8c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfOS0xMS0xLTEtMA_79154cef-585a-44ac-ada5-8c2d97cdd963"
      unitRef="usd">4491000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMS0xLTEtMA_d9a421a8-374b-424a-89e7-815152dcfcc6"
      unitRef="usd">15280000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iadc5f4e7510d42e78b5fcd4d6ca0877d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMy0xLTEtMA_dd4258df-aebf-44b1-b11a-30b3aed06159"
      unitRef="usd">14188000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id7f0fc5632f44fa892279e11d3f5f64a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtNS0xLTEtMA_6ef89fed-c56e-425e-92db-a2c0b15a1b8b"
      unitRef="usd">1092000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtNy0xLTEtMA_6510ad84-bb34-4fb0-b67f-4f9fbaef64f7"
      unitRef="usd">47033000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67baf02b08254808bd4df548744d90af_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtOS0xLTEtMA_be4258f9-6cba-4176-83d9-631ead9435b7"
      unitRef="usd">42375000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ief6af98eb7bd4e238f6b0b2894b4556f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOjIxMjY0OTUwZDhmYzRmMzVhNDI1YmUwZTIwNDE5NTRmL3RhYmxlcmFuZ2U6MjEyNjQ5NTBkOGZjNGYzNWE0MjViZTBlMjA0MTk1NGZfMTAtMTEtMS0xLTA_5befdfba-cea9-4e2c-8437-964be1a556db"
      unitRef="usd">4658000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if3a805e442db408f92e45e37dfa077e0_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0xLTEtMS0w_1d3e74d6-6ee7-440c-90e9-012051a28fb6"
      unitRef="usd">98000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d19f7511cb04600801f9d98fef26b60_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0zLTEtMS0w_29582686-da45-4539-a2f0-9569ba0d100c"
      unitRef="usd">98000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i482a8f6c3a59419eb4648b61db88d5db_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy01LTEtMS0w_0d52cbe1-3c70-4696-bc2b-905b251ebb96"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i15fbd0feab424ce1bcc0b1fb2ec36625_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy03LTEtMS0w_d7ba55dd-69f0-4702-8722-e888aae4ac6c"
      unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic4437cf163a249a1b01639218fdce4af_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy05LTEtMS0w_216d2e07-b211-44d6-b2da-be1c70a963a5"
      unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ida40c86298494cfd939804f4adf6c2c7_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMy0xMS0xLTEtMA_331ab385-fc7e-4fad-bc35-be18c5ceb1b7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iab7b126708c34e6d8b8b6e745bac3bdb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0xLTEtMS0w_1522fd58-5d5a-4a93-b712-e52e5d3247ba"
      unitRef="usd">68000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i22a80d3ff4034599a93526645efcf37d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0zLTEtMS0w_1ef10cf1-012f-45bc-b98c-49c78b35f5a1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1ade2e7c43f8418e9e161bca2328cc73_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC01LTEtMS0w_ad7e7a24-03b9-476f-aaf8-704fa2fd6dae"
      unitRef="usd">68000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6a93ba8c220648ca851f5aecd304d30c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC03LTEtMS0w_574e1c1b-ddcf-4569-9fc3-e8e705d0bed0"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4b41310bebe843d3905f65a72974bd97_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC05LTEtMS0w_0c181407-6bda-4a9c-9d70-f41bb72d8a09"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i45c343d1a1ad409c88aaec6888f258d7_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNC0xMS0xLTEtMA_863f122c-b06d-4219-9390-6880d2c1b80d"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifaeb1dae1cf94b168309faa699ac9f94_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0xLTEtMS0w_9ad62537-5010-4f2e-bb19-3c92e5be4616"
      unitRef="usd">166000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i50342dbb79e5499b9df2cb4e61d5be82_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0zLTEtMS0w_82ffb55d-85e3-41c8-a8a1-ea3aaf05cab6"
      unitRef="usd">98000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id37b023ab7a5491390c1523729301141_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS01LTEtMS0w_d0262fe3-23b8-468e-8b42-493038b39c75"
      unitRef="usd">68000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idf1e2dfcd2804d95882c57e1cd29577d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS03LTEtMS0w_76f69084-a092-4fc9-85cf-9c8bafdbe1a5"
      unitRef="usd">317000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0f56a098641f4adabdbc54bd9bf3cebd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS05LTEtMS0w_da8e2032-e65f-4246-8289-0b8b5bb3ef53"
      unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib36cb5fa1a574affb0e19d405b184779_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNS0xMS0xLTEtMA_1cebb83c-14b3-4bfe-a7a4-6206f9f1b78c"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i85a4ecd57bc74263aa9d096516b7427a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0xLTEtMS0w_aaa1449d-3c2f-40bb-9067-61e9535f4e4b"
      unitRef="usd">14746000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6a70e4d101944330a1355aa4af4afef6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0zLTEtMS0w_5c270d39-0061-4d6a-bb87-239a0d3016ed"
      unitRef="usd">13353000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1db5ea92241540b2a00b5cc4513365e7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy01LTEtMS0w_e5de495f-a97d-49f1-92fa-14976d162ce1"
      unitRef="usd">1393000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i95bbeb2e83814978a01e4b5de1f38535_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy03LTEtMS0w_7b2833b6-4a2d-4a55-b602-92e7500f48ed"
      unitRef="usd">44010000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if1c1e6721d294667908c33dbde50345a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy05LTEtMS0w_a3f86771-287b-457d-9109-81ab08cb5328"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i444bb9b794c448cfbeb71eeb7d6b7942_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfNy0xMS0xLTEtMA_1dd3a04e-2bb8-4816-84eb-cb6500c39bb2"
      unitRef="usd">4910000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2a21751e445646ee893fa1935f34c449_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0xLTEtMS0w_6ff23acc-7a0b-4444-806c-4678f0a50da4"
      unitRef="usd">495000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic68dd4e2cc7543f086a97c70aee4f3fd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0zLTEtMS0w_508adcb6-7f78-4a01-bb05-a61420f41e48"
      unitRef="usd">495000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d2ce83af8934687a4f96e799ec9b7dd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC01LTEtMS0w_b23c1b9c-6121-4f0b-9839-c7ef4e657591"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i32bbacc3c3f74215a538c3cb78cdda7d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC03LTEtMS0w_5db85de2-0ee0-48f4-aa0d-f6453359c91e"
      unitRef="usd">1485000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id68098fe4a9b439eaacc7f7d0c5bcbdd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC05LTEtMS0w_166c8424-406e-48c0-bf6e-f067e13ac098"
      unitRef="usd">1485000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2e195e8a16b54620a94c67cd6bc415f3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOC0xMS0xLTEtMA_9c9f84d6-e19c-438b-aa76-ec8a2015f5c6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i98cefbf199d9465dae391afe67bf6d55_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0xLTEtMS0w_1887b6de-1077-4307-ba89-d6145613dd27"
      unitRef="usd">15241000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3adad74f372a48a99515a279dafd740f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0zLTEtMS0w_cefdcc88-8b02-4345-b3df-6cd6f670df63"
      unitRef="usd">13848000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia9fbfc3f90f54f06aa5a33e2c9b0418c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS01LTEtMS0w_59b58669-f72f-4f50-845a-67becec64a49"
      unitRef="usd">1393000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7264bcffa714400896107154c6920431_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS03LTEtMS0w_1b70f53b-ba34-41f8-8516-e56bfc4f0f8e"
      unitRef="usd">45495000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib7e656f96253442ab7ee60c4d60cfdfc_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS05LTEtMS0w_661d1cd1-9f21-46cf-b015-c22fc4a31ab2"
      unitRef="usd">40585000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieede3c5dcc3a49f1b95a145c32e7e7bd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfOS0xMS0xLTEtMA_3361e824-27a1-40cd-ad27-fb1100d1a669"
      unitRef="usd">4910000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMS0xLTEtMA_85c0c746-c40a-4672-890a-454f08cf05b7"
      unitRef="usd">15407000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1439b9bc31504073b9a6b6f1af0e5f94_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMy0xLTEtMA_73b02a0b-a51c-4e4c-b0c4-db7eabb4cfc8"
      unitRef="usd">13946000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i521d8220c1444234b7c2ff570a6a0903_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtNS0xLTEtMA_cffd39cb-f106-476d-baab-fbce90d7734f"
      unitRef="usd">1461000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtNy0xLTEtMA_903efcb7-e42f-405c-89ba-3340ace7154f"
      unitRef="usd">45812000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i47777114a06c45f2824489ae3e94ab1a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtOS0xLTEtMA_b01cecef-47d2-409b-b15e-ef48db7900ad"
      unitRef="usd">40697000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i16e371b1d2074f71ae9ec6f96bf78fc3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmIyNzMwNjYxNjcwNjQ0M2ZiZWQ5NDViNTVjN2YwZjdmL3RhYmxlcmFuZ2U6YjI3MzA2NjE2NzA2NDQzZmJlZDk0NWI1NWM3ZjBmN2ZfMTAtMTEtMS0xLTA_69feb644-535f-4321-bd8a-334368622700"
      unitRef="usd">5115000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjcxNQ_463d9ead-cab3-41a4-a4f8-ebd72c195874">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In thousands of U.S. dollars ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, which are included in "Trade and other receivables"&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:OtherReceivables
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMS0xLTEtMS0w_e7afb665-0deb-489d-93af-f34575e7753f"
      unitRef="usd">4129000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMS0zLTEtMS0w_85c6a9d7-7e0f-4cdb-9908-986433ae81c3"
      unitRef="usd">4203000</us-gaap:OtherReceivables>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMi0xLTEtMS0w_cc295dbe-bad8-4d9f-81b0-0fe69e8fe7b7"
      unitRef="usd">10738000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RhYmxlOmI3Y2ZhZWM3ZDAyMzRhYTdhNTA0MDM4YWM2ZDg3MWRjL3RhYmxlcmFuZ2U6YjdjZmFlYzdkMDIzNGFhN2E1MDQwMzhhYzZkODcxZGNfMi0zLTEtMS0w_7430e92d-1094-4f57-b61c-a9d2503c003e"
      unitRef="usd">12076000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetCreditLossExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_13abc0fb-9b9e-4224-8118-20bc69bade33"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
    <us-gaap:ContractWithCustomerAssetCreditLossExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_57a7cb29-fc14-44c6-b819-f167fdb81e43"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
    <us-gaap:ContractWithCustomerAssetCreditLossExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_a5ab62eb-68b0-45c3-b550-c7bd216d969e"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
    <us-gaap:ContractWithCustomerAssetCreditLossExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNDc2OA_d3eed59f-014d-4534-87cc-09c7e775510a"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTAxOQ_08b54ac0-aa11-4b63-acd2-18719af0e419"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTAxOQ_3036d832-740d-4566-aee8-240da6ae5a4c"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="i8e5eda16ab0e411eb51123b3346dcd32_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTE5Ng_80fe13f6-edf2-47ce-8fba-7ec94eeb63ae"
      unitRef="usd">0</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="if75c9d8788794de588ddd02a124be433_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNTE5Ng_d7cc7c92-7759-408a-a66f-cdd1242460d8"
      unitRef="usd">0</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjAwOQ_30865db1-d36e-4433-9258-dd7869bf0756"
      unitRef="usd">10700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF80Ni9mcmFnOjRmMTgxNmQ3Zjk5NDRhZTZiOGY5ZmFlOWNmMzQyMmJmL3RleHRyZWdpb246NGYxODE2ZDdmOTk0NGFlNmI4ZjlmYWU5Y2YzNDIyYmZfNjU5NQ_54373609-8e0d-4380-a1ab-d26e09106b6d"
      unitRef="usd">7700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RleHRyZWdpb246YTZkYTcyMmI0NDBlNDAzZDg1ZTk2MTcyZmVhZGM2MWNfNTA5_3ac4ef6e-76a2-4b26-ae53-e1481357321b">Investments - Available-for-Sale&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available-for-sale consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019 (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accrued Interest Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RleHRyZWdpb246YTZkYTcyMmI0NDBlNDAzZDg1ZTk2MTcyZmVhZGM2MWNfNTEw_89b4f93e-abcd-4e65-9e62-1f5e41b3f781">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available-for-sale consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019 (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accrued Interest Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy0xLTEtMS0w_adf8722e-81bc-4bc4-bb1a-c43f714a0c34"
      unitRef="usd">10679000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy0zLTEtMS0w_f7c89f12-b763-4d2d-b2f3-2ff8466a50ca"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy01LTEtMS0w_73bb0ae6-0445-4e43-be33-a69b643fe503"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy03LTEtMS0w_90e6839d-26f8-4bcc-85ec-283df6008870"
      unitRef="usd">21000</rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOjJjMTM5YTBlNjFmNTQ3MGU5ZTdmYzk2YTg1NGU2OTc4L3RhYmxlcmFuZ2U6MmMxMzlhMGU2MWY1NDcwZTllN2ZjOTZhODU0ZTY5NzhfMy05LTEtMS0w_0580e5c4-4a73-4838-8ddc-c5cb317b2294"
      unitRef="usd">10702000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy0xLTEtMS0w_d6f27e5f-adf9-41ad-a950-21c9a6f7dd6e"
      unitRef="usd">14238000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy0zLTEtMS0w_80970e3e-6e0e-42ce-bb3a-b26f6522b47b"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy01LTEtMS0w_589659dd-f52d-4fc4-be12-b6c17f5017c7"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy03LTEtMS0w_6beb2854-f977-4492-878f-cee983454f16"
      unitRef="usd">0</rmti:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81Mi9mcmFnOmE2ZGE3MjJiNDQwZTQwM2Q4NWU5NjE3MmZlYWRjNjFjL3RhYmxlOmY1N2QwOGQzNDNiNzRiNGY5NzU1OTQxOGRiYTI4YjVlL3RhYmxlcmFuZ2U6ZjU3ZDA4ZDM0M2I3NGI0Zjk3NTU5NDE4ZGJhMjhiNWVfMy05LTEtMS0w_ed8ee8c1-f63e-4989-a47e-d9de1c8ef5af"
      unitRef="usd">14250000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNjc5_b32d8533-202b-4c1a-9b21-480190928ae5">Inventory&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of inventory, net of reserves, as of September&#160;30, 2020 and December&#160;31, 2019 are as follows (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw Materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in Process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished Goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, we classified $0.9 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of September&#160;30, 2020, the total Triferic inventory was $3.8 million, against which we had reserved $2.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $1.1 million net value of Triferic inventory consisted of $0.1 million of Triferic Dialysate finished goods with expiration dates ranging from December 2020 to May 2021, $0.3 million of Triferic API with estimated remaining shelf life extending through 2021, and $0.7 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNjgw_8244bc4c-ae20-4404-ac29-57804b346a32">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of inventory, net of reserves, as of September&#160;30, 2020 and December&#160;31, 2019 are as follows (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw Materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in Process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished Goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMS0xLTEtMS0w_1b7c2d8b-fa37-45d7-aa54-1371b8e0b8bc"
      unitRef="usd">2794000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMS0zLTEtMS0w_c8891c37-3807-452a-9aaa-684df4767880"
      unitRef="usd">2471000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMi0xLTEtMS0w_4e2e221c-3f9c-4989-895b-9042d93ff83d"
      unitRef="usd">329000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMi0zLTEtMS0w_4ed24cdd-9673-490c-8c3f-994ff6c96399"
      unitRef="usd">185000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMy0xLTEtMS0w_254d5f88-ec06-4328-a1eb-3becd67cc3a4"
      unitRef="usd">1613000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfMy0zLTEtMS0w_98ced0ba-71e4-4d09-8c74-b3ae9d13751f"
      unitRef="usd">1432000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <rmti:CurrentAndNonCurrentInventory
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfNC0xLTEtMS0w_e56c6151-5214-45c8-ad8c-9d22d8105850"
      unitRef="usd">4736000</rmti:CurrentAndNonCurrentInventory>
    <rmti:CurrentAndNonCurrentInventory
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RhYmxlOjkxZDRmY2ZlZmM3YjRiN2Q5YWEzN2JlODgzNmYzZjEwL3RhYmxlcmFuZ2U6OTFkNGZjZmVmYzdiNGI3ZDlhYTM3YmU4ODM2ZjNmMTBfNC0zLTEtMS0w_aaf570ca-bc72-4b0f-8658-181182a1f27c"
      unitRef="usd">4088000</rmti:CurrentAndNonCurrentInventory>
    <us-gaap:InventoryNoncurrent
      contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMTE5_354a7f61-fcba-40fc-bb34-62bede8da8b2"
      unitRef="usd">900000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryGross
      contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzE0_d2a64fe3-4e7a-489c-b3b7-df3e266a6470"
      unitRef="usd">3800000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzQ4_cd994f70-9ea4-42fb-bfdc-8c3a849b3e1e"
      unitRef="usd">2700000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfMzU2_24c13d9d-4388-4597-9fa0-265039dfe81e"
      unitRef="usd">1100000</us-gaap:InventoryNet>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib11597e3775d4b5f9e6494de29d10293_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNDA0_0c48d718-73e5-4722-a100-e8ac6b9c7112"
      unitRef="usd">100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i5bd74d8095764a1eb76ef37b3b5b33ae_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNTA2_f5d37b68-6319-4078-a7f5-064f4eb22ae3"
      unitRef="usd">300000</us-gaap:InventoryNet>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i9c760a1961f04f77a2e3c6497a544e0c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF81NS9mcmFnOmNjMDM3ZDBhZTMyODQ4NmZhOTJjMzAxZDAxYzAxODBmL3RleHRyZWdpb246Y2MwMzdkMGFlMzI4NDg2ZmE5MmMzMDFkMDFjMDE4MGZfNTg5_9332c4f9-e41f-4aa3-b945-1ccfe18805b3"
      unitRef="usd">700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjUx_036e8cf3-0ead-440e-be70-b75e891b51a9">Property and Equipment&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s property and equipment consisted of the following (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information Technology&#160;&amp;amp; Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended September&#160;30, 2020 and 2019 totaled $0.2 million. Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 totaled $0.6 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjUy_cbf84d31-5456-4f0b-af41-d4d0ce827469">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s property and equipment consisted of the following (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information Technology&#160;&amp;amp; Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia59f19af41fc488a9449247c776c5edd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMS0xLTEtMS0w_403c63b8-559e-45a3-afbb-bc22599ff023"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i490ec924f1484c5ab8de1f20a08eac2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMS0zLTEtMS0w_0bcc1484-332b-46eb-9fc1-5e5921f0de65"
      unitRef="usd">1162000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i09ea955020dc4aeda5d463477492921f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMi0xLTEtMS0w_6e3dd796-c7c5-4999-b5b3-42702cb5aea4"
      unitRef="usd">5454000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i724d030ef47645d9b041ce7ef4a3f9fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMi0zLTEtMS0w_f8c4c0d8-128c-441e-9770-a596cb7f8940"
      unitRef="usd">4673000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7e7800000fe40fdb031acb81db02074_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMy0xLTEtMS0w_157d63b7-a356-4833-836e-cb4f55f364b4"
      unitRef="usd">1822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idcdae022f9c94d2cacaaf617ee81281b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfMy0zLTEtMS0w_7adb3069-5a23-4cc5-b577-b02a17bf6df3"
      unitRef="usd">1810000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icaf6b93155d0417884bb4a768fae1f99_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNC0xLTEtMS0w_57533263-9a87-49d6-a906-7bbc20342231"
      unitRef="usd">653000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied2d61a12cde4716914c1b6f8b1a5984_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNC0zLTEtMS0w_9df952d9-b504-41d1-ba9a-b89c1e840829"
      unitRef="usd">653000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNS0xLTEtMS0w_ed165561-2a93-45f3-a3a7-f06d7d4190d7"
      unitRef="usd">9105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNS0zLTEtMS0w_1903a94b-5fac-4abb-978f-a7c2991f4728"
      unitRef="usd">8298000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNi0xLTEtMS0w_83f3c575-e9a3-471f-a1a5-05c2cc003c64"
      unitRef="usd">6320000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNi0zLTEtMS0w_24deb101-2e61-41e9-a3a1-ee42cca8dd30"
      unitRef="usd">5865000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNy0xLTEtMS0w_a64358e4-2f55-4565-9d5b-ad4d2d5b46dc"
      unitRef="usd">2785000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RhYmxlOjE1ZGUzMWQyYjhjZjQwM2Q4NDY2YTU1MGJkZGJmOTIyL3RhYmxlcmFuZ2U6MTVkZTMxZDJiOGNmNDAzZDg0NjZhNTUwYmRkYmY5MjJfNy0zLTEtMS0w_58bc32d4-8121-4e6b-a608-f8d94a36241f"
      unitRef="usd">2433000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMTgy_1ddac299-e225-43e3-8d88-c46ce3a7a91d"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMTgy_1fe52702-0bbe-465a-8bd9-5d3250bb3b41"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjQ5_3e8ff51b-8afd-4143-bb89-26cc172a1202"
      unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82MS9mcmFnOmM4OTM3ODg1MTU0YTQ4YmM4MDUwZmI4MGMxZTgyZDUyL3RleHRyZWdpb246Yzg5Mzc4ODUxNTRhNDhiYzgwNTBmYjgwYzFlODJkNTJfMjQ5_cdc782a3-0c8e-4691-9f8f-23d4b8127475"
      unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RleHRyZWdpb246YTkwOWFkMzQyOGU2NDAwNDllZjA3MGM4MmU2YmY5MzFfOTQ_d8ef7abc-be5d-41e0-90fd-1843d9fbae92">Accrued Liabilities&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Research&#160;&amp;amp; Development Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Compensation and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Legal Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Marketing Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RleHRyZWdpb246YTkwOWFkMzQyOGU2NDAwNDllZjA3MGM4MmU2YmY5MzFfOTU_0b40db73-3579-4355-8594-6a94b54fbc05">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Research&#160;&amp;amp; Development Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Compensation and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Legal Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Marketing Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMS0xLTEtMS0w_c9d3a0db-9e95-4988-93f7-60d9c353942e"
      unitRef="usd">258000</rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMS0zLTEtMS0w_3065c2af-6723-45a8-b281-58897c94b4bc"
      unitRef="usd">283000</rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMi0xLTEtMS0w_91769ab8-3d10-4a70-b34a-56b339151a8d"
      unitRef="usd">2584000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMi0zLTEtMS0w_fa23d65a-4e90-4dd6-80e3-fa1ea01eeb74"
      unitRef="usd">1018000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMy0xLTEtMS0w_9bdffb1a-cc6a-473c-b212-802a1cd1a08b"
      unitRef="usd">172000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfMy0zLTEtMS0w_4c61b517-9332-412a-8bd5-eb50e23b0c39"
      unitRef="usd">182000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNC0xLTEtMS0w_e048b6c9-3bf9-40fc-9ff8-4f7f09ad4739"
      unitRef="usd">100000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNC0zLTEtMS0w_b9bae5b6-c01b-4df6-bac9-db4b90b154d7"
      unitRef="usd">61000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNS0xLTEtMS0w_fce66b5c-7f55-4ca4-9927-28e16b94ea4b"
      unitRef="usd">1854000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNS0zLTEtMS0w_a00d5e74-3440-4db5-912c-09619e3f5906"
      unitRef="usd">2974000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNi0xLTEtMS0w_48e63a62-06b4-49b9-934f-d946a4eb4c6b"
      unitRef="usd">4968000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF82Ny9mcmFnOmE5MDlhZDM0MjhlNjQwMDQ5ZWYwNzBjODJlNmJmOTMxL3RhYmxlOmY2OTlkMjg0NDQ1ZDQ4YjNiMzlmODI3MTYwZGU4OTEyL3RhYmxlcmFuZ2U6ZjY5OWQyODQ0NDVkNDhiM2IzOWY4MjcxNjBkZTg5MTJfNi0zLTEtMS0w_6d327680-efca-482e-8471-f3e091a81471"
      unitRef="usd">4518000</us-gaap:AccruedLiabilitiesCurrent>
    <rmti:ContractWithCustomerDeferredRevenueTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjg3Ng_0eeae032-42eb-46d1-86be-72811d3da635">Deferred Revenue&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Baxter Agreement totaled $7.7 million as of September&#160;30, 2020 and $9.1 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a &#x201c;Refund Trigger Event&#x201d; occurs under the Baxter Agreement, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from October 1, 2020 to December 31, 2021, Baxter would be eligible for a 25% refund of the Baxter Agreement&#x2019;s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020, Baxter would be eligible for a partial refund of the upfront fee of $5.0 million. In no event does the Baxter Agreement require more than one refund be paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $53,000 and $0.2 million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.8 million as of September&#160;30, 2020 and $3.0 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma  Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate in India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 during the three and nine months ended September&#160;30, 2020, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $92,500 as of September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and  Jeil Pharma, will guide the development and execution for Triferic Dialysate in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of nil during the three and nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</rmti:ContractWithCustomerDeferredRevenueTextBlock>
    <rmti:RevenueRecognitionReceived
      contextRef="i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTMy_1df9de6c-4c42-4674-8ee1-83a3e687856b"
      unitRef="usd">20000000</rmti:RevenueRecognitionReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic9ae312db51145cc9a83894a56a1cbb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQw_4a828cf0-c37d-4b5a-93e4-a0cf58e959e1"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQw_92f9ee07-6b23-4ab8-8204-43000c7a129d"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id517adcb738e4b869a1855cf0dc6e89c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQ3_bf9414b4-e389-42dc-a22d-185b03859e5f"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ifbd0e24d44954042a9d519b591fd1314_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNDQ3_d0534de2-b164-43eb-a759-c8e908da72e4"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id1e27f61e6bc46f59b6508b162a5ddb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTU2_08939702-caf2-4497-88bc-4f7b7171b1b1"
      unitRef="usd">7700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i52774d95e2b2417085a873bc7c2ef34f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTcy_3c6e66ca-56cd-4b23-952a-71bbdb0d2076"
      unitRef="usd">9100000</us-gaap:ContractWithCustomerLiability>
    <rmti:DeferredRevenueBenefitPercentage
      contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfODcx_373e847f-507d-4f76-a2c3-b136a3ed1931"
      unitRef="number">0.25</rmti:DeferredRevenueBenefitPercentage>
    <rmti:PartialRefund
      contextRef="idaeb19ee25fb49769abc3c331474525d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTMxMw_ac5af178-c7b4-4434-b0b1-aeea965252f7"
      unitRef="usd">5000000.0</rmti:PartialRefund>
    <rmti:RevenueRecognitionReceived
      contextRef="ib51e33cf4bfd4008b1b122e6683c1a98_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTUzMg_2472c328-b8f6-48d3-a6f8-3c2cb00e8aa7"
      unitRef="usd">4000000.0</rmti:RevenueRecognitionReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie0427b48c8964f40b6989681e03bf46d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTY5Nw_7bbee17e-1cfa-4610-9dac-2ff04c202568"
      unitRef="usd">53000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i259025889eae4268ae9b6e57e34ee6d7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTY5Nw_c0174cc4-83db-47d8-afdf-9a8beeddef50"
      unitRef="usd">53000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if9668e4db871491a984f75bb8da0189f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTcwNA_0bc09c94-8425-47aa-bfc6-357493599675"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic51b254d9485419498fa51735863171b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTcwNA_f5c9af91-2617-4cd3-b95d-ff0ea2eb3ca8"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie89138f962f14daa953625c2f528ae33_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTgxNA_0759f4c9-9aa6-43cc-b10f-43818e45d686"
      unitRef="usd">2800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4bdc1b8fe88f47298e47838b329a17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMTgzMA_a3d105c1-9a28-41a6-986b-c8c941377217"
      unitRef="usd">3000000.0</us-gaap:ContractWithCustomerLiability>
    <rmti:RevenueRecognitionReceived
      contextRef="i8f8d7d55df774d63a47aea6d31334501_D20200114-20200114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjMxNg_cdbeb386-7c65-49c6-a530-b978e7551929"
      unitRef="usd">100000</rmti:RevenueRecognitionReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if753017f31704051a4c4bf411897fbe2_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjgyMw_49e62233-1689-48a6-8f39-e4bda57f682e"
      unitRef="usd">2500</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i49ae4f19c274445bb160007dae42042b_D20200101-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjgzMA_b65e1b71-32e9-4dff-831c-4910e70313f5"
      unitRef="usd">7500</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4718c450d0ef47158d07ef1e72752de0_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfMjc0ODc3OTA3NTA4MQ_b9e756ba-b0ee-4465-9e05-5bf4d117bda6"
      unitRef="usd">92500</us-gaap:ContractWithCustomerLiability>
    <rmti:RevenueRecognitionReceived
      contextRef="i91abe0affe46442896b337be936db0c0_D20200907-20200907"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNjA0NzMxMzk1NzI0NQ_a1aaf8c5-e6ec-471e-8ad3-c7754627b49b"
      unitRef="usd">200000</rmti:RevenueRecognitionReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8ccd6e7c5ec24a5893a434fbdcebfbb4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTQ5NzU1ODE0NDcwNg_59aa8589-1997-4118-97a1-7eb83a3e16f5"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0eeaf45b733e4e779dfcac83f1129f11_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83MC9mcmFnOjY0YThkYTUwNjJhNjQ0YTQ4YzM3MTQzOGU2MGU2ZDE5L3RleHRyZWdpb246NjRhOGRhNTA2MmE2NDRhNDhjMzcxNDM4ZTYwZTZkMTlfNTQ5NzU1ODE0NDcwNg_d9cc3d1f-91d6-497a-a632-7e0dccad424b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzg4Ng_027a497f-8d3d-48e6-afa9-f5ae1fdb7daf">Stockholders&#x2019; Equity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 93,573,165 and 65,378,890 shares issued and outstanding, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Controlled Equity Offering (or "At the Market" Offering)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 22, 2019, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. (the &#x201c;Agent&#x201d;), pursuant to which the Company may offer and sell from time to time shares of the Company&#x2019;s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company&#x2019;s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018,&#160;the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#x201c;at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#x2019;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes.&#160;The Company may suspend or terminate the Sales Agreement at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company sold 1,840,443 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5,383,079, at a weighted average selling price of approximately $2.92. The Company paid $309,479 in commissions and offering fees related to the sale of the common stock. For the nine months ended September&#160;30, 2020, the Company sold 1,128,608 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $2,325,478, at a weighted average selling price of approximately $2.06. The Company paid $63,000 in commissions and offering fees related to the sale of common stock. Approximately $32.3 million remains available for sale under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not required to sell any shares at any time during the term of the facility.  Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Offering of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp;amp; Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February&#160;6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the "Offering"). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February&#160;21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company&#x2019;s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 23, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;2020 Purchase Agreement&#x201d;) with certain purchasers named therein, pursuant to which the Company agreed to issue and sell to several institutional and accredited investors in a registered direct offering, 21,818,544 shares of common stock and warrants to purchase up to 23,178,509 shares of common stock (the &#x201c;Warrants&#x201d;) at a combined purchase price equal to $1.51 per share. Each Warrant is exercisable for one share of common stock at an exercise price of $1.80 per share. The Warrants are immediately exercisable and will expire on September 25, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also offered to certain purchasers pre-funded warrants to purchase up to an aggregate of 1,360,265 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;), in lieu of shares of common stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is sold to the public in the offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants were exercised in conjunction with the issuance of common stock under the Securities Purchase Agreement. The Company received gross proceeds of approximately $35.0&#160;million in connection with the offering, before deducting placement agent fees and related offering expenses of approximately $2.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A holder (together with its affiliates) may not exercise any portion of the Warrant to the extent that the holder would own more than 9.99% (or, at the holder&#x2019;s option upon issuance, 4.99%) of the Company&#x2019;s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company agreed to pay H.C. Wainwright &amp;amp; Co., LLC (the "Placement Agent") a cash fee of 6.0% of the aggregate gross proceeds raised in the offering, minus $420,000 payable by the Company to a financial advisory firm for services related to the offering.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company agreed to pay the Placement Agent (i) 6.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants through December 25, 2021 and (ii) 4.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants subsequent to December 25, 2021. The Company also agreed to pay the Placement Agent non-accountable expenses of $50,000 as well as $12,900 for the clearing fees of the Placement Agent in connection with the offering.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the common stock for the 2020 Purchase Agreement as equity on the accompanying consolidated balance sheets as of September 30, 2020. The amount allocated to common stock was $26.1&#160;million. This allocation is equal to the total proceeds of $35.0&#160;million less the amount allocated to Warrants of $8.9&#160;million and is also net of the direct and incremental costs associated with the 2020 Purchase Agreement of $2.3&#160;million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the 2020 Purchase Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDI2_97364b1f-6ab2-4c97-8fb6-b5077ba4be4c"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDI2_b445d91d-7341-4834-933e-3b6054e2cdb0"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDU2_38cd7456-0bb7-4349-bda7-2f361ddc392c"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDU2_e51701fa-99f3-43a1-aa4f-513f9a424603"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_162fb920-6c6a-4f90-b70b-6aee23e4af13"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_9470b901-1815-456e-96e0-5d61617f2350"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_94ba16c9-c285-405a-a852-4408e5e11cee"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNDk1_b2c6e3f7-9311-4c03-a846-f33a942b5505"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNTg4_c6a05288-a945-4a51-81b7-41da49dbe67c"
      unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNTg4_d372388e-48c0-4a1b-b03b-730ffc457112"
      unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjE1_4be43020-a2f3-47cd-bfdc-bc3d54bab6e4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjE1_b75bc55f-bdbc-433a-aa0d-898cb40e7e00"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjU0_38bf8eef-abae-41ad-a71e-6fa44996423e"
      unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjU0_f66d9837-8c79-4924-aa69-9660057aef81"
      unitRef="shares">93573165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjYx_c29c2ed6-efdd-4c47-8fde-ede1e43a1cfd"
      unitRef="shares">65378890</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjYx_deb51d24-786f-4167-9421-53535917babb"
      unitRef="shares">65378890</us-gaap:CommonStockSharesOutstanding>
    <rmti:SalesAgreementThresholdSaleOfShares
      contextRef="ice0831beb2ab467c80a2cd6478135fd1_D20190322-20190322"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMTA1MA_0bd73887-684e-4f48-bd54-3ac3777ecd91"
      unitRef="usd">40000000.0</rmti:SalesAgreementThresholdSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjA0OQ_86011ddc-de88-4cbf-977e-f7020f0c0cbb"
      unitRef="shares">1840443</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjEzNg_a2ee3f58-4144-4907-98e8-7ec03c9fc18f"
      unitRef="usd">5383079</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjE5Mw_acede774-94b7-428c-8d4a-fa470eb139cc"
      unitRef="usdPerShare">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if133411b23494ef4a52b411a10736bc0_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjIxNA_4f3e0b3c-809b-439a-adb2-cc541ef4bf2b"
      unitRef="usd">309479</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjMzNw_a1a3a1ba-1ff6-41d6-94fc-a0e2f5e4ba0b"
      unitRef="shares">1128608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjQyNA_b420fc08-c7de-4e11-ab33-8e1ed9d9378d"
      unitRef="usd">2325478</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjQ4MQ_8089fe60-eea9-42cd-b68c-67b59fc67f8b"
      unitRef="usdPerShare">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <rmti:PaymentsOfStockIssuanceCostsAndCommissionsFees
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjUwMg_d0877772-d512-418f-b116-355c19c7895a"
      unitRef="usd">63000</rmti:PaymentsOfStockIssuanceCostsAndCommissionsFees>
    <rmti:SaleofStockRemainingSalesAmount
      contextRef="if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjU4OQ_89509765-8e22-4515-bb68-c1388a32978f"
      unitRef="usd">32300000</rmti:SaleofStockRemainingSalesAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7f2b087a0e4f4228929a2c5ee622983c_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzE4NQ_d2ae286d-efba-4129-a9ab-33e16b59b94f"
      unitRef="shares">3670212</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i05c8a3f51c2d4520bd74c294ecf97017_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzIzMQ_4eb8ec26-d384-4dbb-a05f-70f8abe923de"
      unitRef="shares">478723</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i041fa2ada3f74f73bd7d90fb6dfb76f2_D20200206-20200206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzM3MQ_d2892353-8690-414e-91ae-c4d054794b5e"
      unitRef="shares">3191489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="if132963a047b41d2a24b8a07ea731b8b_I20200206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzQzMw_b0430e48-5552-4a5a-a860-d88e9822aaf4"
      unitRef="usdPerShare">2.22</us-gaap:SharePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib5508c49bd924868bbf229130f33ee19_I20200219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzU1Mg_7b3c98c0-98b4-4add-8db1-e8bf06a3eb73"
      unitRef="shares">478723</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharePrice
      contextRef="iab29bf3438904c79b711f873e3ceeb8c_I20200219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzU3Ng_6c5d542d-7825-4869-9953-895ce580918e"
      unitRef="usdPerShare">2.22</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzY0MA_c43123dc-e165-4e7a-b76e-3506382c5837"
      unitRef="usd">8000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5740a1485a6f44828ea5ab75a48aa392_D20200221-20200221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMzY2OQ_99b347f1-113d-48db-a539-eba73eae17cc"
      unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia502bbba04754e9aba66622648340936_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTA5NQ_9596074a-099c-48f1-a068-27f8e8d04e47"
      unitRef="shares">21818544</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE0Mw_5dfe2f27-f458-4240-95e3-d66b2527754e"
      unitRef="shares">23178509</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE1MQ_628151e3-808c-4356-862a-f12b6d88c9c2"
      unitRef="usdPerShare">1.51</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUyOA_0a45764a-adef-4692-9877-d4debd595d93"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjMyMg_908679d5-f87e-4284-a25f-0ae02a11a079"
      unitRef="usdPerShare">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTEzMA_fec2abe9-3099-4df3-ac50-86aef5c28e50"
      unitRef="shares">1360265000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE2MA_1cadddfc-ced4-4e5b-a83e-602cf151378d"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i782ec4f251e84caf91c4d307a48529b0_I20200923"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfNjA0NzMxMzk2MTE2OQ_1cadddfc-ced4-4e5b-a83e-602cf151378d"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjM3NA_fa3249d6-2cdd-4ffd-bc38-9b4189078441"
      unitRef="usd">35000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjM4OQ_6d4fac02-8f2d-42af-950b-ac0e74e4197d"
      unitRef="usd">2300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <rmti:ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQwMw_7127eb0c-8cd3-46ac-bd9d-8413c9e36a91"
      unitRef="number">0.0999</rmti:ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise>
    <rmti:ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise
      contextRef="i486841c65b234f6cbf7712dbae65542d_I20200923"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQxMA_25500372-e04c-4d3f-b9a6-4e7650bc534b"
      unitRef="number">0.0499</rmti:ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise>
    <rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering
      contextRef="ia502bbba04754e9aba66622648340936_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQxNw_eec594a0-8483-49ef-820b-ba14ad4ec1e3"
      unitRef="number">0.060</rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering>
    <rmti:SaleOfEquityAmountPayableForServicesRelatedToOffering
      contextRef="ia502bbba04754e9aba66622648340936_I20200923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQyMw_5b28d031-d8b1-4048-81f7-82fb74cefd14"
      unitRef="usd">420000</rmti:SaleOfEquityAmountPayableForServicesRelatedToOffering>
    <rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors
      contextRef="ia502bbba04754e9aba66622648340936_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQzMw_7064d758-4c50-449b-a502-638a6f3e9d1c"
      unitRef="number">0.060</rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors>
    <rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants
      contextRef="ia502bbba04754e9aba66622648340936_I20200923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQzOQ_50a9ccbe-0f58-4ac2-a623-48ccb81f756d"
      unitRef="number">0.040</rmti:SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants>
    <rmti:SaleOfEquityPlacementAgentFeeNonAccountableExpenses
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ0NQ_5d55137d-47e8-481d-b790-4ce8eeda6162"
      unitRef="usd">50000</rmti:SaleOfEquityPlacementAgentFeeNonAccountableExpenses>
    <rmti:SaleOfEquityPlacementAgentFeeClearingFees
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ1NA_a7ea0d05-2a8f-4c13-a88a-98110bf83fd4"
      unitRef="usd">12900</rmti:SaleOfEquityPlacementAgentFeeClearingFees>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i1fae665e3ecf4ecaa260ed16b9864327_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ3MQ_ad219307-0168-47b2-8f45-204f38a3ed04"
      unitRef="usd">26100000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjQ4Ng_e9a803b6-e2d0-4241-8614-bdf890ccee72"
      unitRef="usd">35000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUwMQ_fb469cee-6520-4f36-a858-f1fe9c79295e"
      unitRef="usd">8900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i732ed43633d74b469ee1dfbbaa4972eb_D20200923-20200923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF83Ni9mcmFnOjYwZmUzNDNkYjlhNTQyNDRiYjYxZWExMWFmNGMwOWE4L3RleHRyZWdpb246NjBmZTM0M2RiOWE1NDI0NGJiNjFlYTExYWY0YzA5YThfMjc0ODc3OTA4MjUxNQ_3e6c8ea4-b25d-46b2-87fb-8aa8227162d5"
      unitRef="usd">2300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMg_5547e631-8270-449b-ae66-6ede540dee4d">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense during the three and nine months ended September&#160;30, 2020 and 2019 as follows (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Service-based awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Performance-based awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock awards during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Grant-Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock awards during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September&#160;30, 2020, unvested restricted stock awards of 146,800 were related to performance-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Service-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;463,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(247,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;593,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of service&#160;based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of nil and $0.2 million was recognized during the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense of $0.5 million and $1.3 million was recognized during the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, the unrecognized stock-based compensation expense was $0.3 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. Included in the forfeited service-based restricted stock units are 96,541 and 55,556 units related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the former Chief Financial Officer on July 3, 2020, respectively. These forfeited awards reduced stock-based compensation expense by $0.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988,958)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for performance-based restricted stock units was ($0.1) million and ($1.1) million during the three and nine months ended September&#160;30, 2020 and ($0.3) million and $0.5 million for the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, there was no unrecognized stock-based compensation expense related to performance-based restricted stock units. The forfeited performance-based restricted stock awards of 988,958 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense for the three and nine months ended September&#160;30, 2020 by $0.1 million and $1.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Service-Based Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the service-based stock options granted for the nine months ended September&#160;30, 2020 were based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.766%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.17 - $2.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.2% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.31% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 - 6.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based stock option activity for the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based stock option activity for the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,856,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,782,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,340,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, the Company granted stock options to purchase up to 2,252,344 shares of common stock to certain employees. &#160;During the nine months ended September&#160;30, 2020, 440,026 shares were forfeited. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for service-based stock options was $0.2 million and $1.0 million for the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense recognized for service-based stock options was $0.6 million and $1.8 million for the three and nine months ended September&#160;30, 2019, respectively.&#160;As of September&#160;30, 2020, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $2.8 million, which is expected to be recognized over an estimated weighted average remaining term of 2.4 years.&#160;Included in the forfeited service-based stock options are 129,375 unvested options related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and 222,222 unvested options related to the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense by $0.5 million. Included in the expired  service-based stock options are 3,783,335 options related to the settlement with the former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. See Note 14 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the performance-based stock options for the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the performance-based stock options for the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for performance-based stock options was $0.1 million and ($0.4) million for the three and nine months ended September&#160;30, 2020. Stock-based compensation expense recognized for performance-based stock options was $0.1 million and $0.4 million during the three and nine months ended September&#160;30, 2019. As of September&#160;30, 2020, the unrecognized stock-based compensation expense related to unvested performance-based stock options was $0.4 million. The forfeited unvested performance-based stock options of 388,125 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited options reduced stock-based compensation expense by $0.7 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMw_8381af8b-ef60-4a71-bb6b-da552a5a5481">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense during the three and nine months ended September&#160;30, 2020 and 2019 as follows (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Service-based awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Performance-based awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC0xLTEtMS0w_22c142c6-63dc-4d43-be4c-94f733742abd"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC0zLTEtMS0w_64005e50-a56b-4be1-b913-70546e439224"
      unitRef="usd">502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC01LTEtMS0w_559b2ad0-c8ea-48cc-8772-9e38227d0c8a"
      unitRef="usd">243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNC03LTEtMS0w_edd2015c-7f3e-40b0-852a-1b558788a606"
      unitRef="usd">1274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS0xLTEtMS0w_6453742f-7e64-47f6-bd8b-a33acae5bda5"
      unitRef="usd">243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS0zLTEtMS0w_2dde4109-4c88-4a3e-9feb-89213b8586a2"
      unitRef="usd">597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS01LTEtMS0w_59046b5c-43ca-49b2-9890-e7afddd545f6"
      unitRef="usd">1019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNS03LTEtMS0w_f4be3bd6-ff7d-4628-bf68-ca7fba847c98"
      unitRef="usd">1796000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi0xLTEtMS0w_6e3e9018-b4db-4b33-93fc-cb02dfc7e03a"
      unitRef="usd">252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9942ba6c87d84e62962ab243afb9c8b2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi0zLTEtMS0w_d24c0e63-39eb-41f2-9c24-141849d7d2c6"
      unitRef="usd">1099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1198ab5b58240dbb1f5bfeca60211a5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi01LTEtMS0w_773e13a6-21da-446c-b440-42644454c402"
      unitRef="usd">1262000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7fd1a1eeb924cc5b1b07ab373a25223_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfNi03LTEtMS0w_f9ef313d-e3ff-4cde-81fd-52f83ec08c82"
      unitRef="usd">3070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC0xLTEtMS0w_026e0d46-a8dd-44dd-8f3e-b2ac12e458f6"
      unitRef="usd">-123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC0zLTEtMS0w_0c7f5ccc-1e58-4586-830d-6ef2c0276963"
      unitRef="usd">-332000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC01LTEtMS0w_8b986f0b-d15f-4f5d-a9a4-314363c5832c"
      unitRef="usd">-1148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOC03LTEtMS0w_8c1e819b-c9aa-40c4-83ee-e1fb70cd7497"
      unitRef="usd">469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS0xLTEtMS0w_64bc6ced-01a5-43c7-8d12-42d55b73dfff"
      unitRef="usd">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS0zLTEtMS0w_91ed52b9-1a13-4112-b5cb-9595b6b22088"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS01LTEtMS0w_70e59f06-bc3b-4845-85ff-a18dc1f7e6e2"
      unitRef="usd">-390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfOS03LTEtMS0w_e6ba897d-123b-4750-b699-d0b1fd11e244"
      unitRef="usd">357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if383605b1d784fb1a8ff6c886fb8e59d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtMS0xLTEtMA_828bd7b5-db10-45b5-9c4f-66809f761996"
      unitRef="usd">-2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c7e169bbaa94542ac7a76cb79b52918_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtMy0xLTEtMA_e2879e4b-f7bb-443f-96a3-15f3ac75aab1"
      unitRef="usd">-222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1daf26803ee746bc8aea3bb5e7e6adef_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtNS0xLTEtMA_1fa61485-07bc-40d5-98da-2e21bff8b71d"
      unitRef="usd">-1538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id854eccd72ff423c94105e0747d833e3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTAtNy0xLTEtMA_b6449643-cf80-4852-8aef-f9c6c1803e2b"
      unitRef="usd">825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtMS0xLTEtMA_efd86b4b-0a65-4336-8cd7-85ed07648f3a"
      unitRef="usd">250000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtMy0xLTEtMA_b5fad535-deea-474d-b0de-a99fe4747685"
      unitRef="usd">877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtNS0xLTEtMA_176ce488-3229-4509-9483-6ceab39b393c"
      unitRef="usd">-276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjY4ZTgwMTA4ODQzMzQzOGI4M2VhODYzMDU1NTgyMDBjL3RhYmxlcmFuZ2U6NjhlODAxMDg4NDMzNDM4YjgzZWE4NjMwNTU1ODIwMGNfMTEtNy0xLTEtMA_3d91e32a-6084-4caa-98f7-a2cfb615370d"
      unitRef="usd">3895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNg_9afad217-da41-4fd6-a09a-69b477cc54e7">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock awards during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Grant-Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock awards during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i62e59b988f854af6a2f19b812a92527f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMS0xLTEtMS0w_aec8d3d7-4a32-4017-b416-9a52eaf24bd4"
      unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i62e59b988f854af6a2f19b812a92527f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMS0zLTEtMS0w_1f83efc5-7a34-4494-b3bf-8747b709cbe2"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ieb4dad30bf674f2b81a41e72d5349c55_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMi0xLTEtMS0w_6a1eda65-5895-48c4-ac41-56ff942c4a76"
      unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ieb4dad30bf674f2b81a41e72d5349c55_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjkxOWQzZDc1NDMzMjQzYzBhNjg0MmUzM2EwNWJiYjc3L3RhYmxlcmFuZ2U6OTE5ZDNkNzU0MzMyNDNjMGE2ODQyZTMzYTA1YmJiNzdfMi0zLTEtMS0w_176bf418-557a-4b6e-8cc4-fe96b3040196"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i87ac32bf162f4c268157cf1641fa843a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMS0xLTEtMS0w_3acabd80-8da7-4eaf-b214-5ed7bd816c61"
      unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i87ac32bf162f4c268157cf1641fa843a_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMS0zLTEtMS0w_c5b6f091-49de-402a-9efa-9f82e7407261"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMi0xLTEtMS0w_c0eac8b5-e439-4b23-a121-2418d9dbcd70"
      unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6a1c4ac2c07c4d80bd2480a4b1f6fe8b_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjlmYjk3OGMzMWI5MDQzMThiZmUzMjMzNmEwMTAyOGExL3RhYmxlcmFuZ2U6OWZiOTc4YzMxYjkwNDMxOGJmZTMyMzM2YTAxMDI4YTFfMi0zLTEtMS0w_9a094b87-fbf4-49a5-b361-6a83c010e53c"
      unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6646233751964c4fb0aa59ba0eda8b5e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTA1_956e0242-b8b6-47bf-ad45-4161cd64fcbe">P20M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8f27d81d3cfe41f691685d6efd73d522_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTU1_1d02e149-f9c2-49f8-b609-b1aa668542b0"
      unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNw_c100cd3c-99d7-41a7-973f-09a932decf9b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;463,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(247,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;593,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMS0xLTEtMS0w_d2232ad6-d08c-4c58-a15c-cc69598e84fd"
      unitRef="shares">463786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMS0zLTEtMS0w_967f224b-ad43-429b-8093-15c123444cbf"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMi0xLTEtMS0w_0e6455d8-118e-45b0-aea7-9b6fe7da9e8b"
      unitRef="shares">188904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMi0zLTEtMS0w_a582ff66-133a-4db0-acb8-c9542d0ddd36"
      unitRef="usdPerShare">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMy0xLTEtMS0w_fdcf4c2f-cb77-4eec-9b56-8f05b2aeb133"
      unitRef="shares">247561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfMy0zLTEtMS0w_34735c33-b1f5-4315-81fe-e8fd8a71cd80"
      unitRef="usdPerShare">4.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNC0xLTEtMS0w_f5000ab7-46ac-47eb-aca4-22e71253a4cb"
      unitRef="shares">159724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNC0zLTEtMS0w_c87b765c-924b-4011-a493-35e82b2b0529"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNS0xLTEtMS0w_d12ecadb-d448-4dca-b125-b27c8084cab9"
      unitRef="shares">245405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmJjMDk3Y2ZkN2ZmYTQ4MDY5YWY1ZTZiZjZhZDFkOTcyL3RhYmxlcmFuZ2U6YmMwOTdjZmQ3ZmZhNDgwNjlhZjVlNmJmNmFkMWQ5NzJfNS0zLTEtMS0w_75029e95-ca61-4336-a3ab-770cbf27408e"
      unitRef="usdPerShare">2.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6551685fb24049b682909f7a5086db3f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMS0xLTEtMS0w_1f9b22e4-82f3-44fd-9ff3-01111c63f4ed"
      unitRef="shares">472959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6551685fb24049b682909f7a5086db3f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMS0zLTEtMS0w_a38bcebf-9d6e-426e-a6ef-acd5b5f0a411"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMi0xLTEtMS0w_a00bb50a-cdf6-4e01-9b7a-6ba786ea9b93"
      unitRef="shares">222497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMi0zLTEtMS0w_06c86115-1caa-409c-8987-28ba4c7faf3f"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMy0xLTEtMS0w_d7fb8a7d-a222-425b-b529-651b89d19b6d"
      unitRef="shares">4950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfMy0zLTEtMS0w_39471782-4a67-4213-8d44-9901df4358f6"
      unitRef="usdPerShare">4.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0xLTEtMS00MDQ_40d2ccc0-ecf2-4881-84c3-c5503b384f80"
      unitRef="shares">96542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0zLTEtMS00MDg_2f6f812e-b631-461a-9560-af52afb36da4"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i10f9f4004419417e9412857f5acd3c8b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0xLTEtMS0w_12fbdc2e-24f1-4782-ae18-25a5696e422b"
      unitRef="shares">593964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i10f9f4004419417e9412857f5acd3c8b_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjVkMWY2Y2Y4M2NiNTQ3ZmRiOWJjMDdhYmY2MTIzODkyL3RhYmxlcmFuZ2U6NWQxZjZjZjgzY2I1NDdmZGI5YmMwN2FiZjYxMjM4OTJfNC0zLTEtMS0w_586445cf-80fa-4429-bfc9-e92ec0fb98f1"
      unitRef="usdPerShare">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icf4a248d9fbf4a9dbd4e6806f7db82dc_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA0Ng_29147244-ad1f-4755-af61-ebd2465e0e38">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5579dd55e4b6461ba7c91e665d52fee3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA1Mg_7441dac4-4da5-4071-b42e-543c11cdb322">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if84ab7a53fa74260b6f337c13694b413_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA5Mg_f5508d19-b839-47e7-aff6-ac4e82fec0dc"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTA5OQ_acd5ab75-f03a-4a16-9ae3-f518f2726bdc"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf9239d08fca4b8295073a2dd08fd6b4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTE5OA_66286be8-2a19-4e40-b2b7-614292e2b8dd"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fcb8048039b46648a8a784db794bbcd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTIwNQ_9cf26cdd-8018-40d7-b6bb-f7f8da26f0b5"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="icaba2c2351e144d5bcab77648873bd5f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTMzMg_bf90550e-53ca-4c4d-b1f0-23a68a503aea"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib79801249b974542a7353d5d96850c6d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTQyNA_25dfa33c-0f1a-4998-aa1c-20f900ab9494">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8a801e210d094fa18659b7a2f0a4f400_D20200417-20200417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTQ5NQ_eda83b6b-c6db-416c-8fdf-8d27aecce13f"
      unitRef="shares">96541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idcb8a240bd284c4e9463f5dd7b8a6c70_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NjEzMQ_fb8bce1a-9d5e-42ab-b287-f38adc6cd003"
      unitRef="shares">55556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures
      contextRef="i6efe4199c6e74202909ae855d11ce621_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMTY3OQ_75159b14-7903-4fe2-9a38-c114b3f3a7ab"
      unitRef="usd">400000</rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxOA_6b4ab492-d4d0-493d-924a-24d86bc3bd24">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988,958)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i909683c4233b4a22804c27ebf1e6c92b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMS0xLTEtMS0w_98bed087-c2d1-421e-9994-c27e59404b26"
      unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i909683c4233b4a22804c27ebf1e6c92b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMS0zLTEtMS0w_ff280253-58f7-4839-8f67-cec86fabee1e"
      unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMi0xLTEtMS0w_c606bfa4-1d67-4656-bcae-3c5f025e63ce"
      unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMi0zLTEtMS0w_4445a93a-20b1-45ac-9788-60dcf69eb563"
      unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMy0xLTEtMS0w_6efa3812-14cf-4357-98ff-cbe2d537afa6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE3MjYzY2MwOWEwNTRmYWViNGI4MzA2NWVhNDNkZThhL3RhYmxlcmFuZ2U6MTcyNjNjYzA5YTA1NGZhZWI0YjgzMDY1ZWE0M2RlOGFfMy0zLTEtMS0w_25b22fe1-0521-41db-8ed2-15666ae6174c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i564592058228420b94ffbc322e7090c4_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMS0xLTEtMS0w_a571d75e-3b66-4fc4-a0c0-23d5f43ad966"
      unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i564592058228420b94ffbc322e7090c4_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMS0zLTEtMS0w_86df8a00-ee5a-42fe-ae76-9d2379b1f722"
      unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6606daf6bf13495a89c4cb1a8572fecf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMi0xLTEtMS0w_5695007f-a014-4ae1-9e56-dff7a93acdfb"
      unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6606daf6bf13495a89c4cb1a8572fecf_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjRhYjZlNzU2NDA4YzQ3MTFiYzUwNWNhYTBmZmY3ZWJlL3RhYmxlcmFuZ2U6NGFiNmU3NTY0MDhjNDcxMWJjNTA1Y2FhMGZmZjdlYmVfMi0zLTEtMS0w_338da928-92f0-4639-955a-ae957d9f8591"
      unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64921dae3e1741b4a049f8014ce00f87_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA1MQ_de04c420-30ce-4dd1-9672-63bb51d9326f"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib78caa6c595e47d5ad487a7503f5cced_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA1OA_7548598a-62d7-40ed-9e69-d4e209946fff"
      unitRef="usd">-1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11086e4f3d734de2856b9688fbeb4433_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjA5NQ_84e6e78f-c298-438d-9ffe-842878845838"
      unitRef="usd">-300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i074aa7c6e7f442a880aee63746b80035_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjEwMg_9bcfddee-cfa9-42a7-92b0-0a479edf63ed"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i515e2b0a4fef415196a45d1b5751f530_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTQ3OQ_fecfc325-0abb-45b8-985c-f2b06cbc340d"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0c9890f223334395a55787fcbfde8291_D20200417-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjQxOA_fac51f0b-6d39-4f46-96b8-0ab7a8096740"
      unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures
      contextRef="ie0fd29e788d64550b340302d86755201_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjU5NQ_83f318ec-5795-4b87-bbcc-13fa9e434be9"
      unitRef="usd">100000</rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures>
    <rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures
      contextRef="i51825a238efa425a9b7252dd4452dcdd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTQ4OA_a6fb42ba-cc59-428f-ac47-b20439aa3d55"
      unitRef="usd">1400000</rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxOQ_279d8914-015c-456d-9ea1-ac7ebca6fdb6">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the service-based stock options granted for the nine months ended September&#160;30, 2020 were based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.766%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.17 - $2.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.2% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.31% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 - 6.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ibfccd25c8636494a85d9d1d3f1d09ba3_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMS0xLTEtMS0wL3RleHRyZWdpb246MWVjYWM4OTFkNmRhNDM1Yzg5MWUxMTU0NjA3M2Q5NjFfMzg0ODI5MDY5NzIzOA_fd10dfd3-a995-4f7d-b11d-c2f1ce16efe5"
      unitRef="usdPerShare">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i2b5bdfb4ab9b4caa9c0806d213fcfb9a_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMS0xLTEtMS0wL3RleHRyZWdpb246MWVjYWM4OTFkNmRhNDM1Yzg5MWUxMTU0NjA3M2Q5NjFfMzg0ODI5MDY5NzI0Ng_bb5b436d-556e-4450-9ef3-51fed073e45a"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMi0xLTEtMS0wL3RleHRyZWdpb246NWQyZDFjNmVjNDg4NGRjZjljOWExN2I3OWI3ZjY3ZDZfMzg0ODI5MDY5NzIzOA_33bce73d-6477-4403-a96d-caed6eda62be"
      unitRef="number">0.682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMi0xLTEtMS0wL3RleHRyZWdpb246NWQyZDFjNmVjNDg4NGRjZjljOWExN2I3OWI3ZjY3ZDZfMzg0ODI5MDY5NzI0Ng_2c161600-8b62-4142-9cbd-3b1ff8f9554f"
      unitRef="number">0.750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMy0xLTEtMS0wL3RleHRyZWdpb246YTVmNDkxZmFlMjU2NGE1ODliYTZkMWVhZDY5NTgzM2NfMzg0ODI5MDY5NzIzOA_d83c2121-a073-4159-8f11-66c157743ba2"
      unitRef="number">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfMy0xLTEtMS0wL3RleHRyZWdpb246YTVmNDkxZmFlMjU2NGE1ODliYTZkMWVhZDY5NTgzM2NfMzg0ODI5MDY5NzI0Ng_e6483552-0cbb-4c0e-8400-8da0932ce7c7"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3e2d2e0642bf45b09fe5f2a6bfa06696_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1Zjc4ZjkyMTY4NDlhOWJkZGZhMzcwMGRlYTNhNTJfMzg0ODI5MDY5NzIzMQ_d18003ee-ea03-4ab3-bf7e-0da692c062b0">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i07d733cb7a0441e9ae832f027f97a0a6_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE1ZWMyNDAzOWVjMTRjYWVhZGExOWY0M2VmOWVjM2Q2L3RhYmxlcmFuZ2U6MTVlYzI0MDM5ZWMxNGNhZWFkYTE5ZjQzZWY5ZWMzZDZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1Zjc4ZjkyMTY4NDlhOWJkZGZhMzcwMGRlYTNhNTJfMzg0ODI5MDY5NzIzOA_35431f5a-91e9-4286-80dc-9259d87bf710">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMA_937103b4-43b5-43bf-8dd4-c1cc9475b3f6">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based stock option activity for the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,889,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s service-based stock option activity for the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,856,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,782,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,340,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS0xLTEtMS0w_ff2e4092-0639-4efa-a160-2d619200055e"
      unitRef="shares">8210024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS0zLTEtMS0w_28dabc7f-98fb-490e-8c85-223a6bf1fe40"
      unitRef="usdPerShare">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic1282277c8624ede8e591db387da49dd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS01LTEtMS0w_11db5ebd-2360-4fc9-83bc-f83001b816e2">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4f601d2948df4553b7179e093cc01b77_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMS03LTEtMS0w_2853ce24-4845-4f90-8e35-edeb90f24296"
      unitRef="usd">107150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi0xLTEtMS0w_d07a2589-f33e-4b53-a8e9-a77b0437d5a5"
      unitRef="shares">2252344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi0zLTEtMS0w_470c1b4d-5e27-4eb8-b088-f27ab8ea9bf2"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfMi01LTEtMS0w_366e9af5-b3f5-4fb4-a8ac-794f0b583f91">P5Y10M24D</rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNC0xLTEtMS0w_0df79c49-b15d-415a-9d5b-4574def2f679"
      unitRef="shares">440026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNC0zLTEtMS0w_ce1a9afa-bf79-4fad-afac-b5254775c578"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNS0xLTEtMS0w_0dbba6bf-f705-49b8-a0de-bbbb6e0a9cf8"
      unitRef="shares">4090150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNS0zLTEtMS0w_059ed9c7-5675-4397-84f7-d0734cd219e2"
      unitRef="usdPerShare">8.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi0xLTEtMS0w_f3b08667-1c6c-4660-b970-7115305f0318"
      unitRef="shares">5932192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi0zLTEtMS0w_364cc3b2-9e4c-4339-9b17-e9f385cba294"
      unitRef="usdPerShare">4.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi01LTEtMS0w_fb5c8108-6d3b-4100-9a52-90652ae121c1">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfNi03LTEtMS0w_03d05237-bd5e-4a7f-a1e7-992a73733e5f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC0xLTEtMS0w_ababc750-5923-40fc-a4ef-2ae4e2759181"
      unitRef="shares">2889218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC0zLTEtMS0w_a017e088-1ab9-4f3e-a16e-95a6970ccc90"
      unitRef="usdPerShare">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC01LTEtMS0w_3d7bc692-c303-449c-8b4d-10a8a7070938">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOjE0OGQ0NjAwMTRmNTQzZGNhOTBmY2MzMmNiMDAzOWM4L3RhYmxlcmFuZ2U6MTQ4ZDQ2MDAxNGY1NDNkY2E5MGZjYzMyY2IwMDM5YzhfOC03LTEtMS0w_5f480627-303a-4131-b06c-16a5b977df62"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS0xLTEtMS0w_6e0beb0b-0dfe-4581-85a9-2a0d75e45348"
      unitRef="shares">7856480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS0zLTEtMS0w_5dac6ee1-438b-41f4-9b18-ab6bc79df4ff"
      unitRef="usdPerShare">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i744dc4048e2e4f8794db00508bd3d7b5_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS01LTEtMS0w_029b06d3-85e1-46fb-a5d7-fac955ef0c12">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaf0c59b5ae8b4441b2399d2ffc377457_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMS03LTEtMS0w_7e29256d-6d31-49d2-8683-625f4970cb3f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi0xLTEtMS0w_9efef392-3015-4f62-a408-607e92ccfa0c"
      unitRef="shares">576477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi0zLTEtMS0w_3864bec3-ceda-46ab-81bf-6bf6e99388d1"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi01LTEtMS0w_28ac9a87-beaa-4657-80d8-0ea0d8428287">P9Y8M12D</rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMi03LTEtMS0w_ff88d8ae-3842-409c-8809-90ecda2a0637"
      unitRef="usd">12074</rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMy0xLTEtMS0w_bbb7cd79-bae7-44d1-8b83-718dc1ebd1f9"
      unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfMy0zLTEtMS0w_bb229b84-46e4-4958-aa95-1711fafdc074"
      unitRef="usdPerShare">4.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNC0xLTEtMS0w_bb1dd0ed-6e3c-4afa-9275-99b9865ff156"
      unitRef="shares">620700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNC0zLTEtMS0w_022ce076-77ee-4c4b-8cb4-2e532c980582"
      unitRef="usdPerShare">6.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS0xLTEtMS0w_a6ba9e59-6631-4d0a-8faa-b8a930d37813"
      unitRef="shares">7782257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS0zLTEtMS0w_ed11ea6b-de10-484a-9910-03361689949d"
      unitRef="usdPerShare">7.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS01LTEtMS0w_7a3abbe1-46a5-4604-a262-e335301864c9">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNS03LTEtMS0w_9a4b04e6-04b7-44e5-9df6-d501780e7ab0"
      unitRef="usd">12074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy0xLTEtMS0w_e828aaf6-6284-440e-9763-94b2054c5f32"
      unitRef="shares">6340901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy0zLTEtMS0w_640203e0-34a7-4b03-9863-fe941c3bfa6e"
      unitRef="usdPerShare">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy01LTEtMS0w_751fd433-244c-42fc-8808-b847ffdefeef">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7b33a9d825ac4f1abca98c67b705a726_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmQxNjRmZWIxODcxMTRiNzM4ZWY4MmNlZDlmYWQwZWYzL3RhYmxlcmFuZ2U6ZDE2NGZlYjE4NzExNGI3MzhlZjgyY2VkOWZhZDBlZjNfNy03LTEtMS0w_ace568a3-6457-4749-b5f4-6a3fab779eed"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6cc0b7d956b44d84a62ad0c4ec9b6942_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTQ5NzU1ODE0NDc0OQ_d71081b6-b911-4e88-833c-56b0a8fd6a3e"
      unitRef="shares">2252344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTQ5NzU1ODE0NDc1OA_f6f79efb-ae06-4d0f-9a85-b299e924d2a0"
      unitRef="shares">440026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i36bdb27bd14841a79473cdae6887c3d5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzU1Nw_11397310-db49-4a17-b69f-e7501521de7a"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzU2NA_ef744c44-92a6-430a-a46a-83f1f082ec00"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8bed0742ec8d413ba1a547ab4b5e0d71_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzY4OQ_9ed9ca9a-f981-49ff-b55f-6d0fac155734"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7d83a9860cb43d9851e6e57f67a68ad_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzY5Ng_d52953f8-761d-40e4-b021-1391e3e4da42"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if1fe840a7dd542c2836bd0373f092156_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzg1OQ_105b91c2-fa9b-4207-853f-1a3738dc22eb"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMzI5ODUzNDg4ODc0OA_2b8a5683-ef09-4487-a69d-832285f24ad9">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaed2b90c22864608b60a3b3225ad1530_D20200417-20200417"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDAxMw_f899a692-c439-4b41-9c08-b2afa6c238ac"
      unitRef="shares">129375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6bb2ee2e447941fdb9ab2c2d6386827c_D20200703-20200703"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfMjc0ODc3OTA3NTUwMg_842ce612-b858-4aab-a406-c5438be9607e"
      unitRef="shares">222222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures
      contextRef="i40d39c6c2580451195d91bed252a4a52_D20200417-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDIwOA_654f2d0d-38a5-4d17-909a-ea97915e45e2"
      unitRef="usd">500000</rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i885bcca89a364caf8262446d9b98366c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDI2OQ_b1ccd4a3-6cfd-4b9d-8cde-f1a8ce776eb7"
      unitRef="shares">3783335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMyMQ_010e1f07-0f9d-4fe2-a19e-af321812ef2c">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the performance-based stock options for the nine months ended September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the performance-based stock options for the nine months ended September&#160;30, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;388,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i72f1121abfa849c8b1387a55992b3591_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMS0xLTEtMS0w_3c3e8eb2-c69d-4284-8261-b349d5c63c9a"
      unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i72f1121abfa849c8b1387a55992b3591_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMS0zLTEtMS0w_7ac6d377-0141-402a-ac9d-5d392ae717e6"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMi0xLTEtMS0w_e40d5da4-2d8c-45d9-88f7-5c7560d654cb"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMi0zLTEtMS0w_59d03fbc-9777-4977-b4d8-8fb5e0e0a826"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMy0xLTEtMS0w_aee061fb-f9c0-4429-a5b8-43d2d92c897a"
      unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfMy0zLTEtMS0w_e985067d-a597-4aab-ab9e-0011fe09a1e2"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNC0xLTEtMS0w_e42e8a59-56aa-4c04-b9c4-966574e988a8"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNC0zLTEtMS0w_b6fc9cb0-3945-44ef-8529-5a159f7454d8"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNi0xLTEtMS0w_5730d421-edde-43d5-b615-cf6235d75140"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmY5MDMyMjU4ZWI2NDQ1MzQ5MmZhZGZkZGIxYzQyZTlmL3RhYmxlcmFuZ2U6ZjkwMzIyNThlYjY0NDUzNDkyZmFkZmRkYjFjNDJlOWZfNi0zLTEtMS0w_120bc48a-61dc-4708-9d0e-6c8534e92a88"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMS0xLTEtMS0w_e6b03449-a525-432b-a4a7-35ef392593cc"
      unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1345b728324d45fcb1dd3f4e4d71e9f5_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMS0zLTEtMS0w_afdf57fe-169e-4488-8952-983b6369653b"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMi0xLTEtMS0w_a24198e6-b671-4e32-a8c7-77d07f9972a0"
      unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfMi0zLTEtMS0w_7026dd80-5a85-41aa-81de-b534af24b6c8"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfNC0xLTEtMS0w_0a7e1d90-00e8-4fed-a5fe-f7d5c5cdf470"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4ccfec62c27a4c9cae7a78d6d2309e31_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RhYmxlOmE3ZjJkOTBjZWYyYzRjOTJiNDExYjQwZTcxZWVkMmIxL3RhYmxlcmFuZ2U6YTdmMmQ5MGNlZjJjNGM5MmI0MTFiNDBlNzFlZWQyYjFfNC0zLTEtMS0w_ecc8465a-2757-4ccf-b27d-0e1b516fcdca"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd2601e9c7834d66bc6c432adcb277ed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDc4NA_0f0cae9e-1a56-44d5-ae62-9439123c3f9d"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50187dcaa1944e2d9479afde0ff9e75b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDc5MQ_fcc8cdde-5de3-4fad-906a-2867a7d5acce"
      unitRef="usd">-400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5024321720ba4835b96c782b82b00ec5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDkwNg_5fe76d11-f978-4df9-8ffe-1a8c49148a97"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i794e49a2818a48d49d50cdb0162e5f95_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNDkxMw_cd6d24c1-2d1b-4ce3-9d86-bfcf8fcca078"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2b9db72d78c14bd0bafdf4d133155def_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTA3NA_abb53d11-940e-4648-9d20-561a7a5bedd3"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTEzNg_b1195cd6-ca56-4b2f-bcf6-feae2be293ad"
      unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures
      contextRef="i6faeb91362c743a2933125800dfc9ae9_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84Mi9mcmFnOjk3Njc4NTczY2M4MTRmNTViOTc5NTVkOGViM2Y4NDg3L3RleHRyZWdpb246OTc2Nzg1NzNjYzgxNGY1NWI5Nzk1NWQ4ZWIzZjg0ODdfNTMxNA_4e44bbbc-d47c-476b-afd9-bc9b1939d36f"
      unitRef="usd">700000</rmti:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjMxMA_e4c5b834-c324-424d-9d7d-246358d16754">Related Party Transactions&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic&#xae; product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the &#x201c;Charak MSA&#x201d;) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (&#x201c;SFP&#x201d;) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December&#160;31, 2019. As of September&#160;30, 2020, the Company has fulfilled its reimbursement obligation of certain legal expenses and accrued $0.1 million relating to certain IP reimbursement expenses and certain sublicense royalty fees as a related party payable on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the &#x201c;Charak Amendment&#x201d;), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company&#x2019;s Triferic&#xae; product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic&#xae; (now Triferic AVNU), dated as of October 7, 2018 (the &#x201c;IV Agreement&#x201d;), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic&#xae;, dated as of October 7, 2018 (the &#x201c;TPN Agreement&#x201d;), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN&#x201d;) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 805)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Clarifying the Definition of a Business,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company&#x2019;s statement of operations for the year ended December&#160;31, 2018. In addition, because the potential milestone payments are not yet considered probable, no milestone payments have been accrued at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <rmti:NumberOfAdditionalAgreements
      contextRef="i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNTY2_47a1f954-b59a-4c28-a472-ee388bbad32b"
      unitRef="agreement">3</rmti:NumberOfAdditionalAgreements>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i8b2db876957c441ca0969f774801ddfa_I20181007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODEx_72d4d4f5-5121-4e83-9065-75b6afafc799"
      unitRef="usd">1000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <rmti:RelatedPartyNumberOfInstallmentPayments
      contextRef="i2362cb7d4e704216966ce8696c3475f7_D20181007-20181007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODM5_0000b8f7-fb79-4bcc-bbf8-9a074b38ff32"
      unitRef="installment">4</rmti:RelatedPartyNumberOfInstallmentPayments>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i759a54d69ef1425aa8087f8817c5243c_I20181015"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_5a0a84a5-2a68-4686-8c34-505af79cca4b"
      unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i2cc86daf3763428e93f171eb558edf4a_I20190115"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_7a73458c-626d-4e94-a4ac-ca7b5ad7c760"
      unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i9b5fafdd17b044d38ca4687c5c170b5b_I20190715"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_c7928de6-39bf-4306-b350-395753265c8c"
      unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="id6a755fb188b4af39fd3307f039573d2_I20190415"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfODY4_d25232a2-4675-42f3-b427-d84055d92eaf"
      unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <rmti:InstallmentPaymentToRelatedParties
      contextRef="i79757255bddd4b608922f96cd3af93ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTIyNg_ce96be25-2cb5-436f-8c35-d82a155bf926"
      unitRef="usd">1000000.0</rmti:InstallmentPaymentToRelatedParties>
    <rmti:RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses
      contextRef="i79863bdc8a984b328ab874faf1c4b1cf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTI0MQ_603cdcd2-8a26-4e99-aa5f-a545c1204885"
      unitRef="usd">100000</rmti:RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses>
    <rmti:RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfMTQ4Ng_3629f0e0-57b7-440d-bfc7-e8fcd5bdbad6"
      unitRef="usd">100000</rmti:RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees>
    <rmti:PaymentsToAcquireAssets
      contextRef="i5b7cf56169344015943de2cc62f7eab3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjA0NA_5fe92358-e13e-43ac-82a5-e5ebf723d3ce"
      unitRef="usd">1100000</rmti:PaymentsToAcquireAssets>
    <rmti:AssetAcquisitionMilestonePayments
      contextRef="ic2985ad7b6c3459abea9cf473c3ffba0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF84OC9mcmFnOjYxNTgxZTJhNWMzNjQzYjZiOWI2NjM5Y2Y3ZDQ3ODI2L3RleHRyZWdpb246NjE1ODFlMmE1YzM2NDNiNmI5YjY2MzljZjdkNDc4MjZfNjI2NQ_ca7baad7-7649-4dfe-826c-fee39cb5a675"
      unitRef="usd">0</rmti:AssetAcquisitionMilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwNg_086cfe09-cf80-4748-87f2-1a76cf7ddf4f">Leases&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to five years. We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a 57,000 square foot facility in Greer, South Carolina&#160;under a lease expiring February 2023. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021. Finally, we executed a lease for 4,100 square feet of office space in Hackensack, New Jersey with a lease term beginning on April 1, 2019 and expiring on July 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the Company had operating lease liabilities of $2.2 million and right-of-use assets of $2.1 million, which are included in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes quantitative information about the Company&#x2019;s operating leases (table in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total rent expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use assets exchanged for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2020 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idfd4514ac70647b48f7ba3276ef1d345_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjUy_426c0274-915a-49be-9228-bce9a9007330">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i3145caf8d4884ddf8790d54cebdc6132_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjY4_751161ca-8295-436b-9934-bfd05b6d920b"
      unitRef="sqft">51000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="iffda10ef89254fc8b784470695ac1a39_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMjk4_f9d81c50-0beb-43e5-a04c-39ae74d5209c"
      unitRef="sqft">17500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1a68746f2fdd4216add87ba69b052f3f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNDMz_4af7097d-6590-44c5-b3d8-c2bd1c6ece38"
      unitRef="sqft">51000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="idc4ac606416e4e319806c6b97ba5e4a9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNTI0_65826efa-a38f-4f2b-a801-3e276aa12ea1"
      unitRef="sqft">57000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="if68138705a9e4ae8b0ad29ba0248671c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNjM2_2d8b69ab-1b78-4da6-9996-cde6d619bc82"
      unitRef="sqft">1408</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i656a4eb3707c4c909af7978cd89b8b65_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfNzYx_e77e2545-6b20-45ca-afdf-de36a8d135ea"
      unitRef="sqft">4100</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfOTQ3_4dc00ebf-dfee-459a-8d7d-f1c60f468747"
      unitRef="usd">2200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfOTc3_27bdb151-9b39-4127-91f9-b354f6e8a6b4"
      unitRef="usd">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwNw_f1e769bf-a3c0-4bf2-99d6-bc370738cf24">The following summarizes quantitative information about the Company&#x2019;s operating leases (table in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total rent expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use assets exchanged for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi0xLTEtMS0w_d3f971c2-dc2a-49af-b6cd-36abdd664522"
      unitRef="usd">382000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi0zLTEtMS0w_09c64a32-90b4-4cc0-8634-0d5bd9d30526"
      unitRef="usd">532000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi01LTEtMS0w_12f4f8ab-2484-4513-bbc5-89c0a8ae8214"
      unitRef="usd">1228000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMi03LTEtMS0w_27411385-e248-4257-8eab-8d8b9673d73e"
      unitRef="usd">1592000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy0xLTEtMS0w_00dfb168-2a53-42e8-abe5-597fad0baa9d"
      unitRef="usd">90000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy0zLTEtMS0w_921fe085-e380-4469-97fc-9aea2b68b1cf"
      unitRef="usd">90000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy01LTEtMS0w_b158b5a5-5d16-40a3-bdad-ec2709e475ee"
      unitRef="usd">403000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMy03LTEtMS0w_4eff18d4-eafc-4ad4-83aa-910ed0be653c"
      unitRef="usd">258000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC0xLTEtMS0w_6b521346-055b-4c5d-bffb-421fda3499e0"
      unitRef="usd">472000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC0zLTEtMS0w_36faafbe-e60c-4a31-b41f-814f990e6762"
      unitRef="usd">622000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC01LTEtMS0w_541072ad-4edf-47e8-9c03-bf2d5ed13b3f"
      unitRef="usd">1631000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNC03LTEtMS0w_98b824ba-e24d-4a80-a099-6e027482830a"
      unitRef="usd">1850000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS0xLTEtMS0w_d8f80754-13de-4040-a250-150bf69dc58b"
      unitRef="usd">4000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS0zLTEtMS0w_430b86c6-435f-4fb1-a93c-b34fd982bdb2"
      unitRef="usd">4000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS01LTEtMS0w_2db5ed2d-e0ca-4dc9-8f49-e571f250cf67"
      unitRef="usd">12000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNS03LTEtMS0w_b82c6aef-f9d3-4898-999c-e1bf4dc6b755"
      unitRef="usd">12000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi0xLTEtMS0w_2b8d546f-7c8e-4cc4-aaee-031e245336b9"
      unitRef="usd">476000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi0zLTEtMS0w_c8c977c0-19f9-43af-b81d-f478be6df67f"
      unitRef="usd">626000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi01LTEtMS0w_f652673e-a003-43c0-aa08-7b78cd843266"
      unitRef="usd">1643000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfNi03LTEtMS0w_240997dc-e2c7-4f62-abe1-913550af995b"
      unitRef="usd">1862000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS0xLTEtMS0w_deb64223-f1c2-4884-a8aa-fd2a5ff8534a"
      unitRef="usd">393000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS0zLTEtMS0w_ca9452ad-4290-4dda-a024-cbb1f203d4e7"
      unitRef="usd">494000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS01LTEtMS0w_ff03bf99-9881-4d7e-b209-f7fbdcf035cd"
      unitRef="usd">1248000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfOS03LTEtMS0w_227ab767-68a9-44b8-8e3f-f68788ea52e1"
      unitRef="usd">1532000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iad39fc18340148d88260925cf2c71125_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtMS0xLTEtMA_33096f18-53d4-4920-931b-bd22cb514d60"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6e19831abc4544cd96182cc983c0b02c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtMy0xLTEtMA_51a094ac-3060-4151-99db-fa1d160f75fa"
      unitRef="usd">136000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtNS0xLTEtMA_97f9e0fb-394c-4e8a-bcde-cb73fd661698"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTAtNy0xLTEtMA_de8f8823-2d3f-4dc0-86c2-37d6e53a4179"
      unitRef="usd">4442000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtMS0xLTEtMA_758556e1-c65b-4ff2-96e4-258561df0727">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtMy0xLTEtMA_27e375ab-90b2-469a-bf58-8553003df2f1">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtNS0xLTEtMA_44a24fba-d12d-4724-bb80-b599fa1d2f04">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTEtNy0xLTEtMA_14762af6-2b92-4679-9e84-ebc58d30b53f">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItMS0xLTEtMA_f9231bd7-82d5-4a1b-be5f-4ed566852d9b"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItMy0xLTEtMA_ef2b8229-60fb-45e6-8f8c-c2b2081d6a5a"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItNS0xLTEtMA_a77ed023-b68d-4b44-81bd-4436095b41a4"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4ee3fe18e28745aeb5fe98bfdc9fdba5_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmViMWUxOGRlYjdiZjQzNDA4ZTViMjBkMjJkZmUzNTgwL3RhYmxlcmFuZ2U6ZWIxZTE4ZGViN2JmNDM0MDhlNWIyMGQyMmRmZTM1ODBfMTItNy0xLTEtMA_7edc41e2-117d-4d63-87f2-a151cc83fa26"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RleHRyZWdpb246MTgxZWRiYTgxMGNjNDNmOWIyMDcwYzdiYTQzMjYxZmNfMTIwOA_d3613aa3-cfc8-4624-ba2a-2fb3887cb1eb">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2020 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMC0xLTEtMS0w_3b31f111-7949-43b9-9867-7bc7db762c8d"
      unitRef="usd">387000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMS0xLTEtMS0w_28f6ef6f-468c-426b-be21-a70cad7a0b23"
      unitRef="usd">1055000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMi0xLTEtMS0w_359c5e2d-3169-4cc8-b156-a197a046311f"
      unitRef="usd">592000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfMy0xLTEtMS0w_2e041719-033b-43b5-be5c-d96cc3707103"
      unitRef="usd">234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNC0xLTEtMS0w_c8fc04e7-d38b-4530-b2c4-230a0efa1ebb"
      unitRef="usd">98000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNi0xLTEtMS0w_5bcc2c45-39cb-4101-8427-cbc80bbf0ceb"
      unitRef="usd">2366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfNy0xLTEtMS0w_17e465a7-3e01-404d-8582-325d5cd3d666"
      unitRef="usd">172000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85NC9mcmFnOjE4MWVkYmE4MTBjYzQzZjliMjA3MGM3YmE0MzI2MWZjL3RhYmxlOmMzZTYwZjgyOGY3YjQyMzZiNGNiNWE2NGRiYWE4MDc4L3RhYmxlcmFuZ2U6YzNlNjBmODI4ZjdiNDIzNmI0Y2I1YTY0ZGJhYTgwNzhfOC0xLTEtMS0w_3face530-b544-400b-9599-ba3bdfc320b9"
      unitRef="usd">2194000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNzk1NA_188d8371-310b-4eaa-b792-1ddfe80696f5">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Demand Notice&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015.&#160; The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested&#160;$3.0 million&#160;in penalties, plus payment of the cost for certain raw materials.&#160;While the Company believed&#160; it had several defenses to the supplier's claim, the Company and the supplier negotiated an amicable resolution of the dispute.&#160; On July 31, 2020, the Company and the supplier entered into a settlement agreement, which released the Company from any penalties relating to annual minimums under the 2015 agreement, established new minimums under an amended supply agreement and required the Company to pay for certain raw materials with 50% of the cost to be paid upon execution of the settlement agreement and the remaining 50% to be paid no later than December 31, 2020. As of September 30, 2020, the Company has purchased 50% of the required raw materials under the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company&#x2019;s&#160;quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the status of the Company&#x2019;s request to the Centers for Medicare &amp;amp; Medicaid Services (the "CMS") for separate reimbursement status for Triferic Dialysate, the Company&#x2019;s reserving methodology for expiring Triferic inventory, and the basis for the Board&#x2019;s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC&#x2019;s requests for documents and information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shareholder Class Action Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company&#x2019;s drug, Triferic, to quality for separate reimbursement status by the CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company&#x2019;s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company&#x2019;s proposal for separate reimbursement for Triferic; misstated reserves in the Company&#x2019;s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company&#x2019;s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company&#x2019;s business were&#160;materially false and misleading.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ah Kit Too v. Rockwell&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;securities class action with the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spock v. Rockwell&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;securities class action.&#160; On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel.&#160; On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company&#x2019;s securities between November 8, 2017 and June 26, 2018.&#160;&#160;On February 18, 2019, the Company answered the consolidated amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action.&#160;&#160;Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the &#x201c;Settlement Amount") in exchange for a full release of all liability as to all defendants.&#160;This resulted in a settlement expense of approximately&#160;$0.4 million&#160;for the year ended&#160;December&#160;31, 2019. Of the Settlement Amount, the Company contributed approximately $0.1 million, which represented the remaining retention amount under the Company&#x2019;s director and officer liability insurance policy as of September&#160;30, 2020. The remainder of the settlement amount was funded by the Company&#x2019;s director and officer insurance carrier. The settlement was approved by the court on February 26, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shareholder Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the &#x201c;Derivative Complaints&#x201d;) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company&#x2019;s current and former directors (the &#x201c;Individual Defendants&#x201d;).&#160; The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.&#160; The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls.&#160; The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors&#x2019; trading activities, restitution, and attorneys&#x2019; fees. &#160;The cases were consolidated.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. On May 18, 2020, the Company, the Individual Defendants and the Plaintiffs (the "Settling Parties") entered into a formal Stipulation of Settlement, which memorializes the terms of the Settling Parties' settlement of the Derivative Complaints.  A hearing occurred before the court on August 10, 2020 and the court issued a final order approving the settlement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's director and officer insurance carrier has funded the settlement  on behalf of the Company.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfMzA4_ba1388aa-21a0-4ce8-b963-2bb5cc94c9f0"
      unitRef="usd">3000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid
      contextRef="id7bf20809ab9443ebd612edde24ebe08_D20200731-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfODYz_b96f333f-9bca-4ca8-815c-285c9b9456f1"
      unitRef="number">0.50</rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid>
    <rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid
      contextRef="i1d16d753feea42379fc36a6fc4802303_D20200801-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfOTUw_88bda84c-8d5c-4710-ae13-442414b5a989"
      unitRef="number">0.50</rmti:SupplyAgreementPercentageOfRawMaterialsToBePaid>
    <rmti:SupplyAgreementPercentageOfRawMaterialsPaid
      contextRef="ibfa2ec5c25ac44e496b725edbf06211d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfMjc0ODc3OTA3NzcxOA_abcf0799-3b5d-4ab7-92e1-b95c1924461c"
      unitRef="number">0.50</rmti:SupplyAgreementPercentageOfRawMaterialsPaid>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic43d3fec43e04417ac3e08e63a74b5a6_D20190807-20190807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNDc5NQ_eca07ff5-4c5e-4ced-8185-c00f43f00bc9"
      unitRef="usd">3700000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia36da30ff01749b28487000f6715ba77_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNDk0OQ_1465c7af-e31b-4f6c-b18c-e5f200422e5e"
      unitRef="usd">400000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i71d9fbef3e73446cbd0ee3d7923afae2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF85Ny9mcmFnOjQ2MDljMTNkNTMxYTQ4ZjM5NzY2NjU1ZmFjZjYyYWNlL3RleHRyZWdpb246NDYwOWMxM2Q1MzFhNDhmMzk3NjY2NTVmYWNmNjJhY2VfNTA1NA_41385c44-37a0-4316-8aae-464e09921f30"
      unitRef="usd">100000</us-gaap:LitigationSettlementExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM4OTg_4f1136d0-7cdf-45ca-a2af-99645901faa0">Loan and Security Agreement&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three and nine months ended September&#160;30, 2020, interest expense amounted to $0.7 million and $1.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity. As of&#160;September&#160;30, 2020, the Company is in compliance with all the reporting and financial covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#x201c;Warrants&#x201d;) to purchase a number of shares of the Company&#x2019;s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#x2019;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company&#x2019;s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company&#x2019;s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5&#160;million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;September&#160;30, 2020, the outstanding balance of the Term Loan was&#160;$20.9 million, net of unamortized issuance costs and unaccreted discount of&#160;$1.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the schedule of principal payments on the Term Loan as of&#160;September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzQzMg_a828bd05-e505-426a-9434-2a58acc3f4c7"
      unitRef="usd">35000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i74badfe283474cd495162707af80f4c0_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzQ3Ng_96f87b04-374e-4a68-8065-badd23cdeb73"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i550d13f16af14526aa4aba8c018e3653_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzU4MA_f1f73619-3106-4cf6-a43c-7cf7ac8f88f4"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3bca046ce7d4f19a430c177d2515e64_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzc2Ng_42e541ce-dc8a-43bd-a33c-c0efb3881d27"
      unitRef="usd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzkxNg_51e2ddf0-01ae-4e4d-8b9c-132600214b66"
      unitRef="usd">21200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ia6763c2ab917428aa25d81bd49a0bb78_D20200316-20200316"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzk0MQ_ba6a714e-ecdf-49ce-bdfb-5e0a78e29771"
      unitRef="usd">1300000</us-gaap:PaymentsOfFinancingCosts>
    <rmti:DebtInstrumentPeriodOfInterestOnlyPayments
      contextRef="ied6c0e6eb376449797262cd45e197f26_D20200316-20200316"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEwMDc_6b3e6642-e85d-480e-b653-b60c83879441">P30M</rmti:DebtInstrumentPeriodOfInterestOnlyPayments>
    <rmti:DebtInstrumentPeriodOfInterestOnlyPayments
      contextRef="iaa2795cf61054796b20b23bef364d55e_D20200316-20200316"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEwMjA_5073867e-b6b3-4b52-86c4-36972f872b90">P36M</rmti:DebtInstrumentPeriodOfInterestOnlyPayments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyMDA_daafe7f9-48c2-4ead-8f7c-e0691e265196"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyMDk_b435670d-6901-464d-984a-864a9b582dfe"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyNDU_a7ce2f0e-7f2b-4dfc-bed1-b7ded2bc64fa"
      unitRef="number">0.0875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEyOTI_e13d9c82-55dc-4e62-a592-d07b46f2886e"
      unitRef="number">0.109</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage
      contextRef="i918e1ec310cd4501850ee5a1d190849e_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzEzNjA_530ed2c8-8476-4c4e-b9ce-7fa10790e193"
      unitRef="number">0.0100</rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i7ad74bef55824ee587591169cd823d18_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzYwNDczMTM5NTY3MTU_285ea13a-8d0d-45cf-992d-ea861d141bc9"
      unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id21bb6146027445a9e33a3043534e284_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzE2MzE_0ac40b8f-1933-426e-b150-1abfb857acae"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded
      contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI0NDg_a9703c63-cd1a-4efb-b94a-b8e9a1e9d4be"
      unitRef="number">0.035</rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded>
    <rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays
      contextRef="ie32a28ad9a814d2ca356e019fe021461_D20200316-20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI2NTI_235551a4-bdbb-4393-a812-35ac5ba10ae9"
      unitRef="day">5</rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic5bb31ec7a444c18904dfe090598b734_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI5MzQ_11a29178-a735-4414-8ea7-b52242c20f3c"
      unitRef="usdPerShare">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays
      contextRef="i99be750d121e4bba9049423b4facb83d_D20200316-20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzMwMjg_4513e475-f891-4221-8897-b4343d9a53c9"
      unitRef="day">5</rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i74badfe283474cd495162707af80f4c0_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM2MDA_54a87674-f085-4351-b71c-e0bdd70676cb"
      unitRef="shares">477273</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i74badfe283474cd495162707af80f4c0_I20200316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM2NjQ_35b4af24-fdd7-4446-99a8-23e29bdf8f9c"
      unitRef="usdPerShare">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i74badfe283474cd495162707af80f4c0_I20200316"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzI3NDg3NzkwODUyODE_bfd51b0d-ee38-4742-9cb7-c9e0f46d477a"
      unitRef="usd">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM3MzQ_1ca45d31-4a2a-4201-9519-64241ae4bb49"
      unitRef="usd">20900000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM3OTk_e586739a-7d17-43e1-89e4-7b17830a5702"
      unitRef="usd">1600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90ZXh0cmVnaW9uOjk1MTFkMTBjNmY2NTQyMWZiNDczZDg4ZjAyNjYwYzkxXzM4OTk_5cc6d0c1-f392-490e-9065-fd02adb59e1b">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the schedule of principal payments on the Term Loan as of&#160;September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ccffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzEtMS0xLTEtMA_39f79192-b167-4a4d-8303-7d8c0fefc97e"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzItMS0xLTEtMA_0b8ac8f7-b86c-4921-88cd-00ca4f23137b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzMtMS0xLTEtMA_38c032ff-fec3-44e6-bd7e-cf20056d1c04"
      unitRef="usd">2250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzQtMS0xLTEtMA_f54bea8b-94de-4e58-8dcd-4d7ae23f968b"
      unitRef="usd">9000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzUtMS0xLTEtMA_3797c983-6d2f-4f82-b6c5-dbc6c79d05ae"
      unitRef="usd">9000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzYtMS0xLTEtMA_66c31dde-58a4-47ba-9c72-f52b8783f9dc"
      unitRef="usd">2250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia2342dabfb994ca9b8cabed424b37ce7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0M2MxMTdkMDlkZTRmZjI4OWMxMDI5YTc3YzkyM2U0L3NlYzpmNDNjMTE3ZDA5ZGU0ZmYyODljMTAyOWE3N2M5MjNlNF8xMDAvZnJhZzo5NTExZDEwYzZmNjU0MjFmYjQ3M2Q4OGYwMjY2MGM5MS90YWJsZTphODIwMjdhNDM3OTQ0NGExYmVlOWViYWY5NTIxOThjZC90YWJsZXJhbmdlOmE4MjAyN2E0Mzc5NDQ0YTFiZWU5ZWJhZjk1MjE5OGNkXzctMS0xLTEtMA_e791ed95-4090-432b-aec5-7a6956971a43"
      unitRef="usd">22500000</us-gaap:DebtInstrumentCarryingAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280948408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142 S. Wixom Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">411 Hackensack Avenue, Suite 501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281112472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 56,614<span></span>
</td>
<td class="nump">$ 11,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments Available-for-Sale</a></td>
<td class="nump">10,702<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">4,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and Other Current Assets</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">77,943<span></span>
</td>
<td class="nump">36,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Non-Current</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of Use Assets, net</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Non-Current Assets</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">85,236<span></span>
</td>
<td class="nump">44,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">4,190<span></span>
</td>
<td class="nump">3,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities</a></td>
<td class="nump">4,968<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Settlement Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease Liability - Current</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred License Revenue - Current</a></td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Insurance Financing Note Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Customer Deposits</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other Current Liability - Related Party</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">12,708<span></span>
</td>
<td class="nump">12,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease Liability - Long-Term</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term Loan, Net of Issuance Costs</a></td>
<td class="nump">20,856<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred License Revenue - Long-Term</a></td>
<td class="nump">8,558<span></span>
</td>
<td class="nump">9,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">43,161<span></span>
</td>
<td class="nump">23,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,573,165 and 65,378,890 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">370,760<span></span>
</td>
<td class="nump">326,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(328,743)<span></span>
</td>
<td class="num">(306,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">42,075<span></span>
</td>
<td class="nump">20,320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 85,236<span></span>
</td>
<td class="nump">$ 44,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118944142&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280389960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">170,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280531096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Sales</a></td>
<td class="nump">$ 15,280<span></span>
</td>
<td class="nump">$ 15,407<span></span>
</td>
<td class="nump">$ 47,033<span></span>
</td>
<td class="nump">$ 45,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">14,934<span></span>
</td>
<td class="nump">15,424<span></span>
</td>
<td class="nump">44,693<span></span>
</td>
<td class="nump">44,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">346<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and Marketing</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">5,738<span></span>
</td>
<td class="nump">7,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">3,622<span></span>
</td>
<td class="nump">4,623<span></span>
</td>
<td class="nump">11,767<span></span>
</td>
<td class="nump">16,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Product Development</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">5,183<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(6,690)<span></span>
</td>
<td class="num">(7,942)<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
<td class="num">(27,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized Gain on Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant Modification Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">(666)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest Income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="num">(660)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(1,879)<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (7,350)<span></span>
</td>
<td class="num">$ (7,855)<span></span>
</td>
<td class="num">$ (22,227)<span></span>
</td>
<td class="num">$ (26,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (120)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
<td class="num">$ (450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">71,811,322,000<span></span>
</td>
<td class="nump">63,796,723,000<span></span>
</td>
<td class="nump">69,594,167,000<span></span>
</td>
<td class="nump">59,728,446,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281229528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (7,350)<span></span>
</td>
<td class="num">$ (7,855)<span></span>
</td>
<td class="num">$ (22,227)<span></span>
</td>
<td class="num">$ (26,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (7,347)<span></span>
</td>
<td class="num">$ (7,850)<span></span>
</td>
<td class="num">$ (22,230)<span></span>
</td>
<td class="num">$ (26,817)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139200394568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
<th class="th"><div>ACCUMULATED OTHER COMPREHENSIVE INCOME</div></th>
<th class="th"><div>Public offering</div></th>
<th class="th">
<div>Public offering </div>
<div>COMMON STOCK</div>
</th>
<th class="th">
<div>Public offering </div>
<div>ADDITIONAL PAID-IN CAPITAL</div>
</th>
<th class="th"><div>At-the-market offering</div></th>
<th class="th">
<div>At-the-market offering </div>
<div>COMMON STOCK</div>
</th>
<th class="th">
<div>At-the-market offering </div>
<div>ADDITIONAL PAID-IN CAPITAL</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,034,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 27,277<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 299,596<span></span>
</td>
<td class="num">$ (272,388)<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(8,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="num">(95)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Exercise of Employee Stock Options, Net of Tax</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,128,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Mar. 31, 2019</a></td>
<td class="nump">20,161<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">301,166<span></span>
</td>
<td class="num">(281,067)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,034,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">27,277<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">299,596<span></span>
</td>
<td class="num">(272,388)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(26,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,887,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Sep. 30, 2019</a></td>
<td class="nump">23,702<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">322,837<span></span>
</td>
<td class="num">(299,214)<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,034,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 27,277<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">299,596<span></span>
</td>
<td class="num">(272,388)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,840,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">65,378,890<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,320<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">326,777<span></span>
</td>
<td class="num">(306,516)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,128,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">20,161<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">301,166<span></span>
</td>
<td class="num">(281,067)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(10,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,120<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,120<span></span>
</td>
<td class="nump">$ 2,089<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,398,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Jun. 30, 2019</a></td>
<td class="nump">29,592<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">320,877<span></span>
</td>
<td class="num">(291,359)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,887,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Sep. 30, 2019</a></td>
<td class="nump">$ 23,702<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">322,837<span></span>
</td>
<td class="num">(299,214)<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">65,378,890<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,320<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">326,777<span></span>
</td>
<td class="num">(306,516)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,670,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,003<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Warrants related to Debt Financing</a></td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Mar. 31, 2020</a></td>
<td class="nump">$ 21,774<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">336,216<span></span>
</td>
<td class="num">(314,500)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">65,378,890<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,320<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">326,777<span></span>
</td>
<td class="num">(306,516)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(22,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Sep. 30, 2020</a></td>
<td class="nump">$ 42,075<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">370,760<span></span>
</td>
<td class="num">(328,743)<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">21,774<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">336,216<span></span>
</td>
<td class="num">(314,500)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(6,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense', window );">Warrant Modification Expense</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,156,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Jun. 30, 2020</a></td>
<td class="nump">16,211<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">337,551<span></span>
</td>
<td class="num">(321,393)<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Gain (Loss) on Available-for-Sale Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,178,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,677<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 32,675<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">End balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End balance at Sep. 30, 2020</a></td>
<td class="nump">$ 42,075<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 370,760<span></span>
</td>
<td class="num">$ (328,743)<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrant Modification Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281152008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (7,350,000)<span></span>
</td>
<td class="num">$ (7,984,000)<span></span>
</td>
<td class="num">$ (7,855,000)<span></span>
</td>
<td class="num">$ (8,679,000)<span></span>
</td>
<td class="num">$ (22,227,000)<span></span>
</td>
<td class="num">$ (26,826,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,000<span></span>
</td>
<td class="nump">582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276,000)<span></span>
</td>
<td class="nump">3,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant Modification Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Increase in Inventory Reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
<td class="nump">1,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of Right of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090,000<span></span>
</td>
<td class="nump">1,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of Debt Financing Costs and Accretion of Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (Gain) on Disposal of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Realized (Gain) on Sale of Investments Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Assets and Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in Accounts Receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">1,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable', window );">Decrease in Insurance Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) Decrease in Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(953,000)<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in Prepaid and Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">931,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (Decrease) in Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,000<span></span>
</td>
<td class="num">(1,298,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Decrease in Settlement Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,000)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_IncreaseDecreaseInOperatingLeaseLiabilites', window );">Decrease in Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,056,000)<span></span>
</td>
<td class="num">(1,369,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Increase (Decrease) in Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,000<span></span>
</td>
<td class="num">(1,229,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in Deferred License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,338,000)<span></span>
</td>
<td class="num">(1,690,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Changes in Assets and Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,621,000)<span></span>
</td>
<td class="num">(2,281,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash Used In Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,072,000)<span></span>
</td>
<td class="num">(21,954,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of Investments Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,531,000)<span></span>
</td>
<td class="num">(34,202,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of Investments Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,076,000<span></span>
</td>
<td class="nump">30,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchase of Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(970,000)<span></span>
</td>
<td class="num">(449,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchase of Research and Development Licenses (Related Party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash Provided By (Used In) Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="num">(4,922,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,343,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on Short Term Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(763,000)<span></span>
</td>
<td class="num">(763,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the Exercise of Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes', window );">Repurchase of Common Stock to Pay Employee Withholding Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash Provided By Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,317,000<span></span>
</td>
<td class="nump">18,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,820,000<span></span>
</td>
<td class="num">(8,293,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,714,000<span></span>
</td>
<td class="nump">11,794,000<span></span>
</td>
<td class="nump">22,714,000<span></span>
</td>
<td class="nump">$ 22,714,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">$ 56,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,614,000<span></span>
</td>
<td class="nump">14,421,000<span></span>
</td>
<td class="nump">11,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash Paid for Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in Unrealized Loss on Marketable Securities Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAssumed1', window );">Insurance Financing Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair Value of Warrants issued related to Debt Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the Issuance of Common Stock / Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,000<span></span>
</td>
<td class="nump">18,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering Costs from the Issuance of Common Stock / Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,469,000)<span></span>
</td>
<td class="num">(1,488,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the Issuance of Common Stock / Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,478<span></span>
</td>
<td class="nump">2,296,000<span></span>
</td>
<td class="nump">5,383,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering Costs from the Issuance of Common Stock / Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63,000)<span></span>
</td>
<td class="num">$ (207,000)<span></span>
</td>
<td class="num">$ (309,479)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_IncreaseDecreaseInOperatingLeaseLiabilites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_IncreaseDecreaseInOperatingLeaseLiabilites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right Of Use Asset Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of common shares to pay employee withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206195336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. and subsidiaries (collectively, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, or the &#8220;Company&#8221;), is a biopharmaceutical company dedicated to improving outcomes for patients with iron deficiency and iron-deficiency anemia,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate citrate (&#8220;FPC&#8221;) therapeutic platform. The first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients.&#160;We initiated commercial sales of Triferic Dialysate during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. Our lead indication is developing FPC for the treatment of iron deficiency anemia in patients undergoing home infusion therapy. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients&#8217; lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triferic&#174;&#160;is a registered trademark of Rockwell Medical, Inc.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206087928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndFinancialConditionAbstract', window );"><strong>Liquidity and Capital Resources</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndFinancialConditionTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">Liquidity and Capital Resources<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had approximately $56.6 million of cash and cash equivalents, $10.7 million of investments available-for-sale, working capital of $65.2 million and an accumulated deficit of $328.7 million. Net cash used in operating activities for the nine months ended September&#160;30, 2020 was approximately $21.1 million. Management evaluated the Company&#8217;s ability to continue as going concern for at least the next 12 months from the filing of this report. Based on the currently available working capital, capital raise and debt financing described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company sold 3,670,212 shares of its common stock for proceeds of $8.0 million, net of issuance costs. On March 16, 2020, the Company closed a debt financing transaction with net proceeds at closing of approximately $21.2 million, net of fees and expenses (See Note 15 for further detail). On September 23, 2020, the Company sold 23,178,809 shares of its common stock for proceeds of $32.7&#160;million, net of issuance costs (see Note 10 for further detail).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company sold 1,128,608 shares of its common stock as part of its sales agreement with Cantor Fitzgerald &amp; Co. for proceeds of $2.3 million, net of issuance costs. Approximately $32.3 million remains available for sale under this facility. See Note 10 for further detail.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the commercialization of Triferic Dialysate and Triferic AVNU,  executing upon our plans for enhancing Triferic's medical capabilities, generating additional data for Triferic and developing Triferic for new therapeutic indications. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing.&#160;If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company is subject to certain covenants and cure provisions under our Loan Agreement with Innovatus.  As of the date of this report, the Company believes that it will either be able to satisfy such covenants or, in the event of  a breached covenant, exercise cure provisions to avoid an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity (See Note 15 for further detail).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Our international business development activities may also be negatively impacted by COVID-19, especially with the recent surge in infections and resulting quarantines or shelter-in-place orders. Depending on the severity of the impact on our sales and marketing efforts, the timing of our commercial launch of Triferic AVNU could be delayed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, the recent domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndFinancialConditionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndFinancialConditionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndFinancialConditionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity position and financial conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndFinancialConditionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277299800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (&#8220;U.S.&#8221;) of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (&#8220;SEC&#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at September&#160;30, 2020, condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and condensed consolidated statement of changes in shareholder&#8217;s equity for the three and nine months ended September&#160;30, 2020 and 2019 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020 or for any future interim period. The condensed consolidated balance sheet at December&#160;31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2019 and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 as filed with the SEC on Form 10-K on March 17, 2020. The Company&#8217;s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (&#8220;EPS&#8221;), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income&#160;per share in the future that were not included in the computation of diluted loss per share were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,682,192&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,170,382&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,405&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,324,172&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,770,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,501,260&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,412,135&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company&#8217;s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company&#8217;s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company as adopted on January 1, 2020, and did not have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206048872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.&#160;&#160;For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.&#160;&#160;In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under four distribution and license agreements that have been deferred as a contract liability.&#160;&#160;The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (&#8220;Wanbang&#8221;) and Sun Pharmaceutical Industries Ltd. ("Sun Pharma") and amounts to be received Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.&#160;&#160;The amounts received from Baxter Healthcare Corporation (&#8220;Baxter&#8221;), are recognized as revenue at the point in time that the estimated product sales under the agreement occur.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company&#8217;s distribution agreement with Baxter (the &#8220;Baxter Agreement&#8221;), and for the majority of the Company&#8217;s international customers, the Company recognizes revenue at the shipping point, which is generally the Company&#8217;s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:29.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,506&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,470&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,786&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,295&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,996&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,960&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,257&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,766&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:29.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,812&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,697&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material losses recognized related to any receivables arising from the Company&#8217;s contracts with customers for the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and September&#160;30, 2019, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September&#160;30, 2020 and December&#160;31, 2019.&#160;&#160;The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of September&#160;30, 2020 or December&#160;31, 2019.&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020, revenue recognized from performance obligations related to prior periods was not material.</span></div>Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $10.7 million as of September&#160;30, 2020. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $7.7 million as of September 30, 2020, which is being amortized ratably through expiration of the Baxter Agreement on October 2, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277963400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-Sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Investments - Available-for-Sale</a></td>
<td class="text">Investments - Available-for-Sale<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019 (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277285192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of September&#160;30, 2020 and December&#160;31, 2019 are as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we classified $0.9 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of September&#160;30, 2020, the total Triferic inventory was $3.8 million, against which we had reserved $2.7 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.1 million net value of Triferic inventory consisted of $0.1 million of Triferic Dialysate finished goods with expiration dates ranging from December 2020 to May 2021, $0.3 million of Triferic API with estimated remaining shelf life extending through 2021, and $0.7 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139295734712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology&#160;&amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended September&#160;30, 2020 and 2019 totaled $0.2 million. Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 totaled $0.6 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277285192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research&#160;&amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Legal Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Marketing Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277686424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ContractWithCustomerDeferredRevenueTextBlock', window );">Deferred Revenue</a></td>
<td class="text">Deferred Revenue<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Baxter Agreement totaled $7.7 million as of September&#160;30, 2020 and $9.1 million as of December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a &#8220;Refund Trigger Event&#8221; occurs under the Baxter Agreement, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from October 1, 2020 to December 31, 2021, Baxter would be eligible for a 25% refund of the Baxter Agreement&#8217;s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020, Baxter would be eligible for a partial refund of the upfront fee of $5.0 million. In no event does the Baxter Agreement require more than one refund be paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $53,000 and $0.2 million for the three and nine months ended September&#160;30, 2020 and 2019, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.8 million as of September&#160;30, 2020 and $3.0 million as of December&#160;31, 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma  Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate in India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 during the three and nine months ended September&#160;30, 2020, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $92,500 as of September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and  Jeil Pharma, will guide the development and execution for Triferic Dialysate in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of nil during the three and nine months ended September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ContractWithCustomerDeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer Deferred Revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ContractWithCustomerDeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277285192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 93,573,165 and 65,378,890 shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering (or "At the Market" Offering)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell from time to time shares of the Company&#8217;s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018,&#160;the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#8217;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes.&#160;The Company may suspend or terminate the Sales Agreement at any time.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company sold 1,840,443 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5,383,079, at a weighted average selling price of approximately $2.92. The Company paid $309,479 in commissions and offering fees related to the sale of the common stock. For the nine months ended September&#160;30, 2020, the Company sold 1,128,608 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $2,325,478, at a weighted average selling price of approximately $2.06. The Company paid $63,000 in commissions and offering fees related to the sale of common stock. Approximately $32.3 million remains available for sale under this facility.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not required to sell any shares at any time during the term of the facility.  Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering of Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February&#160;6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the "Offering"). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February&#160;21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;2020 Purchase Agreement&#8221;) with certain purchasers named therein, pursuant to which the Company agreed to issue and sell to several institutional and accredited investors in a registered direct offering, 21,818,544 shares of common stock and warrants to purchase up to 23,178,509 shares of common stock (the &#8220;Warrants&#8221;) at a combined purchase price equal to $1.51 per share. Each Warrant is exercisable for one share of common stock at an exercise price of $1.80 per share. The Warrants are immediately exercisable and will expire on September 25, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offered to certain purchasers pre-funded warrants to purchase up to an aggregate of 1,360,265 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of common stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is sold to the public in the offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants were exercised in conjunction with the issuance of common stock under the Securities Purchase Agreement. The Company received gross proceeds of approximately $35.0&#160;million in connection with the offering, before deducting placement agent fees and related offering expenses of approximately $2.3&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder (together with its affiliates) may not exercise any portion of the Warrant to the extent that the holder would own more than 9.99% (or, at the holder&#8217;s option upon issuance, 4.99%) of the Company&#8217;s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay H.C. Wainwright &amp; Co., LLC (the "Placement Agent") a cash fee of 6.0% of the aggregate gross proceeds raised in the offering, minus $420,000 payable by the Company to a financial advisory firm for services related to the offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company agreed to pay the Placement Agent (i) 6.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants through December 25, 2021 and (ii) 4.0% of the aggregate gross proceeds to be received, if any, from the cash exercise of any Warrants subsequent to December 25, 2021. The Company also agreed to pay the Placement Agent non-accountable expenses of $50,000 as well as $12,900 for the clearing fees of the Placement Agent in connection with the offering.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the common stock for the 2020 Purchase Agreement as equity on the accompanying consolidated balance sheets as of September 30, 2020. The amount allocated to common stock was $26.1&#160;million. This allocation is equal to the total proceeds of $35.0&#160;million less the amount allocated to Warrants of $8.9&#160;million and is also net of the direct and incremental costs associated with the 2020 Purchase Agreement of $2.3&#160;million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the 2020 Purchase Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277034792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and nine months ended September&#160;30, 2020 and 2019 as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,538)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(276)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September&#160;30, 2020, unvested restricted stock awards of 146,800 were related to performance-based awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247,561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,405&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service&#160;based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of nil and $0.2 million was recognized during the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense of $0.5 million and $1.3 million was recognized during the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, the unrecognized stock-based compensation expense was $0.3 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. Included in the forfeited service-based restricted stock units are 96,541 and 55,556 units related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the former Chief Financial Officer on July 3, 2020, respectively. These forfeited awards reduced stock-based compensation expense by $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988,958)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based restricted stock units was ($0.1) million and ($1.1) million during the three and nine months ended September&#160;30, 2020 and ($0.3) million and $0.5 million for the three and nine months ended September&#160;30, 2019, respectively. As of September&#160;30, 2020, there was no unrecognized stock-based compensation expense related to performance-based restricted stock units. The forfeited performance-based restricted stock awards of 988,958 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense for the three and nine months ended September&#160;30, 2020 by $0.1 million and $1.4&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the nine months ended September&#160;30, 2020 were based on the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.17 - $2.90</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.2% - 75.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.31% - 1.65%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 - 6.0</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889,218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,782,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted stock options to purchase up to 2,252,344 shares of common stock to certain employees. &#160;During the nine months ended September&#160;30, 2020, 440,026 shares were forfeited. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $0.2 million and $1.0 million for the three and nine months ended September&#160;30, 2020, respectively. Stock-based compensation expense recognized for service-based stock options was $0.6 million and $1.8 million for the three and nine months ended September&#160;30, 2019, respectively.&#160;As of September&#160;30, 2020, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $2.8 million, which is expected to be recognized over an estimated weighted average remaining term of 2.4 years.&#160;Included in the forfeited service-based stock options are 129,375 unvested options related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020 and 222,222 unvested options related to the resignation of the Company's former Chief Financial Officer effective July 3, 2020. These forfeited awards reduced stock-based compensation expense by $0.5 million. Included in the expired  service-based stock options are 3,783,335 options related to the settlement with the former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. See Note 14 for further details.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based stock options was $0.1 million and ($0.4) million for the three and nine months ended September&#160;30, 2020. Stock-based compensation expense recognized for performance-based stock options was $0.1 million and $0.4 million during the three and nine months ended September&#160;30, 2019. As of September&#160;30, 2020, the unrecognized stock-based compensation expense related to unvested performance-based stock options was $0.4 million. The forfeited unvested performance-based stock options of 388,125 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited options reduced stock-based compensation expense by $0.7 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206042184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic&#174; product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the &#8220;Charak MSA&#8221;) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (&#8220;SFP&#8221;) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December&#160;31, 2019. As of September&#160;30, 2020, the Company has fulfilled its reimbursement obligation of certain legal expenses and accrued $0.1 million relating to certain IP reimbursement expenses and certain sublicense royalty fees as a related party payable on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the &#8220;Charak Amendment&#8221;), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company&#8217;s Triferic&#174; product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic&#174; (now Triferic AVNU), dated as of October 7, 2018 (the &#8220;IV Agreement&#8221;), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic&#174;, dated as of October 7, 2018 (the &#8220;TPN Agreement&#8221;), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN&#8221;) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 805)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Clarifying the Definition of a Business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company&#8217;s statement of operations for the year ended December&#160;31, 2018. In addition, because the potential milestone payments are not yet considered probable, no milestone payments have been accrued at September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277260776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to five years. We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a 57,000 square foot facility in Greer, South Carolina&#160;under a lease expiring February 2023. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021. Finally, we executed a lease for 4,100 square feet of office space in Hackensack, New Jersey with a lease term beginning on April 1, 2019 and expiring on July 1, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company had operating lease liabilities of $2.2 million and right-of-use assets of $2.1 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company&#8217;s operating leases (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"/><td style="width:44.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,643&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term &#8211; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate &#8211; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2020 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277000168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Demand Notice</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015.&#160; The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested&#160;$3.0 million&#160;in penalties, plus payment of the cost for certain raw materials.&#160;While the Company believed&#160; it had several defenses to the supplier's claim, the Company and the supplier negotiated an amicable resolution of the dispute.&#160; On July 31, 2020, the Company and the supplier entered into a settlement agreement, which released the Company from any penalties relating to annual minimums under the 2015 agreement, established new minimums under an amended supply agreement and required the Company to pay for certain raw materials with 50% of the cost to be paid upon execution of the settlement agreement and the remaining 50% to be paid no later than December 31, 2020. As of September 30, 2020, the Company has purchased 50% of the required raw materials under the settlement agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company&#8217;s&#160;quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the status of the Company&#8217;s request to the Centers for Medicare &amp; Medicaid Services (the "CMS") for separate reimbursement status for Triferic Dialysate, the Company&#8217;s reserving methodology for expiring Triferic inventory, and the basis for the Board&#8217;s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC&#8217;s requests for documents and information.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Class Action Lawsuits</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company&#8217;s drug, Triferic, to quality for separate reimbursement status by the CMS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company&#8217;s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company&#8217;s proposal for separate reimbursement for Triferic; misstated reserves in the Company&#8217;s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company&#8217;s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company&#8217;s business were&#160;materially false and misleading.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ah Kit Too v. Rockwell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;securities class action with the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spock v. Rockwell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;securities class action.&#160; On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel.&#160; On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company&#8217;s securities between November 8, 2017 and June 26, 2018.&#160;&#160;On February 18, 2019, the Company answered the consolidated amended complaint.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action.&#160;&#160;Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the &#8220;Settlement Amount") in exchange for a full release of all liability as to all defendants.&#160;This resulted in a settlement expense of approximately&#160;$0.4 million&#160;for the year ended&#160;December&#160;31, 2019. Of the Settlement Amount, the Company contributed approximately $0.1 million, which represented the remaining retention amount under the Company&#8217;s director and officer liability insurance policy as of September&#160;30, 2020. The remainder of the settlement amount was funded by the Company&#8217;s director and officer insurance carrier. The settlement was approved by the court on February 26, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Derivative Actions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the &#8220;Derivative Complaints&#8221;) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company&#8217;s current and former directors (the &#8220;Individual Defendants&#8221;).&#160; The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.&#160; The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls.&#160; The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors&#8217; trading activities, restitution, and attorneys&#8217; fees. &#160;The cases were consolidated.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. On May 18, 2020, the Company, the Individual Defendants and the Plaintiffs (the "Settling Parties") entered into a formal Stipulation of Settlement, which memorializes the terms of the Settling Parties' settlement of the Derivative Complaints.  A hearing occurred before the court on August 10, 2020 and the court issued a final order approving the settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's director and officer insurance carrier has funded the settlement  on behalf of the Company.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206175976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans and Security Agreement</a></td>
<td class="text">Loan and Security Agreement<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three and nine months ended September&#160;30, 2020, interest expense amounted to $0.7 million and $1.3 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. We cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. Our ability to comply with these covenants may be adversely affected by events beyond our control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on our sales activities, among other factors, we may not be able to satisfy such covenants in the future. Based on our annualized Triferic sales through September 30, 2020, we may not satisfy this covenant as of December 31, 2020. If we are unable to comply with the covenants under our Loan Agreement, we intend to pursue all available cure options in order to regain compliance. However, we may not be able to mutually agree with Innovatus on appropriate remedies to cure a breach of a covenant, which could give rise to an event of default. If we are unable to avoid an event of default, any required repayments could have an adverse effect on our liquidity. As of&#160;September&#160;30, 2020, the Company is in compliance with all the reporting and financial covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company&#8217;s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5&#160;million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2020, the outstanding balance of the Term Loan was&#160;$20.9 million, net of unamortized issuance costs and unaccreted discount of&#160;$1.6 million.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of&#160;September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:0 1pt"/><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500&#160;</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277165176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (&#8220;EPS&#8221;), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div>Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company&#8217;s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company&#8217;s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company as adopted on January 1, 2020, and did not have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277081192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of potentially dilutive securities</a></td>
<td class="text">Securities that could potentially dilute net income&#160;per share in the future that were not included in the computation of diluted loss per share were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,682,192&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,170,382&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,405&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,324,172&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,770,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,501,260&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,412,135&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139206025992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:29.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">609&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,506&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,470&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,786&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,295&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,996&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,960&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,257&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,766&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:29.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales &#8211; Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee &#8211; Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,812&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,697&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277809416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Investments available for sale</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019 (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277007672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule components of inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of September&#160;30, 2020 and December&#160;31, 2019 are as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277219176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of major classes of property and equipment, stated at cost</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology&#160;&amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277204584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research&#160;&amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Legal Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Marketing Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280462168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and nine months ended September&#160;30, 2020 and 2019 as follows (table in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,538)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(276)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock awards during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247,561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,405&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988,958)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock units during the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988,958&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.48&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of stock option assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the nine months ended September&#160;30, 2020 were based on the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.17 - $2.90</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.2% - 75.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.31% - 1.65%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 - 6.0</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889,218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s service-based stock option activity for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,782,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the nine months ended September&#160;30, 2019 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139276981912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of operating leases</a></td>
<td class="text">The following summarizes quantitative information about the Company&#8217;s operating leases (table in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"/><td style="width:44.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,631&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,643&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term &#8211; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate &#8211; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future minimum rental payments under operating leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2020 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139200382456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of principal payments on term loan</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of&#160;September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:0 1pt"/><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500&#160;</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281116792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2020</div></th>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndFinancialConditionAbstract', window );"><strong>Liquidity and Capital Resources</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_WorkingCapitalNet', window );">Working capital net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,072<span></span>
</td>
<td class="nump">$ 21,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common shares sold (in shares)</a></td>
<td class="nump">23,178,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,670,212<span></span>
</td>
<td class="nump">1,128,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from issuance of common shares, net of issuance costs</a></td>
<td class="nump">$ 32,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net draw down proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleofStockRemainingSalesAmount', window );">Remaining amount available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndFinancialConditionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndFinancialConditionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleofStockRemainingSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Sales Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleofStockRemainingSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_WorkingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of working capital, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_WorkingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139279006984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">33,501,260<span></span>
</td>
<td class="nump">12,412,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">6,682,192<span></span>
</td>
<td class="nump">8,170,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">245,405<span></span>
</td>
<td class="nump">1,324,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">26,426,863<span></span>
</td>
<td class="nump">2,770,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277359080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Nature of Goods and Services (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>agreement</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_NumberOfDistributionAndLicenseAgreements', window );">Number of distribution and license agreements</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AveragePaymentTermOfCustomers', window );">Customers average payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AveragePaymentTermOfDistributors', window );">Distributors average payment term</a></td>
<td class="text">45 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AveragePaymentTermOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the average payment term of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AveragePaymentTermOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AveragePaymentTermOfDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the average payment term of distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AveragePaymentTermOfDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_NumberOfDistributionAndLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of distribution and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_NumberOfDistributionAndLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139288397624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">$ 15,280<span></span>
</td>
<td class="nump">$ 15,407<span></span>
</td>
<td class="nump">$ 47,033<span></span>
</td>
<td class="nump">$ 45,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_DrugRevenueMember', window );">Drug products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember', window );">Concentrate Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">14,996<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">46,257<span></span>
</td>
<td class="nump">45,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">14,188<span></span>
</td>
<td class="nump">13,946<span></span>
</td>
<td class="nump">42,375<span></span>
</td>
<td class="nump">40,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Drug products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Concentrate Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">13,960<span></span>
</td>
<td class="nump">13,848<span></span>
</td>
<td class="nump">41,766<span></span>
</td>
<td class="nump">40,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">5,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Drug products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Concentrate Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">4,491<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | Drug product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | Concentrate product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">14,506<span></span>
</td>
<td class="nump">14,746<span></span>
</td>
<td class="nump">44,786<span></span>
</td>
<td class="nump">44,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | U.S. | Drug product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | U.S. | Concentrate product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">13,470<span></span>
</td>
<td class="nump">13,353<span></span>
</td>
<td class="nump">40,295<span></span>
</td>
<td class="nump">39,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | Rest of World | Drug product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales &#8211; Point-in-time | Rest of World | Concentrate product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">4,491<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | Drug license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | Concentrate product license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | U.S. | Drug license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | U.S. | Concentrate product license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | Rest of World | Drug license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee &#8211; Over time | Rest of World | Concentrate product license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugLicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugLicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductLicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductLicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139204478824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Receivables, which are included in "Trade and other receivables"</a></td>
<td class="nump">$ 4,129<span></span>
</td>
<td class="nump">$ 4,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 10,738<span></span>
</td>
<td class="nump">$ 12,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139278970904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCreditLossExpense', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue performance obligation</a></td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember', window );">Concentrate Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Reserve for returns</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember', window );">Baxter Healthcare Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue performance obligation</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCreditLossExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCreditLossExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118944142&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139278455528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 10,679<span></span>
</td>
<td class="nump">$ 14,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Accrued Interest Income</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 10,702<span></span>
</td>
<td class="nump">$ 14,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281336840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw Materials</a></td>
<td class="nump">$ 2,794<span></span>
</td>
<td class="nump">$ 2,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in Process</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_CurrentAndNonCurrentInventory', window );">Total</a></td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">$ 3,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember', window );">Triferic Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw Materials</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory, reserve</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember', window );">Triferic Dialysate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember', window );">Triferic API</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_CurrentAndNonCurrentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of current and non-current inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_CurrentAndNonCurrentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280933992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 9,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(6,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,865)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">5,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Information Technology&#160;&amp; Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">1,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139204296216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent', window );">Accrued Research&#160;&amp; Development Expense</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Compensation and Benefits</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued Legal Expenses</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued Marketing Expenses</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">2,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Liabilities</a></td>
<td class="nump">$ 4,968<span></span>
</td>
<td class="nump">$ 4,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280500008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2020</div></th>
<th class="th"><div>Jan. 14, 2020</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,076,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember', window );">Baxter Healthcare Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DeferredRevenueBenefitPercentage', window );">Refund eligible for, percent of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_PartialRefund', window );">Partial refund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember', window );">Wanbang Biopharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember', window );">Sun Pharma Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember', window );">Jeil Pharma Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DeferredRevenueBenefitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Benefit Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DeferredRevenueBenefitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_PartialRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial Refund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_PartialRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RevenueRecognitionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration received during the period for the milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RevenueRecognitionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139278891176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
<th class="th"><div>Mar. 22, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 19, 2020</div></th>
<th class="th"><div>Feb. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleofStockRemainingSalesAmount', window );">Remaining amount available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Amount allocated to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,840,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,325,478<span></span>
</td>
<td class="nump">$ 2,296,000<span></span>
</td>
<td class="nump">$ 5,383,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average selling price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
<td class="nump">$ 309,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees', window );">Commissions and offering fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleofStockRemainingSalesAmount', window );">Remaining amount available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-market offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SalesAgreementThresholdSaleOfShares', window );">Sales agreement, threshold sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,191,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,000<span></span>
</td>
<td class="nump">18,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000<span></span>
</td>
<td class="nump">$ 1,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (up to) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,670,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (up to) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,723<span></span>
</td>
<td class="nump">478,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common share issuance costs</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (up to) (in shares)</a></td>
<td class="nump">21,818,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from issuance of common stock and warrants</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering', window );">Placement agent, cash fee, percentage of aggregate gross proceeds raised in Offering</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering', window );">Amount payable to financial advisory firm for services related to offering</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors', window );">Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of warrants issued to investors</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants', window );">Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of any warrants issued in the offering from the exercise of warrants during the remainder term of such warrants</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses', window );">Placement agent fee, non-accountable expenses</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleOfEquityPlacementAgentFeeClearingFees', window );">Placement agent fee, clearing fees</a></td>
<td class="nump">12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Amount allocated to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock for which warrant is exercisable (in shares)</a></td>
<td class="nump">23,178,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares of common stock each warrant is exercisable for (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise', window );">Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise', window );">Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants, at holder's option upon issuance</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock for which warrant is exercisable (in shares)</a></td>
<td class="nump">1,360,265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Stock Issuance Costs And Commissions Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Amount Payable For Services Related To Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityPlacementAgentFeeClearingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Placement Agent Fee, Clearing Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityPlacementAgentFeeClearingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleofStockRemainingSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Sales Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleofStockRemainingSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SalesAgreementThresholdSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold offering or sale of shares under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SalesAgreementThresholdSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rmti_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rmti_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rmti_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rmti_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280619096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember', window );">Service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember', window );">Performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(1,538)<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280600744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Awards (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">20 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember', window );">Restricted stock awards - performance based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">146,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139308028648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,786<span></span>
</td>
<td class="nump">472,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,904<span></span>
</td>
<td class="nump">222,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(247,561)<span></span>
</td>
<td class="num">(96,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,724)<span></span>
</td>
<td class="num">(4,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,405<span></span>
</td>
<td class="nump">593,964<span></span>
</td>
<td class="nump">245,405<span></span>
</td>
<td class="nump">593,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.09<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30<span></span>
</td>
<td class="nump">4.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
<td class="nump">4.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 1,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember', window );">President, chief executive officer, and chief financial officer | Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures', window );">Estimated expense reduction in stock compensation expense related to forfeited stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember', window );">President and chief executive officer | Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief financial officer | Restricted stock units - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(55,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281470024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Performance Based Restricted Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 877,000<span></span>
</td>
<td class="num">$ (276,000)<span></span>
</td>
<td class="nump">$ 3,895,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,958<span></span>
</td>
<td class="nump">988,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(988,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">988,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="num">$ (123,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (332,000)<span></span>
</td>
<td class="num">$ (1,148,000)<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember', window );">President, chief executive officer, and chief financial officer | Restricted stock units - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(988,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures', window );">Estimated expense reduction in stock compensation expense related to forfeited stock awards</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139291121256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details) - Stock option awards - service based awards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">68.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139278364376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Underlying Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">8,210,024<span></span>
</td>
<td class="nump">7,856,480<span></span>
</td>
<td class="nump">7,856,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,252,344<span></span>
</td>
<td class="nump">576,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(440,026)<span></span>
</td>
<td class="num">(620,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expirations (in shares)</a></td>
<td class="num">(4,090,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,932,192<span></span>
</td>
<td class="nump">7,782,257<span></span>
</td>
<td class="nump">8,210,024<span></span>
</td>
<td class="nump">7,856,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">2,889,218<span></span>
</td>
<td class="nump">6,340,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.95<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">3.96<span></span>
</td>
<td class="nump">6.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expirations (in dollar per share)</a></td>
<td class="nump">8.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">4.54<span></span>
</td>
<td class="nump">7.35<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">$ 8.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Granted, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,074<span></span>
</td>
<td class="nump">$ 107,150<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280229816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,026<span></span>
</td>
<td class="nump">620,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 1,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted average remaining term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,090,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_CertainEmployeesMember', window );">Employee stock options | Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,252,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember', window );">President, chief executive officer, and chief financial officer | Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures', window );">Estimated expense reduction in stock compensation expense related to forfeited stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember', window );">President and chief executive officer | Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief financial officer | Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember', window );">Chief executive officer, chief financial officer, and director | Stock option awards - service based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,783,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_CertainEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_CertainEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281079032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Performance Based Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,125<span></span>
</td>
<td class="nump">388,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">388,125<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">388,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">2.20<span></span>
</td>
<td class="nump">4.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember', window );">President and chief executive officer | Stock option awards - performance based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(388,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures', window );">Estimated expense reduction in stock compensation expense related to forfeited stock awards</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_PresidentandChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280627960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2018 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_NumberOfAdditionalAgreements', window );">Number of additional agreements | agreement</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees', window );">Related party transactions, accrued reimbursement of IP expenses and sublicense royalty fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rmti_MasterServicesAndIpAgreementMember', window );">Master services and IP agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_PaymentsToAcquireAssets', window );">Payments to acquire assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AssetAcquisitionMilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember', window );">Executive vice president and chief scientific officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total amount due</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RelatedPartyNumberOfInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_InstallmentPaymentToRelatedParties', window );">Installment paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses', window );">Related party transactions, accrued reimbursement of legal expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AssetAcquisitionMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments related to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AssetAcquisitionMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_InstallmentPaymentToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with installment payment to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_InstallmentPaymentToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_NumberOfAdditionalAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_NumberOfAdditionalAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_PaymentsToAcquireAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount paid to acquire assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_PaymentsToAcquireAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RelatedPartyNumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Number Of Installment Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RelatedPartyNumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of related party transactions accrued reimbursement of legal expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rmti_MasterServicesAndIpAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rmti_MasterServicesAndIpAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280997128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities | $</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use assets | $</a></td>
<td class="nump">$ 2,099<span></span>
</td>
<td class="nump">$ 3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">Grapevine, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Hackensack, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityOneMember', window );">Lease facility one | Wixom, Michigan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityOneMember', window );">Lease facility one | Greer, South Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityTwoMember', window );">Lease facility two | Wixom, Michigan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityTwoMember', window );">Lease facility two | Greer, South Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rmti_LeaseFacilityTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139277621656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease rent expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total rent expense</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets exchanged for operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139205969960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Rental Payments Under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year ending December 31, 2020 (remaining)</a></td>
<td class="nump">$ 387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2021</a></td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2022</a></td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2023</a></td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2024</a></td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139281481352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Amount of penalties sought from supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid', window );">Percentage of raw materials to be paid</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SupplyAgreementPercentageOfRawMaterialsPaid', window );">Percentage of raw materials paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=rmti_SettlementAgreementWithAllPartiesMember', window );">Settlement agreement with all parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid', window );">Percentage of raw materials to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SupplyAgreementPercentageOfRawMaterialsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Percentage Of Raw Materials Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SupplyAgreementPercentageOfRawMaterialsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Percentage Of Raw Materials To Be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=rmti_SettlementAgreementWithAllPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=rmti_SettlementAgreementWithAllPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139280313912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net draw down proceeds</a></td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, base percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, additional percentage added to base percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Initial interest rate percentage</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage', window );">Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded', window );">Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays', window );">Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance, net of unamortized issuance costs and unaccreted discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,900,000<span></span>
</td>
<td class="nump">20,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and unaccreted discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period for which company is entitled to make interest-only payments</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period for which company is entitled to make interest-only payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan, first tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net draw down proceeds</a></td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Closing costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock for which warrant is exercisable (in shares) | shares</a></td>
<td class="nump">477,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Additional debt discount recognized</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan, second and third tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays', window );">Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan, second and third tranches | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan, second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Term loan, third tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest-Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoAndTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoAndTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140139279474856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term loan - Term loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2025</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Payments</a></td>
<td class="nump">$ 22,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJFVA'UQGX'E0&L&2)?R=&.;.DIS2*NZF$0]#<I4F\'-2V(\E.B5Y(+7@IY7
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M(BS7^_P4D[2P9NW_I69B%K#L;4EUE9JI1++ENN03]YY$G, G&:Q%G K@4AI
M)=%&%P9F<<QPBKZU@"J1LWXQ=Q;,K!*8WU9%E6@^_(%9LT1FE8C\EBJJ1-$Y
M[Q1W:O-H ]JD9MF^?$(\LV&RVXO.K^9[_X-LQ[MI;]_]<7#/36:7D%#,(=1I
MG,.\4;N]^-V)EJML.WLFM991=K@4W!?*W "_SZ74AQ/S@/P?D?Y_4$L#!!0
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MI&.(XOY03!3/[1$\X4H?Z':8ZCL7%@:@]Z><J_>).=6K6USW+U!+ P04
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MM/=W[8OBF^:"ZIDKQ<OF<<UHQD0-P/=+SM7K2]U!?XLZ^1=02P,$%     @
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MQ-"44)_*8J[+6FZ+6IP+M;CHGE$9"Q30B$0-?+^=_[Z%;X(OE3G.BSFW3FO
MD.RND6N]0X[E6 WU3%]-M]\WR?F_[,$_9S\QPZU6BJOCN9?B22P)= B)V 9-
M609M*5;]8D_0C*Y91M"7R4I(#I_^UY9TW2I=5Z?K7D@WAQYYQT3C,BJ8GF:J
M1K@?=_IN#SS:'[^<)M2@USM%^0TH!W[]4UC0!/,&CE?!3D3V*I&]5I%+"KT]
M37Z3"'V$GH[>*L57"!KH9(^3%*]2TH&]H!/BE""?K"18#1;G^C7,Z)X(J8:-
M)A69>T<5.S6#SA%>S9QS1,>V:\Z<8VRKV16O<L5K=05V .CO%$USS@E=_T(+
MCJE(L=Y9)M&WO$6U=UY-3?4YHE.#^.>004UT:Y 3T?U*=+]5].D7=6GE]YM6
M?K>V6*=-J$']^_ ;4+#PW1HL:()Y [M?DVL>[4$9X5N]^0NT9CF519.I9JOS
MQ41OJ[7Y6_MF:C?,^W >*8X/?\,7AYE[S+<)%2@E&TAE7??AO?#B@%#<2+;3
M.^"*2=A/]3"&,Q7A"@#/-XS)EQN5H#JEC?\ 4$L#!!0    ( *J):5%<:N")
MG P  *!0   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULS9QK<]JZ%H;_
MBB>S9TX[LRG67=Z39B8!TM#F=D+2/>>C T[#*=C9MM/+^?5'!@=A:4F&A&::
M#RTDK\22+.MYM22S_SW+OQ;W25(&/^:SM'B_=U^6#W]UN\7X/IG'Q;OL(4G5
M7^ZR?!Z7ZFW^I5L\Y$D\612:S[HX#'EW'D_3O8/]Q>\N\X/][+&<3=/D,@^*
MQ_D\SG\>);/L^_L]M/?TBZOIE_NR^D7W8/\A_I*,DO+FX3)7[[JK6B;3>9(6
MTRP-\N3N_=XA^NLTXE6!A>+S-/E>K+T.JJ;<9MG7ZLUP\GXOK")*9LFXK*J(
MU7_?DEXRFU4UJ3C^J2O=6WUF57#]]5/MQXO&J\;<QD72RV9_3R?E_?L]N1=,
MDKOX<59>9=]/DKI!K*IOG,V*Q;_!]UH;[@7CQZ+,YG5A%<%\FB[_CW_4';%6
M !%' 5P7P)L6('4!8A3 PE& U@6H6<#5!E878$8!$CD*\+H -]O '05$74"8
M(4E' 5D7D$8!BAT%HKI 9'Z"JUM1^'3E0K/9S%5D=;'-JTU=/86>+C=:7._N
M<F M1F4_+N.#_3S['N257M57O5@,[45Y-1BG:747CLI<_76JRI4'-^>'-_WA
M]: ?]"[.^X/ST?+5Z.)TV#^L?CVZ5O^=#<ZO1\'%<= [.3S_,!@%PW/UAXO>
MIY.+T_[@:O2O8/#OF^'U?X).<#/J!V_^>!O\$4S3X/H^>RSB=%+L=TL5;/61
MW7$=V-$R,.P([#HKXQE0K.<OUKLX.[NH@P-*]_VE#_NJ+X87YX>GP>7AL-]1
MS>P=7@ZO#T^!N@8M=?5Z-V<WIXM.[ ^.A[WA-5#)\>:57%R?#*[4Q3F[O!J<
MJ"LU_#Q0UT&]'P#U?O#7>_EX.YN.@^SN+LFGZ1>@@I.M*FCI]N%6E6UU%3ZV
M=&#9*>^3CB+,5X4T3WL_/:>>EF:?/J?.35O?57?ZZG;'J]L=+SZ2.C[R*/DR
M35/U*0I=LS@=)\$;=9L6]W&>%&^#N SZR?A=0-"? 0Z1A&Z_9?UL47^%^&\'
M3(2$(D;WN]^ R,@J,K)E9!M$<[2LDZ]%@P468A7*,F9;Q9N*/E!/%+'(D UL
M64=]'I&RJ3L&/I# W4-7W4,798BC>X;I6)FL0ETOU2>+5V^K"7947;G[;#9)
M\D)-PO\\3LN?GF'"5I_&O!?C7(W'TZP IVUF#8".Y"(R>JI-U0B+K\+BWK!N
M4M7RV?1_R23XH QF\*:*\6V@S-SAMW@ZBV]G24<9T\XHGB7!,/V6%*4RC"78
M#&X': R;8Z^DT0"Q:H#P-D 91V4+TZ#WF.=).OX97.=Q6LSBA2$]G/SWT1.P
ML*()C7A]BD:X<A6N](;[675@=4=F=T%7W8LSY9?SG]6[<3:?JXB5/QE_#1Y3
M-?IF/ROAE2J03\>END"CQ=]NTFE9!,.B>$PF?P;I8IH+ROA'4BBG4][?)[/)
M^@P$33C2:A6G2#ANIVC5LFC3ECTG9NCZ1/9HB9@Q$476O&!<P[Z_ED9;4:@]
M7NAM[>!'DH^G:O)0#4GF#[/L9Y+4%R][J,9>L=[.M@M2?]AZC"14/XXHUYPH
MVCC*P5.4RTMR\13E^3+*Z_@'Z"B1%1FBQMS<JT6^B]!23[-]&KW(S]Y%4SK5
MDG$2]+*Y6D<7RQL_^5&]3L 6V;A%# DSWA95,V!-9.1'\B"=N&S"69ROP!R!
M@X0 /@%A2; K+$U"1#<.:X-0CNKJUD-14H[,<4%;70)0$PD1XJ9- '0=+%'(
M3<( 0L8=_:/9C?SP?KG'0S:]_28/:8(C/\*?9_.0C6+(Y]4R[R4$:H*<'J"#
MK1X@='D]I&T"$J_@]I#F//*#WN?WD W@#N82N\:I1C#R,WB7;@[9W$0.(&&-
M3>S'YDO<&K8AV4&.@#0A<0LAW1/R*'E0MU#HGI"QS32N1K,@TG%/X[4UI1]L
MQH3<%LH1MG&%B0BQ<3?7,M_=#-1$L(*,,3$, %U'W?884>-N!H0NJXDU1_&V
M2]NM%]T037T3,M8TQ7Z:/F]"QC8LH0D9D%F7$* S-"$#.GA"!H2N"1EKIF+V
M"A,RUIC$?DQ6JX_%Q3 66RN?_I0M4G\MU&K%;]D_8AM22-*04E?':%)A_XK6
M,R6M#R)X'K 7K)P1(644FN-H V6S 1I]V(\^8_)J#UK:(S\DV(K8EIFN'=M@
M)9@+\R8: +H."3E#W!SYMI!A1_]H2F,_I5LGK]:E +;9[%\*$$UHXB<T.'FU
M+@B(S69H05#+O&E#:"D,+ @ ';P@ (2N!0'1MH&@5YB\B/8#Q.\'?&Z2 "1&
M(8ZPV6.MNF9P:VEF/XQWZ3J)C66$S2OJU30;H:%-_-!^B3,E-A_-1*)7T@Q9
M$Y3X5Z6[)=H) 9:HDJ@?P]%] H14F4T7^8A&--DIHJ$].F*O5]4T9++D!) 9
MDN%F-7T$9#B4D=EEK9]WVE91LT^UFR!^-_&<%!FQO0%BYF*BWZ9J!JS= ]G<
M/1A<_/B8^E=D!,AL$Q))-3@=86EH$S^T#5/3%LH1L1&-E0<W5V3$SE];1+1K
M4N9(6J8&T*D5&2(L,N<B6\@=J5BJ?0,-7X&(5!.8^A?N/B)2>V'>$9(96P>#
M5EDS- UKZH?U+GE(;6B;'M4K:39!(YWZD?X2&E(;SQUDQNS5-(->V\_U(WS'
M/*0VLBEF4CJX336WZ4ZY#6&.V@A6'MFXT4]JE8]R;14UFZA)3OTD_RVV.2F0
M1\;2M:M&-5*I'ZF_8*>3VBSM2'.KLQ;YMME:ZFDV6".9^I'\' ]!;11+8:*M
M1=0,5Z.:;H[J;7.Z%&"C-Z?+-"%9RY;QECE=9B^6H9PN(#.[F0%K:BBG"^C@
MG"X@=.5TF28Z\Q-]JYPNW&- 0A[.?FVB;#9#TY]M>QYLH]#MS#R4 P-D9@Z,
M00E\( <&Z. <&"!TY<"8-AB,O()=9-H;,+\W\!Z_ O+@(I+4[+ V63.TM8-A
M?CNP2[O(@$-B9D+,KVDV0@.?^8'_$L/( $Z;,?LDS9 UQID?XSNVB\Q&+^%J
MNG:EIIC&+_/C=P=^D0&@#4-B^$5F9]A-O]A64;.)&MG,C^SU)OX=YVKLJ [/
M$S5^U%U19FK^O"V#XVFJ-/!9XR,&I,1#9,Z-?E'S!*4&._>#_3GVB-L$C8AA
M^/HMHF:XFK/\V5O>:WG^"CVV/>( -Z.01LB5]^&:FWRK+>^V4(XX0$PDA#%K
M]P"924P.$)-P;()P .@Z!%$6FLE>0,A<HTP3D^]PRQOT&-Q>=#OLT2;*9C,T
MB/D+-\?AT('-<< > 3+K8@,'SB![!.A@>P0(7?:(:T_ 7V-SG*^= O?CVV>/
M.'1N2_TX/ /7 .9^ ._T[#FP\$6N>TZ3E_O)^Q)7PVV8.I*L7&.2;X[)'9QA
MX, 1+X0E#QV!"HU$L?E:U[T$AR=V 5)/$,3-A,@FRF8#-"3%YI#<*&C["#3%
MH; BMF5&TJXO;,2J5;_@QEPW '0=@J6@AJL[!H34D> 3FM;BA4\]M5H) :2M
MO59":%2*9SSXU&HHA T]R% (^TDDDS% 3:"A '2PH0"$+D,A-(G%:SS_)#33
MA'^=ZV., -:D7$;$[+ V63,TC3_Q>D]!"0"7IF?P:YJ-6'L0ZA<^"07LY9HQ
M^R3-D#5?Q4Y7MBT\^R3LQ6DDA4"NKM7<%3OE+L1:86_THD@8)RT_ 2KSG(
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M\CZ)U211"=3?[[*L?'I3?<O9ZDL)#_X/4$L#!!0    ( *J):5$ U(_>J@D
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M"V>7['.GVU@A6])YYZ'@_<DLP+FHS/+>T7ERM/B.H]?TWII0>7IK"BX>V\\
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M^.,?EN/Q_)6XPTPQNA0_I@1D<PA&=!C)=P(K>_/&1_,*9;DLYPD"ML[TEKW
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MSE26*VR@*O5Q&GKEO=09*SV*V/=A=>B4V:@FA:?I@4SU#HLX9G6Q /M5^:#
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M"C71T@ \WQA3AA^DH/DKC;?_ 5!+ P04    " "JB6E1?%%&ZU,#   ("
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MBCZ;_1_8Y7/J\7*C7/B&?6M[RA'SQI&I.V>6:ZG;7_'0U>' 89)\QR'K'++
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M0'H(2'W> Y'/\II9MEIHM0?MO G-;7RI/IJ2:Z6[E#NKZ6E+<7:UT72_VC[
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M)[,B #WHZ'"PJO/:M566E-!O&_KTH'8.]+Q6RCX>','X,5O]#U!+ P04
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MO#=[_KE3.'-9VH#UC3&^>2 ![??ZU_\!4$L#!!0    ( *J):5%*AEF8IPD
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M"P'IPWWG[PT@BZCX XIG#-=Q[*Y1P-C,W\='C+X@<S[>'?FCT/V3,"8VGCV
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M/IL(%_]T('X)MN+7]2N+\BGX(YP-W] "_+ZV-J0O=$#[]QNO_@M02P,$%
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M&&)B+!K:C28*HMDI10!<6NB,=S3EOSL9[BO)7OGQ',C%P022/.#34\>4YDH
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M4A*U0 OP?6%M:!Y(0?M'EJL_ %!+ P04    " "JB6E1+Y H*#P)  "<&
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M_?E3;+??\Z+;\_7BJ,&E:B;BY6PL%K/%[(B]EWT,7[*]E\_8.Q25?U^M?'#
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M,%FDII93K\COA'KN1N8T/E&[M(:R,]FK8/656S+Z;8E8G3*N4AF@_9%?7%
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M2?&455>!=A,C-Z[J6TJ#&^J&-1;M7%D!_+Z2T@P3ZV#\&W#Q-U!+ P04
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M-+C22W3$728'^S!<"JG$1.$^;_?^6"B$G:]>=[N]F#B=#XJS&GI40:>O0)_
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MO,,O<MF)YV]X]P7=,KWETH# #4&CL_%Y +J3=6=8U7@IK94E8?IE13\A:A=
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MMJ3!C-HYT'VAE-T=7(!NU,_^ 5!+ P04    " "JB6E1Q/UPG](&  "A'
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M[5B*@526 -:'96GF#W:#^JODR;]02P,$%     @ JHEI46B9UN7) P  K@D
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MB\8[T'FEM3L:/L$PO/-G4$L#!!0    ( *J):5&GTNC&@ 8  /0I   9
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MH, WJ;(QP@M,HFP0;G,BK!4=NR6]INF9VH>UIF)_8+:TSN*@%UL!E#;"K!Y
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MZ:;ZN);A0F8EH/A^F:;JZ:*<H#GH>?4_4$L#!!0    ( *J):5'7#I:%5 (
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M 55A=/YRTG6ZCOZ=1-/ \,CE;NER]URJ ]#9EH#FG(6;X#3?1[37)>WU6WT
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M>><Q9B6;QMI,M*AL;UH*C9W.#G-\BT : ]Q?":%?)Z;==:];\@]02P,$%
M  @ JHEI49?; 99* P  M P  !D   !X;"]W;W)K<VAE971S+W-H965T-# N
M>&ULK5?1;MHP%/T5*^I#*W5-[ 02*D!J0=V05@F5=GV8]N & U:3F-D&VK^?
MG80D$"=4&B\0)_><>^[-]<'T=XR_BQ4A$GS$42(&UDK*]:UMBW!%8BQNV)HD
MZLF"\1A+M>1+6ZPYP?,4%$<V<IRN'6.:6,-^>F_*AWVVD1%-R)0#L8ECS#_O
M2<1V PM:^QM/=+F2^H8][*_QDLR(?%E/N5K9!<N<QB01E"6 D\7 NH.W(Y0"
MTHA?E.Q$Y1KH4MX8>]>+R7Q@.5H1B4@H-0567ULR(E&DF92.OSFI5>34P.KU
MGOTA+5X5\X8%&;'HE<[E:F %%IB3!=Y$\HGM?I"\H([F"UDDTD^PRV*]C@7"
MC9 LSL%*04R3[!M_Y(VH *#7 $ Y 'T5X.8 -RTT4Y:6-<82#_N<[0#7T8I-
M7Z2]2=&J&IKHUSB37#VE"B>'DV1+$LGX)[@<$XEI)*[ -_ R&X/+BRMP 6@"
MGE=L(W R%WU;JHP:9X<Y^WW&CAK89V1] USG&B '.0;XJ!T^)J&"0PV'O4.X
MK>HLBD5%L2CE<T\6^_NG>@0FDL3B3PNQ6Q"[*;'70/R$=^ 12\(ICHQMRN#=
M%*YWUG:(_)[7M[?59AB"/!\600?*O$*9UZKL56TB_1*GG(5$&+5E!)U*6A?U
MCJ358V#0,2OK%,HZK<H>:$+5W,[!=\;,L]6I)^U"]TB9(<ASD5E:MY#6;97V
MS"2.3(JZM62>[W:/%!F"G" P*_(+17ZKHF)RKT'"DG##N5J:%/JUY$'G^&76
M8SRO8<R"0E_P97W$*"RH3UG@^T?*@MH.<+N>;Y;6*Z3UVE\FIPNU,4-0:&S9
M\- I?=,YKY? BB7#_W.3'%]MIN\XYC;!TAPA.L^,Y3S5]+W&]*6%PG8/K:1?
M<F:VJISB<(H:4Y<>"=M-LI*:$T'XEAB3UTT0-;>]M$'8[H.GMPXT>!QL3%R:
M'#SA<ON-,59S]BG4P+5-;^E4T#_SQBA-!K:[S.F?#%BWF>9.E0X"OV@A=]-)
MVS&D- ]T9O- I7F@=O,X/4XYP8'+UGID5XZ4^CS_B/F2)@)$9*%0SHVO6LRS
M(W*VD&R=GC+?F%1GUO1RI?Y6$*X#U/,%8W*_T ?7XH_*\!]02P,$%     @
MJHEI48)S52_" P  DP\  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
MK5?O;YLZ%/U7+-XT;=)6,+]"NB12FX3W*JUZU;KM?7;!"6A@,]LT[7__;"!
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MS9@I@'R^HU0<;U2 N@]?_0]02P,$%     @ JHEI47SS\5:X @  OP<  !D
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MA?)6 O#]DG.Y>Z,>E-L_<7KV/U!+ P04    " "JB6E1R8.L0 ,$  #=$@
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M!$OTY8K@B' E(-\O&1.[&W4&7OYN,_L?4$L#!!0    ( *J):5&2J>Q=>@0
M .H1   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;*U876^C.!3]*U:T
M#QVI*1@((54:J6F3_9!F537JS+,+)K$*=M9VDLYJ?_S:A@ )Q,E,VX<&S+WG
MWGM\[8,9[QA_$RN,)7C/,RKN>BLIU[>.(^(5SI&X86M,U9.4\1Q)=<N7CEAS
MC!+CE&>.Y[JADR-">Y.Q&7OBDS';R(Q0_,2!V.0YXC^F.&.[NQ[L[0>>R7(E
M]8 S&:_1$B^P?%D_<77G5"@)R3$5A%' <7K7NX>W<\\X&(MO!.]$XQKH4EX9
M>],W?R9W/5=GA#,<2PV!U,\6/^ LTT@JCW]*T%X54SLVK_?H<U.\*N85"?S
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M9I4,Q]]*-*C/M(;[[UOU.^>\<69*%%X+]HMF>C$(>@%D."-+IA_%^@M6#CG
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MZKO)!XMP1),$,ZZ&"O+ZN2ML^N<S.C4[:=DGY;17D5ZH&77=U: [NA*/#*D
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MZ^L>[+TO?*/SA=0+_<DXQW,R(_(Y?^+JK5]RB6A*,D%9!CB)KWLW\.,C\C7
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M;+67VV[;.!"&7X70!HL6<".1DD]=V\#61@^+) WJ'BX6>\'((XN()*HD'3M
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M-34N>&ULK5=MCZ,V$/XK%KU6=]+M@LU+8)M$V@TYM5)/M[K<RX>J'YS@!'2
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MF +(YVM*Q?.-<M",S]/_ %!+ P04    " "JB6E1+I=:K:<"  "&!P  &0
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M VP]*K]VYQ,CD^R"M9 &+VS9<(.?*J"L ;Y?26D>)O;.5G[\3/\"4$L#!!0
M   ( *J):5$<:8US$08   D;   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;+59;6_;-A#^*X31 2V0VA(IVTGA&$B=#@O0=$&SKA^&?: EVB(BB1Y)
MQ?&P'[\C)8MR(]-.6^=#+(F\X[WPGN=$3=9"/JB4,8V>\JQ0E[U4Z]6[P4#%
M*<NIZHL5*V!D(61.-=S*Y4"M)*.)%<JS 0Z"T2"GO.A-)_;9G9Q.1*DS7K [
MB529YU1NWK-,K"][86_[X#-?IMH\&$PG*[ID]TQ_6=U)N!LT6A*>LT)Q42#)
M%I>]J_#==82-@)WQ)V=KU;I&QI6Y$ _FYB:Y[ 7&(I:Q6!L5%'X>V8QEF=$$
M=OQ3*^TU:QK!]O56^Z_6>7!F3A6;B>PK3W1ZV3OOH80M:)GISV+]&ZL=&AI]
ML<B4_8_6]=R@A^)2:9'7PF!!SHOJES[5@6@)1/L$<"V OQ' X1X!4@N08P6B
M6B"RD:E<L7&XIII.)U*LD32S09NYL,&TTN ^+TS>[[6$40YR>OI1T$(A6B3H
MGL6EY'J#KI:2,4BM1F_1)RHE-9E!KZ^9ICQ3;R8##>L:Z4%<K_&^6@/O6>.6
MRCX*1V<(!SCX<G^-7K]ZD]#-*S1 *J62J>I_A^*97_$]6_41"784=VBY_E$M
M PAJ$UG<1!9;M62/VFLVU^BF4%J6-IA_?80)Z$:S7/WM44\:]<2JC_:H_P28
MD$BZ1HE8%V@E1<Q8TA7#]Y6>D=5C8.!QBD. !?B;#!X[+(@:"R*O!7\PF:,,
M]@_Z#S77'L^&C=[A*0(W:M2/O&9?+6%_+ZEF$#1>Q'Q%,T1S41:Z*WBC9\$C
MP\ 3O'%CQ=AKQ4VA&>QYC:"\V)F%+K1B,@:' 6Z[+/'KB_KCX2^>Z)PW=IV_
MQ"Z:)-S@,\3(66>>L@1I<8S9_N6B?A#XS+YHS+XX8#:8"4;RMOD'+/-K/#\0
MT#!P"!MX-7U8+)AEMUWK.G'4KRD,^A?><(4MV ^]JGY?6=J%'$(ROPE;50UF
M#!H%I8$<>+%L5<N<9K2(C3LHXZQ$8H%6=&/FJ#).M^(P&E.5GAW(P@$[PP,;
M)'1P'.+C=C9[@J9)=1DSJU6TRWV\6^PUH3R?%Q(/*H0.U4,_K,]H%I<9M<F!
MK@X593YGTH2X(DES%8L\AV'H#>('1.<9LZ4(V[V4<0H5F:#Y!JT-<Q>Z'7Z;
MJ&\PSSR3T(4]4I/Q!M$796%*O/KI3)O?#=(?^M/F2";TL\S7R@_(&OC!E45M
MV'NQBY-UD0O8Q7G.$@X[.-O +!8SNV]!,"YM/,%5ZQS=-CAGK?!J2>UT:$P4
M$!K\=+I=&3ML)7ZX)^6.[L*AOQ1;15:7%AC&;&K* M(D-?\7DL&5*FW=Q4+I
MJF>#X3B63,-HPE6\A\1FM0%MJW%PT;FQCYBYZZ:CW=#/NU]^CBO/"3D<=7IR
M>.*N(XZY0S_5=O8]<'W+"YZ7N6_7.Q8.ST_1 X6.+T,_O=U5)6,@9IUR0&T
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M:+-Z^[M=GK]H"O;O[N@O4$L#!!0    ( *J):5&7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ JHEI4:8 !QO-!
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M!7R%A?:<E_FM8?[/?B4YS?QJT*HNRPFTW2B@*(YO@1W?8/OR+U!+ P04
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M<',O87!P+GAM;%!+ 0(4 Q0    ( *J):5&>*A5*[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "JB6E1YJHRB^<"  #1"0  &
M    @($=%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MJHEI48UT,31H!0  414  !@              ("!.A@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *J):5'7RS/,1@,  +$)   8
M          " @=@=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "JB6E17&K@B9P,  "@4   &               @(%4(0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ JHEI40#4C]ZJ"0  D"T
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *J):5%\44;K4P,   @(   9
M      " @?]>  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ JHEI46/L+LA[ P  X <  !D              ("!B6(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "JB6E1H-00/OX"  #8!@
M&0              @($[9@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( *J):5'"(MUQK@(  /4%   9              " @7!I  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ JHEI4<3E4^%\
M!@  9A4  !D              ("!56P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "JB6E1/P*B\P\+  "['P  &0
M@($(<P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *J)
M:5%*AEF8IPD  'PG   9              " @4Y^  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ JHEI4>;I4QC8"   .1T  !D
M         ("!+(@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " "JB6E1%F1!#V<%   F#0  &0              @($[D0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *J):5'$R1-WW L  ,LA
M   9              " @=F6  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ JHEI49=S^&?H"0  <!D  !D              ("![*(
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "JB6E1+Y H
M*#P)  "<&   &0              @($+K0  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( *J):5&01BN(! ,  '$&   9
M  " @7ZV  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MJHEI48TJI)64!   $@P  !D              ("!N;D  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "JB6E1U_[K++\"  !@!@  &0
M            @(&$O@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( *J):5'=SEJ%AP(  &<%   9              " @7K!  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ JHEI4<,2[[$  P
M2@8  !D              ("!.,0  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "JB6E1T('!F< "  #V!0  &0              @(%O
MQP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *J):5'$
M_7"?T@8  *$<   9              " @6;*  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ JHEI46B9UN7) P  K@D  !D
M     ("!;]$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J):5&GTNC&@ 8  /0I   9              "
M@1WB  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ JHEI
M4=<.EH54 @  6 4  !D              ("!U.@  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "JB6E1^BQXPQL#  !*"P  &0
M        @(%?ZP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( *J):5$&>1ZMEP(  .D&   9              " @;'N  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ JHEI49?; 99* P  M P
M !D              ("!?_$  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "JB6E1@G-5+\(#  "3#P  &0              @($ ]0
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *J):5%\\_%6
MN (  +\'   9              " @?GX  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ JHEI4:+GA>$:!   9!,  !D
M ("!Z/L  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "J
MB6E1:)GD^5T(  !]*@  &0              @($Y  $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *J):5')@ZQ  P0  -T2   9
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M970T.2YX;6Q02P$"% ,4    " "JB6E1YQ9/CD(%  #!%P  &0
M    @($8'@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M *J):5$S._;YD00  +X4   9              " @9$C 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ JHEI4?9#$)U_!   ?1,  !D
M             ("!62@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "JB6E18^'3**P#  "3#0  &0              @($/+0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( *J):5'!;T5X?P,
M  T.   9              " @?(P 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ JHEI4>I2 IGH P  2@\  !D              ("!
MJ#0! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "JB6E1
M+I=:K:<"  "&!P  &0              @(''. $ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( *J):5%-K>F65@,   @-   9
M      " @:4[ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ JHEI41QIC7,1!@  "1L  !D              ("!,C\! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "JB6E1*6[-\&8"  ";!@
M&0              @(%Z10$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( *J):5%83]!I10(  (0+   -              "  1=( 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ JHEI49>*NQS     $P(   L
M         ( !ATH! %]R96QS+RYR96QS4$L! A0#%     @ JHEI4:8 !QO-
M!   12<   \              ( !<$L! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *J):5%9=@'X]0$  #@C   :              "  6I0 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *J):5$7R,P;VP$
M -$B   3              "  9=2 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !# $, 3!(  *-4 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>338</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LiquidityandCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Investments - Available-for-Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/InvestmentsAvailableforSale</Role>
      <ShortName>Investments - Available-for-Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/PropertyAndEquipment</Role>
      <ShortName>Property And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/DeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2142113 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2147114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2149115 - Disclosure - Loans and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LoansandSecurityAgreement</Role>
      <ShortName>Loans and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/RevenueRecognition</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Investments - Available-for-Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/InvestmentsAvailableforSaleTables</Role>
      <ShortName>Investments - Available-for-Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/InvestmentsAvailableforSale</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Property And Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property And Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/AccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Loans and Security Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LoansandSecurityAgreementTables</Role>
      <ShortName>Loans and Security Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/LoansandSecurityAgreement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/LiquidityandCapitalResources</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails</Role>
      <ShortName>Revenue Recognition - Nature of Goods and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Investments - Available-for-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails</Role>
      <ShortName>Investments - Available-for-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/InvestmentsAvailableforSaleTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/InventoryTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425410 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/DeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/DeferredRevenue</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429412 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/StockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432413 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433414 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434415 - Disclosure - Stock-Based Compensation - Service Based Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Service Based Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - Stock-Based Compensation - Performance Based Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Performance Based Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Service Based Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails</Role>
      <ShortName>Stock-Based Compensation - Service Based Stock Options - Others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Performance Based Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/RelatedPartyTransactions</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Leases - Summary of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Leases - Future Minimum Rental Payments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Rental Payments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rockwellmed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451426 - Disclosure - Loans and Security Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails</Role>
      <ShortName>Loans and Security Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rmti-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails</Role>
      <ShortName>Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="rmti-20200930.htm">rmti-20200930.htm</File>
    <File>rmti-20200930.xsd</File>
    <File>rmti-20200930_cal.xml</File>
    <File>rmti-20200930_def.xml</File>
    <File>rmti-20200930_lab.xml</File>
    <File>rmti-20200930_pre.xml</File>
    <File>rmti-20200930x10qex311.htm</File>
    <File>rmti-20200930x10qex312.htm</File>
    <File>rmti-20200930x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rmti-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 338,
   "dts": {
    "calculationLink": {
     "local": [
      "rmti-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rmti-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "rmti-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 488,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 45,
   "keyStandard": 336,
   "memberCustom": 39,
   "memberStandard": 27,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://rockwellmed.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Revenue Recognition",
     "role": "http://rockwellmed.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Investments - Available-for-Sale",
     "role": "http://rockwellmed.com/role/InvestmentsAvailableforSale",
     "shortName": "Investments - Available-for-Sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Inventory",
     "role": "http://rockwellmed.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Property And Equipment",
     "role": "http://rockwellmed.com/role/PropertyAndEquipment",
     "shortName": "Property And Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - Accrued Liabilities",
     "role": "http://rockwellmed.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmti:ContractWithCustomerDeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Deferred Revenue",
     "role": "http://rockwellmed.com/role/DeferredRevenue",
     "shortName": "Deferred Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmti:ContractWithCustomerDeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://rockwellmed.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130111 - Disclosure - Stock-Based Compensation",
     "role": "http://rockwellmed.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Related Party Transactions",
     "role": "http://rockwellmed.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142113 - Disclosure - Leases",
     "role": "http://rockwellmed.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147114 - Disclosure - Commitments and Contingencies",
     "role": "http://rockwellmed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149115 - Disclosure - Loans and Security Agreement",
     "role": "http://rockwellmed.com/role/LoansandSecurityAgreement",
     "shortName": "Loans and Security Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://rockwellmed.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Investments - Available-for-Sale (Tables)",
     "role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleTables",
     "shortName": "Investments - Available-for-Sale (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Inventory (Tables)",
     "role": "http://rockwellmed.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Property And Equipment (Tables)",
     "role": "http://rockwellmed.com/role/PropertyAndEquipmentTables",
     "shortName": "Property And Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://rockwellmed.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Leases (Tables)",
     "role": "http://rockwellmed.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Loans and Security Agreement (Tables)",
     "role": "http://rockwellmed.com/role/LoansandSecurityAgreementTables",
     "shortName": "Loans and Security Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Liquidity and Capital Resources (Details)",
     "role": "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
     "shortName": "Liquidity and Capital Resources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "rmti:WorkingCapitalNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)",
     "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rmti:NumberOfDistributionAndLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)",
     "role": "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails",
     "shortName": "Revenue Recognition - Nature of Goods and Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rmti:NumberOfDistributionAndLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "us-gaap:ContractWithCustomerAssetCreditLossExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Investments - Available-for-Sale (Details)",
     "role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails",
     "shortName": "Investments - Available-for-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Inventory (Details)",
     "role": "http://rockwellmed.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Property And Equipment (Details)",
     "role": "http://rockwellmed.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property And Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425410 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://rockwellmed.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Deferred Revenue (Details)",
     "role": "http://rockwellmed.com/role/DeferredRevenueDetails",
     "shortName": "Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031",
      "decimals": "-6",
      "lang": "en-US",
      "name": "rmti:RevenueRecognitionReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429412 - Disclosure - Stockholders\u2019 Equity (Details)",
     "role": "http://rockwellmed.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432413 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
     "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ieb4dad30bf674f2b81a41e72d5349c55_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433414 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ieb4dad30bf674f2b81a41e72d5349c55_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434415 - Disclosure - Stock-Based Compensation - Service Based Restricted Stock Units (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Service Based Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - Stock-Based Compensation - Performance Based Restricted Stock Units (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Performance Based Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i909683c4233b4a22804c27ebf1e6c92b_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
     "shortName": "Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Service Based Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
     "shortName": "Stock-Based Compensation - Service Based Stock Options - Others (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)",
     "role": "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Performance Based Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i72f1121abfa849c8b1387a55992b3591_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rmti:NumberOfAdditionalAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Related Party Transactions (Details)",
     "role": "http://rockwellmed.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rmti:NumberOfAdditionalAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Leases - Narrative (Details)",
     "role": "http://rockwellmed.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i1a68746f2fdd4216add87ba69b052f3f_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Leases - Summary of Operating Leases (Details)",
     "role": "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails",
     "shortName": "Leases - Summary of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Leases - Future Minimum Rental Payments Under Operating Leases (Details)",
     "role": "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails",
     "shortName": "Leases - Future Minimum Rental Payments Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://rockwellmed.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i988157eb43c948b0b48c71a792211e1c_D20200316-20200316",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451426 - Disclosure - Loans and Security Agreement - Narrative (Details)",
     "role": "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
     "shortName": "Loans and Security Agreement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i918e1ec310cd4501850ee5a1d190849e_I20200316",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ia2342dabfb994ca9b8cabed424b37ce7_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)",
     "role": "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails",
     "shortName": "Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ia2342dabfb994ca9b8cabed424b37ce7_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i32f5bee8a4224cc9bb993e924ffa5275_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://rockwellmed.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmti:LiquidityAndFinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Liquidity and Capital Resources",
     "role": "http://rockwellmed.com/role/LiquidityandCapitalResources",
     "shortName": "Liquidity and Capital Resources",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200930.htm",
      "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmti:LiquidityAndFinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]",
        "terseLabel": "Former Address"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrant Modification Expense",
        "label": "Adjustments to Additional Paid in Capital, Warrant Modification Expense",
        "terseLabel": "Warrant Modification Expense"
       }
      }
     },
     "localname": "AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_AssetAcquisitionMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payments related to asset acquisition.",
        "label": "Asset Acquisition Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMilestonePayments",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_AtthemarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At-The-market Offering [Member]",
        "label": "At-the-market Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtthemarketOfferingMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_AveragePaymentTermOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the average payment term of customers.",
        "label": "Average Payment Term of Customers",
        "terseLabel": "Customers average payment term"
       }
      }
     },
     "localname": "AveragePaymentTermOfCustomers",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmti_AveragePaymentTermOfDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the average payment term of distributors.",
        "label": "Average Payment Term of Distributors",
        "terseLabel": "Distributors average payment term"
       }
      }
     },
     "localname": "AveragePaymentTermOfDistributors",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmti_BaxterHealthcareOrganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Baxter Healthcare Organization [Member]",
        "label": "Baxter Healthcare Organization [Member]",
        "terseLabel": "Baxter Healthcare Organization"
       }
      }
     },
     "localname": "BaxterHealthcareOrganizationMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_CertainEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This represents information pertaining to certain employees.",
        "label": "Certain Employees [Member]",
        "terseLabel": "Employee stock options"
       }
      }
     },
     "localname": "CertainEmployeesMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chief Executive Officer, Chief Financial Officer, And Director",
        "label": "Chief Executive Officer, Chief Financial Officer, And Director [Member]",
        "terseLabel": "Chief executive officer, chief financial officer, and director"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded",
        "label": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded",
        "terseLabel": "Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days",
        "label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days",
        "terseLabel": "Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days",
        "label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days",
        "terseLabel": "Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise",
        "label": "Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise",
        "terseLabel": "Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants, at holder's option upon issuance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise",
        "label": "Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise",
        "terseLabel": "Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_ConcentrateProductLicenseFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentrate Product License Fee [Member]",
        "label": "Concentrate Product License Fee [Member]",
        "terseLabel": "Concentrate product license fee"
       }
      }
     },
     "localname": "ConcentrateProductLicenseFeeMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ConcentrateProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentrate Product Sales [Member]",
        "label": "Concentrate Product Sales [Member]",
        "terseLabel": "Concentrate product sales"
       }
      }
     },
     "localname": "ConcentrateProductSalesMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ConcentrateProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentrate Products [Member]",
        "label": "Concentrate Products [Member]",
        "terseLabel": "Concentrate Products"
       }
      }
     },
     "localname": "ConcentrateProductsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ContractWithCustomerDeferredRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer Deferred Revenue [Text Block]",
        "label": "Contract with Customer Deferred Revenue [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerDeferredRevenueTextBlock",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmti_CurrentAndNonCurrentInventory": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of current and non-current inventory.",
        "label": "Current And Non Current Inventory",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentAndNonCurrentInventory",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage",
        "label": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage",
        "terseLabel": "Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage"
       }
      }
     },
     "localname": "DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_DebtInstrumentPeriodOfInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Period Of Interest-Only Payments",
        "label": "Debt Instrument, Period Of Interest-Only Payments",
        "terseLabel": "Period for which company is entitled to make interest-only payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnlyPayments",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current",
        "label": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current",
        "terseLabel": "Accrued Interest Income"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures",
        "label": "Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures",
        "terseLabel": "Estimated expense reduction in stock compensation expense related to forfeited stock awards"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_DeferredRevenueBenefitPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Revenue Benefit Percentage",
        "label": "Deferred Revenue Benefit Percentage",
        "terseLabel": "Refund eligible for, percent of upfront fee"
       }
      }
     },
     "localname": "DeferredRevenueBenefitPercentage",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_DrugLicenseFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug License Fee [Member]",
        "label": "Drug License Fee [Member]",
        "terseLabel": "Drug license fee"
       }
      }
     },
     "localname": "DrugLicenseFeeMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_DrugProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug Product Sales [Member]",
        "label": "Drug Product Sales [Member]",
        "terseLabel": "Drug product sales"
       }
      }
     },
     "localname": "DrugProductSalesMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_DrugRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug Revenue [Member]",
        "label": "Drug Revenue [Member]",
        "terseLabel": "Drug products"
       }
      }
     },
     "localname": "DrugRevenueMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to Executive Vice President and Chief Scientific Officer.",
        "label": "Executive Vice President And Chief Scientific Officer [Member]",
        "terseLabel": "Executive vice president and chief scientific officer"
       }
      }
     },
     "localname": "ExecutiveVicePresidentAndChiefScientificOfficerMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_IncreaseDecreaseInOperatingLeaseLiabilites": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.",
        "label": "Increase Decrease in Operating Lease Liabilites",
        "terseLabel": "Decrease in Lease Liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilites",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_InstallmentPaymentToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with installment payment to related parties.",
        "label": "Installment paid",
        "terseLabel": "Installment paid"
       }
      }
     },
     "localname": "InstallmentPaymentToRelatedParties",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_JeilPharmaAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Jeil Pharma Agreements",
        "label": "Jeil Pharma Agreements [Member]",
        "terseLabel": "Jeil Pharma Agreements"
       }
      }
     },
     "localname": "JeilPharmaAgreementsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_LeaseFacilityOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Lease facility one.",
        "label": "Lease Facility One [Member]",
        "terseLabel": "Lease facility one"
       }
      }
     },
     "localname": "LeaseFacilityOneMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_LeaseFacilityTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Lease facility two.",
        "label": "Lease Facility Two [Member]",
        "terseLabel": "Lease facility two"
       }
      }
     },
     "localname": "LeaseFacilityTwoMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_LiquidityAndFinancialConditionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Liquidity and Capital Resources",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndFinancialConditionAbstract",
     "nsuri": "http://rockwellmed.com/20200930",
     "xbrltype": "stringItemType"
    },
    "rmti_LiquidityAndFinancialConditionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of liquidity position and financial conditions.",
        "label": "Liquidity And Financial Condition [Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndFinancialConditionTextBlock",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResources"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmti_MasterServicesAndIpAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Master services and Ip agreements.",
        "label": "Master Services And Ip Agreement [Member]",
        "terseLabel": "Master services and IP agreements"
       }
      }
     },
     "localname": "MasterServicesAndIpAgreementMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_NumberOfAdditionalAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of additional agreements.",
        "label": "Number of additional agreements",
        "terseLabel": "Number of additional agreements"
       }
      }
     },
     "localname": "NumberOfAdditionalAgreements",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmti_NumberOfDistributionAndLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of distribution and license agreements.",
        "label": "Number of Distribution and License Agreements",
        "terseLabel": "Number of distribution and license agreements"
       }
      }
     },
     "localname": "NumberOfDistributionAndLicenseAgreements",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmti_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Right Of Use Asset Amortization",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of Right of Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_PartialRefund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Partial Refund",
        "label": "Partial Refund",
        "terseLabel": "Partial refund"
       }
      }
     },
     "localname": "PartialRefund",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Stock Issuance Costs And Commissions Fees",
        "label": "Payments Of Stock Issuance Costs And Commissions Fees",
        "terseLabel": "Commissions and offering fees paid"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsAndCommissionsFees",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_PaymentsToAcquireAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount paid to acquire assets.",
        "label": "Payments to Acquire Assets",
        "terseLabel": "Payments to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireAssets",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_PerformanceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to performance based awards.",
        "label": "Performance Based Awards [Member]",
        "terseLabel": "Performance based awards"
       }
      }
     },
     "localname": "PerformanceBasedAwardsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PerformanceBasedRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "na",
        "label": "Performance Based Restricted Stock Awards [Member]",
        "terseLabel": "Restricted stock awards - performance based"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockAwardsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Based Restricted Stock Units [Member]",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Restricted stock units - performance based awards"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PerformanceBasedStockOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "na",
        "label": "Performance Based Stock Option Awards [Member]",
        "terseLabel": "Stock option awards - performance based awards"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionAwardsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "President, Chief Executive Officer, And Chief Financial Officer",
        "label": "President, Chief Executive Officer, And Chief Financial Officer [Member]",
        "terseLabel": "President, chief executive officer, and chief financial officer"
       }
      }
     },
     "localname": "PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_PresidentandChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "President and Chief Executive Officer [Member]",
        "label": "President and Chief Executive Officer [Member]",
        "terseLabel": "President and chief executive officer"
       }
      }
     },
     "localname": "PresidentandChiefExecutiveOfficerMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs",
        "terseLabel": "Proceeds from issuance of common shares, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Registered Direct Offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_RelatedPartyNumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Number Of Installment Payments",
        "label": "Related Party Number Of Installment Payments",
        "terseLabel": "Number of quarterly installment payments"
       }
      }
     },
     "localname": "RelatedPartyNumberOfInstallmentPayments",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees",
        "label": "Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees",
        "terseLabel": "Related party transactions, accrued reimbursement of IP expenses and sublicense royalty fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of related party transactions accrued reimbursement of legal expenses.",
        "label": "Related Party Transactions Accrued Reimbursement of Legal Expenses",
        "terseLabel": "Related party transactions, accrued reimbursement of legal expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repurchase of common shares to pay employee withholding taxes.",
        "label": "Repurchase Of Common Shares To Pay Employee Withholding Taxes",
        "negatedLabel": "Repurchase of Common Stock to Pay Employee Withholding Taxes"
       }
      }
     },
     "localname": "RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Research and Development Related Liabilities, Current",
        "terseLabel": "Accrued Research\u00a0&amp; Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentRelatedLiabilitiesCurrent",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_RevenueRecognitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition [Line Items]",
        "label": "Revenue Recognition [Line Items]",
        "terseLabel": "Revenue Recognition [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionLineItems",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmti_RevenueRecognitionReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of consideration received during the period for the milestone.",
        "label": "Revenue Recognition Received",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionReceived",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_RevenueRecognitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition [Table]",
        "label": "Revenue Recognition [Table]",
        "terseLabel": "Revenue Recognition [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionTable",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Amount Payable For Services Related To Offering",
        "label": "Sale Of Equity, Amount Payable For Services Related To Offering",
        "terseLabel": "Amount payable to financial advisory firm for services related to offering"
       }
      }
     },
     "localname": "SaleOfEquityAmountPayableForServicesRelatedToOffering",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_SaleOfEquityPlacementAgentFeeClearingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Placement Agent Fee, Clearing Fees",
        "label": "Sale Of Equity, Placement Agent Fee, Clearing Fees",
        "terseLabel": "Placement agent fee, clearing fees"
       }
      }
     },
     "localname": "SaleOfEquityPlacementAgentFeeClearingFees",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses",
        "label": "Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses",
        "terseLabel": "Placement agent fee, non-accountable expenses"
       }
      }
     },
     "localname": "SaleOfEquityPlacementAgentFeeNonAccountableExpenses",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants",
        "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants",
        "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of any warrants issued in the offering from the exercise of warrants during the remainder term of such warrants"
       }
      }
     },
     "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors",
        "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors",
        "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of warrants issued to investors"
       }
      }
     },
     "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering",
        "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering",
        "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds raised in Offering"
       }
      }
     },
     "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_SaleofStockRemainingSalesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Stock, Remaining Sales Amount",
        "label": "Sale of Stock, Remaining Sales Amount",
        "terseLabel": "Remaining amount available for sale"
       }
      }
     },
     "localname": "SaleofStockRemainingSalesAmount",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_SalesAgreementThresholdSaleOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of threshold offering or sale of shares under the sales agreement.",
        "label": "Sales Agreement, Threshold Sale Of Shares",
        "terseLabel": "Sales agreement, threshold sale of shares"
       }
      }
     },
     "localname": "SalesAgreementThresholdSaleOfShares",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_ServiceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to service based awards.",
        "label": "Service Based Awards [Member]",
        "terseLabel": "Service based awards"
       }
      }
     },
     "localname": "ServiceBasedAwardsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "na",
        "label": "Service Based Restricted Stock Units [Member]",
        "terseLabel": "Restricted stock units - service based awards",
        "verboseLabel": "Restricted stock units - service based awards"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ServiceBasedStockOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "na",
        "label": "Service Based Stock Option Awards [Member]",
        "terseLabel": "Stock option awards - service based awards"
       }
      }
     },
     "localname": "ServiceBasedStockOptionAwardsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_SettlementAgreementWithAllPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent information relating to settlement agreement with all parties to the class action.",
        "label": "Settlement Agreement With All Parties [Member]",
        "terseLabel": "Settlement agreement with all parties"
       }
      }
     },
     "localname": "SettlementAgreementWithAllPartiesMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NA",
        "label": "Aggregate intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NA",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2",
        "terseLabel": "Granted, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmti_SunPharmaAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sun Pharma Agreements [Member]",
        "label": "Sun Pharma Agreements [Member]",
        "terseLabel": "Sun Pharma Agreements"
       }
      }
     },
     "localname": "SunPharmaAgreementsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_SupplyAgreementPercentageOfRawMaterialsPaid": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supply Agreement, Percentage Of Raw Materials Paid",
        "label": "Supply Agreement, Percentage Of Raw Materials Paid",
        "terseLabel": "Percentage of raw materials paid"
       }
      }
     },
     "localname": "SupplyAgreementPercentageOfRawMaterialsPaid",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supply Agreement, Percentage Of Raw Materials To Be Paid",
        "label": "Supply Agreement, Percentage Of Raw Materials To Be Paid",
        "terseLabel": "Percentage of raw materials to be paid"
       }
      }
     },
     "localname": "SupplyAgreementPercentageOfRawMaterialsToBePaid",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmti_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TermLoanTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche One [Member]",
        "label": "Term Loan, Tranche One [Member]",
        "terseLabel": "Term loan, first tranche"
       }
      }
     },
     "localname": "TermLoanTrancheOneMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TermLoanTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche Three [Member]",
        "label": "Term Loan, Tranche Three [Member]",
        "terseLabel": "Term loan, third tranche"
       }
      }
     },
     "localname": "TermLoanTrancheThreeMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TermLoanTrancheTwoAndTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche Two And Tranche Three [Member]",
        "label": "Term Loan, Tranche Two And Tranche Three [Member]",
        "terseLabel": "Term loan, second and third tranches"
       }
      }
     },
     "localname": "TermLoanTrancheTwoAndTrancheThreeMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TermLoanTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche Two [Member]",
        "label": "Term Loan, Tranche Two [Member]",
        "terseLabel": "Term loan, second tranche"
       }
      }
     },
     "localname": "TermLoanTrancheTwoMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TrifericAPIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Triferic API [Member]",
        "label": "Triferic API [Member]",
        "terseLabel": "Triferic API"
       }
      }
     },
     "localname": "TrifericAPIMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TrifericDialysateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Triferic Dialysate [Member]",
        "label": "Triferic Dialysate [Member]",
        "terseLabel": "Triferic Dialysate"
       }
      }
     },
     "localname": "TrifericDialysateMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_TrifericInventoryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Triferic Inventory [Member]",
        "label": "Triferic Inventory [Member]",
        "terseLabel": "Triferic Inventory"
       }
      }
     },
     "localname": "TrifericInventoryMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_WanbangBiopharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (\u201cWanbang\u201d) for the rights to commercialize the Triferic and Calcitriol drugs.",
        "label": "Wanbang Biopharmaceutical [Member]",
        "terseLabel": "Wanbang Biopharmaceutical"
       }
      }
     },
     "localname": "WanbangBiopharmaceuticalMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmti_WorkingCapitalNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the monetary amount of working capital, as of the indicated date.",
        "label": "Working Capital Net",
        "terseLabel": "Working capital net"
       }
      }
     },
     "localname": "WorkingCapitalNet",
     "nsuri": "http://rockwellmed.com/20200930",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief financial officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r127",
      "r199",
      "r203",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r128",
      "r199",
      "r204",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r156",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r129",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MI": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MICHIGAN",
        "terseLabel": "Wixom, Michigan"
       }
      }
     },
     "localname": "MI",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Hackensack, New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "Greer, South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TEXAS",
        "terseLabel": "Grapevine, Texas"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r130",
      "r131",
      "r200"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued Liabilities",
        "totalLabel": "Total Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails",
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued Marketing Expenses"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued Legal Expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r151"
     ],
     "calculation": {
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "verboseLabel": "Stock-based Compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r170",
      "r181",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Warrants related to Debt Financing"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r208",
      "r231",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expenses",
        "verboseLabel": "Total share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r91",
      "r250"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of Debt Financing Costs and Accretion of Debt Discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Securities excluded from diluted loss per share calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Earnings per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "verboseLabel": "Facility sqft."
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r279",
      "r289"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r53"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r134",
      "r141"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "netLabel": "Investments available-for-sale",
        "terseLabel": "Investments Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails",
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r209",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r32",
      "r93"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r93",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r245"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (Decrease) in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r107",
      "r189",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares of common stock each warrant is exercisable for (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares of common stock for which warrant is exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r155",
      "r284",
      "r294"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (up to) (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "COMMON STOCK"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "End balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Amount allocated to common stock",
        "verboseLabel": "Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,573,165 and 65,378,890 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Contract balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCreditLossExpense": {
     "auth_ref": [
      "r140",
      "r194",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCreditLossExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r191",
      "r193",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r191",
      "r192",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails",
      "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r191",
      "r192",
      "r200"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred License Revenue - Current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r191",
      "r192",
      "r200"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred License Revenue - Long-Term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Recognized deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.",
        "label": "Contract with Customer, Refund Liability",
        "verboseLabel": "Reserve for returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Customer Deposits"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Loans and Security Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r280",
      "r281",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate, additional percentage added to base percentage"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r171",
      "r281",
      "r288"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Principal Payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r249",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Initial interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r174",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "verboseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, base percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r104",
      "r182",
      "r185",
      "r186",
      "r187",
      "r248",
      "r249",
      "r251",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r248",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Additional debt discount recognized"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r172",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized issuance costs and unaccreted discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized Gain on Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Investments available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSaleTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r91",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r91",
      "r125"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r36",
      "r108",
      "r270"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Other Current Liability - Related Party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r108",
      "r270",
      "r283",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Total amount due"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued Compensation and Benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years)",
        "verboseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r91",
      "r177"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Warrant Modification Expense",
        "terseLabel": "Warrant Modification Expense"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss (Gain) on Disposal of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedLabel": "Realized (Gain) on Sale of Investments Available-for-Sale"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase (Decrease) in Accounts Payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in Accounts Receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Decrease in Deferred License Revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) in insurance liability balances during the period.",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "verboseLabel": "Decrease in Settlement Payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.",
        "label": "Increase (Decrease) in Insurance Settlements Receivable",
        "negatedLabel": "Decrease in Insurance Receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "(Increase) Decrease in Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedTotalLabel": "Changes in Assets and Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in Assets and Liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Increase (Decrease) in Other Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease in Prepaid and Other Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r124",
      "r247",
      "r250",
      "r286"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r74",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r86",
      "r88",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash Paid for Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r145"
     ],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "rmti_CurrentAndNonCurrentInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished Goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r143"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "terseLabel": "Increase in Inventory Reserves"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r47",
      "r142"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, noncurrent",
        "verboseLabel": "Inventory, Non-Current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r145"
     ],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "rmti_CurrentAndNonCurrentInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw Materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r47",
      "r110",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory, reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r145"
     ],
     "calculation": {
      "http://rockwellmed.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "rmti_CurrentAndNonCurrentInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in Process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r123"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest Income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Investments - Available-for-Sale"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InvestmentsAvailableforSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total rent expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future minimum rental payments under operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "Year ending December 31, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Year ending December 31, 2020 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r282",
      "r292"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r43",
      "r155",
      "r164"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Settlement Payable"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Settlement Expense",
        "verboseLabel": "Settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r173",
      "r281",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balance, net of unamortized issuance costs and unaccreted discount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r109",
      "r168"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r109",
      "r168"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r109",
      "r168"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r109",
      "r168"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r109",
      "r168"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Term Loan, Net of Issuance Costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r163",
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r155",
      "r158",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Amount of penalties sought from supplier"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash Provided By (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Cash Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r63",
      "r65",
      "r69",
      "r92",
      "r114",
      "r285",
      "r296"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAssumed1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of notes assumed in noncash investing or financing activities.",
        "label": "Notes Assumed",
        "terseLabel": "Insurance Financing Note Payable"
       }
      }
     },
     "localname": "NotesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r15",
      "r281",
      "r290"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Insurance Financing Note Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Information Technology\u00a0&amp; Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r259",
      "r268"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "totalLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails",
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease Liability - Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease Liability - Long-Term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of Use Assets, net",
        "verboseLabel": "Operating lease, right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r265",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate \u2013 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r264",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term \u2013 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r9",
      "r39"
     ],
     "calculation": {
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Non-Current Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r56",
      "r57",
      "r59"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments",
        "verboseLabel": "Unrealized Gain (Loss) on Available-for-Sale Investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r55",
      "r246"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Change in Unrealized Loss on Marketable Securities Available-for-Sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income (Expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Receivables, which are included in \"Trade and other receivables\""
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Closing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Offering Costs from the Issuance of Common Stock / Public Offering",
        "terseLabel": "Common share issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r78",
      "r133"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of Investments Available-for-Sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Purchase of Research and Development Licenses (Related Party)"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchase of Equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, shares authorized (in shares)",
        "verboseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net draw down proceeds"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
      "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the Issuance of Common Stock / Public Offering",
        "verboseLabel": "Proceeds from the issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from Term Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds from issuance of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r77",
      "r133"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sale of Investments Available-for-Sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r234"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the Exercise of Employee Stock Options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r150"
     ],
     "calculation": {
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r152",
      "r293"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and Equipment, net",
        "totalLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of major classes of property and equipment, stated at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Payments on Short Term Note Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r238",
      "r302"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and Product Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r188",
      "r291"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "ACCUMULATED DEFICIT"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r197",
      "r199"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net Revenue",
        "verboseLabel": "Net Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r263",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets exchanged for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Common shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of potentially dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r208",
      "r230",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r208",
      "r230",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of total stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of principal payments on term loan"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LoansandSecurityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r101",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r209",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r212",
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of stock option assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r103",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling and Marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)",
        "verboseLabel": "Unvested, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)",
        "verboseLabel": "Unvested, weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Fair value assumptions:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stock option awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expirations (in shares)",
        "terseLabel": "Expirations (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r214",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Underlying Options",
        "verboseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r207",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
      "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
      "http://rockwellmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average selling price (in dollars per share)",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expirations (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r260",
      "r268"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease rent expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Fair Value of Warrants issued related to Debt Financing"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r181",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r17",
      "r181",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r181",
      "r188",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of employee stock options, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r181",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r181",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of Restricted Stock Units Issued, net of taxes withheld"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.",
        "label": "Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)",
        "terseLabel": "Exercise of Employee Stock Options, Net of Tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r132"
     ],
     "calculation": {
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "End balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/StockholdersEquityDetails",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred at point in time.",
        "label": "Transferred at Point in Time [Member]",
        "terseLabel": "Product Sales \u2013 Point-in-time"
       }
      }
     },
     "localname": "TransferredAtPointInTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "License Fee \u2013 Over time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesNarrativeDetails",
      "http://rockwellmed.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r261",
      "r268"
     ],
     "calculation": {
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r303": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r304": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r305": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r306": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r307": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r308": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r309": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001628280-20-016121-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-016121-xbrl.zip
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M9G5GM4'D+]"$)@']C;C!X]&H9C(/WM'H+H0UYR]+UOI$+HE0L@(-GE\]HG
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M@1/)DF&AO/"AB2GTJQ"8^$F%<(E0-,&,^&EE8>&G!_+3M89E7A'-C?40N2'
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MTLXPD6&"\$5BI[Q,[-3S"&XF%3H>W%<,V*D,V$_CN.;9-O[(2*0:)PM6R\"
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MSQJ#'XT,?PR1NE$RTF@ZKKV<GF3&$<&!&>^EIAA3:Y4Q2A&O, U!,RQ8.K!
M$F&"2L;1Y6<7Q_&SXP_LT\Z_OWT\_G=[__ MW/OIVA\//Y[N'W[\\?'P&]W[
M^]]?/^*W/\^?77P\?G7\Z;#S+9U/?#S>1?L[;W_NXW\?[>?SCE='!X=??GP\
MWO_Z:6<_[+5')\SOX>EGZJ@4(9<C@AA0)QC0EE#@$$8B&"^P1QM;3+0@H2W$
M+I:57J.3BV55];Z/D\\AZ;6/D^\$<E8.I*]_9KST\Z\IU"X(1[\1SCZ?.)V'
M0]"?$P05%&$AH 9$.@<HE!0HF(J\>6\%Y,92QS:V> '. IP%.!\+."TR CH1
M% N*PHB:!GOL!")>6NR5O1PXGWU$S<-A*II@JI%4>8(T4%P(0 -&0&//@!%6
M(:@DA8%L;&&E6DP59"W(6I#U\5)ND(XJ20A%$!/JE%%$8NR"H$0;;)VZ'%I+
MRLW#8RR98JS23"CH@#%! ^J5 MI1!B#&GG#$&"$R8JS +2+E+=)M"L05B%M!
MB%NF!W2PWC =C3R'J(CT0QDH:+"&6(^LP,7J?BCT8A/T\C3R=JXA$"IB%J4,
M 16T!Q*SX!@FP5D8K>Z+>8*%'!;D+,CY0,CI"(,A8$&4])1[(KEC7@A-8'#8
M65?,[A4 U1^3\G/;GX7GGE,1 +8ZPFHTMX'1D )-$,)"8>T#3J2PA84HT/K<
M:GPNGOI]/ZA>]_K]9];#M#1D*F(J8BIB>E9B6L8QR")=8)A[BIFA5FE%4;39
MG$ZU>+R"-M5B1PJB7(L]OB!WX2&,F]%NU_:.?=J1"A-<A@F>S3@'"7,L6M$*
MN.!Q-*\#!$I9#0C!F@>,L?!F8TNVN+A8>V+I2CQ%?0O*%C'=$&6#HT8(*U!0
MF$(D%%12<N52\3.$H"DHNVHH.VMO4ZJ)"$P"IC4$U$ &I,=15-9Q'J@CSL&5
MPMFG%2Z^6/T^=&L?A_'3NVS75E$!M[_K=B=E](*H(^!]7.[5;O>['W6&N4W@
M^!K"T\UVD<4+X3$=UD5,14Q%3$5,14Q/1TS+4&>G6&#::..EI(PCHXFV05&$
MG)1(DV6H\SP_/A@<^3HU@ZO]D>_VV]_]E"Y/J,2K7IV(Q'MOAW5[T/;]::^Y
MW(/]4/\HU'H):KW_8B8^ "'-3$ &,!<(H-BEO*:@@: (JM1TW5J\L77Q#&OI
MN*:BVJNHVG=I%1?57@75GK6:"0J6)KU64B! D8= ><N!XXC0*$5"U.HH]W,X
M H[K/?ZS6[T8UK7OVK/JL(YWZ^0^J-5,"]5R1%S<K45,14Q%3$5,14SKTE3]
M#NSDV9.EG[[N.=T_6H99CPC&F%]D>M$,?+OK9LA&X=FWX]GO9TQHYC154'!
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M4Q'3NE#I.["1K]./Y"J"/2(88WZ1Z44S\.VNFR$;A6[?DF[OSMK1FB'D;?"
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MWLW0A_=QH2?JD X8Q^G(V]]UNY-*N8'(S4&ZXIFY+AXXA>0R;$HS?Q!F)%.
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M(]OCQJ).[*P7^J0]2-\H&+8$AKV=I2E4&B298@ )HR--40I(#2-7(8Q@XT7
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M\I%K69I!-5[^U8M>_]GU05_U#+"#D&0T%E&64 &FI8!IKNP3CM*+PC(IW$D
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MA3"!:"J4U,0*3 UGG,. (+__4Y%&<EEP!;V60J^/<U6JB9=<*0*(C_2",B*
M3 4MB.%(T<@) ],;6Y2T$+W83:/$1S\9A=:(2>$\YEP9JN*B$*ELL4<0<\(L
M-?>5!UX4^DX4>N9@1'.K(>% >XL!E1X"Y1(GH0(&8;$4(I6=ERTA+C8W+^Z+
MAU+-,<5HCD0>C)P\$[OI(=G)Q*#*<BI^V)OCV%S5/!CM)Y%B#@ES.E7-,T R
M3 'DRD5N @5"/L5&TU5ICES<'W>MQ@_*28H:WZ$:3^D(EMIHP3@(BBA H4;
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M/J(;@^@BW&Q-3:1V,@I]8UW,+IFQ47YNBVF*^TX.'LQ94\LJ;5;Y29."=_S
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M-W+)#J0QB4Q0/%O<)#E^)H?#(S'F/:;.9_$I*&):M.4*IT^_,KU4++[*#:5
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MX%DMMX)3+9S0*066/(_:&<H%2U%%[[$P.A8%7R@%GX12@XT<&TZ15BPA;KU
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M:^+=2$8#,R R&I29<!VTIA(;*GRB7A%"Q5";5='FIUSFP&(, MPR6)0 R\P
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MPIN@E=;*\!"%UB$$3"VAW('CPZ[??LK"SGIA QBIRAO +24,XEA;9*5,R(<
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M<6$4,LEB1*7 S(04=191LG8UVVR\I^82J'&UZS6[%2QNO]7/^RB\?Q=!<(3
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M &!4&#DEHC;$"6+-9986KKPW"2=K9.0F,B<MQE98(0%?B;Y"S#%:@\I(&B_
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MLCRF)G]Z[N'W=LR_ ""MUYW.J]=O!*N"4W?!J>D(OF:)>?#G4306;!1% *+
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MK*LU=8?ZN;?EVCSB(*A2/!@1*5P/45@+JQ5S7GD:$^/I%K]I*0Z/%P=_><B
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M:48\: 2"H\*@D9-865?3Q2!TBYRL!WKDYG7$36-\#_+%<46T!YX1<$SP6.B
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MELAYYA#77" M4D*6Z.!)4E'&'$4WD_MW=N.\W+K+JW"5X9$;2S71H' #-T&
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MLI![_5M$>=#2>99C8CV<JS>[8%AD<"K6)6+J&+4<4VL4)3*0I!)/GBJP'B*
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MI+;I?U;W_CRI@8V^3S\>5S\=P'6&QO[I/]<S$JU0)"@1$7-2(J!X'%GL<Y^
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MC'$&%KX02JOD70I14S/1O;3L KSTDOXY-WA,U@-@88=DR'.-$I= [$'$<1Y
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MH\^-6=."/213A>=//JSIYWVM.PE[DCZCM#S9UW6RL^5!O=>$I5[;UIRI] T
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M:@".&3;(\-P ;X@D8D6#PRDH9^UBGO98".HFRL/#?@B%2"Q ! "P3T)JQQP
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MI/-<2 X J(QZ:$?-TIS-W>#%>5R@6#I0O?W9W,+/O[2<\*YG<W=#R>9L[GG
MXX0!VCPZ[2Q&3'.1NLY$I 08@\(0H:/D@GOUH!ZLI^HYPQ?J.?,X'?4>ND_*
MTX[R)?#P&_JD/ @/_U7ZI#P=%[^V9F[3(N6I]IGI\U(A&?:<$A2\#\G+*)#-
MB4 NYI0)+P7A^,%*Y=Y%OQZ[\/_#4/%?I*SXO>CX<R\K_M,I^4^&RH:H/QR
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MO^3,4 W"EMJ[8A^=!D+9=-I>4DE[>P[;K4T]> %ND2M8OZ5@NKN8HQA,H#;
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ML--O+Z'8TR->G&@_+,^>4.%)0&^_F!_ ^^YHV*\YUV\K\#3CR,&K"7@)*?5
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MHQ0_V\]"54B@V@7F[S[9I*?"]JLSA<E&4YP_IUW^S^#,:% >PZ2SYG3',]#
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M,(YG AQ3IKV1,GA,&;*Y M/><HX4,!#$.<NQ%I83PQO@:("C81P-<&Q..S<
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MK@>@\48UNQ--T=I+L&?MIB32)W8YO&\/VP>%?7C;@<X82$0]YLB+*[YJ#\%
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M\4170MT/:5$'LT!8?#7MS45#M\G*@_@:!^--VTUZDN/VH!-,@92#,;N!2QX
M]M<6R@D0)%AR$*QZ:YC?=WQ_!'9(O;6L)M %"R8%G]QB@[-GY36W/B\(N<N*
M1Q-SC5_$I$KC/Y_TW+<Q*@W:,!+3?V)TNEH72A@JQWP!B.;>?E0HJF%H%F$N
M$\FI&]?@T>I]+Y=%%<LB+X>/@EX\%'84:S$-"L7ZS%WK%.#>G";&6.E!=MH;
M=<HC77C(P2A<^H0G_1Y8TY567J%BT^3QCZ3LA9+[BBC"@U7R,G_MRO_0.:O0
M9:SYL=T'R:G=$[ B:=K^*,[OS-@KEYV"'=Q-L=_ ,=()&8@BO)O@J-_K +A_
M3R?F8_)7WJ)P9=0'9LFI5TQ?;Q FOP-EBS&A\?< O+H_F?D$?8<!IFP\@FF_
MQP3-QN1W[(R9?_#"0NH!$76])*!I1E.0]"!T5BN"Z,-)*% F\["1.?CR>+<J
M&/,?Z7NKJ:Z=2=,\ZM2GI6GWJP[O81U&:?^<@EQC>Z/AI4.RHT&[F,Q3F)/2
M/50_)JQ/-)W!/)3_<CA*10VD$5!NK#B#(2!/R6_KS?"X5^[5Z0CUY*27=#A-
M2G92 S#,>O'&S*HFO][$Y$^K,!N^][/I_!7.R F=_;X&MW#?3D.G\\ACO'9$
MY2Q=A?$U(5G&N2PWK><PC5/Q"=N -DD="*[5H3R9+3;^!"E%R$,1(3HESS6-
M&Y[VJDN"#E3*D3YS/32G(H5.U&]7BC(UC/'QW60<Q3<_3"Y0$QLW[4BKXQ#&
MVVN-]^VNZXQ\M5T.X&LE4)I2E<V@>!]PON"@XU^7PX2)"@6Q+6)#!O,D8HY1
M7<8F'HU,3 >3;D_%DY'R)WH^PF1P&FK+Z/IY^T7P?7UT &/*9#T;A9T)Q*(]
MB?V9P9.K0V[&,0I3LW:)#I7_?DB4"NRG^A[)LU6+?->W2Z&[)IYA=ME.V\6H
M2QMF2@,6B9USG'D&Q(:S@#DGTCAXH4+.C$PG['G5\EMAB>H7=X^=&Y\X?AX_
M6YGYM0X4%,1LI[>=K/4/L!!G+S:.KK7A1.OC?G &RQ@%XDZ$%$GGD2)*((=Q
MY"QB;)U.D707:U#6D70SUO]DQK,JV>[W1,!#;2 DD@VFTZC3J6/&:O=+G:UT
M5J!AKWAOX@BHQ+NP74K*66C)K(Z$'R?I<*.XX@G8#C_:B45VSA8/]30L]X;A
M& 'V4A"SXDH"6,1<$F&-E',=ZN?C<>XMKF_+)WG!POD-;W_<)SP73IJ( B.I
M9W/ND"7*H2 BQ9A3&D18>8W7+N:FS(9YUJ;=654XIH[+K+?Y\J\R5(?HM6R[
M=GO-"?,L+A9&6]N.B@UL6MX60D9)O(XV1!8DXSQWUN,0F)>:,A--N#S/HA&U
MAQ.UG?64A\$)4\)QCIA,$<6,Y$@9 XB8\X"UIB3"O(.HD2M%;6+:5^G@83XF
ML!\*+V.*4RC$:2JRYX*[L3*\BTV[<J9/062[.QCU3=<ESR58 P5F3@>750*-
MZ]BSG?$X?.G3F-_YR_$D-TT<%4RL=EG>9ER3T3C3[[=#O[SAU/4+_T]2D>^3
M2Y>DOC>=A9!7XUWD[/E9'E5MP$6_EZR]/*^ZZW'[DE'>B1/XST0:WX=T*-?N
MCXVE?])EVX5K=^S7F)Z,B8L5Y&+]I-_N9)25J)QV^S>)+[1Z:QEY131RWQ&F
M3++2P3&Y]=^]PV[VH8C;O\MMMX#I5F;?53>5<O;,X[)+#>K#CX=R:J_.>)1G
MC,#I7>DW4+5N+QUD3_&G\DRG]HK7D5-7'/R#(=BO@YJKX[R)'W#ZL3?!EOC>
M]BF*?W(V-C[SF4KMN71^*KL6,&,T*(_#*M-]QGM_Z3T*&IE"D0!NX7<1/G?M
MA"!^-#Q;36@S+%C@Q,.9[I7.[=(SC;I):X 'P P?%B&4-P^U\&I>,Z!R,+"\
M,(+"ACZ[/&CM),48# OKO/:4UB[KTDE:1A0?&Y_< =7Q89+C]/.Y0ZM)^,8M
M7..E/_C-UN>2P\#U_S,RL'',RL#_#"9^\](7/.?8OGFJ?)DS9[*C43\=>[9-
M9Q4&&+X5,1N];A@6"U4F-$T[H0^2S[Q;;",SMX9= ZR2U(6E'Y(XIIB)HU&W
M\)$G(R*%6?2Z%]:FEMA*K(L#V&+:TP^KP]U^BB\<%N']I6@8 -E^-YR-?Q5#
M&*QEM?&1-K@DJ\F+,6.*KS7AA=>$%_(FO+ )+_SUPPL7SOJ]-![Q%O&%/_G9
MB4BU"*=SYR:'ER&=Z@$.#Z;(K9_L"_6.#K*1SDEO9SW\-BB#!JLLR?&AY'$W
MF3ZES92N9E*>8IGZ.&</M1-H;U=43EV29K-ZS59>API.>3JKX(!DSZ0MY$/I
MP5WY?=Y?6QCB2<K;)Z/..)!P8FO7)N)Q..ZEC1'F?S#EH.U-N1VF[O,_E_B!
M+]U[U[)L/3L,IHB"[+F"QX&YE7;-,&MR57YI4AF(XV>>/6@I#K [U6E+:;Z-
MN<=X1&N/<ZQ$;B65V1.=:<VKQ/_<5K:+_*[*Q)ZSP:^D]!-R<44+Q-O7)H&-
M<HF+DXBU[)$KDFP$.URZTB-PC?7O>]V_#_?.>Z*U\_;'WL;;T]WSO>/6T1>\
M=?3N>/?H(]NB'_GV7[NG6T>[=.LO^.UGC??^WR%VQ_]TS5<]VC[Z1K9VWGU+
MU89:Q\G-]?%LZ^M>N[7ASO<V#OC>T?I9ZV@7KOOMQ_\[W^+;.P?[/!+"<H^1
M=#XB+IQ!AIJ(M,ZYT)C ].+Y\'><<VJ9-D)2DQRR1@AJE(E1<AF]HO.U1][W
M3)F64\40GF7CS,*'KCQR\]!F'\5:ISUA@@2A4CT'BX,'<<*YC#A:D5_)II?,
MZ;)=!8V65@K)Z_VN/O>OXO/!#-OLNK5B,<8?[0 Z#9)3P91&4/I&$=GS9Z_?
M[YT6$;QSF]PU*UIME,4WQF_"-EF$26QVN[WOA<7Z'DS2[#/LTMV4*_"^JN3^
M#E QVUS-WG_(?EL9?WGE]V(X14/+81%O!W;"5,9UI^ B@^)4M? K]L.PMUH&
ME54GH.6>.[YB%;A4_G"U//0LXF..S;<P]HVD'3GKP(.,#VJG2I<4O.?@()GC
M8+B>P'[KVB=I:*4;%>"[S*1;Y!Q $Q5(<(Q@Y[G 1 D<@C#$I]-0KD.5O,M(
M?B%Y]];^_P1_F]T!:&9:F'?&A;F*F$_L_'\")/QXOG6P;Q15UF.!@H!_.,T-
MTIQQ1!,/=XY%[N3*:R:NJ2=2Q[$GL4GR/TBQHTFDJT",263A0H=#W!H? U6,
M2PYRH07)J01+("H,@\*-4#R.4+#6P;[.HY(6IQ,A'A WN4(*YP+!BG@*G"-8
MF;I_T+6+'=#&0C%,Y ]6_M14(;<AV<.]V2C_^H!F*OLG%1/H=0]2>BSL..UD
MX@"<^)07WBL/O5,@Q_CR(%\+%3(2&/:]2'(3"1<@[88;:Y0#T DL%ZR1JD>1
MJB]\:WT_DBA93G2J]Y8C[F*.#+!VH& 1['L5E8I\Y?5U2%,;D4FFANURZRHV
M)'>82@[55F*]D<&OPF#8ZQ9.Z20Z529&EGPSLX)W;%(:RA4B-SQL]^\L<9Y9
MEUIVN2 ]L$X-CXP=D=)3043(>2-QCR)QC@*.<0J&$W$!>:=,ZF+DD6$@<0Z'
MHC<[\10V-WD=C!65<*Z1L524,_VB*.=4B]MJ%?18NPRN^.WX@&( BY2\(?TP
M2(ZDP1KPXV$I@+YWVBW/ 8*OO.\+1?/D,F>.&JN)Y%090X57Q,)V:K"ULJ[+
ME,[\+Q/#A4(L/E2C?-?O'2>)A&?8CIN#1$9=>-,;# <O6!Z__0!Y!'N+>A\Q
MPB3%5X141-QJAPBC.<:4<)N*B%.R=K&*^%@@"X,B6?%E=&_*=%T0D7ZJ3%3]
M,5+7[,(3WCUX\9* MS[N6Y,;28!<A<+_H &CK(\6B8"-5(%J*<G*:[+&KA2$
MM6R!PILKS[Q@YQQ'+')4.U.F:W%B"N"+>MW.65W'L#PKO]:MYG/8"O)@F<PY
MUU)+FM-D@P:B9:3YI9HP)?OP..Z5'_5/>WT_"-V96E*S>_('N'G/ QQ6 ]V&
M<=:Z\>(TX.WIUH;;SRT+><XI"BH5C5(85  8./R#G6)*:LY)*M;03MZ-8UBV
MPPL%>U=3^G'I;[ANF0'AI!; -PD67.K<TM3#.04>YMP+$9IE?JQE/EK?%U@R
ME<NTN)8A;@5%*G=@6N:@;6!F4JMQO<R "3^N6.JL/>%-4Y'\*:_R. RKS/"Q
M!Z(,W(?U2[$3\S:G* ,>BJ_8%!9;HT=6I6X>](.I$B!_:_^>?>@#E&6?DK\K
M11CY$(NLZ\H9-NOQ*Z.-?FO#SQ8K8'</']AUMD MB&GTQ0FTGQ2U6YH2=D\A
MFV=PSWUO3 PR:D ?1U,%<N!C43H4<*Z!JN6":.!C?$U>-!#^NZJ9N]@J!T8-
M,"ZOC2+<4V>8R ,F.H;$_G)R _6Z<;G_3#5>/I^ _/KM[C^FWTY'Q&GMR4M?
M[&_[EL-D2^Q1KE,''X!^I!4W@$;<:"L4]3&DQ<:7E2DL6+?ICO/4QI!1Q&\!
M4/Q4.>"W5_J-HA9=N2^];!EH;7S9-](%&H%I +NSB/OHD V>("M]\-2ZG$>S
M\EI=JO I@+&HW'Q<QLMULW&^^GW%X6[@?Z$EV-52\+8>:8/^I3!L[VSN!\*\
M=HHB(;P#],\I,D)3Y+&T/(]4J1P @> U?5$89KV'AU46:^^D/$HL W7&=*7=
M=Z/CP3"Y009%^13C%ZUO>V]Z< E9W2Y&N]-;]WY:5DK7X4YO>S1,8TY.K _U
M,=^?II.>8K/[OAU&V[&BMHU0%4)UWDITEV% $J>0XC(YN<'$M\FZE]$0+#4&
MRY(EP_[272;%,X^*E.EI.*F.5NN$UL/0S7J3M9DZ@[7EZB1FVH'U*9*@S5E1
M_2==M;I.DD@S.%S+WE6I8<GO6(::=8'85OQ[OCCI;%K-ZF2(=>9A>?72)E_H
MG,]XR<$6$[ #<Y!I)84F)-?.*\H\&5>.?X@DL%K,J\2OI XOV!&U>YK>W]K9
M@OO!D^Y\V:=*!$,8<"(//(F#R8RTIAX%HW* &DZ*C%A\749L$J.%CD<HL38'
MSH.IY%P8'1@S# -78SQ0Q6^1 ]BL\36@1+?.W^YCXSBV*B( 'Y8.^0&4B,"(
M&!NM$M(X$Z[W-A8) R<EA^B<79VE]DNY'L>ACK,V?O) %C4CRH2^E*U=YMC,
MYR/=&&Z4?1@?[)3.B&R4(LB3V_*TUR_21IPY26EV90+4( 7W7C*@JA1<RE\:
M#.&1^V>35,RZSD;R>)@^#*)(TBD+(GP/W;*FWV!DCV!QBU(YXTLXTP=JF[::
MNCI24<AC,%7<:7R)LN!TB?Z=]G]&;5^DLY<']44*3S:$:?@^WE[*(R^8L$E=
MN7&).[A2<K_8<-#N=F>J@)X4=DQ6A4U=TFG@:PHW[:;:6K DR?ESUAN5-;E.
MBT^RE A:.9&.3SKM8K\<7W[R."6#2^6(9J=Z',9LSNKZ3T4WIBQ\KP[W?(@&
MWE[+MN''==)J48+H./5GJ>\UF+Y;=?IL_/?0'Z0L:E/P]5*^BBNGTB1G*>XA
M#:G*2"IW\/##I."*U4N<45-R45'1*U>N*J9:KLH5):ZR7O>@E[[X9ON?S0W
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M*<<;&CMW.'"QZ#&"*]0C%*:,3""0#S )D'UZ#<<4> QR P_[+@C1P@+[8-F
M[_; ;V\D3''N(D&BA8(]K(CXA=*6)JI%<@8."\S@"[S4"S(>J[0.1F&6Y@Q
M@=*)6Q<LE'/=:KJ5(!E8=!?((\=AF)*K!=4#\9W-RGAAD(KG>(\R[\ \9PKO
M;)@/\A4^LF3]0]N\6L:EV5F0Q'\(STEGH5B!I;K.7-]K.Q<BA0^@K14!.6 7
MW/%,/-A\2U +GIE2B<MVQA4H0;P03"&\;$$,+ FYF+">+V^Z?L2I:.YJY^KU
M&^XF_^;+:?TDMSJ=Z]&.F@ZL-[DW(T1O3"W[HTUV&.\#P-DVM/5P7#6&">.\
M$2G:J,2&ATFTB@*B-6-%:DZ38LV.%=%\\YK.2^WMJNKNFI)K_(-Q$J)'F4R
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MZ.^]YT]];P7&58G7$HQ\>1[#%-P/+P-R3HK&F:L%6 I9NJ10.:G!^&=^#K:
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M%'I!_,7(4$[])0=-XE6EGW0S\S=A?MU*&%RZ%@$Y@#50/<6^9!);R/@#0GQ
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MSO,@JD_IR 7#D#8'/L-J8 ;>1; PYL1-B$,D56K]KQ%OXVAD05HZWG8 >[L
M2%*^8+W_DH/'N*F5VOV4@*[_]P%6V[]-L-X!M+9^7V<=N8&86@=$ 30P4#QN
M$[8/]#L#TV/Z_)'[_"1(L%OHJ[CXXPS#HI'WG\%R]1R^TZD,<GSFO'I3LT0"
MS$4<%MLF<=T0X/9RB!?4K< =FE9P3>E$%;A;M_L!S4^[%1LRMMSI4;>WGC\9
M=OWA<.!\,2YJ7W"72:GAU:TD'EIOEO;#R$)V^=Q.D8\:50!L%7FF:%,DWBQM
M1>O=S:;]:D;9*H@)#<S*$FYNNXSSW+2%,N XU%*M!M=$1%*)^UW#^\PXS5%
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M5GWT<IB4T'==/3@M]5%$VW2I(.'.1]R98A[ CSEWS6D>2-^[,M_*W:^)P&^
M@YU=\<B(+7J5"DRDI%IU,/8%&FN 5Y[?P'H.70A/;#PYT04-U*CH +)$(4K=
M([495Y,:5U<BP3*:"RK+V7[DPC;-?B5ZP.5\MIDG3"J?7S%'V=E6D1P]TT^>
ML)4I-DA%_.MW%3G?-OC!]>?U-\F5HK\I178-Q-840ZD=\W8D);5<D9@6Y%-
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M=<@7'M(<;O5Q<G7FG(D'ESO>R;%SR*R9<=-<CEN@U<!F&4P\8:C\',T[G5=
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MCQ-*(<2" Q'CU#O=G#N,F6,A_,*3'G=5V2((R;:8HLF14GNPJ<#+]UZ6&2S
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M3_Y^/%,VI*Q3S;C ![F]%C1"1;DXYPJ>)9QZH5N"2>KUDKH/2\>PT#82QKI
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MC-6@6V5RLYRFDC#IW.,T6*_D"084 N64Q=1@Q(9IEDF+VH9ZJO7SK?2C7:L
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MW/62"$?@KOVR0>"N^;'NW%6U-UZIT6:OU+-9&EW!'^?%<O'G_P]02P,$%
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MA"6.BB0,2Y8;T8(=-T&LP@+U/%FPL:R;SA'HHYR/TSTV9K1T:(A @O6XJMF
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MH\TII(PAIC:G>1?CZ9/O57LJJ:"!%EN)Z/PO&*FUBAE(B"H7M\0R=$8$520
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MJ<6&>]<B;"SV>G[\DO,E#]<+_KYI=2T'"-Z+H($P2BW:73$0*Y(AF6=O8RD
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MR)QPKJ3%N1K%UJ2@[Z: 5R&>_E]$O,VUN6+@_/+]\J,4__G'W_X_4$L#!!0
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MZ49S627K0>DVL=;-H1Y%08]-N++BXG5+[32PI+^]*BYL1$.CIR7>&5KQ8V'
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M8S$Z<!$ST ?VPZ N<+\C:O6NO0:-"M9OT6_@RWSUQ%BX0(?,.F5JN"#3UFR
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M:TD4PILCF:222X_<>ZWY7ECU -#OCU]]:JY!M*Z[> ;1^7IQ5;*05#W(E>2
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M;1:Z"-[$[EC"<0#UM]#7G73\[87=(,;T>CQ*--*OT?A1OC&\YQ/@9M!)B5#
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MGNF36^'B!9V[@.K;&%N+9O_&V.Z*NJOUGJ3<9M*O *>=M$[4WC81:@<QSEF
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M)?<DSKTD=KR;T6]K6B-.IC4+9;95RXX53]D]H/D0M.7[_MQG6A13$3;JF&+
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MP=LC/T,-[BVXG6OP**44/[%!5B[.:/$]X>>Z$,GB_-IP&Z-47:^!1RQCM[\
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M@Y[_1;.*4:C$**-7HL7K\>YKLP:?4,@:%$7;I=W#$=C%:']4=O55U C5!WN
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MNTU@[&ESN7^,1ONH6\_8,[*_:XT^?K\-[Z/X>LV8WDRSA3[-6:A?6>W9J+,
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M5))K#GB^>BA<^>O,9J]S_SKSB/$V'S->=G8.PUMZB'VUS4CM=%5D5]7+]R)
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ME)406@\XW.*I\@UL@I@Z<30)1W.%SM"A9$T^@R(4*$K;/!>PIM49:#916Z[
M&_\(6Y\4DTK\:E=IFRVBCXP7RP5L_\Y:9ER=&QLAUAWVU/F$$4.63#C9#3<R
MNL-%#ZO?U$N@\W[^(;BN-Z9G>:;D:1ARI=1Q1@E$2MU3.EX402](*8E)2.+
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M66.R+\[L']#79EI4C_E[5CZ^617E\DGDZVJ7FHBF$E\HB0AQK.RG2!"(@C"
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M@+:VR_K%6\>M7(&#FL854D!#!316]:'J!.);AIK_243%.&?NSQ%+,]2<.HO
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M9>3:)C>;@FYF)@P"Y="J_K&\9DWV\.W?K>%RF^UL.OC(&<^6F!QF/=L^H)_
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MARGU/!;VB&WM'M5H@8P?ZJH)!M]KTG\ :G'4E"OK6U><K@BW4XG/(&^F[SH
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MSF_/:L;4AOM<*YD6'N .+ T<YFX0&EAV-$2"+2I!2Z8;I"Q\Y6X0&\M7_B@
MJ<I@U2D>BR+CE7&C$,P;L@%?515N2G5M72RZDL/ZSZ=L+HIRN1"N(CK/@]?I
M4^^X?3R?^GD>=GSJ!I?W3)_=,5/;RIF1C])$X @&7.J"'7X(,1(!K(XC \QY
MP(F-,^OH*%/S7&V<+_.JBX7H4X/T.)YF2MC%* TL00^\4\[KDG8BX#2G\^A
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M4]KT_*7IQR&VCMZ^GBO&XW:2#4S5D:9N8&%5<0%NU]6.P&T.*DZN0#NA:V;
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M$A2%L3 _\3T^QM1D3D4ED V98+DP]/EUP6B@FET.SM#66X5+2R%0)/;1RDX
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MX1VG/>H'V01)%'IGM; M^F4';O^]:R_ WFF[NI%UV"WI 21#[T*W$[[[QO-
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M"$>HKG&494'&&"<LR.)^O1,\2CDUBO.P[[NL&8//)\".-]]]7:>_E1^N%<0
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M1Y9[:K;NCMC@)\T,8CF?TZ(T+91K;Z=CO\*QEG]@3\IPBSI]1\KQI,Q6?]
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M<G4),%#M9(Y/((IYJ/6?1)RS=^7^&I'00ZVIMUCIP01TLQ5,\_2/BU4EBOY
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MR[&J4I]5L#/L!\9VX(_6!M;O6GS0RG]5UVBJCH@V.H _*RV 40-4>GB,)KD
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M+%>0&Z.@P)@3D2(D5=!I>&!_8S/&M;AE*O.QP)&,4%=@#CL7ZQ"\GNWP9=Q
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M/\^].&">9H/<Q_F430^V\U/OG\Q2^"HW)3GJ9T^I?&]_6?G3$K.>*HV$9-9
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M "\LN)\'7M<T WO=+^H$KIYM56NDHEREJTC<X#)=;GLPU^FJ>H<NU/6'6];
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MB/=L8;ST_J2IDG\"]N"7*O@R>B6'/CQ0 [P=!OR(/5G/@S#07JV?P8C;R-V
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M5R\QKJ^^N\A=40I(=-HS&;5F.B7.(@1D4J+38,A7B/=DD0U@LYY'YSA5#PU
MUU(_/< OI=K28O4!$]**(C[?X?J"EVQ= >=J/2()3W-G6;3>,QY\LIH;(>0]
M!S@#8.T1HL8ID&@!K*$DOS.**,:(BX%P]&;^C>A>++\3$Q,+*4O#-<M&&*9%
M20S DVR$\AH=.C#W' +OCYOK1(Q3&=$ )SM+M@/K\GZ)7V&:7_WY%><KI+W[
M>/V% MN-<"Z@KD7(TEO:H%$(@GJ,%-W6,K* 15H/8.4]^6O[@V4+VL;I?]8
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MW0%6'ICE=<Y,P#J<0M>\S'IB2LX_HR54#V:%X1I2DOR0T]1Z<(6&Q]!P*N@
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MD_)MRE@[;2>U'P:>Z"+U'%EW$)H\W,VFI!PMYS7)T9-,C"#;S6-@"67TV6;
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M:9T$\\;5KV*PF)S3HDD-SS-H'+?W0G=0;:7=+J![-\__4HSG94B7,E0J1ZO
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M/IKGMU.(T]ET_?T6B]P@)A,MDTYSLL;@60PJ,:XR-U9'$5.3Q;@#K>-&RH=
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M:A1<LQ0*9[JV-(V>ASK!(<;D-/K;X]D? ,J#KQCG;NQ &!E&L&/#X[_C=/8
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MM^O-VZO+JTV^T8R%MH$YSPMHY0TH:S6XY RPHI0)22@?1VEXTGNGW7 WSV>
M$635 !AWY%Q[@:*V::)8'91#VCE7'GRQ%*I;G6JO-Y_&>:^\VT(W^,SH[O]
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M4Y8K<,)XL*ATLF@DP7\PZ=]?>9KS8C#I'\S$!M(@'A9%L6(*MR:#R%A+23&
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MCS@/9[>%Y$5.S (3=:YVO<7'1,ZHM9*K9)B4?)2BO_[C&F<PE^F0&XOCQ=(
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M=?TJ[5$X&\D2,E<'OM7X.3@9P*G$C7>Z"#G*!-#7M];B:^V!2.B0(72$6!H
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M_34@5_EC':PP:J8]+XHTRWHH(?GZ^BC 696AE!28,CP9-HJM.^:Y[50O',?
M:@A^G^$U\H(_)&[\B^0%G_PJ^3'1MY?)_^- "?RP_OQY>;E;%E>I5I+1DGD5
MEX<-"WCIXX;@7>?M#G3+?F^]-X_6JR\[%^LM"?%6RZWSP<FB@"(H#2J0@J/1
M%KAVRJG"7%:C)"7TVN6QYK_38G=-RH-5SG)OP7)5ITD75M-1'&CM2G(83$RC
MY.3WV^:T=_'CH>SQ63*B\!H]8EZP&$>\1W;XU)'-W9AOB_WP*%QP,0<*H3@/
MM<!+@^>*OI06>6*"BSS*8.N36KU?UMOM@R6NVP8$GK+R(I-&:/+!O"_@BQ'
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M$1P.I_4E7G3)#=O_H/X1<)O_G__K_P=02P,$%     @ JHEI44KI[<^F!P
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M\07$*SY16ODEU0G;IJ7=%J 84!8WRBW1M?HV9*#KRJ&BM 50[D)=DR3&BF!
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MC)2@6#(!8$9*V@GUH&89&))8DIX3:6.E;8E^Q)U&JP"6PNA8)"BV; _82 3
M%@!P>1=/>#X6[ RT=%,J8;=4VF!/!(,Z@V2]+!1*DIMY0"U-R(C,UL <P$7&
M_9Z9TQTSIYB95N(^YM&.M,#SM-9&P'K[CR.[\0VAO5+++P#:W3ZMPX6P6"E$
MU&?"Q_%7IR0=\](^O0MERT@ .M5,(?_JTF  D-I46D^5:"5R/PXI[A7)KA.U
M$8I[+%8)> 6?>D7B5"E!N+#%:B43?P"V961E(KF1Y( ,,L&GCIQ&*BVE;K^=
MK<_SGEAQPH9!./KZ3@44J8Q+Q2D?P"UOQ$H"H$<0%.LZ"-\B00U!V>@ODN=1
M]'<%[>C%0/NHN7^PC>PGT]P6P)].D$_&.?;&5"8$7VYUSBDU< OHDSXE3'.3
M+/ %Q$L>227=G'3"KFEIMWDH>I2%C;+1=$W?^@QT5SE4E*8 RJW7-7&L3>(-
M\$IW+'+(%06PHT84M(NH"51\ #1VFRP\Y[]:2,<O!M)+MKZ<<E5Z2J. BS2%
M^I13A,KN4)%+H?($B@Z/NX6EAS Z@EYMD*^1+MW7+7A*$N'+UH*T>?KX<8I%
M"]7O=Z4(*P%[/ )I@M>)PN3%H'!)K"&^VSBA8WZE"7W-3C ^@TY)!N@X+@VA
M82WG[A@UT]:AG"Y/,9:-,5!UB<3VOM(E!:Q!=/=:5X;C=";\#05=7N3ETJYW
MP:H)MTN!0A3IMP%=&H)>_7I4O#YG2MX*55U7W&M?_Z^7Z/G0?[G'OL'K.?;Y
M&\UDL4OJ*^8B(EU'ZHK$"&O/D"A;\G=I'8<$=MK8I2KP!1@RRZ1S0CR0)B(-
MW4'UB81]?I ]X!FL;(GU\9>$^&(3BM]*"?/]ABOSV%]LO/O_V>W/5 -G"MH.
M:R6!/SI!T^$\E@)HJ3+Z\@PU$_R64G30>CY)>Y7J;UP7]U+/PF!UW DW'#O8
MCB?H:,62[+Z*UTK;H@M !PE:#SK!0B38,@-DL$K>F2K)[+S!>^4:X.4=KLZ0
MZE,#;JD#",(S(J#DK\PKS-5#II3Y5*NIH'29\W%U\V\J$A59H?1<H'8VT8$V
M^0:B@< _1$LT'\-%I)W3V9!^AEY#BD\#)\X?T*KV$2 J3 -KKWAAQ7#QY1A\
M7R@^'\K<KZ#O=#RE+ %Y4>$*8U:_<@\ZW6:W&M[@?[(8O_H1O-GV=2V7;%?V
M>\WV ]4/]GUXX/W!PJC'.[>\W6;18H&8RB=2\<H6/']?Z]46;2HD#;O%'>ML
M[C@"U_W5"C'Y1EON C#>S&;5BCS/+_\ZPHMR[!I[)(NP38[J_LV/#?]V![7W
MA)BVR?/:@\M4;1U/P07\INLYMG!XYSA?,>?HC['G>X+CVS=]$)[_W'I5@5Z0
MV55V/I$B91^6;/@IZ-3M@+<\6>T@QWLOZ!0ZO*$T#->P4['URLXJU)Y.VZLN
M/$*\2[?=Y9&W?*K/\,Z1?_OI]#]02P,$%     @ JHEI4<95'#,1!0  Q1,
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M:2TR,#(P,#DS,"YX<V102P$"% ,4    " "JB6E11CN_(CTA  #-60$ %0
M            @ '94 ( <FUT:2TR,#(P,#DS,%]C86PN>&UL4$L! A0#%
M  @ JHEI42G")5O<<   TPX% !4              ( !27(" ')M=&DM,C R
M,# Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( *J):5&T:(:8D^T  */,"0 5
M          "  5CC @!R;71I+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4
M" "JB6E1\L$)I#^3  #T\P8 %0              @ $>T0, <FUT:2TR,#(P
M,#DS,%]P<F4N>&UL4$L! A0#%     @ JHEI44KI[<^F!P   B,  !H
M         ( !D&0$ ')M=&DM,C R,# Y,S!X,3!Q97@S,3$N:'1M4$L! A0#
M%     @ JHEI49@UD8[F!P  6"4  !H              ( !;FP$ ')M=&DM
M,C R,# Y,S!X,3!Q97@S,3(N:'1M4$L! A0#%     @ JHEI4<95'#,1!0
MQ1,  !H              ( !C'0$ ')M=&DM,C R,# Y,S!X,3!Q97@S,C$N
9:'1M4$L%!@     )  D 8@(  -5Y!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
